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The UK National Guidelines on HIV Testing 2008 recommended that adults in areas where 
more than 2/1000 people were living with HIV be considered for an HIV test at the point of 
registration with general practice.  The RHIVA2 trial of rapid HIV testing in primary care 
implemented and evaluated this recommendation across 20 general practices in a single UK 
borough using a pragmatic cluster randomised controlled trial (RCT) design. This trial, and 
the policy that underpinned it, reflected two more general developments: first, the move 
towards population screening to detect and treat disease in early and latent stages and second, 
the emergence of ‘pragmatic’ clinical trials that seek to account for complexity and measure 
interventions in their context of use.  
This interdisciplinary case study uses multiple methods and theoretical frames to explore 
what happened in the RHIVA2 trial at both an empirical and a theoretical level. Sub-studies 
reveal how the trial was justified, enacted and became meaningful as a policy, as a trial, and 
as an intervention in the lives of patients. My analyses show that two operating logics 
informed the justification and enactment of the trial and patterned patient and provider 
experiences.  The first, the logic of normalisation for HIV aims to treat HIV infection as a 
medical condition ‘like any other’.  This logic emphasises general practice as a site of 
increased value and position in HIV management and as a space where population screening 
can be undertaken.   Second, the logic of the pragmatic trial aims to measure interventions in 
the ‘real world’ but is revealed to produce unintended effects, raising questions about the 
claims of such trials to generalisability and reproducibility. 
This thesis demonstrates how contrasting versions of the research event (‘multiplicity’) can 
be produced through different modes of inquiry, raising questions about the tension between 
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Chapter 1: INTRODUCTION  
 
 
‘To explain how the world works is not to explain it away but to make new 
connections between social ‘facts’ that may provide unprecedented insight into the 
working of social worlds in general.  One such insight concerns the excess of social 
experience - the historical surplus - at any point in time, that is experience which is 
not captured by current categories, and which points to alternative ways of seeing 
things and acting upon them - and hence to possible sites of social resistance or 
creativity; as the case may be.’ (Hastrup, 2004: p.466)  
 
‘While good arguments are unambiguous, good stories leave room for a variety of 
interpretations.  While sound arguments should be clear and transparent, powerful 
stories work by evoking people’s imagination, empathy and irritation. While 
conflicting arguments work against each other, conflicting stories tend to enrich each 
other.  And while adding up arguments leads to a conclusion, adding on stories is 
more likely to be a way of raising ever more questions.  How might what went wrong 
here be prevented elsewhere? How could we transport what was successful here to 
other sites and situations?  And if there is nothing to be done, if nothing is likely to 
lead to any improvement, then stories may be a source of consolation.’  (Mol, 2008: 
p.76) 
 
This thesis tells two stories.  One is about human immunodeficiency virus (HIV) and how 
new approaches to testing for HIV in the United Kingdom (UK) impact general practice 
organisations, health care providers and patients.  The other is about how innovations such as 
HIV testing are evaluated in their context of use, using the experimental design of the 
randomised controlled trial (RCT).   These two stories were brought together in a study of 
HIV testing in general practice where the innovation of point-of-care rapid HIV testing for 
newly registering patients in general practice was implemented and evaluated using a 
pragmatic RCT design.  I was a member of the study team, acting first as a research assistant 
and then as the manager of the trial.  This work left me with a number of questions about trial 
designs, HIV and innovations in health care.  These questions, often surfacing as tensions, 





My initial research question was about variation in the uptake of HIV testing amongst general 
practices participating in the research trial in which this work is nested. Here, general 
practices were expected to implement opt-out rapid HIV tests to newly registering patients. 
Intervention practices showed wide variation in achieving this goal and I aimed to learn why 
some practices were better able to implement HIV testing than others. I hoped to explore, and 
to some degree explain, the variation in the uptake of rapid HIV testing in general practice.  
Over time, as I worked through this question it became apparent that a greater consideration 
of the policy context and the research design was required to account for my findings and 
provide explanations for the confusion and questions they were surfacing.   My research 
questions began to transform and I started to ask what could be learned about the 
implementation and evaluation of a service innovation, such as the rapid HIV test, as part of 
a pragmatic trial specifically?  In thinking through these questions and in recognition of the 
breadth of methods and data sources this would require, I recognised the need for a structure 
upon which to hang my work.  It was then that I began to construct the two stories that are 
woven through the work presented in the thesis. 
 
1.1 Story 1: Implementing a ‘normalised HIV’ through a population screening 
approach in general practice: the logic of normalisation for HIV  
 
The first story concerns population screening for HIV with emphasis on how such approaches 
inform transitions in what it means to be a ‘diseased’ body. Changes in the biomedical 
landscape of HIV mean that patients may live healthily with an HIV infection with little risk 
of passing the virus to others if they adhere to drug therapies.   When such conditions are met, 
HIV can shift from a deadly acute infection to a chronic, manageable condition.  As a result, 
there has been a large-scale push by the biomedical and HIV policy community to 
‘normalise’ HIV testing and, to some extent, HIV infection, with an emphasis on the early 
detection of the disease. The logic of normalisation for HIV refers to a coherence of ideas, 
practices, approaches and ways of speaking and engaging with HIV where HIV infection is 
promoted as chronic, treatable, potentially non-infectious and considered as ‘any other 
medical condition’ with the right medical intervention.  Within this logic, the altered potential 
of what it means biomedically to live with HIV is meant to and hoped to produce an 
improved social reality for HIV-positive individuals. I argue that the featured trial aims to 




potentially non-infectious HIV - through enacting many of the discursive practices enabled 
by a logic of normalisation surrounding HIV infection in the UK at the time of the trial.  
 
1.2 Story 2: Evaluating ‘the scientific and the social’: The logic of the pragmatic clinical 
trial 
 
Story 2 is about the conduct of a pragmatic randomised controlled trial (RCT).  The 
pragmatic trial research design is an explicit attempt to account for context while maintaining 
an RCT logic. It aims to overcome some of the limits of the traditional RCT by also 
accounting for ‘external’ factors and integrating the experimental design into the ‘real world’ 
of everyday clinical practice.  Such trial designs are seen by the biomedical and health policy 
community as key to measuring complex interventions and in helping orient decisions in 
population health by providing evidence that aims to account for contextual factors (the 
‘social’) while still providing a standard of evidence desired by biomedical paradigms (the 
‘scientific’) (Kelly, 2008).   Pragmatic trials are one response to the broader calls within 
health research to consider context and complexity and to better address the effectiveness of 
interventions in practical settings.  The findings of such trials are also meant to be relatively 
generalisable to other similar settings. I argue that in RHIVA2 the pragmatic trial design was 
more productive as an experimental device than the current methodological approach 
recognised, potentially occluding some of what enabled the trial results.  
 
1.3 A tale of two logics: The RHIVA2 Trial  
 
The RHIVA (Rapid Human Immunodeficiency Virus Assessment) 2 trial, the study in which 
this work is nested, simultaneously implemented and evaluated national guidelines on HIV 
testing. It brings together the story of population screening for HIV and the logic of 
normalisation, and the story of the logic of the pragmatic trial. By offering HIV testing to 
newly registered patients in general practice in a London borough where HIV is highly 
endemic, a recommendation from the UK National Guidelines for HIV Testing 2008 
[henceforth referred to as: 2008 National Guidance] was being implemented. As this was a 
new method of HIV testing for which UK RCT evidence did not exist, the RHIVA2 trial also 




to determine whether offering HIV testing to new patients, in the context of a new patient 
health check, would lead to the earlier diagnosis of HIV and at a greater rate of detection, 
which were public health priorities at the time (BHIVA et al., 2008). Offering testing in this 
way, informed by a logic of normalisation for HIV, was a novel form of population screening 
in the UK (Story 1). To measure whether this intervention would lead to earlier and greater 
diagnosis of HIV, an experimental research design accounting for interventions in their 
context of use, the pragmatic trial, was used (Story 2).  The results of the RHIVA2 trial aimed 
to provide generalisable conclusions about the impact of the intervention and be applicable to 
other UK boroughs with similar epidemiological indicators.  
 
1.4 What’s in a logic?  
 
The decision to describe the two stories told in this thesis as ‘logics’ was a considered 
one.  What I required was a term that not only encompassed ideas and actions but described a 
patterning of thought and language along with bureaucratic processes, apparatuses and 
general orderings. I first came across this form of description in Annemarie Mol’s The Logic 
of Care where she contrasts the ‘logic of care’ with ‘the logic of choice’ (2008).   Mol uses 
the term logic to convey the ‘rationale’ of what she describes which is fitting to my objective 
here.  Both the logic of normalisation for HIV, and the logic of the pragmatic trial contain a 
reasoning which the term ‘logic’ helps to depict by inviting ‘exploration of what is 
appropriate or logical to do in some site or situation, and what is not.  It seeks a local, fragile, 
and yet pertinent coherence’ (Mol, 2008: p.10).  The logics I describe emerged from, and are 
situated in, the work undertaken as a part of the PhD and while they structure the presentation 
of my findings, they also reflect them.  My choice to tell the two stories in this way relates to 
my desire to locate the PhD project in the broader scenes of biomedicine.  By presenting 
these two stories I hope to engage the reader in a way that enables them to consider the two 
logics as situated within, and related to, pertinent realities in the current organisation of 
biomedicine, disease and evidence.   
 
1.5 Study design, research questions and aims 
  
My work is nested within the RHIVA2 trial of rapid HIV testing in primary care.  The trial 




and directly explores questions related to the experience of the trial.  In attending to what 
took place throughout RHIVA2, the PhD and the overarching research question have a dual 
focus, attending to both the logics of the implementation mechanism (population screening 
for HIV and the logic of normalisation), and the evaluation of the intervention (RHIVA2 and 
the pragmatic clinical trial logic). The overarching research question can be summarised as:  
How did population screening for HIV become national policy (?), and to what 
extent could its implementation, through the RHIVA2 pragmatic randomised 
controlled trial, be regarded as successful (by participating practices and newly 
diagnosed patients)?  
The PhD project involved three sub-studies that take place at the policy, the general practice 
organisation and the patient level.  Using a case study methodology, I trace the 
recommendation of HIV testing for newly registered patients in primary care from its policy 
origins to its enactment on patients.  By exploring the basis of the policy, the lived experience 
of a trial which encompassed a potential mechanism for the enactment and demonstration of 
the policy, and the intervention’s meaning for patients, I develop a fuller understanding of 
what policy enactment looks like in practice.  The study context offered a unique opportunity 
to illuminate ‘evidence creation’ and notions such as the ‘roll out’ of interventions as a part of 
experimental research.   
 
My aim is to make visible some of the complex social practices that are enacted in the design, 
conduct and evaluation of the RHIVA2 pragmatic trial and to broadly elucidate findings 
related to population screening programmes for HIV in the UK and the conduct of pragmatic 
trials, such as RHIVA2, more generally. 
The policy study asks: 
a) How was HIV testing for all new registrants in general practice in areas where 
more than 2/1000 people are living with HIV justified as a national policy 
recommendation?  
b) What were the key interrelated discourses in operation in the policy community 





The organisational study asks:  
c) In RHIVA2 trial intervention practices, what organisational level influences and 
interactions explain variation between practices in the uptake of rapid HIV 
testing? 
The patient study asks: 
a) What are the experiences of patients undergoing rapid HIV test diagnoses in 
general practice as a part of the RHIVA2 trial and how did the trial become 
meaningful to them?  
b) How did the logics of normalisation and the pragmatic trial interact with patient 
experiences, and how did these experiences help produce the trial results?  
 
1.6 Structure of the thesis 
 
Following this Introduction is Chapter 2: Background, where I first explain my personal 
context for the work. I then describe the state of HIV in the UK at the time of the RHIVA2 
trial, including HIV prevalence, treatment norms and contemporary public health priorities 
related to the infection. In describing the policy context, I introduce some relevant research 
undertaken in the UK including the RHIVA1 research, an acceptability and feasibility study 
preceding RHIVA2, and RHIVA2, the study in which this PhD is nested.  
 
This is followed by Chapter 3: Background to methods, where I articulate my philosophical 
approach to the work with an essential outlining of ontology, epistemology and paradigm, as 
well as variable positions on the philosophical spectrum.   This includes outlining six 
‘sensitising concepts’ that have shaped my analytic approach: the experiment, the surplus, 
dwelling in doubt and tension, novelty and being a beginner, pragmatism and experience.  
Following this, in Chapter 4: Methods, I outline the main methods used for data collection.  
These include case study, qualitative interviews, process evaluation and auto-ethnography.  I 





The findings of the thesis are presented in three parts. The choice to break the work down this 
way was made to assist readability and coherence.   Each part includes a description of some 
relevant literature, the theoretical frame used to analyse the data and a summary of the data 
sources called upon in the analysis. The decision to break up the literature, theory and data 
sources in this way was out of consideration for the reader and a concern that frontloading the 
thesis with literature and theory would have made for a less cohesive presentation of the 
work.  As a result, the thesis can be read in three parts.  Each parts aims to build on the 
preceding and draw out the experience of the RHIVA2 trial from its conceptualisation as a 
way of evaluating and implementing policy (Part 1) through to its enactment in general 
practice organisations (Part 2) and its implications on patients and research conclusions (Part 
3).  
 
Part 1: Population screening for HIV and the logic of normalisation, presents findings 
from the policy-level study.  I begin with a summary of some literature related to the 
sociology of screening and diagnosis and a description of data sources: 14 in-depth 
interviews with policy stakeholders and four key policy documents (Chapter 5). I then 
present two findings chapters (Chapters 6 and 7). Part 1 provides a ‘thick and theorised’ 
backdrop for the remainder of the thesis through a detailed consideration of the circumstances 
enabling the RHIVA2 trial.  
 
Chapter 6: An empirical study of the policy context for the HIV testing of newly registering 
patients in primary care in the UK, explores a key policy document: the UK National 
Guidance on HIV Testing 2008, which contains the recommendation of considering HIV 
testing for all new registrants in primary care in high prevalence areas (defined at the time as 
where more than 2/1000 people are living with HIV).  I seek to understand how this policy 
was justified and enabled.  Through a combination of textual analysis of this policy document 
and in-depth interviews with members of the HIV policy community, I identify 17 themes 
across four broad categories I term ‘micro-streams’.  The four ‘microstreams’ include: public 
health and epidemiology, treatment technology and techniques, health setting factors and 
socio-cultural dimensions of HIV in the UK.  I draw on Kingdon’s policy windows 
framework (2003) and Wilson and Jungner’s principles for the early detection of disease 




result of a coupling between the ‘problems’ stream and the ‘policies’ stream related to 
Kingdon’s model.  Epidemiological indicators regarding the late presentation of HIV as 
undesirable for individuals, populations and the economy created a pressing policy problem.  
The construction of undiagnosed HIV as a ‘problem’ was supported and enabled by 
stakeholders in the HIV policy community.  Existing policy precedence within the UK and 
abroad, which included population screening approaches to HIV testing, were integral aspects 
of the ‘policies’ stream.  New emphasis on primary care was facilitated by the availability, 
feasibility and apparent simplicity of rapid tests, abbreviated pre and post-test counselling, an 
emphasis on settings with access to the general population, and the cost-effectiveness of non-
specialist health professionals offering HIV testing.  The application of Wilson and Jungner’s 
principles for the early detection of disease revealed that HIV in its contemporary form 
broadly justifies population screening approaches in highly endemic areas.   
 
In Chapter 7: Screening for a ‘normalised’ HIV: A discourse analysis of policy documents 
and stakeholder interviews, I present a discourse analysis of four key policy documents 
(BHIVA et al., 2008; NICE, 2011a; NICE, 2011b; HPA, 2011) and the 14 in-depth 
interviews.   I explore how discourses circulating in the HIV policy community and key UK 
policy documents justify and uphold population screening approaches for HIV testing in UK 
general practice. It is here that Story 1: the logic of normalisation becomes more apparent.  
After identifying key discourses in the HIV literature and a subsequent analysis of the data 
set, three main discourses were identified.  These include a risk/surveillance discourse, a HIV 
normalisation discourse and a HIV generations and dynamism discourse.  The 
risk/surveillance discourse works to position the general population and undiagnosed HIV-
positive individuals as the site of embodied risk for HIV.  Biomedical advances in HIV care 
blur the boundaries between health and illness and the testing of asymptomatic individuals 
for HIV takes on heightened status.  The HIV normalisation discourse presents a tension 
between the historic exceptionalism of HIV as a lethal infectious disease and its related 
practices in biomedicine and public health, and the new normalisation project which positions 
HIV as a chronic disease ‘like other medical conditions’.  The normalisation discourse brings 
new forms, sites and practices of HIV testing into focus and primary care takes on new and 
increased responsibilities.  The HIV generations and dynamism discourse positions HIV as 
historically situated and dynamic, with multiple enactments and states of infection that have 




enthusiasm partially due to its prior prohibited status.  The changing and multiple nature of 
HIV infection alters professional roles and identities around HIV care and impacts on 
professional relationships and policy making activities.  
 
In Part 2: RHIVA2 in practice: Implementing and evaluating a complex intervention, I 
explore the trial ‘in practice’ by theorising the variation of uptake in rapid HIV testing in 
RHIVA2 intervention practices.  Here, the logic of normalisation and the logic of the 
pragmatic trial converge on site in a single London borough, highly endemic for HIV1.   I 
begin with a description of methods and how contemporary research practice aims to account 
for complexity and context through a variety of methodological manoeuvres (Chapter 8). I 
then describe the data sources for the process evaluation2.  Chapter 9:  Explaining the 
variation of rapid HIV testing among RHIVA2 intervention practices using diffusion of 
innovations theory, presents findings from the organisational-level empirical study. Using 
process evaluation methodology and the construction of four case studies, I explore the 
experience of health care providers and organisations taking part in RHIVA2. Using 
Greenhalgh et al.’s model of ‘diffusion of innovations in health care settings’ (2004), I 
consider what factors led to the uptake and successful implementation of rapid HIV testing in 
some practices and what factors impeded uptake in others.   I retrospectively compile 
quantitative data in the form of testing and diagnosis rates, practice level data such as the size 
and staffing of participating practices and qualitative data in the form of 21 semi-structured 
interviews with health care professionals providing rapid testing. The application of the 
model reveals that successful practices (those able to offer many rapid HIV tests) appear to 
be innovative practices.  These practices demonstrate good managerial relations, readiness for 
change and a culture of staff training and support.  Here, adopters appear personally 
motivated and see the value of the innovation to the patient population. In these settings local 
adaptations to the innovation helped embed the new practices into organisational routines.  
Early experience of a reactive rapid HIV test appeared to reinforce a commitment to testing.  
                                                
1!Highly endemic of HIV in this case refers to the definition outlined in the 2008 National Guidance, where 
greater than 2/1000 people with known HIV status reside in the borough (BHIVA et al., 2008).!
2!The findings presented in Part 2 were also published as a paper: Explaining high and low performers in 
complex intervention trials: a new model based on diffusion of innovations theory, by myself and colleagues in 
the journal Trials in 2015. The research was undertaken as a part of the PhD project. This is acknowledged in 





Practices with less successful implementation of rapid testing had less good managerial 
relations, significant resource and time constraints and some key staff appeared less 
comfortable with the test.  No early positive results were evident in these practices.   The 
adapted diffusion of innovations model, as applied retrospectively to explore the RHIVA2 
trial, was an effective method of investigating and explaining the variation in uptake of rapid 
testing in RHIVA2. 
 
In Part 3: Experimental end-points: Patient experience and the pragmatic trial, I shift 
focus to the HIV-positive patient, as detected by rapid testing, and to the logic of the 
pragmatic trial more explicitly.  A successful trial and patients with HIV diagnoses were the 
anticipated end points of the RHIVA2 trial and, to some extent, the 2008 National Guidance 
policy recommendations.  I explore how the trial became meaningful to patients and therefore 
how RHIVA2 produced statistically significant results. These results support the policy 
recommendations and achieve the broad objective of greater detection of HIV in the UK.  It 
was at this point in the PhD work that a deeper engagement with theoretical literature felt 
necessary to describe the tensions the data was surfacing.  It follows that I begin with a 
discussion of some literature from the fields of science and technology studies, the 
philosophy of science, and anthropology (Chapter 10). I then describe the data sources before 
presenting two findings chapters.  
 
Chapter 11: Producing difference in RHIVA2: HIV-positive patient experiences of rapid 
testing, calls upon five in-depth interviews with patients testing HIV-positive, with the first 
test being a rapid HIV test as a part of RHIVA2.  I first explore experimentality through the 
work of philosophers of science, Hans-Jörg Rheinberger and Vinciane Despret and consider 
RHIVA2 and the rapid HIV test as devices aiming to detect ‘difference’ (Rheinberger, 2015; 
Despret, 2004).  Analysis of the five patient cases reveals that rapid testing in RHIVA2 
becomes (to some extent) meaningful to patients through the trial’s ability to respond and 
attune to patient questions and subjectivities.  The normalising technology (Philbin, 2014) of 
HIV screening in general practice allows for patients to interact with testing in a ‘normalised’ 
fashion; however, post-diagnosis secondary care services appear as spaces where HIV 
infection is ‘less of a big deal’, and are experienced as more ‘normalising’ for patients.  




patients, with implications for the reporting of trial findings.   This is taken up in the 
following chapter where I explore findings related to the pragmatic trial logic.   
 
Chapter 12: Considerations of the pragmatic trial, draws on various data sources from my 
empirical work and offers methodological reflections. It is here that the logic of the pragmatic 
trial is described and explored more overtly. Calling on theory from philosophy and 
anthropology (Kelly, 2008; Savransky and Rosengarten, 2016; Viveiros de Castro, 2004; 
Mol, 2002) and dialogically engaging the experience of the trial with different methods and 
epistemological assumptions allows for varying accounts of the research events to come 
forward, which have implications for the claims of the pragmatic trial design and the 
presentation of findings from RHIVA2. In the attempts of the pragmatic trial design to 
account for the ‘real world’ while seeking to provide ‘gold standard’ evidence much 
transpires. I outline how the logic of the pragmatic trial occludes much of the ‘work’ the 
pragmatic trial does in accounting for the ‘social’. The pragmatic trial appears as a productive 
device that is to some extent successful at merging the ‘gold standard’ methods of the RCT 
design with the complex and situated world of everyday clinical practice.  Two data 
fragments, written up as cases and termed ‘ambiguities’, illustrate how the method is unable 
to account for this partial success within the restrictive evaluation and reporting methods of 
the pragmatic trial design.  While the method is designed to produce clear, generalisable 
answers to complex research questions about the ‘real world’, my analysis shows that while 
the experimental design may produce such data, they are not always recognisable by the 
method and may remain unaccounted for.  This has profound implications for determining the 
mechanisms of ‘successful’ interventions and the generalisability and reproducibility of trial 
findings.  
 
Parts 1, 2 and 3 are followed by the Discussion in Chapter 13.  Here I summarise the 
findings from the policy, provider and patient level analysis.  I provide broad and overarching 
reflections on Story 1: the logic of normalisation for HIV, and Story 2: the logic of the 
pragmatic trial as well as the resonances and tensions between the two stories.  I then 
comment on the research process and some of the unique contributions of this research.  This 





Table 1. A guide to the research questions, methods and data sources 
 
A guide to Parts 1, 2 and 3  








study)   
a) How was HIV testing 
for all new registrants in 
general practice in areas 
where more than 2/1000 
people are living with HIV 
justified as a national 
recommendation?  
b) What were the key 
interrelated discourses in 
operation in the policy 
community and policy 
documents at the time of 
the RHIVA2 trial (2008-
2011)?  
a) Content 










and interviews  
a) Kingdon’s policy 
windows theory 
(2003) and Wilson 
and Jungner’s 
principles for the 
early detection of 
disease (1968) 
b) Parker’s method of 
discourse analysis (as 
adapted by Shaw) 
(2009) with reference 
to existing discourses 
in the HIV literature  
1) Interviews with 14 
stakeholders in the HIV 
policy community  
 




3) Ethnographic field notes 
collected over 100 hours 
spent on side in RHIVA2 
intervention practices 








level study)  
a)What factors impacted 
the variation of offer in 
HIV testing as a part of the 
RHIVA2 trial of rapid HIV 





a) Greenhalgh et al. 
model of the 
diffusion of 
innovations in health 
care organisations 
(2004)  
1) 21 interviews with 23 
providers of rapid HIV 
testing as a part of the 
RHIVA2 trial  
 
2) Trial data in the form of 
numbers of tests 
performed and diagnoses 
made 
 
3) Ethnographic field notes 
collected over 100 hours 
spent on side in RHIVA2 
intervention practices  
 
4) Practice level data – list 









level study and 
all findings 
synthesis)  
a) What are the 
experiences of patients 
undergoing rapid HIV test 
diagnoses in general 
practice as a part of the 
RHIVA2 trial and how did 
the trial become 
meaningful to them?  
!
b)How did the logics of 
normalisation and the 
pragmatic trial interact 
with patient experiences 
and how did these 
experiences help produce 






b) Synthesis of 
methods and 
analysis - pulls 
on all methods 
and data 
sources 
a, b)Theory emerging 
from science and 
technology studies 
and philosophy of 
science including 
Rheinberger (2015) 
and Despret’s (2004) 
and Mol’s work on 
experimentation and 
multiplicity (2002) 
and Savransky and 
Rosengarten’s work 
on RCT ontology 
(2016)  
1) Five in-depth interviews 
with HIV-positive patients 
(out of a possible 11) 
diagnosed as a part of 
RHIVA2 with the first test 
being a rapid HIV test in 
an intervention practice  
 
2) Synthesis of methods 
and analysis – including 
trial results, interviews 
with patients and 
providers, ethnographic 





Chapter 2: BACKGROUND  
 
This PhD is based upon the experience of the RHIVA2 trial of rapid HIV testing in primary 
care.  RHIVA2 was established to evaluate and implement the national HIV testing 
recommendations outlined in the 2008 National Guidance, which recommended men and 
women in areas where more than 2/1000 people were known to be living with HIV should be 
considered for an HIV test at the point of registration with general practice (BHIVA et al., 
2008).  In this chapter I will describe some of the broader research and policy context for the 
recommendations and therefore the trial. I also describe how the questions addressed in this 
PhD became relevant to me in my then role as trial manager for RHIVA2 and what inspired 
my interest in this work.  I now present my personal context, the policy context and the 
RHIVA studies. 
 
2.1 My personal context  
 
The immediate context for this PhD is my work on the RHIVA2 trial.  For nearly three years, 
I acted as a research assistant and then as the trial manager of the study.  With a background 
in sexual and reproductive rights and having completed an MSc in research methods, 
investigating HIV testing in highly endemic areas interested me, I saw the trial as a useful 
way to apply what I learned in the MSc.  HIV appears to me as a highly social and dynamic 
infection with a fascinating history and unpredictable future.  The way HIV and its 
implications transition and play out in medical, social and political realms has always 
intrigued me, not least after having lost a family member to the infection shortly before anti-
retroviral drugs (ARVs) became widely available. I was also interested in how we might 
determine evidence and measure the effectiveness of interventions. Having worked for many 
years in social programmes among young people with complex life circumstances, as well as 
in international development with distant and politically charged issues, I was curious about 
how to measure social phenomena, account for complexity and establish an ‘evidence base’.  
I was often struggling to find funding for complicated social programmes that I believed were 





As a teenager I worked with six close friends on a programme for young women entitled 
‘Revolution Girl Style’.  In my community, a remote city in northern Canada, with a number 
of complex social problems, our programme was strongly personal and political.  Through 
the development of a summer camp for girls aged 11-17 we promoted self-esteem and 
leadership, deconstructed our experiences using our budding knowledge of feminism and 
politics, and promoted health and well-being.  When two of our programme leads 
unexpectedly became parents it troubled what I thought was an effective ‘health promotion 
technique’.  Our programme included sessions on sexual health, contraception and essentially 
many aspects of what would fall into the understood category of ‘prevention’ regarding 
young parenthood. Our funders were indeed interested in reducing unplanned conceptions as 
a programme outcome.  I wondered if our programme had failed.   
 
Over time, as I sat with my friends throughout their pregnancies and early motherhood it was 
clear that the skills and resources which formed a part of our programme were mobilised 
throughout their pregnancies and onwards in perhaps unexpected ways.  They managed 
motherhood in a manner contrary to the perceived young parent norm. For example, they 
drew on formal and informal local resources, actively participated in on-line forums, used 
feminist approaches to birth, continued with education, and essentially evaded much of what 
causes us to understand young parenthood as a social problem.  If our programme was 
evaluated on reducing conceptions alone it may have been considered a failure. I wondered 
however if my friends’ decisions to keep their children (what they really wanted, both were 
pro-choice) and their manner of managing their unexpected pregnancies possibly 
demonstrated programme benefits? While this is hard to say, what became clear to me was 
how what we measure matters, as do the questions we ask and the research outcomes we 
choose and value.  
 
I did not imagine finding myself eventually managing an RCT. The questioning that began 
through considering our young woman’s programme stuck with me throughout the process of 
the trial.  In my role as trial manager I was involved at most levels, from the research design 
meetings down to everyday trouble shooting with practice health care assistants and even 
acting as a ‘simulated patient’ where I underwent numerous HIV rapid tests.  Throughout the 




limits of the pragmatic design and how ‘pragmatic’ to be, what constituted the ‘real world’, 
and how and why we place so much trust in statistical methods. I wanted to better understand 
how we determined RCTs as the ‘gold standard’ and how contrasting data and other forms of 
‘knowing’ were approached in academia.   
 
When I started the PhD we did not know the results of the RHIVA2 trial and the research 
team felt unclear as to whether the intervention was ‘effective’ or not.  During the trial period 
the National Institute of Health and Care Excellence (NICE) released guidance supporting the 
recommendations evaluated in the trial, further establishing this approach as national 
guidance (NICE, 2001a; NICE, 2001b).  The adoption of opt-out testing as national policy 
and the positive results of the trial made the PhD research questions highly topical. In the 
face of a statistically negative trial we would have been looking for explanatory factors and 
troubling approved national guidance.  While the contextual aspects of trials are often 
explored to explain non-statistically significant trial findings, positive trials also contain all 
the variables explored in the instances of ‘failure’. Throughout the trial, our experiences, 
perceptions and rough calculations were not leaving us with clear impressions about the 
intervention. Some would say this is a good thing, because as researchers we should be 
neutral and unsure. However, post-statistical testing, rapid HIV testing as done in RHIVA2 
was deemed a ‘success’ and suddenly the need for explaining appeared diminished if not 
redundant. It was assumed the trial had located the ‘active ingredients’ that make the complex 
intervention of rapid testing in general practice successful and that the protocol could ‘plug 
and play’ in a similar setting.   
 
Despite feeling relief at the success of the intervention I felt unsatisfied with the conclusion 
as presented in formal reports of the trial.  It seemed reductive in the face of everything that 
had transpired in the process.  Much of what was observed is not presented in the published 
trial findings and there were information and complexities that seemed overlooked.    In the 
case of our trial and the small number of patients with reactive rapid HIV test results, a 
positive finding (that is, the finding that point-of-care HIV testing in UK general practice 
significantly increased the number of people identified with HIV at a treatable stage) hung on 
very few patients to produce the statistically significant results. As a result, this PhD explores 




of ‘data’ in the logic of the trial.  I hope to open up the trial and the intervention to learn more 
about how these results were produced as well as what it means for patients and providers to 
offer HIV testing in this way.  These tensions present the personal and professional setting for 
the work reported here.  
 
2.2 The policy context  
 
HIV testing in the UK   
At the time of writing, approximately 104,700 people are living with HIV in the UK (PHE, 
2015).  In 2008 it was estimated that 83,000 people were living with HIV in the UK and that 
one third of these infections remained undiagnosed (BHIVA et al., 2008).  Of those newly 
diagnosed, approximately 25% were presenting at a late stage in the infection3 (BHIVA et al., 
2008).  In the UK, two broad groups are consistently considered to be at ‘high risk’ for the 
contraction of HIV: men who have sex with men (MSM) and black Africans (NICE, 2011a; 
NICE, 2011b). 
 
Since AIDS was identified in 1982 (AIDS Gov., 2016), there have been constant transitions 
in the treatment possibilities and health care innovations surrounding the infection.  The virus 
has been recognised as a truly ‘biosocial’, where biological and social factors interact to 
generate variable forms of living with HIV (Persson et al., 2014).  The speed, scale and 
dynamism of the clinical, social and political picture of HIV have led many to consider it an 
epidemic unlike any other, garnering levels of unprecedented scientific, social and political 
mobilisation (Persson, 2013; Smith and Whiteside, 2010).  Presently, it is possible to be 
living well with HIV infection.  When individuals are aware of their HIV-positive status and 
able to access and adhere to treatment, survivorship dramatically increases and the potential 
for virus transmission decreases.  As a result of developments in the detection and treatment 
possibilities for HIV, greater emphasis has been placed on testing, particularly at an early 
stage, to improve life expectancy, reduce transmission and conserve health care resources 
(BHIVA et al., 2008). 
                                                
3 Late presentation for HIV is defined as a stage where CD4 count is less than 350 cells/µl or presenting with an 
AIDS defining illness.  Very late detection or advanced HIV disease is defined as a stage where the CD4 count 





In 2008 the British HIV Association (BHIVA), the British Infection Society (BIS) and the 
British Association for Sexual Health and HIV (BASHH) produced UK national guidance on 
HIV testing entitled the UK National Guidelines for HIV Testing 2008 (2008 National 
Guidance).  Amongst these recommendations was the promotion of opt-out HIV testing for 
newly registered patients in primary care in areas where more than 2/1000 people are living 
with HIV.  Increased testing of individuals accessing primary care services was 
recommended as a way of decreasing the late detection of HIV, reducing health care 
spending, and lessening mortality, morbidity and virus transmission (BHIVA et al., 2008).  
This recommendation informed the RHIVA2 trial and is an important aspect of the findings 
reported here, Part 1 of this PhD explores this guidance in depth. 
 
These recommendations reflected, and were concurrent with, a number of advances in HIV 
science.  Of prime importance was the finding that treatment can act as prevention by 
reducing the HIV viral load present in an individual to undetectable levels, therefore 
significantly lowering the likelihood of transmitting the infection (Cohen et al., 2011).  The 
evidence base to support this claim was established with the 2011 publication of the landmark 
HPTN 052 study (Cohen et al., 2011).  However, the HIV community had been attentive to 
these developments since at least 2008 with ‘The Swiss Statement’ (Vernazza and Bernard, 
2016; Vernazza et al., 2008).   This statement indicated that ‘An HIV-infected person on 
antiretroviral therapy with completely suppressed viraemia (“effective ART”) is not sexually 
infectious, i.e. cannot transmit HIV through sexual contact.” (Vernezza et al., 2008: p.1).  
This statement was said to hold if:  
•  the person adheres to antiretroviral therapy, the effects of which must be 
evaluated regularly by the treating physician, and  
•  the viral load has been suppressed (< 40 copies/ml) for at least six months, and  
•  there are no other sexually transmitted infections.’(Vernazza et al., 2008: p.1) 
Despite these positive developments, the treatment possibilities for HIV vary internationally, 
meaning care and nuance is required when broadly discussing HIV.  The consideration of 
HIV as a chronic treatable medical condition is only possible in the context of treatment and 




throughout the eighties and early nineties.  Despite access to free specialist medical services 
for HIV through the National Health Service (NHS) an individuals’ experience of HIV in the 
UK is highly variable and it is widely acknowledged that social and cultural factors strongly 
influence an individual’s ability to equally access and benefit from such services. Social 
support, poverty, multi-morbidities and other factors impact upon an individual’s ability to 
live well with an HIV-positive status (National AIDS Trust, 2014; Hodgson, 2014). 
 
Rapid, ‘near patient’ testing, where a test is carried out in close proximity to the patient and 
the results are provided within minutes, has been proposed as significantly advantageous for 
reasons including its portability, accessibility and speed (Prost et al., 2009).  Patients may be 
tested in more diverse locations, by a greater number of providers, and are likely to receive 
their diagnosis more quickly and easily.  Rapid delivery of HIV-negative results is also 
considered valuable by providing an opportunity for health education and by encouraging a 
‘know your status’ approach to HIV infection (National AIDS Trust, 2016).  
Correspondingly, rapid HIV testing is now offered in non-clinical setting by individuals with 
variable levels of expertise.  Such locations include community spaces such as churches, and 
additional medical settings such as dermatology clinics and accident and emergency units 
(Rayment et al., 2012). More recently, HIV testing is available at home with self-testing 
initiatives and the legal commercial sale of HIV testing kits (Stephens, 2014).  
 
While HIV testing has been available in general practice since early in the history of HIV, the 
manner of delivering testing has seen various transitions.  Rapid testing is relatively new to 
general practice in the UK and the routine offer of an HIV test to all new registrants in highly 
endemic areas, as suggested in the 2008 National Guidance, represents a new mode of offer.  
 
While such tests are considered simple to use and implement in various settings, their use has 
social meaning and alters practices, relations and diagnostic experiences.  Practices 
surrounding testing are in constant adaptation to testing and treatment technologies, making 
HIV a dynamic infection with multiple enactments influenced by location and circumstance 
(this will be further discussed in Part 1 of the thesis). Rapid testing is possible due to a long 




experience.  The way in which it is acceptable for individuals (not always patients) to be 
offered a test exemplifies these changes.  The reduced emphasis on pre and post-test 
counselling for HIV provides an example as it was once considered best practice and an 
essential activity to accompany the offer of a HIV test.  Since 2008, at least in some settings, 
pre and post-test counselling has been discouraged and is regarded as time-consuming and a 
hindrance to efficient testing (BHIVA et al., 2008; Cohan, 2009).  
 
Population screening approaches for HIV  
Screening can be defined as ‘a testing strategy that involves testing persons regardless of 
whether they have a recognised behavioural risk or presence of signs or symptoms of 
infection.’ (CDC, 2011: p.4). A characteristic of screening is that it is population based and 
may involve all individuals in a population or all those with a specific characteristic and tends 
to involve little interaction with patients in determining whether to offer a test (CDC, 2007b).  
Population screening for HIV is not an official screening programme endorsed by the UK 
National Screening Committee (UKNSC).   Despite this, the offer of routine opt-out testing 
for HIV to new registrants in a highly endemic borough, as was recommended in the 2008 
National Guidance, constitutes a population screening approach to HIV testing.   This method 
of offer is in contrast to previous HIV testing approaches, which have typically been ad hoc, 
triggered for example by patient characteristics or behaviours or by morbidity, such as a 
presentation of  indicator conditions for HIV infection such as pneumonia or shingles 
(BHIVA et al., 2008).  
 
In an attempt to diagnose HIV infections and initiate those testing HIV-positive on treatment, 
a push for routine testing of new registrants in primary care settings began in September 2006 
with the Centers for Disease Control and Prevention (CDC) in the United States. This 
followed on from policy shifts in 2001 when the CDC altered the protocol for pre and post-
test counselling, in an attempt to reduce barriers to testing (Branson et al., 2006). They also 
recommended screening high risk patients at least annually, removed the requirement for 
written consent for HIV testing, added HIV to the routine testing panel for pregnant women, 
and proposed third trimester screening in highly prevalent areas (Branson et al., 2006). 
Importantly, the CDC also indicated that wherever possible HIV testing should be opt-out 




‘In all health-care settings, screening for HIV infection should be performed routinely 
for all patients aged 13–64 years. Health-care providers should initiate screening 
unless prevalence of undiagnosed HIV infection in their patients has been 
documented to be <0.1%. In the absence of existing data for HIV prevalence, health-
care providers should initiate voluntary HIV screening until they establish that the 
diagnostic yield is <1 per 1,000 patients screened, at which point such screening is no 
longer warranted.’(Branson et al., 2006: p.4)  
These recommendations marked a distinct shift away from earlier best practice. This 
international precedence set by the CDC made way for more accessible and widespread HIV 
screening programmes, particularly in high resource settings.  
 
A similar policy was promoted in the UK in 2008 when BHIVA issued the aforementioned 
guidance indicating that in all areas where more than 2/1000 people were living with HIV, 
testing should be considered for all new registrants in general practice – the 2008 National 
Guidance (BHIVA et al., 2008).  It was this guidance that the RHIVA2 trial implemented and 
evaluated. The National Institute for Health and Care Excellence (NICE) echoed the 
recommendations in 2011, following a series of pilots conducted by the Health Protection 
Agency (HPA) (HPA, 2011; NICE, 2011a; NICE, 2011b). At this time the RHIVA trial was 
already underway. In 2008, 42 of the 152 local authorities across England had a diagnosed 
HIV prevalence greater than 2/1000 in 15-59 year olds and the policy was seen as a potential 
solution to the stated problems of undiagnosed HIV and late detection (PHE, 2014).  
 
In an aim to bolster the evidence base and explore the feasibility and acceptability of new 
modes of HIV testing in the UK national funding from the Department of Health (DoH) was 
granted to support pilots of HIV testing in non-traditional (largely community and A&E) 
settings. Separate to these DoH funded pilots was a small Medical Research Council (MRC) -
funded feasibility study of HIV testing (RHIVA1), which took place in a single general 
practice in a borough highly endemic for HIV.  A member of the RHIVA2 study team was a 
GP at this practice, and had just completed a borough-wide trial of screening for tuberculosis 
(Griffiths et al., 2007). This GP became the principal investigator of the RHIVA2 trial after 
collaborating on RHIVA1 and proposing a trial testing the impact of HIV testing in primary 
care – the RHIVA2 trial.  The main funding source for the RHIVA2 trial was the public 




Queen Mary University of London (QMUL), further elaborated the design of RHIVA2 with 
the director of public health, in collaboration with a consultant at the Department of Sexual 
Health at the local hospital.  The RHIVA studies will be further described later in the Chapter 
(See section 2.4). 
 
At this time, the HIV policy climate was one of experimentation and curiosity about the 
potential of population screening approaches to HIV.  A push of research on HIV testing in 
‘non traditional settings’ using new tools such as rapid tests was taking place across Britain 
with findings beginning to roll in and add shape to the UK HIV policy scene.   
 
2.3 The UK policy and research context  
 
In this section, I will briefly describe studies relevant to the policy context of RHIVA2 in the 
UK.  In 2009 and 2010 the HPA took on a number of pilots related to HIV testing outside of 
specialist settings.  Eight projects explored the expansion of HIV testing in the UK. All pilots 
had observational, non-experimental (uncontrolled) designs. Specific emphasis was placed on 
non-traditional settings and diverse testing models. Two pilot studies were held in primary 
care settings. Over an 8-month period in Brighton and Hove (where the HIV prevalence was 
7/1000), finger-prick rapid testing was offered to new patients aged 15-59 in 10 general 
practices. Patients were also asked to complete a questionnaire regarding their experience. 
2478 tests were offered with 1473 performed and two patients were identified as HIV 
positive. Practices were paid £500 to participate and £20 per test or questionnaire completed. 
Practice variation in offering tests ranged from 17% to 88% of eligible participants. The 
majority (88%) of patients found rapid testing acceptable as part of a new patient check. The 
research team concluded that the successful extension of testing was dependent on various 
factors including practice-level adaptation to variations on the new patient check as well as 
sufficient training and support for clinicians offering testing (HPA, 2011).  
 
In Lewisham, a similar pilot took place. The known HIV prevalence was 5.88/1000 in 2008. 
Of the 48 practices invited, 18 participated. Practices were paid £5 per test performed. Over 9 




patients were detected as HIV positive and one patient experienced a false reactive result. Of 
the 19 positive results, 5 were diagnosed at a walk in centre and not as part of the regular new 
patient check, 4 never transitioned into secondary care and most never revisited their GPs. 
The pilot highlighted challenges with data collection and estimated that INSTI testing adds 
one to five minutes of additional time onto a consultation (HPA, 2011).  
 
 
Overall, the pilots were viewed as a success and encouraged the push for the routine offer of 
testing, citing the rapid point of care method as an effective means. Cost analyses applied to 
the pilot data also allowed for estimates for endorsing routine testing of new patients in high 
prevalence areas as national policy. Estimates were placed at £1.6 million for the national roll 
out of routine rapid testing, at an average of £8 per test (HPA, 2011) A number of letters of 
support and news articles began to appear in publications such as the British Medical Journal 
(Gulland, 2011; O’Dowd, 2011)  
 
On September 1st, 2011 the House of Lords Select Committee on HIV and AIDS in the UK 
backed calls for the expansion of opt out testing (Select Committee on HIV and AIDS in the 
United Kingdom, 2011). Later in 2011, NICE issued clinical guidelines on the routine 
screening of new patients in primary care in high prevalence areas. This was contained within 
specific guidance for enhanced testing of high risk populations including men who have sex 
with men and black Africans (NICE, 2011a; NICE, 2011b). 
 
As the UK adopted clinical guidance on HIV screening in general practice and explored the 
data produced from the pilots, the RHIVA2 trial continued, enacting the policy in the form of 








2.4 The RHIVA studies  
 
The RHIVA1 feasibility and acceptability study  
The RHIVA1 study was designed to assess the acceptability and feasibility of offering rapid 
HIV tests to patients registering with primary care in a London borough with a high 
prevalence of HIV.  The study took place in 2007 and 2008 and was led by a single 
researcher. The RHIVA1 study aimed to determine whether the recommendation from the 
2008 National Guidance was feasible and acceptable both to patients and the primary care 
setting and test the rapid testing mechanism.  
The study took place in one large and diverse general practice in a highly endemic borough.  
Over a 6-week period all Anglophone and Francophone registrants between 18 and 55 were 
invited to participate in the study by undergoing a rapid HIV (saliva) test as a part of their 
new patient registration (Prost et al., 2009). Throughout the research period there were 111 
new registrants, of whom 85 were eligible for rapid HIV testing.  Of the 38 who agreed to 
have a rapid test, one patient had a reactive rapid HIV test which was later confirmed as HIV 
positive (Prost et al., 2009).  Patients were asked their reasons for declining or accepting tests 
and were also invited to participate in semi-structured interviews to explore their feelings 
regarding the acceptability of rapid testing in primary care, 20 patients agreed.  The study 
demonstrated that black African and black Caribbean participants were more likely to accept 
rapid testing than patients from other ethnic groups (Prost et al., 2009).  This was seen as 
positive as black Africans remain a ‘high risk’ group for infection and late diagnosis (NICE, 
2011b).  Participants listed a number of reasons for accepting and declining testing including: 
not being presently at risk, having recently had a test, being offered as a part of a routine 
check, reducing waiting times for results and the reduced stigma of attending general 
practices versus sexual health centres (Prost et al., 2009).  
 
Despite the overall positive acceptance of rapid testing, patients outlined some potential 
disadvantages, including the speed of the test, meaning patients may not feel adequately 
prepared for their results, inappropriate support for the newly diagnosed due to the primary 
care setting, the accuracy of the test and a concern regarding false reactive results and feeling 




recommendation of the GP.  All felt that the GP should be the professional who shares results 
with patients (Prost et al., 2009) 
 
The qualitative and ethnographic work in RHIVA1 revealed key challenges for 
implementation around the sharing of the test result, appropriate quality assurance and the 
time and space to adequately offer testing.  Overall, the research concluded that rapid HIV 
testing is feasible and acceptable during registration health checks within general practice 
settings. The offer of rapid testing in this way was recommended with caveats to ensure best 
practice, including quality assurance procedures, psychological resources for new patients, 
guidelines regarding patient confidentiality and clear referral pathways into secondary care 
(Prost et al., 2009). 
 
The RHIVA2 study of rapid HIV testing in primary care  
 
The RHIVA2 trial of rapid HIV testing in primary care followed the RHIVA1 study and 
aimed to further investigate the impacts of offering rapid HIV testing to new registrants in 
primary care settings in an experimental fashion.   Now that rapid testing had been shown to 
be feasible and acceptable in general practice, the trial aimed to determine if it was effective 
in diagnosing HIV at an earlier stage in the infection and in greater numbers.  At the time of 
the trial there was an acknowledged lack of quantitative, high quality evidence regarding the 
effectiveness of the HIV screening guidance being promoted by BHIVA and the CDC.  The 
trial aimed to contribute to the evidence base regarding HIV screening and to potentially add 
weight to the recommendations in the form of ‘gold standard (randomised trial)’ evidence. 
The pragmatic cluster RCT design was chosen due to the desire to see how rapid testing 
worked in its context of use.  In a cluster design, units such as hospitals or schools are 
randomised rather than individuals but analysis may still be at the individual level (Eldridge, 
2010).  The cluster design was chosen for various reasons.  There was concern regarding the 
cooperation of general practices, in that practices asked to offer testing to some patients and 
not others may find the intervention unethical.  Administratively, it is easier to deliver the 
intervention by organisation than by individual, speaking to the pragmatic design of the trial 




considered, as once practitioners are trained in offering rapid testing, they can’t ‘unlearn it’ 
and may feel conflicted offering testing to some patients and not others, additionally they 
may be ‘thinking HIV’ more than previously if a new HIV intervention is present in the 
practice, which may alter other HIV testing practices (Leber et al., 2015 personal 
communication, February 5). 
 
Over a 28-month period the trial took place in the same borough as the RHIVA1 study; 40 of 
a possible 45 eligible practices agreed to take part and were randomised to either intervention 
or control arms.  Intervention practices were trained to offer opt-out rapid HIV testing to 
newly registering adults whereas control practices continued with care as usual.  The primary 
outcome was CD4 count at diagnosis, an indicator of the stage of HIV infection.  The 
secondary outcome measures included the number of new HIV diagnoses, expressed as a 
rate, and the percentage of patients with a CD4 count less than 350 and 200, indicators of 
infection stage4. 
 
The intervention in RHIVA2 was not solely rapid testing, rather a complex, multifaceted 
educational programme for practice teams, promoting rapid testing   As described by a 
participant in the research presented here, rapid testing is a ‘cluster’; testing in this way has 
consequences for practice roles and algorithms.   Intervention practices received a 90-minute 
training session, delivered by me with a colleague (usually the local HIV nurse and 
occasionally a research team member GP or consultant).   The training comprised theoretical 
elements (the rationale for the study, HIV as a public health problem and so on) and a 
practical element (rehearsing phrases, practising rapid testing).   I often acted as a simulated 
patient or hired a community member to do so.  In order to be able to offer rapid testing, 
intervention, practice staff were required to attend the training and perform three rapid tests, 
two on a person and one with a serum sample that would indicate the presence of HIV-
positive antibodies.  These three practice tests were to be undertaken using the appropriate 
phrasing and with correct interpretation of the results.  If problems arose, I would usually 
                                                
4 The outcomes were changed mid-trial with the approval of the data monitoring committee as it was discovered 
the original sample size and subsequent power calculations had been incorrect.  This meant that the initial 
primary outcome, increased diagnosis of HIV, was no longer feasible. What had originally been a secondary 





spend time re-training and undertake more practice tests.   To assist study coordination, 
practices would select a lead for the RHIVA2 study, this was a nurse or health care assistant 
(HCA).   Training in quality assurance activities and research algorithms would take place 
with the practice lead at a separate one-hour session, led by me.  I would also administer a 
competency ‘quiz’ during this session and discuss any incorrect answers with the lead.   
Quality control procedures took place monthly for the first year of the trial and every three 
months for the remaining 16 months.  I installed dedicated ‘read codes’ on clinical computer 
systems at the intervention practices.  This was the mechanism with which the trial team 
captured practice-level performance data, meaning an additional component of intervention 




Rapid testing was to be offered as part of the new patient health check without any questions 
to patients about their risk factors for HIV.  The main phrasing taught in the RHIVA2 
training is show in Figure 1 below, in the reproduction of a slide from the GP training slide 
deck.  
 
Figure 1. Phrasing from the RHIVA2 GP education session training slide deck 
 
 
The new patient health check is a means to collect baseline health and lifestyle data on new 




where the RHIVA2 electronic template was added.  Raising the possibility of HIV to a 
patient during a new patient check represents a new method of offering HIV testing in the 
UK.  To a degree, this alters the nature of the appointment, as diagnostic testing is not 
normally a part of new patient registration checks.  In the case of giving reactive5 test results 
to patients, suggested phrasing was also provided.  This will be further discussed in Part 2 
and Part 3 of the thesis, where both provider and patient experiences of rapid testing are 
further explored.   Importantly, the RHIVA1 feasibility study indicated that reactive test 
results should be shared by the GP (Prost et al., 2009) and this was adopted in RHIVA2; 
providers of rapid testing were taught to immediately contact the GP if the rapid test was 
reactive, to ensure appropriately trained staff were sharing the results.  
 
A complex intervention is described as an intervention that contains several interacting 
components (Craig et al., 2008).   Such interventions contain multiple elements and 
evaluations often aim to determine which ‘active ingredients’ make such interventions 
effective (McMullen et al., 2015).   It is easy to conceptualise the intervention rolled out in 
RHIVA2 as solely the rapid test device. However, as described above, the test is enmeshed in 
context, as a part of the new patient health check to be delivered by HCA’s and nurses and in 
the primary care setting. Additional aspects such as quality assurance, the insertion of results 
systematically into electronic system templates, and communication, both with the research 
team and onwards, also formed a part of the intervention.  So while rapid testing may appear 
simple and easy to use, the confluence of activities and contextual aspects surrounding the 
test add to the complexity, as does the fact the test aims to identify HIV, which remains a 
highly stigmatised infection.  
 
The rapid test  
 
The INSTI™ HIV-1/ HIV-2 antibody test was the rapid point of care test used in the RHIVA2 
trial.  This single use rapid assay for the detection of antibodies to HIV virus types 1 and 2 is 
                                                
5 A reactive test on the INSTI™ test device indicates that there is a likelihood of HIV infection.  The term 




a 1-minute point of care rapid HIV test developed by bioLytical Laboratories and sold in the 
UK by Passante pharmaceuticals.   




The test requires 50 µl of finger-prick blood to produce a result.  The test kits come as a 
single packet including all the material elements required to perform the test on an individual.  
This includes a lancet, pipette, a membrane unit which will display the result and three vials 
of fluid including a sample diluent, colour developer and clarifying solution.   All materials 
are single use.  The finger is pricked with the lancet and blood is drawn into the pipette, the 
blood is then emptied from the pipette into Vial 1, the sample diluent.  This vial is then closed 
and shaken before being poured onto the well of the membrane unit.  Vial 2, the colour 
developer, and Vial 3, the clarifying solution, are then poured onto the membrane.  The test 
can produce four categories of result. A reactive result is indicated by the appearance of two 
circular dots, blue in colour on the membrane unit.  A non-reactive result is indicated by one 
dot, the control dot, at the top of the membrane unit.  An indeterminate result will 
demonstrate some blue colour, likely the shape of a hollow circle on the bottom of the 
membrane unit.  An invalid result may produce a number of results, such as no control dot, 
lines or strange colouring to the device etc.   The results are visualised in Figure 3. 
 







Trial results  
 
Throughout the RHIVA2 trial, intervention practices offered a total of 11,187 rapid tests, of 
which 4,978 (44.5%) were accepted.  There were 14 reactive tests and 11 were confirmed 
HIV positive.  Three were considered false reactives and were confirmed HIV-negative.  
Overall 43 patients were thought to be diagnosed as HIV-positive through both rapid and 
serology testing in intervention practices.  Of these, 11 had been previously diagnosed, giving 
a total of 32 new diagnoses in intervention practices during the trial period, including three 
cases identified through antenatal screening.  Control practices identified 21 cases of HIV 
through serology testing although seven had been previously diagnosed, leaving 14 new 
diagnoses, four of whom were diagnosed through antenatal screening.   
 
The mean CD4 count in patients diagnosed during the trial period was significantly higher in 
intervention practices than control practices after pre-planned sensitivity analyses.   The 
sensitivity analyses excluded patients diagnosed via antenatal screening and patients who had 
been previously diagnosed in the UK.   There was a non-statistically significant trend towards 
diagnosis of HIV at an earlier stage of infection in the intervention group over the control 




of HIV was statistically significant in intervention practices where the rate of diagnosis was 
four times higher than in control practices.  
 
The trial demonstrated the effectiveness of offering rapid HIV testing to new registrants in 
general practice in a borough with a high prevalence for HIV.  Promoting opt-out rapid 
testing in general practice led to an increased and earlier detection of HIV once antenatal 
screening and prior diagnoses were excluded.   Additionally, a high number of the cases 
diagnosed were in black Africans (62%) who are considered a high-risk and hard to reach 
group.  The final trial paper was published in the Lancet HIV in 2015, stating: ‘Promotion of 
opt-out rapid testing in general practice led to increased rate of diagnosis, and might increase 
early detection, of HIV. We therefore recommend implementation of HIV screening in 












Chapter 3: BACKGROUND TO METHODS 
 
3.1 Philosophical and methodological approach 
 
‘the initial moment of discovery in clinical or field bound situations (for those 
fortunate enough to have this experience) invariably evokes the sense that the whole 
project is turning to dust.’ (Fine and Deegan 1996: p.435 as quoted in Locke et al. 
2008: p.910) 
This study calls on different disciplinary traditions and modes of inquiry to produce a case 
study that elucidates why and how a particular intervention was deemed an effective 
mechanism for enacting national policy.  By bringing a range of different disciplinary lenses 
to the RHIVA2 trial, I will describe contrasting versions of the ‘same’ event.  These different 
perspectives have forced me to ask if the pragmatic RCT, and the evidence it produced, was a 
helpful way of interpreting and explaining RHIVA2.  What does the ‘pragmatic randomised 
controlled trial’ account of events tell us, what is left out of this ‘telling’, and does it matter?  
Is the particular account provided by the trial one that moves toward the aims of producing 
better care and evidence for patients and the health care system?  Are the different alternative 
accounts of this ‘same’ event complementary, non-coherent or otherwise? Exploring 
information drawn from different methods helps elucidate these questions through the 
provision of other knowable accounts or possible ‘evidence’ that both challenges and 
complements that produced by the trial.   
 
My entry point into questions of epistemology has been through exploring methodology.  I 
learned about different methods and the evidence they claim to produce without overt 
consideration of how these methods might be constructed and called upon to privilege 
particular modes of knowledge located in differing philosophical positions. Exploring 
methodology, versus methods, has meant learning more about how to think; what can be 
determined as ‘knowledge’ and ‘truth’ and claimed as the ‘real’.  I will consider ways of 
understanding knowledge, truth and reality, and what the consequences may be for the 






3.2 Ontology, Epistemology, Paradigm  
 
Within social science it is widely agreed that researchers approach their work and subjects 
through philosophical frames. The frames include perspectives on the nature of reality, truth, 
evidence and the best means for discovering and representing knowledge (Vasilachis de 
Gialdino, 2009). Ontology refers to the nature of being or reality, it is a branch of 
metaphysics concerned with existence (Law, 2004; Lincoln et al., 2011).  Ontology and 
epistemology are related and form parts of paradigms.  Ontology is often seen as the starting 
point for considering one’s philosophical position.  Epistemology is defined as the study of 
knowledge and justified beliefs; it considers how we know things to be true and how we 
come to these conclusions (Lincoln et al., 2011; Law, 2004; Hastrup, 2004). While ontology 
asks ‘what is reality?’, epistemology explores thought and knowledge with a concern for 
what constitutes our sense of justifiably knowable things. Methods are separate from but 
relate to epistemology as these are the means by which we come to know, and inform how we 
represent knowledge to publics (Denzin and Lincoln, 2011). 
 
Paradigms include ontologies, epistemologies and methods and are a space where these 
different levels of consideration coalesce to produce social realities.  Kuhn has defined a 
paradigm as ‘the entire constellation of beliefs, values, techniques and so on shared by the 
members of a given community.’ (Bryant, 1975: p.364 quoting Kuhn, 1962).  A further 
clarification by George Ritzer helps us see how this might be enacted in science:  
‘It is the paradigm that defines what the scientist should and should not study, the 
paradigm that tells the scientist where and where not to look for the entities of 
concern to him; the paradigm tells the scientist what he can expect when he finds, and 
examines, the entities of concern to him.’ (Ritzer 1975: p.5)   
Methods are often discussed as sitting within particular paradigms, though paradigms tend to 
be described less in regards to methods. The RCT, for example, is commonly cited as a key 
evaluative tool for production of evidence within the evidence-based medicine paradigm, 
linked to a positivist philosophical position (Goldenberg, 2006). Much discussion has taken 
place regarding the possibility of mixing paradigms and their contents: views and 






Denzin and Lincoln draw a distinction between paradigms and perspectives and indicate that: 
‘If paradigms are an overarching philosophical system denoting particular ontologies, 
epistemologies and methodologies, one cannot move easily from one to the other.  
Paradigms represent belief systems that attach the user to a particular worldview.  
Perspectives, in contrast, as less well developed systems, it can be easier to move 
between them’.  (Denzin and Lincoln. 2011: p.5) 
This point relates to debates in the research community around mixing methods and whether 
methods do in fact represent paradigms.  This tension will be discussed at points throughout 
the thesis.  First, I will briefly outline common positions on the philosophical spectrum.  
 
3.3 Positions on the philosophical spectrum  
 
Positivism refers to a philosophical position where reality is knowable, external and enduring 
(Lincoln et al., 2011; Law, 2004).  Within this paradigm the goal of science is to uncover the 
pre-existing reality of the world; knowledge is comprised of objective descriptions of this 
reality, making the truth empirical and proven by what we can observe and measure (Laudan, 
1996; Lincoln et al., 2011).  Positivist approaches often deal in facts and laws and typically 
rely on experimental and quantitative methods.   Scientific truths are supported with rigorous 
empirical data that follow laws and can be objectively described (Law, 2004).  The 1970s 
saw this paradigm subjected to wide critique, partially spawning the rise in alternative 
paradigms and methods (Denzin and Lincoln, 2011). 
 
Post-positivism is used as an umbrella term encompassing some of the approaches 
challenging and critiquing (rather than just amending or refining) positivist assumptions. A 
number of positions fall under this umbrella including subjectivism, interpretivism and 
constructivism (Denzin and Lincoln, 2011). These approaches tend to suggest that individuals 
construct the world through their experiences, perceptions and reflections on phenomena 
(Law, 2004).  This implies that there is not one knowable reality.  Knowledge and truth are 
constructed in relative and subjective ways. Post-positivist approach gained ground in 




understanding of social and cultural phenomena (Law, 2004; Denzin and Lincoln, 2011; 
Crotty, 1998).  The range of approaches that embrace constructivism consider that human 
beings shape phenomena through perceptions, interpretations, and symbols of meaning (Law, 
2004).  They attribute these to the world around them and their experience of it.  This means 
that knowledge and reality do not sit solely outside of individuals and that society is 
constructed through the interpreted meanings and understandings of human beings (Denzin 
and Lincoln, 2011; Law, 2004; Crotty, 1998).   
 
Interpretivists do not believe the world can be objectively observed but that our relationship 
to phenomena is socially mediated.  We attribute meanings to experiences and this relates to 
how we understand things to be true and accurate.  Interpretivists focus on naturalistic 
methods and value narrative, reflection and context (Greenhalgh and Russell, 2010).  
Depending on one’s orientation they will abstract or focus in on particular aspects of 
phenomena, demonstrating the role of the individual’s relative perceptions in understanding 
reality (Crotty, 1998; Bastalich, 2015).  Social Constructivists and interpretivists place 
meaning on language and interaction (Bastalich 2015).   This view holds that ‘all knowledge, 
and therefore all meaningful reality as such, is contingent upon human practices, being 
constructed in and out of interaction between human beings and their world, and developed 
and transmitted within an essentially social context.’ (Crotty,1998: p.42). Reality is relative, 
knowledge is subjective and hermeneutic; dialectical methods are often used to represent 
multiple truths and versions of reality (Lincoln et al, 2011; Law 2004). 
 
The critical perspective highlights the ways in which knowledge and its production are 
infused with power relations that have political implications (Denzin and Lincoln, 2011).  If 
the production of knowledge is reductive and selective and each research performance tries to 
organise information in a way that tells us something deemed important (from a particular 
perspective) then the political implications of knowledge production are more apparent 
(Hastrup, 2004).  Methods can sit within a paradigm that positions the method as able to 
produce information qualified as knowable.  However, in the process of ascertaining this 
knowledge there is a choice of what information to privilege and clarify, some information is 
inevitably left in the background, inexplicit and unaccounted for.   What is important is how 




of the method and the presentation of its results.  Knowledge may be transformed into a neat 
and useful piece of evidence ‘ready-to-use’ in particular paradigms, which reflects but may 
not explicitly acknowledge its creation within a particular mode of knowledge and inquiry.  
As stated by Harstrup: ‘knowledge, therefore is no simple ‘object’, because it bears all the 
marks of its institution, including a particular ‘style of reasoning’ that by itself becomes a 
standard of objectivity’ (Hastrup 2004: p.456).  This‘ knowledge’ may lend itself to creating 
evidence that better serves some populations, systems of belief and interpretations of the 
world than others, potentially contributing to the upholding of power amongst some groups 
and the repression of others.  
 
3.4 Methodology: Between philosophies and methods 
 
Before moving onto a description of the methods used within this project, I will outline my 
approach to methodology.  Here, methodology is defined as the set of assumptions, postulates 
and logics that inform the researcher’s inquiry and choice of methods (Hesse-Biber, 2015).  It 
can be seen as the design behind the choice of methods, or the construction of the ‘road map’ 
for the research (Crotty, 1998).  Throughout the PhD, I have felt in need of guidance in 
working with the different forms of data combined here as well as the modes of inquiry used 
to obtain it.   What became clear is that key ‘sensitising concepts’ have been integral in 
effectively thinking through the work presented here.  
 
Sensitising concepts in moving towards methods  
 
'in studying any set of phenomena directly, we pass them before our eyes in the 
attempt to discover recurrent patterns and, if possible, to make out the entire 
configuration of events...These recurrent patterns gradually crystalise into 
concepts.  Concepts result from the capacity of the mind to perceive the similarity of 
configurations perceived in succession.  Concepts may be defined as transposable 
perceptual patterns to which we have given names. Imagination is often called into 
play to fit together pieces of configurations, to perceive with insight configurations of 




There are 6 key sensitising concepts that inform the methodological approach of this PhD.  
They include: the experiment, the surplus, novelty, dwelling in doubt and tension, 
pragmatism and experience.  I will describe each below.  
 
The experiment  
 
‘Experimental systems are extremely tricky and thick arrangements, as it were.  One 
can see them as spaces of emergence – cultures of ‘access to an emergence’, in the 
words of Bachelard – as structures created by research in order to let things 
materialize that were not otherwise able to manifest themselves (to become thing-
able) and therefore thinkable.’ (Rheinberger, 2015: p.168) 
 
RHIVA2 was an experiment, a trial to see what would happen when we offered rapid testing 
to new registrants in general practice.  It was, however, a highly bounded experiment with 
pre-determined outcome measures ordered, primary, secondary etcetera.  I was drawn to the 
role as trial manager partially due to the drama of the experiment and its definitive claims.  I 
wanted to see how this study was going to work out, if the findings would be statistically 
significant, if people would be diagnosed with HIV, and onwards. The generative nature of 
the trial device troubled and intrigued me. Steven Brown describes experiments as devices 
that ‘have the basic structure of creating a situation of “ordinary people being challenged” in 
order to facilitate some form of learning experience.’ (Brown 2012: p.64).  He refers to 
experiments as social technologies that identify and organise individuals in a way that tries to 
isolate particular experiences, can be repeated and are ‘open for coding, such that what may 
be learnt from the experience is rarely as straightforward as those who articulate the 
challenges (i.e. the experimenters) may intend or those who enact the challenges (i.e. the 
participants) experience at the time.’ (Brown 2012: p.64). Brown quotes philosopher Isabelle 
Stengers on experiments to also describe them as ‘methods of inventing or creating new 
forms in which the world is deemed able to “speak” ’ (Brown 2012: p.64).  This, Stengers 
claims, requires a ‘complex game of construction and mobilization, where a network of 





A process of construction and mobilisation is, in many senses, what I thought my job was as 
trial manager, defining the bounds of the experiment, imparting knowledge, and inspiring 
actions to make the trial productive. While these authors are discussing the psychological 
experiment, broadening thinking about the experimental method beyond how it is described 
in the pragmatic trial appeals to me (this will also be taken up further in Part 3). It is with this 
view that the experience of the trial opens up and where I felt I could engage with some of 
the ‘surplus’, some of what the trial, the experiment, produced but was not made explicit in 
the trial design. In considering experimentality in this way, I am approaching the trial as a 
broad experiment, as a device that probes and creates with multiple effects. Annemarie Mol, 
in her work The Body Multiple, encourages us to consider methods as interferences and as 
mediators versus tools that uncover the truth of something.  With this view, she encourages 
us to consider not only ‘is this intervention effective?’ but also ‘what effects does it have?’ 
(Mol 2002: p.183).  
 
The surplus  
 
Attending to the effects of the trial beyond those intended requires paying attention to the 
‘surplus’ (Hastrup, 2004). In her article ‘Getting it right: Knowledge and evidence in 
anthropology’, Kirsten Harstrup discusses the nature of evidence in a ‘post-positivist era’ 
(2004).  She argues that is it not supportable to consider evidence as external to the context of 
a moment or relation:  
‘‘Knowing is a matter of perspective; there is no knowledge without someone who 
knows in a particular way.  Knowledge, therefore, is a social phenomenon rather than 
simply a substance.  To maintain scholarly authority one must be able to account for 
the particular mode of interest that gives direction and shape to knowledge’ (Hastrup 
2004: p.146). 
She goes on to discuss ‘anthropological knowledge’ (Hastrup 2004: p.458) as emergent, 
without an ontological status.  She points out, quoting Diley, how we tend to treat context and 
situation as objects that can be added and removed from scenarios.  She continues, quoting 
Daston, on how facts are transformed into a particular kind of knowledge - evidence - and 
how as a result they lose their status as facts since persuasion has been attached (Hastrup 




‘fieldwork discloses the fact that there is always a historical surplus of events, actions 
and thoughts that may linger without necessarily contributing to the larger order as 
perceived, but providing possible sites of resistance or sources for new historical 
turns’ (Hastrup 2004: p.464).   
What she describes here resonated deeply with what I feel this PhD moves towards, the 
surplus from my initial inquiry and the surplus of the trial, the data emerging from RHIVA2 
that never gained status as data, evidence, or was even recognised as information by the trial 
logic. When the trial is explored through a different set of epistemological assumptions and 
methods, new ways of considering the impact of the trial, with implications for the pragmatic 
trial, may be demonstrated and spaces opened up that seemed closed down or non-existent 
when thinking with the trial logic alone.   
 
Another dimension of Harstrup’s considerations also resonates strongly with my process 
throughout this study.  She discusses the role of the ethnographer as a form of ‘double agent’, 
acting as a researcher on the one hand and in the role required by the environment on the 
other.  Within this, she discusses the importance of ‘living the character’ and essentially 
buying into the assumptions and the logics in the setting under study.  In my case, the ‘buying 
in’ was easily done in my role as trial manager and in living through what often felt like the 
‘dysfunction’ of the trial. The tension between my questions (described in Chapter 2: 
Background) and the trial is what initially inspired this PhD.    Hastrup describes this role:  
‘The point is to get away from the dualism of thought and action in recognition of the 
fact that knowledge is practical, and that theoretical or abstract knowledge is a special 
case of this (Jenkins, 1994:442).  This is a correlate to claiming there is no opposition 
between practical (material) experience and its theoretical (linguistic) rendering: they 
are deeply implicated in one another.’ (Hastrup 2004: p.466)  
The process of acting and thinking the research means it can be difficult to untangle where 
methods end and analysis begins. 
 
Novelty and ‘being a beginner’  
 
I have come to consider my ‘beginner’ status as a key aspect of the work presented here.  




also new to the UK and had very little work experience in London or the health care system.  
In ‘The Structure of Scientific Revolutions’ Thomas Kuhn describes ‘the normal science’ 
(1962), where work is undertaken in an established paradigm or explanatory framework 
which the scientific community acknowledges as foundational.   As a beginner in this field, I 
was unaware of the ‘normal science’ of trials. This is relevant in that I was often unsure of 
where and how to attune my focus, questions and observations.  While experience and 
knowledge may allow us to see depth and nuance, I feel that my attention to particular 
dimensions of the trial was a result of not knowing what was ‘normal’ or of having 
entrenched ‘habits’ or tacit understandings of how things worked.   This naïvety, while 
sometimes difficult, meant I often could not filter out what was or was not important and may 
have contributed to some of the most productive research tensions, which inspired the 
approach to methods here.  One common feeling was that of doubt, sometimes in myself, in 
our interventions potential, in the positivist approach, and onwards. 
 
Dwelling in doubt and tension  
 
‘This feeling of unsettledness causes us to start and sustain our inquiry. Doubt is an 
experiential signal that there is a need to reconsider and revise our ways of 
understanding’ (Anderson 2005, Hildebrand 1996)’ (Locke et al. 2008: p.910) 
My position as a beginner relates to a passage encountered in the article ‘Making Doubt 
Generative: Rethinking the Role of Doubt in the Research Process’ by Locke et al., a text 
which highlights another important dimension of my methodological process (2008).  Here, 
the authors discuss the generative potential of doubt to improve theorising.  In valorising 
abductive reasoning, as opposed to induction or deduction, space is opened for speculation, 
conjectures, and assessments of plausibility, which they articulate as a part of the abductive 
process, described in the quote below. This sits in contrast to hard facts and pre-set truths, 
emphasising the emergent and the ‘unanticipated and unexpected’, with an explicit role for 
emotion (Locke et al. 2008: p.908).  In describing the pragmatic philosopher Peirce’s 
description of doubt they write:  
‘Pierce indicates (CP 5:394) that he uses ‘doubt’ ‘to designate the starting of any 
question, no matter how small or great’, and ‘belief’ to designate the resolution of it.  
“Beliefs, as doubts which have been resolved, are the habits of interpretation and 




received, they represent continuance and are the steady state of our everyday 
understanding, living, and working: we engage the world with habit-laden ways of 
apprehending that are developed in the course of our lives.  Doubts, on the other hand, 
arising when that continuance is interrupted, represent a potential inadequacy in these 
habitual ways of understanding and acting. Doubt is the ‘privation’ of habits.  As 
“privation”, doubt represents a “condition of erratic activity” (CP 5:417); its irritation 
excites the “action of thought” that only ceases when “belief is attained” (CP 5:394) 
when the questioning is resolved.’ (Locke et al. 2008: p.908). 
In retrospect, and without any intended negative association, I doubted the research process 
we were engaged in throughout the trial.  While I did not doubt that the trial was being 
enacted ‘correctly’, I doubted its ability to adequately describe events and account for the 
‘scientific and the social’ as claimed by the pragmatic trial design.  The more open process of 
abduction is an appealing approach to methods and the project as a way of exploring this 
broad phenomenon.  
 
Pragmatism vs. pragmatism  
 
‘The principle of pragmatism, according to James, was first enunciated by C.S. 
Pierce, who maintained that, in order to attain clearness in our thoughts of an object, 
we need only consider what conceivable effects of a practical kind the object may 
involve.  James, in elucidation, says that the function of philosophy is to find out what 
difference it makes to you or me if this or that world-formula is true.  In this way 
theories become instruments, not answers.’ (Russell, 1996: p.727) 
When beginning the trial, I thought the pragmatic key of the trial related to demonstrating the 
overall utility of an intervention in context.  I believe this to be a generally accurate and 
widespread understanding of what the pragmatic trial refers to.  As I engaged in PhD-level 
inquiry, I started to learn about pragmatism as a philosophical stance. I wondered how the 
two forms of pragmatism relevant to my work were related.  In considering the ‘pragmatic’ 
trial and in what sense it aims to be pragmatic, I was struck by a line in Bertrand Russell’s 
lengthy History of Western Philosophy.  In describing the work of James, a seminal 
pragmatist, he writes: ‘our obligation to seek truth is part of our general obligation to do what 
pays… We cannot reject any hypothesis if consequences useful to life flow from it’ (Russell, 
1996: p.728).   As the pragmatic trial aims to evaluate interventions in their context of use, in 




way? Are the consequences useful?   However, which consequences we attend to, and which 
productive experiences we evaluate affects the question.   Despite this resonance, additional 
dimensions of pragmatist philosophy seemed in sharp contrast to the logic of the pragmatic 
trial.  These may include, the emergent nature of reality, reality as non-static, and emphasis 
on abductive reasoning.  As will be discussed later, in Part 3 of the thesis, pragmatic trials 
retain enough of the RCT logic – that reality is positioned as external, enduring and 




If a pragmatist philosophy emphasises experiences - events as constitutive of consciousness 
and beings as ‘the experiences we have’ (DeForge and Shaw, 2012: p.88) - applied to this 
project, it asks what forms of experience are produced by an experiment such as a pragmatic 
trial of a population screening programme.  If ‘truth as practical consequences’, is a 
pragmatist approach to the real, what are the ‘real world’ consequences of a population 
screening programme for HIV rolled out as a pragmatic randomised controlled trial? 
 
The emphasis on ‘experience’, as the generative goal of an experiment, as comprising ‘the 
surplus’, as the ‘interferences’ of methods and, in pragmatism, as constitutive of practical 
consequences, beings and the real, demonstrates how experience is an object of study in this 
research. In exploring experiences related to the population screening intervention for HIV 
and the pragmatic trial, I am not seeking to reveal the whole ‘truth’ of the trial or of the 
impact of population screening programmes. At best, I aim to explore some of the 
consequences or experiences produced by the intervention and their impact on general 
practices, staff and patients.   This approach resonates with the concepts outlined above and a 
loosely pragmatist approach to knowledge, where ‘pragmatism would not seek to identify any 
real causes as such, the methodological guidance it provides simply leads us to focus on 
different things – in this case, on contextualized experiences that inform the consequences of 




Chapter 4: METHODS  
 
 
‘Studying methods empirically, then, generates another understanding of what they 
are. No formal guarantees, but specific mediators, interferences.  The question to now 
ask is how they mediate and interfere.’  (Mol 2002: p.155) 
While using multiple methods has been a challenge, it has also provided some of the more 
interesting insights and findings of the project, which should become apparent throughout the 
thesis. Having already described my sensitising concepts and discussed the philosophical 
underpinnings of methods, I will now describe the methods used to collect the empirical data 
analysed in this PhD. It is my hope that the accounts produced through these methods will 
allow for a ‘thick’ description of the experience of a rapid HIV testing trial in general practice 
(Geertz, 1973).  
 
4.1 Case study  
 
‘A case carries knowledge, not in the form of firm rules or statistically significant 
regularities, but in the form of a story about an occurrence that, even though it may 
have happened just once, is still telling, indicative, suggestive.  It condenses 
experience that is not general, but inspirational.  As cases are idiosyncratic, those who 
seek inspiration from them still have to think for themselves.  They have to adopt the 
lessons learned to the situation in which they find themselves.  Cases, then, do not 
transport knowledge smoothly.  It requires work to draw on them.  The implications 
here of a case that occurred elsewhere, have to be carefully thought through and 
tinkered with.  Such tinkering may serve highly varied goals.’  (Mol, 2015: p.2) 
 
The main research method used in this PhD is case study.  Principally, this is a case study of 
a rapid HIV testing trial in general practice.  However, case study is also used in other ways 
throughout the PhD, for example in Part 2, where four case studies of general practices with 
varying performances in innovation implementation are developed and in Part 3, where 
patient cases are presented, as a result, case study is understood as an overarching method for 





Case study allows for ‘in depth, multi-faceted explorations of complex issues in their real life 
settings’ (Stake 1978: p.5).  The RHIVA2 trial demonstrated the overall efficacy of rapid 
testing in achieving key indicators such as the early detection of HIV. However, 
understanding the complexity of practice level characteristics such as patient demographics, 
practice size, culture and attitudes towards testing, while including trial performance data, 
demands a methodology that accounts for complexity and a diversity of data types.  Stake 
discusses case study as strongest ‘when the aims are understanding, extension of experience, 
and increase in conviction’ (Stake 1978: p.5).    He describes case study as:  
‘descriptions that are complex, holistic and involving a myriad of not highly isolated 
variables; data that are likely to be gathered at least partly by personalistic 
observation; and a writing style that is informal, perhaps narrative, possibly with 
verbatim quotation, illustration and even illusion and metaphor.’ (Stake, 1978: p.7) 
While case studies may include statistics and quantitative data, what is central to the method 
is the ability to draw on experiential knowledge and multiple data sources to develop a deeper 
understanding of complex human phenomena (Stake, 1978; Mol, 2015). 
 
In discussing what knowledge is best gained from case study method, Stake contrasts tacit 
with propositional knowledge.  He describes propositional knowledge as mostly gained 
through observations of objects and events, while tacit knowledge also includes the 
knowledge gained from one’s experiences of these events and their ruminations about them 
(Stake, 1978).   The RHIVA2 case study allows for the inclusion of both tacit and 
propositional knowledge about HIV testing in primary care, as the work presented here 
combines my lived experience of the trial, testimonies of the experience of patients and 
providers, ethnographic data and also quantitative data in the form of results from RHIVA2.  
 
Undertaking a case study can be broken down into five general phases of work. Of primary 
importance is defining the case. This requires articulating the boundary of the case which 
includes the population or site, the time period, geographical area of interest and the types of 
evidence needed.  This may include the inclusion of theory. Second is selecting the case. 
Case study sampling might include deviant or atypical sampling or some other selection 
method; case studies are not normally chosen at random (Flyvberg, 2006).  Data collection is 




qualitative and quantitative spectrum.  While researchers are cautioned about over-collection 
there should be multiple sources of data to add validity and the potential for triangulation 
(Crowe et al., 2011).  Analysing and interpreting the data can be a long and immersive 
process.  It is suggested that for collective case studies, cases are looked at independently of 
each other primarily and analysed together only after in-depth engagement and interpretation 
of each individual case.   Commonly used in analysis is the framework approach articulated 
by Spencer and Ritchie (Spencer and Ritchie, 2003).   The role of theory in the case study is 
quite important at this stage, as this may be the point where theory testing or development is 
articulated (Crowe et al., 2011).  Finally comes reporting the findings.  Here is where a 
cohesive narrative and instructive example is offered to the target audience.  Readers should 
have enough information about the case and the context to be able to evaluate the data 
collection and sampling methods but also be offered some overarching analysis which allows 
for greater overall insights into phenomena (Crowe et al., 2011).  The ethical considerations 
of case study are dependent upon which methodologies and data collection practices are 
employed in building the case, different cases will have unique ethical considerations which 
may include anonymising data, gaining agreements and permissions, managing the role of the 
research sponsor, and negotiating the use of data and the extent of publication with 
participants, amongst other considerations (Simons, 1989). 
 
 
The N of 1 
 
A commonly cited limitation of case studies is a lack of generalisability. It is argued that case 
studies are informative about that which they directly investigate but that these findings can 
rarely be extended beyond the case to larger populations. When compared to experimental 
studies that aim to produce widely generalisable results, it does appear that case studies are 
small in their applicable scope.  However, Stake proposes that what causes case studies to be 
ungeneralisable in some senses (discussion of the specifics, the subjective and the 
experiential) is paradoxically what allows them to be generalisable (Stake, 1978).  He argues 
that they are ‘naturalistically generalisable’ due to their epistemological coherence with the 




‘naturalistic generalisation, arrived at by recognising similarities of objects and issues 
in and out of context and by sending the natural covariations of happenings.  To 
generalise this way is to be both intuitive and empirical, and not idiotic.’  (Stake, 
1978: p. 8) 
Investigating the ways national HIV testing policy was implemented in one borough, with 
emphasis on intervention adoption and overall performance, may be instructive to other 
boroughs which share similar patterns of HIV epidemiology and qualify for the BHIVA and 
NICE guidance. The shared health system, policy guidance, likeness of epidemiological 
factors and location within the same city may mean that there is greater likelihood for 
effective generalisability.  On a larger scale, the explicit inclusion of theoretical approaches 
such as the diffusion of innovations model by Greenhalgh et al. (see Part 2) aims to extend 
the utility of the findings through the suggested theoretical benefit of insight generation 
across domains.  
 
In her article ‘In praise of small N, and of N=1 in particular’, Lindsay Prior outlines some of 
the strengths and benefits of studies that use a single exemplar.  Listing five key factors she 
describes how such studies can be seen as a ‘natural kind’, where a single case can ‘contain 
and exemplify the essential characteristics of its kind and a study of one is, in so many ways, 
a study of all’, allowing us to be informed ‘about the essential features of a much larger 
category’ (Prior, 2016: p.115-116).  N=1 studies can also ‘focus entirely on the specificity 
and singularity of the case because its unrepeatable nature is of critical importance (Prior, 
2016: p.116), such as the disastrous space shuttle Challenger launch, which crashed and 
therefore prompted intense investigation so that any like error could be avoided (Prior, 2016).  
Such studies may also: 
‘explore the multiple intricacies and interconnections that arise both within the case 
and between the case and the world’ and finally ‘the single, isolated ‘1’ can, if 
required, be used a disconfirming instance of some generalisation or other, i.e. as one 
of Karl Popper’s black swans’ (Prior, 2016: p.116).  
Flyvberg also discusses how the instructive value and ‘force of’ example is underestimated in 
research (Flyvberg, 2006).   He goes as far to say that generalisation is overvalued as a source 
of scientific development and quoting Beveridge asserts that ‘more discoveries have come 
from intense observations that statistics applied to groups’ (Flyvberg, 2006: p.35).  He also 




illustrative example of the black swan.  If ‘all swans are white’, the discovery of a black swan 
invalidates a generally held belief, also indicating that ‘what appears to be ‘white’ upon 
closer examination often turns out to be ‘black’ (Flyvberg, 2006). 
 
The BioMed Central review of case study methodology indicates that other limitations to 
case study method might include lack of scientific rigour, subjectivity and over-collection of 
data (Crowe et al., 2011).   They indicate methods of mitigating these limitations, which 
include an emphasis on transparency.  This can be achieved through ‘describing in detail the 
steps involved in case selection, data collection, the reasons for the particular methods 
chosen, and the researcher’s background and level of involvement’ (Crowe et al. 2011: 
p.100), including clarity about how the researcher influenced and has been influenced by the 
study.   My role in the RHIVA2 trial was trial manager, which meant regular in-depth 
engagement with the practices and the research team. I had a vested role in the study and a 
specific relationship with the practices but also a front row seat and active experience of 
trying to implement HIV testing policy.  Here we see the strength and problem of experiential 
data collection as the depth of tacit knowledge could not have been achieved without this 
role, however a set role within the process invalidates any claim to neutrality.   
 
 
Telling stories  
 
Many of the methods used to answer the main research question and sub-questions (listed in 
Table 1) are aligned with research that ‘emphasizes episodes of nuance, the sequentiality of 
happenings in context, the wholeness of the individual’ (Stake, 1995: p.1).  In other words, 
they acknowledge the subjective nature of human experience and reality and embrace these 
particularities, versus placing emphasis on causality and representative sampling. However, 
the scientific objective of gaining insight remains. The lack of objectivity forms a part of the 
methodological approach, emphasising that the thoughts and impressions of the researcher 
are an important source of data. Qualitative approaches acknowledge that knowledge is both 
internally and externally derived (Gomm et al., 2000).  As pointed out by Richard Winter in 
his creative discussion of case study in ‘Fictional-critical writing: an approach to case study 




it- in anecdotes, jokes, dreams, ambitions, and gossip.’ (Winter,1986: p.176).  This 
articulation of the ways we collect, reflect upon and share our experiences demonstrates the 
importance of qualitative data and the usefulness of the case study methodology in 
developing understanding.    
 
Much of the qualitative work, which comprises a part of my case studies, manifests itself in 
the way described above, as nurses, health care assistants, patients and GPs reflecting upon 
their experiences and sharing anecdotes.  At once, one learns about their layered interactions 
with rapid HIV tests, how it made them feel, the conflicts it encapsulates, the interactions 
with patients, the arguments about how to roll it out within the surgery, and onwards.  It is 
only by including these ‘stories’ as data that we are able to see what information they store in 
regard to rapid HIV testing in primary care and what the innovation in action actually 
presents as to those enacting it.   The stories help to complete the larger picture of the trial, 
ripe with various players, contexts and dynamics that come together to determine the 
theoretical possibilities around a policy and intervention in action.  
 
Finally, the use of case study as an appropriate method, despite its strengths and limitations, 
is relative to the fit to the research question.  Case study has the ability to sit on a continuum 
between the objectivist and subjectivist approach based on the data utilised. The trial 
demonstrated the efficacy of testing but does not capture the level of implementation or the 
challenges faced in rolling out the intervention. To answer the central questions of the 
research project, engagement with the messy work of policy in practice is required, and this 
links well with the case study method for the reasons articulated in the above discussion.  
Overall, the wider project demands an interpretivist approach, employing qualitative 
methodologies to paint a rich picture of a policy from articulation to action and of the role of 
an experimental trial within that evolution. 
 
The broad case presented here is comprised of three sub-studies with emphasis on the 
synthesis of the findings from each.  The sub-studies take place at the policy, provider and 
patient level (Parts 1,2,3 of the thesis) and aim to trace the RHIVA2 trial and its interventions 





As mentioned above, data sources will be discussed separately in Parts 1, 2 and 3 of the 
thesis, preceding the findings chapters presented in each.  This approach was chosen to 




While case study forms the broad method used in the PhD, another overarching method is 
autoethnography. Carolyn Ellis and colleagues describe autoethnography as a combination of 
autobiography and ethnography where personal experiences are described and systematically 
analysed in order to better understand culture (2010).  She understands the turn to 
autoethnographic methods as a response to the critiques of canonical ideas about research 
conduct and the growing field of cultural studies and its critique of the ‘view from nowhere’: 
‘Autoethnographers recognize the innumerable ways personal experience influences 
the research process.  For instance, a researcher decides who, what, when, where and 
how to research, decisions necessarily tied to institutional requirements (e.g. 
Institutional Review Boards), resources (funding), and personal circumstances (e.g. a 
researcher studying cancer because of personal experience with cancer)…. 
Consequently, autoethnography is one of the approaches that acknowledges and 
accommodates subjectivity, emotionality, and the researcher’s influence on research, 
rather than hiding from these matters or assuming they don’t exist.’ (Ellis et al., 2010:  
p.2)  
Personal experience is reflected upon and written up.   The experiences reflected upon were 
not assembled as part of a research project, but constitute elements of the author’s life.  As a 
result, this process is usually done in hindsight and intentionally infuses emotion, personal 
detail and factual information about the events or phenomena under consideration. This 
process is described in the quotes below: 
‘When writing an autobiography, an author retroactively and selectively writes about 
past experiences.  Usually, the author does not live through these experiences solely 
to make them part of a published document; rather, these experiences are assembled 
using hindsight.’ (Ellis et al., 2010: p.2)   
Leon Anderson aims to articulate different forms of autoethnography in his article ‘Analytic 




‘evocative’ autoethnography proposed by Ellis et al., which he describes as becoming 
popularised alongside the post-modern critique of anthropology.   Analytic autoethnography 
is suggested as an alternative to ‘evocative’ autoethnography in that it aims to be ‘consistent 
with qualitative inquiry rooted in traditional symbolic interactionism’ (Anderson, 2006: 
p.374).   Anderson outlines analytic autoethnography’s five key features, including, 1) the 
researcher is ‘complete member researcher (CMR), (2) analytic reflexivity, (3) narrative 
visibility of the researcher’s self, (4) dialogue with informants beyond the self, and (5) 
commitment to theoretical analysis.’ (Anderson, 2006: p.378).   In relation to Anderson’s 
criteria, my work fulfils the criteria of analytic autoethnography and is aligned with this 
description to a greater degree than ‘evocative autoethnography’.  I will briefly describe how 
my work fulfils the criteria. 
 
Anderson stipulates that analytic autoethnography requires that the researcher be a ‘complete 
research member’, linking to the experiential knowledge of the phenomena being explored. 
As the only full-time staff member of the RHIVA2 research team I spent each day 
implementing and managing the trial.   Progressing from a part-time research assistant to the 
full-time trial manager I had a close relationship to many of the trial actors and a close view 
of what was taking place day to day.  As described in the Introduction and Background, my 
regular activities included all that made the trial ‘work’ along with fulfilling many of the 
bureaucratic activities associated with working in research. Much of the reflection informing 
this PhD pulls on this experience.   
 
For a time, the autoethnographic approach was unintended in that I had no aim of conducting 
the research presented here.  At some point I became interested in the process and began 
collecting more extensive field notes. As a plan for a proposed PhD project developed, the 
ethnographic work become more intentional. Hundreds of hours of ethnography were 
undertaken.  My prior experience working on the trial also impacted my perceptions and 
interactions throughout the PhD research.  When interviewing providers, we had pre-existing 
relationships: I had a good knowledge of their practices and in some cases their colleagues; I 
had observed many of them performing tests; I had provided the training on the use of rapid 




on EMIS, amongst other activities.    This experience qualifies me as a ‘complete research 
member’ in the view of Anderson’s criteria for analytic autoethnography.   
‘It entails self-conscious introspection guided by a desire to better understand both 
self and others through examining one’s actions and perceptions in reference to and 
dialogue with those of others.’ (Anderson 2006: p.382)  
Throughout the trial and the PhD, I have engaged in reflexivity.  This has been hopefully 
reflected in the presentation of the findings herein.  I have aimed to be a reflexive researcher 
in regards to the phenomena under study but also throughout the process of the research 
itself.  The engagement with theory and the analytic process described throughout relates to 
this criterion.  
‘A central feature of autoethnography is that the researcher is a highly visible social 
actor within the written text.  The researcher’s own feelings and experiences are 
incorporated into the story and considered as vital data for understanding the social 
world being observed.’ (Anderson 2006: p.384)  
I have included my reflexive narrative in an obvious way by using the first person tense and 
actively including emotion and subjectivity as an integral aspect of my research philosophy, 
process, analysis and presented conclusions. I have not claimed neutrality nor a view ‘from 
nowhere’.  Aligning with my analytical themes of ‘doubt’, ‘the surplus’ and ‘experience’ 
(See Chapter 3) - all of which rely on a situated, thinking, feeling researcher - I have been 
explicit about my desire to consider subjectivity as essential to my research process.  
‘The ethnographic imperative calls for dialogue with ‘data’ and ‘others’. (Anderson 
2006: p.386)  
‘Unlike evocative autoethnography, which seeks narrative fidelity only to the 
researcher’s subjective experience, analytic autoethnography is grounded in self-
experience but reaches beyond it as well.’ (Anderson 2006: p.386)  
A number of formal qualitative interviews have taken place with providers, patients and 
policy makers (N=42) and these interviews form a key data source for the work presented 
here. Throughout the period of the trial and the PhD I have also engaged with various 






Anderson describes how the intention of analytic autoethnography is to contribute to large 
understandings of social phenomena through improved theorising.  He is sure to articulate 
that this is not to produce ‘unbeatable conclusions’ (Anderson 2006: p.388), but to contribute 
to a ‘spiraling refinement, elaboration, extension and revision of theoretical understanding’ 
(Anderson 2006: p.388). A number of different theoretical perspectives have been employed 
throughout the PhD to account for the findings presented here.   In some cases, these theories 
have been extended - such as in Part 2, the organisational study - based on the findings 
presented.  In other areas the theories provide frames for which to make both theoretical and 
applied contributions (Part 2, Part 3). 
 
Case study and autoethnography form the overarching methods used in the thesis.  Each sub-
study, comprising the larger case study, draws additionally on different methods to construct 
the findings.  Below, I will describe discourse analysis and qualitative interviews before 
concluding with a description of process evaluation.  
 
4.3 Discourse analysis: Parker’s model as adapted by Shaw 
 
Discourse analysis is a broad and varied analytic method with substantial origins in 
linguistics and popularised in sociology and the political sciences by Foucault (Fairclough, 
2003). Discourse can be broadly considered as: 
‘a level of component of language use, related to but distinct from grammar.  It can be 
oral or written and can be approached in textual or sociocultural and social-interaction 
terms.  And it can be brief like a greeting and thus smaller than a single sentence or 
lengthy like a novel or narration of personal experience and thus larger than a 
sentence and constructed out of sentences or sentence-like utterances.’ (Sherzer, 1987: 
p. 296)  
Foucault has acknowledged his role in the development of the term discourse, adding: 
‘I believe I have in fact added to its meanings: treating it sometimes as the general 
domain of all statements, sometimes as an individualizable group of statements, and 
sometimes as a regulated practice that accounts for a number of statements.’  
(Foucault as quoted by Fairclough, 2003: p.123) 
Shiffrin at al., in their introductory text to discourse analysis, describe the method in three 




as the study of ‘social practices and ideological assumptions associated with language or 
communication’ (Shriffin et al., 2009: p2).   The third approach, the sociocultural approach, 
appears most relevant to the work undertaken here as it places emphasis on the ‘general 
characteristics of speech/ discourse communities’ (Shriffin et al. 2009: p.2). This critical 
approach questions the position of discourse subjects and the ways discourses impact upon 
and maintain power.  Sara Shaw, whose adaptation of Parker’s framework is drawn upon in 
this chapter, describes discourses analysis as:  
 ‘the study of social life, understood through analysis of language in its widest sense 
(including face-to-face talk, non-verbal interaction, images, symbols and documents).  
It offers ways of investigating meaning, whether in conversation or in culture.’ (Shaw 
and Bailey, 2009: p.413) 
Shaw and Bailey outline four approaches to discourse analysis.  Firstly, a micro level analysis 
would include a close look at language in use and draw from conversation analysis 
techniques (Shaw and Bailey, 2009).  Analysis in this case may explore discourse from 
moment to moment between two participants with an emphasis on uncovering ‘cultural and 
communicative patterns’ (Shaw and Bailey, 2009).  Meso-level analysis places focus on 
broader contexts yet may include face-to-face analysis (Shaw and Bailey, 2009).  This 
includes social and cultural norms.  Macro studies look at wider society and its ideologies and 
how language plays a role in shaping social possibilities (Shaw and Bailey, 2009).  This can 
include knowledge construction and its link to what it is possible to imagine and therefore 
enact.   Finally, discursive analysis tends to be more critical, looking at power and how 
groups use language to gain, maintain and exert control (Shaw and Bailey, 2009).   Shaw and 
Bailey discuss how different levels of discourse analysis are often combined in studies 
utilising this method.   
 
I aim to explore the key discourses operating in my sample of interviews and the policy 
document, with the intention to uncover how these discourses contributed to and justified the 
recommendation of offering new patients in general practices in areas endemic with HIV an 
HIV test at the point of registration.  In analysing both the policy documents and the 
interviews, I draw on Parker’s method of discourse analysis, as adapted by Shaw for health 
policy, and provide a meso-level analysis with some discussion of the macro elements and 
discursive implications.   Parker’s approach to discourse analysis as well as Shaw’s 


























 Parker’s 20 steps in discourse analysis  
1. Convert the text into written form  
2. ‘Free associate’ the text 
3. Systematically itemise ‘objects’ that appear in the text  
4. Consider these now, to be the ‘objects ‘of your study  
5. Systematically itemise the ‘subjects’ who appear in the text  
6. Construct the rights and responsibilities of the most important subject in the set that describes the 
network of relationships that position this subject with others. 
7. Map the versions of the social world that co-exist in the text. 
8. Speculate upon the counter-argument of the addressor and their treatment of addressees who 
objected to the addressor’s stance and who took the contrast stance. 
9. Identify contrasts between ‘ways of speaking.’ 
10. Identify where these ‘ways of speaking’ overlap (and also where they remain apart?) 
11. Consider other texts in the same domain and how the different ways of speaking address different 
audiences, or the same audience in different contexts. 
12. Choose appropriate terminology to label the emergent discourses you have identified. 
13. Engage in a study of where and when these discourses developed. 
14. Describe how the discourses have operated to so naturalise the things they referred to that they have 
become ‘taken for granted’ and that it appears perverse and nonsensical to question them. 
15. Examine the role of the discourses in reproducing and preserving these institutions. 
16. Examine which discourses subvert the above. 
17. Who would be advantage, disadvantaged, supported and threatened by each of these alternative 
discourses? 
18. Who would choose to support and who would choose to discredit these alternative ‘ways of 
speaking.’ 
19. How does each discourse entail other discourses that enjoy power? 





Table 3.  Shaw’s adaptation of Parker’s method of discourse analysis (Shaw and Bailey, 













In Part 1, where this method is used, I suggest how discourses contribute to the policy making 
landscape in the field of HIV in the UK and in particular to the promotion of universal HIV 
testing for new registrants in primary care.    
 
4.4 Qualitative interviews 
 
Conducting interviews is a widely used approach in qualitative methodology.  This PhD uses 
qualitative interview data as the main data source and interviews were undertaken with three 
groups: policy stakeholders, providers of rapid HIV testing and patients who tested HIV-
positive with the first test being the rapid HIV test.  While the PhD also calls upon ‘naturally 
occurring’ materials (Peräkylä and Ruusuvuori, 2011), such as ethnographic data and policy 
documents, these interviews allow for the exploration of subjective experiences, attitudes, 
and impressions about HIV testing in general practice (Peräkylä and Ruusuvuori, 2011).    As 
I was not able to directly observe the offer of rapid HIV testing to newly registering patients, 
the construction of HIV testing policy, or the diagnostic experiences of patients, interviews 
 
 
Shaw’s adaptation of Parker’s method of discourse analysis  
1. Discourse is realised in texts  
2. A discourse is historically located  
3. A discourse is about objects 
4. A discourse contains subjects  
5. A discourse is coherent system of meanings 
6. A discourse refers to other discourses  
7. A discourse reflects on its own way of speaking  
8. Discourses support institutions  
9. Discourses reproduce power relations  




allow for the recounting of these key events by overcoming these temporal, spatial and access 
issues.   These benefits are understood as a driving rationale for the use of qualitative 
interviews in health research (Peräkylä and Ruusuvuori, 2011).   
 
A total of 42 qualitative interviews were undertaken in the PhD. The details of these are 
described more fully in Parts 1, 2, and 3, in the description of data sources.  The qualitative 
research has aimed to be dialogically engaged with data from others sources throughout the 
PhD, versus presented alongside other findings (Pope and Mays, 2009).  In their 
methodological review paper for the National Center for Research Methods entitled: How 
many interviews is enough?, Sarah Elsie Baker and Rosalind Edwards explore this question in 
regards to qualitative research by collecting a number of expert views on the subject (2012).  
The overarching response to the question was: it depends and relates to the setting, questions 
and context of the research (Baker and Edwards, 2012).  Data saturation was not reached but 
the number of interviews it was possible to undertake was constrained by eligibility and 
agreement to participate.  For example, only 11 patients were identified as HIV-positive 
through rapid testing, making for only 11 eligible patient interviews, of which 5 agreed to an 
interview.   
 
4.5 Process evaluation  
 
In Part 2 of the thesis, which explores the organisational level study, process evaluation is the 
central method used to explore the variation in uptake of rapid testing amongst RHIVA2 
intervention practices.  Process evaluation emerged as a method able to incorporate multiple 
forms of data and explore the dose, reach and fidelity (these concepts are further explained 
later in the chapter) of the rapid HIV testing intervention (Moore et al., 2013).  Process 
evaluation has been suggested as a method to be applied alongside randomised controlled 
trials, particularly those analysing clusters (such as RHIVA2), as a way of better 
understanding the mechanisms of interventions and determining whether or not the 
intervention itself is ‘faulty’ or if the process of implementation hindered the impact of the 
intervention (Oakley et al., 2006).   By taking into account dimensions that may affect the 
outcomes of trials, process evaluations can help interpret outcomes and provide insights that 




generalisable (Oakley et al., 2006; Moore et al., 2013).  Pragmatic trials, such as RHIVA2, 
are said to benefit from such studies in the feasibility and conduct phases of the trial as a way 
of accounting for ‘external’ and contextual factors that impact upon the intervention.   
 
The literature on process evaluation and the calls for its greater inclusion in experimental 
approaches to research comes alongside the increased attention to, and interrogation of, 
complex interventions and their measurement which some have termed the ‘turn to the 
complex’ (Mowles, 2014). 
‘The argument that process evaluation is most useful in cluster trials, and where the 
intervention is non-standardised, also applies to many ‘pragmatic’ clinical RCTs, as 
does the idea that process evaluation in feasibility studies is crucial to developing 
appropriate and effective interventions.’ (Oakley et al., 2006: p.415)  
Key concepts related to the outcomes of process evaluations are implementation, mechanisms 
of impact and context.  The implementation process may aim to measure the fidelity, dose 
and reach of interventions. Fidelity refers to how faithful the implementation of the 
intervention was to what was intended (Moore et al., 2015).  Dose and reach refer to the 
extent to which the intervention was implemented and sustained and reached the intended 
audiences (Moore et al., 2014).  Process evaluations are meant to consider the ‘relations 
between implementation, mechanisms and context’ (Moore et al., 2014: p.1) as well as these 
aspects independently.  
 
Literature on process evaluation tends to treat context as a defined and manageable aspect of 
research. For example, Moore et al., in summarising the MRC guidance on process 
evaluation, define context as ‘anything external to the intervention that may act as a barrier or 
facilitator to its implementation, or its effects’ (Moore et al., 2014: p2).   Positing context as 
‘external’ to interventions and as something that can be isolated, measured and accounted for 
accordingly has been problematised (Cohn et al., 2013; Mowles, 2014). 
 
Theory driven process evaluation will be discussed in the literature in Part 2 (Oakley et al. 
2006) as a way of considering and coupling the method with research hypotheses and 




innovations model for health care organisations was coupled with the method to explore rapid 
HIV testing variation in RHIVA2 general practices.  This approach is desirable as the 
theoretical model chosen (diffusion of innovations in healthcare organisations) was 
developed through the systematic review of literature related to the diffusion of innovations 
and created a more robust method of investigation.  Linking with some of the literature 
described in the ‘tinkering with trials’ section of the literature review, process evaluation has 
been positioned as another attempt to improve the conduct of trials on complex phenomena, 
to manage context, account for the ‘social’ and attempt to isolate key mechanisms that drive 
research outcomes.  
 
The RHIVA2 trial aimed to implement a complex intervention in various sites using a 
clustered experimental design.  There was significant variation in the uptake of testing.   
Process evaluation is well suited to combine various forms of data such as qualitative 
interviews, trial data and ethnographic field notes.  In aligning with the key concepts 
informing this research, outlined earlier in the chapter, process evaluation within this study 
provides other accounts of the research event than provided by the trial but does not aim to 
entirely account for context or uncover true causal pathways regarding the intervention.   
Using this method, it is possible to learn more about the process of delivering rapid HIV 
testing and what may have helped or hindered practices and practitioners in delivering the 
intervention. 
 
4.6 Data sources 
 
A short description of the method and the data sources will be provided in each findings 
chapter.  However, as data sources are called upon in different ways in each findings chapter, 









Ethnographic field notes 
 
Throughout the trial period, I acted as a member of the study team and was responsible for 
practice recruitment, training, monitoring and general liaison. As a result, I made numerous 
practice visits.  I typed up notes from these visits when possible; additionally, informal 
conversations and email exchanges also took place with practice staff and the trial team. 
These materials form a part of the ethnographic field notes included as a part of the 
autoethnographic method. Over 100 hours of ethnography were undertaken.  Field notes were 
compiled into binders including overarching field notes and reflections and those specific to 
each sub study. 
Qualitative interviews 
 
Policy stakeholders:  In-depth interviews were undertaken with a purposive sample of 14 
policy stakeholders.  Interviews were conducted at the participants’ place of work during 
normal working hours in 12 of the 14 interviews; the other two were undertaken on Skype 
and the telephone.  Written, informed consent was undertaken in all cases. Interviews lasted 
between 30 and 60 minutes. More details are provided in Part 1. 
 
Providers of rapid HIV testing: Semi-structured interviews were undertaken with a purposive 
sample of 23 staff in 16 of the 20 intervention practices; the other four practices failed to 
respond to requests. Most were nurses or HCAs who primarily offered the rapid HIV test as a 
part of the New Patient Health Check. One practice manager, one clinical manager and one 
GP were interviewed in relation to their role in rapid testing (e.g., managing patients with 
reactive or indeterminate rapid test results, overall coordination of testing within the 
practice). Interviews were conducted at the practice during normal working hours and were 
one-to-one, except for two nurse and HCA pairs who asked to be interviewed together. 
Written, informed consent was obtained from all participants, who also completed a short 
demographic survey regarding age, ethnicity, length of time at current practice, part-time or 
full-time employment and previous HIV-related experience. Interviews lasted between 30 




the following year. Participants were given a £10 voucher as compensation for their time.  
More details are provided in Part 2.  
Patients testing HIV-positive with an initial INSTI test as part of RHIVA2:  Of the 11 
potential patient participants testing positive with rapid HIV testing as part of the trial, five 
patients participated.  Patients were approached by the HIV liaison nurse at the local hospital 
and consent was obtained prior to being introduced to me.  Interviews took place at the local 
hospital and lasted between 30 and 60 minutes.  Written, informed consent was obtained in 
all cases.  More details are provided in Part 3.  
 
Trial performance at practice level 
 
Practice-level performance data were collected through the remotely accessible electronic 
record systems used in participating practices. These were the EMIS and VISION systems 
(EMIS, 2015; In Practice Systems, 2015).  Through electronic management, the RHIVA team 
was able to gather monthly testing numbers for each participating practice.   When the trial 
was completed, monthly data was aggregated and used to produce the trial findings. Practices 
were allocated to trial arms using the minimisation criteria of practice size, index of multiple 
deprivation score and male level of serology HIV testing in the years prior to the trial.  These 
criteria, along with other practice-level criteria were compiled while gathering data to inform 
the four practice level case studies presented in Part 2.  More details are provided in Part 2.  
4.7  Ethics and governance 
 
The RHIVA2 trial was approved by Camden and Islington Community Research Ethics 
Committee (09/H0722/67). The trial is registered as ISRCTN Registry 
number: ISRCTN63473710 with the date assigned: 22 April 2010. Ethical approval for the 
PhD qualitative research for the policy, patient and provider studies was gained from 
Bloomsbury National Research Ethics Service committee (11/LO/0324) in April 2011 with 
an amendment in December 2013.  Queen Mary University of London acted as the sponsor 
for the research undertaken: ReDa 007610. All participants provided written, informed 




(Appendix 3). Care has been taken to aim to anonymise participants.  Details have been 
altered and names changed. 
 
4.8 Patient and public involvement  
 
Efforts were made to include patients and the public in the formation and sharing of the 
research presented in this thesis. To a degree, these activities formed a part of the 
methodological approach as they involved receiving feedback on study design, analysis and 
plans for dissemination from groups with an interest in the research.   I met regularly with 
patient representatives throughout the PhD, discussing my emerging research and gained 
feedback and best practice on issues such as recruitment and compensation, for example.  I 
also presented my work-in-progress to various HIV-related community groups and 
organisations so as to share and encourage discussion about my findings.  On one occasion I 
organised a research-training workshop where people living with HIV and research nurses 
learned about qualitative methods and coding.  I used this session to discuss my approach to 
the patient-level study and gain comment on my analytical work.  Undertaking patient and 
public engagement activities enriched the project and allowed me to remain engaged with the 





















PART ONE:  Population screening and the logic of normalisation for HIV    
 
Part 1 of the thesis explores the policy context for RHIVA2.  As described in the background 
chapter, the 2008 National Guidance for HIV Testing in the UK (2008 National Guidance) 
recommended all women and men registering with primary care in highly endemic areas be 
considered for an HIV test.   In the coming chapters I will explore how this recommendation 
was enabled and justified and some of the key discourses circulating at the time of the policy 
and the RHIVA2 trial.  Much of Story 1, population screening for HIV and the logic of 
normalisation, is described here.  I begin with a review of some literature related to screening 
and diagnosis before going on to describe the data sources informing Part 1 of the thesis.  I 
will then present two findings chapters (Chapters 6 and 7).  
 
In Chapter 6 I present the first findings chapter of the thesis.  Here, I explore the justification 
for the 2008 National Guidance, the impetus behind RHIVA2.  Using Kingdon’s policy 
windows theory and Wilson and Jungner’s principles for the early detection of disease, I call 
on 14 in-depth policy interviews and the 2008 National Guidance policy document to explore 
how the policy was justified and upheld (Kingdon, 2003; Wilson and Jungner, 1968).  I find 
that four, what I term, ‘micro-streams’, converged to enable the 2008 National Guidance 
recommendations and subsequently the RHIVA2 trial.  It also becomes apparent that 
population screening for HIV fulfills the majority of Wilson and Jungner’s principles for the 
early detection of disease.   This chapter acts as a theorised background chapter, with findings 
related to how the RHIVA2 trial came to be and the overall public health aims informing the 
study.  
 
In Chapter 7, I further explore the policy stakeholder interviews and analyse four key policy 
documents circulating at the time of RHIVA2.   A discourse analysis, with reference to 
existing discourses in the HIV literature, reveals three key discourses circulating in the HIV 
policy community and informing RHIVA2.  These include: the risk/surveillance discourse, 
the HIV normalisation discourse and the HIV generations and dynamism discourse.  Together 
these discourses pattern perceptions, activities and experiences related to HIV and inform 




Chapter 5: IDENTIFYING DISEASE: INTRODUCTION TO PART 1 
 
5.1 Population screening for HIV  
 
‘It’s not a black thing, it’s not a white thing, it’s not a gay thing, and it’s not a straight 
thing.  Testing for HIV is everyone’s thing’ (Orasure, 2012, as quoted in Banda, 2014: 
p.13) 
 
Screening forms a regular and significant part of contemporary medical practice. Be it smear 
tests, mammography, antenatal or cancer screening amongst others, the majority of citizens 
will undergo some form of screening in contemporary UK life.   With rapid advances in 
testing and diagnostic technologies, screening has become more accessible and portable.  It is 
now possible, for example, to test for HIV in the privacy of one’s home with a self-testing kit 
(THT, 2016).  Much is present in a screening test; an intersection of systems, disciplines, 
diseases, individuals, practices and settings, touching on fundamental human concerns. For 
patients, a screening tests may relate to matters of life and death, relationships, access and 
onwards. For practitioners it may be a matter of logistics, accuracy, targets and providing 
good and thorough care.  For public health officials and policy makers it may be a discussion 
of thresholds, statistics, budgets and timing.  For all it is quite possibly a combination of 
many emotional, logistical, temporal, financial and relational factors.   
 
Population screening is defined by the United Kingdom National Screening Committee 
(UKNSC) as:  
‘a process of identifying apparently healthy people who may be at increased risk of a 
disease or condition.  They can then be offered information, further tests and 
appropriate treatment to reduce their risk and/or complications arising from the 
disease or condition’ (Armstrong and Eborall 2012: p.162) 
The line between screening and diagnosis can be a fine one (Kaufert, 2000), as was the case 
in RHIVA26. Implicit within screening programmes is the possibility of false results.  This 
introduces themes of uncertainty and liminality, which are present in much of the sociology 
of screening literature (Armstrong and Eborall, 2012).  The testing of an asymptomatic 
                                                
6!While patients were made aware that a confirmatory test was required before being told they are definitively 
HIV-positive, a patient with a reactive rapid test is nonetheless left looking at the material test with a visible 




population for the presence or potential of conditions and diseases represents an important 
aspect of what some consider ‘the new public health’ where there is emphasis on prevention, 
early detection and patient choice (Tulchinsky and Varavikova, 2010).  Seminally, in 1968, 
Wilson and Jungner produced criteria for the implementation of screening which continue to 
mark the conditions in which screening is seen as appropriate. The criteria are outlined by 
Mant and Fowler in their 1990 paper in the British Medical Journal entitled ‘Mass screening: 
theory and ethics’.  The criteria are roughly summarised in the quote below and listed in Box 
1:  
‘the rules are essentially as follows ‘the disease should be common and serious, its 
natural history should be understood; there should be a good screening test; 
acceptable treatment should be available; this should favourably influence the 
outcome’ (Mant and Fowler, 1990: p.916) 
 
Box 1. Wilson and Jungner’s principles for the early detection of disease (1968) 
 
 
Wilson and Jungner’s criteria will be further discussed in Chapter 6, where they form a part 
of the analytical frame for findings presented. 
 
Some sociological work on screening explores the assumptions and messages that may be 
present in a screening program.  In their review on the sociology of screening for a special 
issue in The Sociology of Health and Illness, Natalie Armstrong and Helen Eborall discuss 
Wilson and Jungner’s principles for the early detection of disease (1968) 
1) The condition sought should be an important health problem. 
2) There should be an accepted treatment for patients with recognised disease. 
3) Facilities for diagnosis and treatment should be available. 
4) There should be recognisable latent or early symptomatic stage. 
5) There should be a suitable test or examination. 
6) The test should be acceptable to the population. 
7) The natural history of the condition, including development from latent to 
declared disease, should be adequately understood. 
8) There should be an agreed policy on whom to treat as patients. 
9) The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible expenditure 
on medical care as a whole. 




the disparate and interdisciplinary literature on screening citing contributions from health 
psychology, social theory, sociology, philosophy and biomedical science (Armstrong and 
Eborall, 2012). Key literature is the work of David Armstrong on ‘surveillance medicine’ 
(1995) (Armstrong and Eborall, 2012).  This work outlines a 20th century medical era replete 
with the concepts of danger, fear, deception and obedience transmitted through policies and 
practices that include the monitoring of healthy populations which imply that everyone is at 
‘risk’ (Armstrong, 1995; Armstrong and Eborall, 2012; Kaufert, 2000).  Particia A. Kaufert’s 
discussion of mammography and cervical smear testing in her book chapter: Screening the 
body: the pap smear and the mammogram in Lock, Young and Cambrosio’s edited 
collection: Living and working with the new medical technologies: Intersections of inquiry 
(2000), explores these ideas through the lens of science and technology studies (STS).   
Kaufert situates screening historically and explores the varying ways screening can be 
presented and experienced, dependent on where and how one looks.  Kaufert highlights 
elements of ‘surveillance medicine’ in her discussion of the transition of thought and medical 
practice from the differentiation of the well and unwell to practices enacting the idea of a 
knowledge external to the sensing body, yet to be uncovered. See this quote:  
 ‘for modern screening, philosophy and practice requires agreement with a set of 
assumptions on the nature of disease which are in some ways counter-intuitive.  
Older, commonsense notions, which assume a relationship between feeling well and 
being well, needed to be replaced by the idea of the deceptive body, which may feel 
well, but is a hiding place for disease’ (Kaufert, 2000: p.170). 
She continues with a discussion of morality and the imperative to test, citing the critical work 
of Deborah Lupton in: ‘The Imperative of Health’ (1995).  This work explores screening 
through a Foucauldian lens claiming it is hard to challenge due to its ‘manifest benevolent 
goal of maintaining standards of health’ (Hausman, 2011: p.91; Lupton,1993). 
 
Foucauldian, concepts including surveillance, discourse, governmentality and ‘technologies 
of the self’ as well as Nikolas Rose’s discussions (as informed by Foucault) of biocitizenship 
also feature in the screening literature (Rose, 2001; Banda, 2014; Armstrong, 2007; Lupton, 
1995).  ‘Biocitizenship’ refers to a concept that draws connections between someone’s 
biological status, for example, as diseased or not, and their conception of the self or identity, 
re-orienting ideas of what is to be a human. Linked to this understanding is the way that 




biomedical technologies such as drugs (Banda, 2014). Jonathan Banda illustrates this concept 
in his discussion of HIV home-testing, positing that such forms of self-screening create new 
divisions between people who are HIV-positive and those who have tested and those who 
have not (2014). He describes the latter as an increasingly problematised category of 
individuals:  
‘the moral and social responsibility of HIV testing implicates biocitizens who are 
expected to self-monitor in order to improve their own health and to minimize the risk 
posed to others.  Nevertheless, the expansion of testing options is also inexorably 
linked to the relationship of biocitizens to medical authority’ (Banda 2014: p.4)  
The messaging on the untested body explored by Banda in relation to HIV and more broadly 
discussed by Armstrong, Lupton and others is relevant to contemporary approaches to HIV 
screening in the UK.   Presently, the untested and the undiagnosed are represented as the most 
significant challenge in reducing transmission rates (PHE, 2014), particularly in light of the 
‘treatment as prevention’ revelations, definitive as of 2011(Cohen et al., 2011) (As described 
in Chapter 2: Background).   
 
5.2 Sociology of diagnosis  
 
Screening and diagnosis form natural counterparts. In Jutel and Nettleton’s introduction to 
the special issue of Social Science and Medicine on the sociology of diagnosis, they 
summarise important concepts and literatures related to the experience and practice of 
diagnosing illness (2011). They suggest diagnoses as ‘a prism which absorbs and reflects a 
panoply of issues central to the experience and practice of medicine and health care’ (Jutel 
and Nettleton 2011: p.793).  The authors explain how changing understandings of health and 
disease impacts diagnostic experiences, definitions and practices. Jutel and Nettleton outline 
how at present ‘diagnostic categories are less bounded with the dualism of disease and non-
disease, collapsing in the face of new categorisations of potential disease and risk factors.  
Patients now bring expertise, knowledge and expectations to the clinic.’ (Jutel and Nettleton 
2011: p.793).  Diagnoses are productive events and bring much into being, for example, 
diagnosis validates what counts as disease and legitimates illness, it offers explanations and 
can facilitate access to resources; being diagnosed can cohere patient symptoms and enable 
access to the ‘sick role’, which impacts social structures and performances (Jutel and 




upholds medical authority and represents operations of power and access which have 
significant effect on an individual’s well-being (Jutel and Nettleton, 2011).  The review 
suggests three major themes in the sociology of diagnosis.  Calling on Blaxter, a seminal 
thinker in bringing forth a sociology of diagnosis, they propose considering diagnosis ‘as 
category’, ‘as process’ and ‘as consequence’ (Jutel and Nettleton, 2011: p.793). 
 
Diagnosis as category describes how a diagnosis is an attempt to classify experiences and 
provide definitions.  Seminally, Bowker and Star discussed diagnosis as a classification 
activity (1999). Such categories can be contested, withheld, imposed, convenient and variable 
in different spacio-temporal sites. ‘Diagnosis as process’ highlights how generative a 
diagnostic act can be, leading to further diagnoses or re-categorisations, bringing forth a 
series of health related actions and processes and inspiring changes in identity. 
 
 Emphasising the processual aspects of diagnosis also brings into view the temporal 
dimensions and the numerous actors, locations, and interpretations related to a diagnostic act 
and its effects.  This may allow for different ontological understandings of disease to be 
acknowledged and demonstrate how ‘reading and interpreting the body’ is not a stable act, 
but contingent on locations, context, cultures and other ‘more fluid aspects’ (Jutel and 
Nettleton 2011: p.796).  Shubert, for example, treats diagnosis as a practical accomplishment 
and a coordination of various categories, locations, actors and agentic roles (Schubert, 2011).  
Gardner et al. discuss diagnosis in reference to Foucault’s theory of bio-power and describe 
the event as where ‘the medical gaze delves into a body with concrete form, shape and 
colour’ (Gardner et al., 2011: p.71).  Here, they describe individuals as encountering ‘various 
intertwining forces’, both social and material, in a process of diagnosis.   In making disease 
intelligible through diagnostic practices they call on Mol’s ethnography of atheroscleroses to 
describe diagnostic acts as a ‘patchwork singularity (Mol 2002: p.171)’: ‘since the 
intelligibility of the disease is the product of diagnostic practices, multiple practices enact 
multiple forms of the disease’ (Gardner et al. 2011: p.71). 
 
The third theme of ‘diagnosis as consequence’ highlights how diagnostic acts have 




can legitimate or stigmatise, can facilitate access to resources just as it can restrict 
opportunities.  A diagnosis can be welcomed or eschewed.’ (Jutel and Nettleton 2011: p.797) 
 
A nascent discourse on the ‘normalisation’ of HIV has been taken up and explored by social 
scientists with an interest in HIV (Persson, 2013; Mazanderani, 2015; Mattes, 2014; Philbin, 
2014; Moyer and Hardon, 2014; McGrath et al., 2014; Flowers et al., 2013).    Overall, this 
literature challenges the positioning of HIV as ‘any other illness’ and explores the 
complexities of interacting with an infection with such a socially and symbolically charged 
history.  In Chapter 7 and Chapter 10, as the discourse of ‘normalisation’ becomes more 
apparent and patient experiences described, this literature will be further explored. 
 
While the rapid HIV test has been presented as a ‘quick’ and ‘simple’ test that can easily be 
implemented within existing medical settings and practices, the literature described above 
begins to expound the ways screening programmes cluster, contain and enact structural, 
discursive and personal meaning while reinforcing medical authority and particular forms of 
citizenship.  In presenting the policy-related findings chapters below, these themes are 
explored more explicitly in relation to RHIVA2.  
 
5.3 Data sources  
 
The methods used in Part 1 of the thesis are described in detail in Chapter 4 of the thesis.  I 
will now describe the data sources informing the findings presented in Chapters 6 and 7.  
Data sources include in-depth interviews with policy stakeholders, analysis of four key policy 
documents, and insights gained through the ethnographic method. 
 
In-depth interviews with policy stakeholders  
Interviews were undertaken with 14 stakeholders in the UK HIV policy community. 
Participants were sampled purposively. Inclusion was determined by the individual’s role in 
the development of HIV testing policy, recommendations from other participants, a review of 




were held at a location convenient to the participant and lasted approximately 1 hour.  All 
participants provided written informed consent.  Most (n = 12) interviews were undertaken at 
the participant’s place of work and on occasions where participants were not working locally, 
both the telephone (n = 1), and Skype (n = 1), were used.   Participants were not provided 
with any compensation for their time but did receive a thank you card.   All interviews were 
recorded and transcribed.   
Interviews were semi-structured.   A list of questions was drawn up and delivered to all 
participants with space to explore other topics as appropriate. The topic guide for the 
interview included:  
• Overall role in HIV policy 
• HIV testing policy and the 2008 National Guidance 
• HIV testing policy in the UK  
• Policy actors and processes  
• Rapid HIV testing  
 
 Table 4 provides a description of participants and their role in HIV policy in the UK. 
 
 
Table 4.   Policy interview participants and their described role in UK HIV policy  
 
 
 Role Organisation 
1 Senior position Government body related to sexual health and HIV 
2 Policy lead UK HIV charity 
3 HIV Consultant / Policy-maker HIV consultant with a role in professional medical 
associations and government consultant roles  
4 Senior position Patient organization / HIV charity 
5 Senior epidemiologist National health organisation 
6 Patient representative London HIV clinic / Participant in policy guidance with 
various organisations 
7 GP with specialism in HIV HIV lead in a professional association / NHS 
8 GP with specialism in HIV Member of national medical associations / lead on HIV 
education programmes/ NHS 
9 GP with specialism in sexual health / 
part time academic / active member 
of national medical associations 
Academia / professional medical associations / NHS 
10 Senior position National HIV charity  
11 HIV consultant and member of 
professional association 
NHS/ member of professional association related to HIV and 
sexual health 
12 Senior position National health body 
13 Academic with HIV specialism Academia 




Policy documents  
Policy documents were sampled based on their role in promoting the 2008 National Guidance 
recommendations, particularly, the offer of an HIV test to all new registrants in general 
practice in high prevalence areas.   Document 1, The UK National Guidelines for HIV Testing 
2008 (2008 National Guidance) was the first piece of national guidance recommending this 
testing strategy and served as the benchmark for HIV testing policy in the UK until 2011.  In 
an aim to evaluate the recommendations in the document, HPA pilots were undertaken and 
are reported in Document 2: Time to test for HIV: Expanding HIV testing in healthcare and 
community services in England (2011).  This report extended the evidence set out in the 2008 
National Guidance and contributed to justifying the development of the 2011 NICE 
guidelines on HIV testing for specific populations which comprise Documents 3 and 4: 
Increasing the uptake of HIV testing among black Africans in England: NICE public health 
guidance 33’, and the ‘Increasing the uptake of HIV testing among men who have sex with 
men: NICE public health guidance 34 (NICE, 2011a) (NICE, 2011b).  During this period 
were the strongest pieces of policy and clinical guidance regarding universal testing for new 
registrants in primary care in the UK.   A brief description of each document follows.  
 
Document 1: The UK National Guidance for HIV Testing 2008 is the BHIVA, BASSH and 
BIS produced document that inspired the RHIVA2 trial.  This 23-page document was seen as 
the foremost national guidance on HIV testing in 2008, until the arrival of NICE guidance in 
2011.  The objectives of the 2008 National Guidance were to: 
‘facilitate an increase in HIV testing in all healthcare settings as recommended by the 
UK’s Chief Medical Officers and Chief Nursing Officers [1-4] in order to reduce the 
proportion of individuals with undiagnosed HIV infection, with the aim of benefiting 
both individual and public health.’  (BHIVA et al. 2008: p.1).  
 
It is within this document that the approach evaluated in RHIVA2 was recommended: 
 
‘An HIV test should be considered in the following settings where diagnosed HIV 
prevalence in the local population (PCT/LA) exceeds 2 in 1000 population (see local 
PCT data):  
1. All men and women registering in general practice 
2. All general medical admissions 
 
The introduction of universal testing in these settings should be thoroughly evaluated 
for acceptability and feasibility and the resultant data made available to better inform 




Document 2: The second document chosen for analysis is the HPA’s:  Time to test for HIV: 
Expanding HIV testing in healthcare and community services in England final report (2011).  
The 42-page report provides the results of eight pilot projects undertaken with the financial 
support of the DoH, to evaluate HIV testing in hospital, primary care and community 
settings.  This work was undertaken to ‘assess the ways in which the testing guidelines might 
be best implemented’ (HPA, 2011: p.2) and essentially to establish a stronger evidence base 
for the national testing guidance, and determine aspects of feasibility and cost effectiveness 
(HPA, 2011). The pilots related to general practice were described in Chapter 2:Background, 
Section: 2.3. 
 
Documents 3 and 4: The National Institute of Health and Care Excellence (NICE) jointly 
produced 2 pieces of guidance related to targeted testing: Increasing the uptake of HIV testing 
among black Africans in England: NICE public health guidance 33, and the Increasing the 
uptake of HIV testing among men who have sex with men: NICE public health guidance 34.  
Produced in 2011, the guidelines incorporate much of what was recommended in the 2008 
National Guidance with specific consideration of the UK’s most highly endemic groups for 
HIV.  These also form the 2nd and 3rd policy documents analysed. These guidance documents 
are aimed at NHS and other commissioners, managers and practitioners who are directly or 
indirectly involved with, and responsible for, increasing the uptake of HIV testing among 
black African and MSM communities (NICE , 2011a; NICE, 2011b).   They also mention 
local authorities, the wider public, private, voluntary and community sectors as well as both 
black Africans in England and MSM as audiences. Both sets of guidance, 54 and 58-pages 
respectively, aim to increase the uptake of HIV testing, to reduce undiagnosed infection and 
prevent HIV transmission in black African and MSM communities in England.  Both sets of 
guidance also promote the 2008 National Guidance as seen in the quote below:  
‘In areas where more than 2 in 1000 population have been diagnosed with HIV: 
• primary care and general medical admissions professionals should consider offering 
and recommending an HIV test when registering and admitting new patients (this is in 




Chapter 6:  AN EMPIRICAL STUDY OF THE POLICY CONTEXT FOR THE HIV 





This chapter explores questions related to the development of the UK National Guidance for 
HIV Testing 2008, jointly produced by BHIVA, BASHH and BIS (2008).  This was the 
guidance prevailing at the time of the RHIVA2 study and formed the policy context in which 
practices were implementing the intervention. I aim to determine why HIV testing in primary 
care for new registrants in highly endemic areas was considered as a policy objective.  In 
providing a broad description of the context for the guidance and therefore the findings of 
this study, micro and macro factors are pulled apart and insights regarding the policy process 
are gathered.  This paints a picture of the public health and policy terrain of which the 
RHIVA2 trial formed a part.   RHIVA2 trial was dually tasked with implementing and 
evaluating the recommendation simultaneously. I use Kingdon’s policy windows theory to 
delineate the converging elements that led to an increased push for the early detection of HIV 
and a subsequent renewed interest in HIV testing (Kingdon, 2003).  I will also evaluate the 
decision to recommend opt-out testing to the general population using Wilson and Jungner’s 
principles for the early detection of disease (Wilson and Jungner, 1968). 
 
In this chapter, I take the themes enabling the policy, in a sense, at face value, without in-
depth consideration of how these themes may have been constructed through discourses, 
power relations and broad philosophical assumptions related to the organisation and values of 
UK society and of evidence more broadly. I feel this is an important move to enable an 
understanding of the policy and the trial from the perspective of the research team and the 
UK HIV policy network. In the next Chapter, Chapter 7, I will explore discourses operating 
within the policy network which allow for a deeper discussion of what else may have been at 







6.2 Theoretical Frame  
 
Kingdon’s policy windows  
 
In 1984 John Kingdon published: Agendas, Alternatives, and Public Policies, a case study of 
policy making practices in the United States.  Kingdon pays close attention to ‘agenda 
setting’, an area he claims was widely overlooked in academic policy studies at the time 
(Kingdon, 2003).  He aimed to understand why some items make it onto the policy agenda 
and others not, how such problems are defined, why some policy options are prioritised, 
others neglected, and the role of politics within these processes (Kingdon, 2003: p.xxvi).   
This led to the development of the policy windows theory of agenda setting.  In later years 
the theory has been extended by Nikolas Zahariadis, termed multiple streams, and applied to 
the wider policy process, not just agenda setting (Zahariadis, 2007). 
 
Kingdon describes the policy process as including a set of practices. First, setting the agenda, 
second, specifying options or alternatives from which a choice is made, third, an authoritative 
decision regarding the policy choice and finally the implementation of the decision (Kingdon, 
2003).    Agendas are defined as the list of items or problems policy-makers, civil society or 
politicians are paying attention to.  What is on this agenda is heavily influenced by who the 
active participants related to these items might be and the ‘processes by which the items have 
come to prominence’ (Kingdon, 2003:p.15).  Other factors in agenda setting may be events 
that highlight particular problems, or a change in an important indicator related to the policy 
item.  Additionally, specialists and experts may reach a breaking point on particular issues 
after accumulating substantial knowledge and analysis; this may culminate in a policy issue 
coming to the fore.  Finally, political factors may also play a key role, for example new 
political players, or the rise of interest groups, may lead to the inclusion of new policy items 
(Kingdon, 2003). 
 
Kingdon describes the three processes of problem recognition, generation of policy proposals 
and political events as able to act as facilitators or barriers to policy formation and setting of 




that attempting to pinpoint a single origin is futile.  Instead, a complex combination of factors 
is generally responsible for the movement of a given item into agenda prominence’ (Kingdon, 
2003: p.76), he goes on to summarise his observations and puts forth the policy windows 
theory.  Here the streams of problems, proposals and politics are defined as independent and 
‘coequal’ elements of the policy puzzle, converging and diverging in ways that support or 
detract from policy possibilities. Kingdon describes the streams below: 
‘These three streams of processes develop and operate largely independent of one 
another.  Solutions are developed whether or not they respond to a problem.  The 
political stream may change suddenly whether or not the policy community is ready 
of the problems facing the country have changed… The streams are not totally 
independent however.  The criteria for selecting ideas in the policy stream, for 
instance, are affected by a specialists’ anticipation of what the political or budgetary 
constraints might be… Despite hints of connection, the streams are still largely 
separate from one another, largely governed by different forces, different 
considerations, different styles.’  (Kingdon, 2003: p.88)  
 
The problem stream relates to the acknowledgement and recognition of problems or items for 
the agenda.  The policy stream includes the proposed solutions for tackling said problem, and 
the politics stream includes the national mood and political climate surrounding the issue.  
New or changed political appointments, public events and general political jostling can 
impact the political stream. The theory suggests that when the three streams of problems, 
policies and politics are successfully aligned, often by a ‘policy entrepreneur’ (someone who 
champions and facilitates implementation of new ideas into practice) a policy window is said 
to open (Kingdon, 2003:88): 
‘The key to understanding agenda and policy change is their coupling.  The separate 
streams come together at critical times.  A problem is recognized, a solution is 
available, the political climate makes the time right for change, and the constraints do 
not prohibit action…I label an opportunity for pushing one’s proposals a ‘policy 
window’ – open for a short time, when the conditions to push a given subject higher 
on the policy agenda are right.  But the window is open for only a while, and then it 
closes.’ (Kingdon, 2003: p.88)  
 
Zahariadis has critiqued Kingdon’s model, suggesting that perhaps the streams are not 
independent of each other, that there is a lack of clarity around the role of the window in the 
coupling of streams, the entrepreneurial strategy for coupling, solutions following an 
incremental evolution in the policy stream and the lens being merely a heuristic device 





Despite these potential limitations, Kingdon’s model proved a useful analytical tool for 
exploring the occurrence of the 2008 National Guidance, which appeared to follow a fairly 
rationalistic course of responding to a policy problem with feasible policy solutions.  The 
exploration of discourses inherent to the policy, in Chapter 7, allows for a more critical 
discussion of the policy objectives. 
 
Wilson and Jungner’s principles for the early detection of disease  
 
‘in theory, screening is an admirable method of combating disease … [but] in 
practice, there are snags’ (Wilson and Jungner, 1968:p.7). 
I will now introduce a contrasting set of criteria related to public health policy, with emphasis 
on screening. While discussing the sequences of evidence, events and arguments that enabled 
Kingdon’s ‘policy window’ regarding opt-out HIV screening in primary care to open, I will 
also consider Wilson and Jungner’s principles for the early detection of disease.  Including 
Wilson and Jungner allows for another level of analysis of the policy, which sits within the 
epidemiological literature.  The criteria are considered a longstanding and widely accepted 
best practice guide for the justification of screening activities in healthcare (Andermann et al., 
2008). 
 
Determining when a population screening approach is appropriate requires some evaluative 
criteria.  A primary concern in screening has been the ethical hallmark of ‘do no harm’.  In an 
attempt to gather clarity and guidance on when a screening approach would be beneficial, the 
World Health Organisation (WHO), in 1968, commissioned Wilson and Jungner to assemble 
criteria.  Summarised in the literature review, but reproduced below in Table 5 with added 
description, the criteria raise key considerations for justifying a screening program and 
consider dimensions of feasibility, patient wellbeing, economic impact and the 









Table 5. Wilson and Jungner’s principles with description (1968) 
 Principle Description 
1. The condition sought should be an 
important health problem. 
High prevalence of disease is not a necessary factor.  Individual, 
community and social factors should be considered alongside 
disease prevalence.  
2. There should be an accepted treatment 
for patients with recognised disease. 
In order to avoid harm, acceptable treatments should be available for 
those screened for disease.  Key questions: 1) Does treatment at the 
pre-symptomatic border-line stage of a disease affect its course and 
prognosis? 2) Does treatment of the developed clinical condition at 
an earlier stage than normal affect its course and prognosis?  
3. Facilities for diagnosis and treatment 
should be available. 
Those diagnosed with early stage disease should be able to access 
treatment; this may be in terms of clinical provision, cost or other 
accessibility factors. 
4. There should be recognisable latent or 
early symptomatic stage. 
The disease must have a latent period sufficient enough to detect the 
illness through screening programmes. If it does not, the value of 
screening is limited, as symptoms will cause individuals to seek 
health services. 
5. There should be a suitable test or 
examination. 
Tests may be divided between screening and diagnostic tests.  While 
screening tests may have a larger margin of error, this margin must 
be reasonable and be more likely to deliver false positive than false 
negative results. 
6. The test should be acceptable to the 
population. 
Aspects such as the nature of the risk of the disease, the level of 
public education regarding the disease, and the ease of use of the 
diagnostic or screening test may be important factors.  
7. The natural history of the condition, 
including development from latent to 
declared disease, should be adequately 
understood. 
Understanding the natural history of the infection, and any 
pathological changes in the disease over time is important, as is 
determining how such changes may interact with available 
treatments.  That treatment remains relevant to whom and when and 
under what conditions is important to determine when possible.   
8. There should be an agreed policy on 
whom to treat as patients. 
‘Borderline subjects’ must be clearly defined.  This may be variable 
based on setting, clinician and individual case however whenever 
possible treatment parameters should be clearly identified, as should 
follow up procedures for ‘borderline subjects’. 
9. The cost of case-finding (including 
diagnosis and treatment of patients 
diagnosed) should be economically 
balanced in relation to possible 
expenditure on medical care as a 
whole. 
Early detection lengthens the productive life of patients; it may also 
allow health services to avoid costly interventions and specialist 
care.  Wilson and Jungner indicated that economic assessment may 
not be easy to determine and that screening programmes may be 
costly initially or even in the long term.   Technological shifts are 
acknowledged as opportunities in cost reduction. 
10. Case-finding should be a continuing 
process and not a ‘once and for all’ 
project. 
One-off screening may be of little value.  Determining how often 
populations should be screened is important in determining the value 




6.3 Analysis  
 
Transcripts and the 2008 National Guidance policy document were coded twice.  In the first 
instance I applied Kingdon’s policy windows theory, broadly identifying themes related to 
the problem, policy and politics streams. I then applied Wilson and Jungner’s criteria to the 
data to pull out themes related to the 10 principles. It became evident early in my analysis 
that the application of Kindgon’s policy streams theory would explain and describe some but 
not all of the themes emerging in the data.  Accordingly, I sought to supplement my 
theoretical approach with the identification of further ‘streams’ that appeared important to the 
development of the guidance.  The primary thematic analysis of interview transcripts and 
policy documents identified approximately 17 key themes related to Kingdon’s model. For 
manageability, I divided these 17 themes into four, what I have termed, ‘micro-streams’.   
 
The micro-streams identified include 1) epidemiology and public health, 2) health setting 
factors, 3) treatment, technology and techniques and 4) socio-cultural dimensions of HIV 
infection.  In the findings I will describe the micro-streams and the themes that comprise 
them. The ‘micro-streams’ categorise the themes but can also be discussed in relation to the 
three main streams as outlined by Kingdon, the problems, policies and politics streams.  The 
delineation of these ‘micro-streams’ formed emergently while working through the findings 
related to the policy. Through this analysis and demonstration, I hope to illustrate how the 
policy window enabling the 2008 guidance was opened.   The consideration of Wilson and 
Jungner’s principles alongside this analysis helps determine the rationale for a population 
screening approach.  With Wilson and Jungner’s criteria I analysed the data for points of 
fulfilment and contention.  The results are displayed in Table 6, using a colour-coded system, 









6.4 Findings  
 
Micro-stream 1: Epidemiology and public health  
 
The micro-stream of epidemiology and public health outlines key indicators in HIV that 
signified a need for emphasis on the early detection of the virus.  The picture was one where 
the importance of early detection and access to treatment was becoming evident through the 
emergence of large, reliable studies, local data and a shifting general tone. This data indicated 
that late-diagnosis, HIV testing, and access to treatment were important factors in reducing 
HIV-related mortality and morbidity.  The ‘post-HAART era’, referring to the period from 
which highly active anti-retroviral therapies (HAART) have been widely available 
demarcates a new generation of HIV treatment and survivorship (Newman et al., 2010).  The 
transition of HIV from a ‘death sentence’ to a treatable condition is discussed later in the 
chapter and informs an important part of the ‘logic of normalisation’, which comprises a 
central story in this thesis.  The logic surrounding screening is largely informed by the 
rationale assigned to detecting latent disease in non-health seeking populations.  
 
The data described in this micro-stream, when brought together, created the evidence base for 
a pressing policy problem.  Kingdon cites changes in key indicators as a main factor in 
problem definition and the ability of the ‘problem stream’ to converge with the politics or 
policies stream (Kingdon, 2003).  A government employee describes the accumulating 
evidence: 
‘I mean it was opportunistic.  We had the time, we had some money, there were, as I 
say, all these drivers coming around the guidelines…that’s right, the BHIVA 
guidelines, international influences, the audit report from BHIVA, and this sort of, I 
suppose groundswell of thinking, well our data’s so good, we know we’ve got these 
late diagnoses, what’s happening? What can we do?’ (Employee at government 
agency concerned with health)  
 
What is described in this micro-stream also works to fulfill Wilson and Jungner’s first 
principle: the condition sought should be an important health problem (1968). The themes 
described below were identified within the 2008 National Guidance itself, as well as by 




HIV screening and the arguments present in the HIV policy community, as informed by 
public health and epidemiological data.  
 
Undetected and undiagnosed HIV  
 
Unwitting transmission and undiagnosed HIV have become important public health priorities 
in light of the changing treatment possibilities for HIV-positive individuals.  Approximately 
one-third of people living with HIV in 2006 were estimated to be undiagnosed (HPA, 2007). 
If individuals are unsuspecting of an HIV infection there is little impetus to seek out testing 
or request a test when presenting at health services.  Undiagnosed HIV has also been 
acknowledged as a major cause of continued transmission of the virus (Vernazza et al., 2008; 
Cohen et al., 2011). When individuals are aware of their HIV status they tend to alter ‘risk’ 
behaviours (unprotected sex, needle sharing), reducing transmission (BHIVA el al., 2008).  
The finding (increasingly demonstrated in high impact studies) that treatment can act as 
prevention and virtually render HIV non-infectious (when medications are properly adhered 
to and HIV-positive individuals are able to maintain an undetectable viral load) has been one 
of, if not the, most dramatic shifts in the HIV landscape in recent years (Vernazza et al., 
2008; Cohen at al., 2011). This repositioning of risk away from HIV-positive individuals and 
onto those unaware of their HIV status will be further discussed in Chapter7. 
 
Additional data indicates that late diagnosis negatively impacts upon morbidity and mortality.  
The HPA cites 2006 data indicating that 33% of new HIV diagnoses were at a late stage and 
that it was more likely for heterosexual men and women to be presenting late, with 
heterosexual men thought hard to reach with existing health promotion techniques (HPA, 
2007).  These findings added impetus to the screening approach which aims to bring the 
wider population into view. 
 
Mortality and morbidity and late-presenting HIV 
 
Participants in the in-depth interviews cited the 2006 British HIV Association National Audit 




(BHIVA, 2007). The audit is the first piece of evidence mentioned in the 2008 National 
Guidance:  
‘A national audit by the British HIV Association (BHIVA) showed that of deaths 
occurring amongst HIV-positive adults in the UK in 2006, 24 per cent were directly 
attributable to the diagnosis of HIV being made too late for effective treatment.’ 
(BHIVA et al., 2008: p.2)  
 
Within the growing body of evidence in support of early HIV detection, the 2006 BHIVA 
mortality audit brought the UK population into sharp focus with the presentation of results 
clearly demonstrating the role of late detection in local HIV-related deaths.  A GP with an 
interest in HIV explains: 
‘clearly the driving force behind all of this is the undiagnosed population of HIV and I 
think that one of the key drivers for this work was really the publication of the 
BHIVA audit, which was 2006 I think.  The BHIVA audit looking at deaths amongst 
HIV-positive patients and which highlighted not only was late diagnosis the single 
biggest cause of death but also that these people, it wasn’t that they weren’t attending 
health services, they were attending and with the benefit of hindsight were clearly 
presenting with conditions that were related to their HIV but they weren’t being 
offered HIV tests.  And they were often presenting in a general practice setting.’   
(GP with key role in the development of the UK National Guidelines for HIV Testing 
2008) 
 
 Impaired response to medication  
 
Definitions around ‘late diagnosis’ have evolved.  HIV and AIDS have been defined through 
the demarcation of particular levels of immune response in the body, CD4 counts and viral 
loads, as well as the presence of HIV antibodies (Wailoo, 1997). Individuals with HIV who 
are detected at a late-stage of the infection demonstrate an impaired response to medication 
and require significantly more medical care (BHIVA et al., 2008; Stöhr et al., 2007).  This 
raises the cost and health care burden, adding not only to the definition of the ‘problem’ and 
the economic argument, which form a part of Wilson and Jungner’s criteria, but contributing 
as well to the ‘politics’ stream of Kingdon’s model.  
‘Late diagnosis of HIV infection has been associated with increased mortality and 
morbidity (7), impaired response to HAART (8) and increased cost to health care 






Missed opportunities for testing  
 
Of particular relevance to the guidance was data indicating that individuals attending general 
practice in the UK who were infected with HIV were routinely seeking medical care and 
opportunities to test were present, yet patients were not being offered tests (BHIVA et al., 
2008).   In some cases, patients were presenting (sometimes repeatedly) with conditions 
indicative of HIV infection (Sullivan et al., 2005; Wellesley at al., 2015).  This finding 




The Centres for Disease Control (CDC) in the United States were the first to suggest opt-out 
HIV testing for new registrants in health services (CDC, 2006).  Their data also contributed 
to the threshold of 2/1000 included in the guidance and the economic analysis indicating 
likely cost effectiveness (CDC, 2006).   The CDC were also first to make recommendations 
around abbreviated counselling and consent procedures for HIV testing and are widely 
acknowledged as leaders in HIV science and practice internationally, as described by a public 
health consultant below:  
‘The CDC, like Public Health England, had to roll and review the evidence into 
feeding the evidence into policy.  And both of them are also involved in discussing at 
a global level which WHO and the - what is it? UN AIDS in Geneva.  So there are 
policy trends… So…in many respects this could be a trend within the UK and the US 
leading.  France have also had similar policies.  The Netherlands have had similar 




Micro-stream 2: Treatment, technology and techniques  
 
The treatment, technology and techniques surrounding HIV are high-tech and rapidly 
changing.  Treatment possibilities have largely dictated the acceptability of practices 
surrounding HIV. New rapid diagnostic tests, more effective HIV drug therapies, a shift 
towards treatment and prevention, and the general movement of HIV from a ‘life sentence’ to 




including rapid and point of care testing and abbreviated consent and counselling procedures.   
These broad changes in HIV treatment, technologies and techniques shape the policy terrain 
and the 2008 National Guidance reflects and was enabled by these shifts.   
 
The factors outlined in this micro-stream contribute substantially to the feasibility of policy 
proposals, as contained in Kingdon’s ‘policy stream’: factors that facilitate reasonable and 
practicable solutions to the policy problems and promote the opening of the policy window 
(Kingdon, 2003). 
 
In regards to Wilson and Jungner’s criteria, a suitable test and examination that is also 
acceptable to the general population form Principles 5 and 6 for the early detection of disease 
(1968).  The discussion of treatment, technology and techniques and what is now available in 
HIV treatment and care also implies an advanced understanding of HIV aetiology, including 
the transition from latent to advance stage disease.  Wilson and Jungner highlight such an 
understanding of the disease subject to screening as essential in Principles 1 and 6 of the 
criteria (1968).  
 
HIV drug treatment possibilities  
 
Easily one of the most important shifts in HIV has been the continual improvement of HIV 
therapies to prolong and improve the lives of HIV-positive people.  These therapies are in a 
constant process of improvement and expansion. The amount and frequency with which 
individuals take medications has reduced along with the severity of side effects.   The 
opening line of the 2008 National Guidance highlights this:  
‘Whilst the availability of highly active antiretroviral therapy (HAART) has 
transformed the outcome for individuals with HIV infection, there continues to be 
significant and avoidable morbidity and mortality relating to HIV infection in the 
UK.’ (BHIVA, 2008: p.2) 
 
While less evident in 2008, there was some evidence that that treatment was likely to impact 
prevention, thought it was not until 2011 that definitive high level evidence confirmed the 




Rapid tests  
 
The first rapid HIV test was developed in the United States in 1992 (Kaiser Foundation, 
2014).  Rapid tests are considered single use, disposable devices, using minimal reagents that 
provide an HIV test result in under-60 minutes (CDC, 2007). They are meant to be 
technically simple to operate, performed near patient and use whole blood or saliva fluid 
specimens. The first rapid HIV finger-prick test was developed in 2002, gaining approval by 
the Clinical Laboratory Improvement Amendments (CLIA) waiver in 2003. The first saliva-
based test, with CLIA approval, followed in 2004 (Kaiser Foundation, 2014). HIV testing is 
constantly in transition. From 1985 when the first HIV test was licensed (the ELISA test), to 
the present when in 2013 the first rapid test that detects both antigens and antibodies as well 
as distinguishes between acute and established HIV-1 infection was developed, there is 
constant test development in the pipeline (Kaiser Foundation, 2014).  
 
Presently, the detection possibilities for HIV continue to improve, making HIV testing more 
portable and self-contained, moving testing for HIV further out of the clinic and into the 
private sphere. Home testing was approved in the UK in 2014 and the first commercially 
available rapid tests available for purchase to the general population were legally available in 
stores from April 2014 (Stephens, 2014).  
 
Consenting and counselling  
 
When delivering an HIV diagnosis meant telling someone that they were on an accelerated 
path towards death, HIV testing held a different status.  The surrounding practices aligned 
with the gravity of the infection.  Much debate and consideration took place regarding when, 
how and who to test as well as who was suitably qualified to offer testing (Baggaley et al., 
2012).  Pre-test counselling and preparation was considered best practice and lengthy 
consenting procedures ensured that individuals knew the impact testing and a positive 
diagnosis might have (Cohan, 2009).  While it would be inaccurate to assume that receiving 
an HIV diagnosis today is not a serious and life-changing event, in the UK the diagnosis need 
not dictate the same steady trajectory towards mortality.  Following the Centre for Disease 




counselling procedures and promoted opt-out verbal consent practices for testing there was a 
ripple effect across other nations with similar epidemiological and health system profiles, 
including the UK (CDC, 2006; BHIVA et al., 2008).  These changes allowed more diverse 
health care personnel to offer HIV testing, a shift evident in the RHIVA2 trial where health 
care assistants conducted the majority of rapid tests. 
As indicated in the 2008 guidance: 
‘The primary purpose of pre-test discussion is to establish informed consent for HIV 
testing, lengthy pre-test HIV counselling is not a requirement, unless a patient 
requests or needs this (1-4).  The essential elements that pre-test discussion should 
cover are:  
o the benefits of testing to the individual. 
o the details of how the result will be given 
This approach has been successful in GU and antenatal clinics and is generally 
acceptable.’ (BHIVA et al., 2008: p.11)   
 
This demarcates a large shift in historic HIV testing approaches where there is no mention of 
the psychosocial aspects of delivering an HIV-positive result and emphasis on counselling 
practices for HIV testing is not encouraged.   This move also forms an important aspect of the 
‘normalisation’ of HIV and a move away from historic exceptionalism.   
 
Ability to be evaluated  
 
The 2008 National Guidance suggested that pilot studies explore the effectiveness of the 
recommendation, which was taken up by the HPA in 2011 which the funding of the 
aforementioned pilots for testing in non-traditional settings (BHIVA et al., 2008; HPA, 
2011).  The ability of the guidance to be evaluated and measured for impact was understood 
as key in contributing to the evidence base. RHIVA2 was also developed for this purpose, to 
lend ‘gold standard’ evidence to the recommendations. Less tangible recommendations that 
are not quantifiable or able to be tested through experimental designs may not be as appealing 
to policy makers (Kingdon, 2003).  The benefit in evaluation of screening programmes is also 






Micro-stream 3: The health care setting  
 
The organisation of the UK health system is an important contextual influence on the ability 
to develop and implement policy options.  In the case of HIV testing in primary care, 
organisational aspects of the UK health care system make recommendations such as the offer 
of tests to all new registrants more feasible.  As outlined by Kingdon in his discussion of the 
policy streams, an important aspect of the converging ability of the policy stream, that is, the 
proposed solutions to the policy problem, is feasibility (Kingdon, 2003). That new policies 
can work with pre-existing systems and infrastructure, and are able to streamline with 
contemporary practices and policies, plays an important role in implementation and 
acceptance of new directives. 
 
Wilson and Jungner highlight the important role of acceptable facilities for diagnosis and 
treatment in Principle 3 (1968).  Here, primary care takes on this role and is centralised for its 
position in the community and inclusion of practices such as new patient registration 
procedures and checks, sites of obvious consideration for the implementation of screening.  
 
New Patient Health Checks  
 
New Patient Health Checks (NPHC) were routine practice in most GP practices participating 
in the RHIVA2 trial (39/40), though were variable in their make-up and offer (McMullen et 
al., 2015). Typically, the NPHC includes the collection of baseline data on health and 
lifestyle from new registrants by asking a series of questions (NHS, 2014).  Data collection is 
prompted by a computerised clinical system and information is entered on the patient record 
(Robson et al., 2015). The provision of this service lends itself to the opt-out offer of tests.  
This enhances the feasibility of the recommendation of offering new registrants in high 
prevalence areas HIV testing and for screening strategies in general. This health setting factor 
may have contributed to the perceived feasibility of the guidance. The GP in the quote below 
describes the important role of the new patient health check as well as its transition in UK 




‘But of course new registration checks are no longer part of what we have to deliver, 
right? So good practices do them and I worked in good practices that offered them 
and we would make sure they were worthwhile because they’ve got a whole lot of 
other stuff in them as well.  So that’s another thing that doesn’t work for me.  I’ve 
forgotten this, which is new registration checks are not the norm in practice or 
practices.  So when you’re commissioning on a return of new patient checks…We 
used to get paid for new patient check in the old days… How on earth do you run HIV 
screening without a new patient check? (GP with role in HIV on professional medical 
associations)  
 
What the GP describes here is variability in the offer and make up of new patient health 
checks, largely brought on due to policy changes since the time of the trial.  
 
Universal health care / Free HIV treatment  
 
‘In a sense, having a NHS in the UK could facilitate implementation of some policies 
and can facilitate an early uptake of, or early implementation of evidence based 
interventions.’ (Public health consultant with national health organisation) 
 
 
Universal access to healthcare on the NHS means that UK residents can access medical 
services free of charge.  This includes primary care, secondary care and Genito-Urinary 
Medicine (GUM) clinics.  There is no charge to the patient for HIV testing and treatment is 
freely available if one is found to be HIV-positive.   Previously, if someone was diagnosed 
HIV-positive and not a legal UK resident, they might experience complications accessing 
free medical treatment for an HIV infection (Anderson, 2012, personal communication, July 
12).  At the time of the RHIVA2 trial and the release of the 2008 National Guidance, some 
boroughs offered free treatment for any HIV-positive individual while other boroughs only 
covered UK residents. In 2012, legislation was passed indicating anyone in the UK regardless 
of their immigration status could access free HIV treatment (MRN, 2012). At the time of the 
guidance and the trial, the borough in which the trial was being rolled out offered free HIV 
treatment to any individual living with HIV, regardless of immigration status.   
 
Wilson and Jungner discuss how testing should be acceptable to the general population, if 




include undocumented migrants, then some may consider screening to be inappropriate 
(1968).  
 
Existing and precedence setting policy 
 
Existing policies in the UK also demonstrated wide scale acceptance and the successful 
implementation of HIV screening approaches.  Antenatal screening for HIV has been widely 
acknowledged as one of the UK’s most successful HIV testing policies.  This policy is widely 
promoted and, to a degree, celebrated as demonstrative of the wide-scale acceptance and 
implementation of HIV screening strategies (BHIVA et al., 2008: p.2) A community HIV 
worker describes the success as well as comments on the ‘logic of normalisation’: 
‘It sounds a bizarre thing, but normalise HIV testing as much as possible.  I think that 
one of the things that has been really successful if we are looking at testing has been 
the antenatal testing, where women now opt out of testing.  We do a pregnancy 
project and we see quite a few women coming through who are diagnosed in 
pregnancy.  So we know we are catching people there, people who would otherwise 
go unnoticed.  That is a huge success.  So how can we replicate that model in other 
settings?’  (Lead at HIV-positive patient group)  
 
 
Opt-out testing for HIV has also been shown to be widely accepted by the UK population and 
abroad; much of the introductory paragraph in the 2008 National Guidance discussed this: 
‘The only randomized controlled trial published to date (13) on testing methods shows 
that a universal ‘opt-out’ approach to HIV testing in antenatal patients was acceptable, 
did not cause anxiety and had a higher uptake than other methods’ (BHIVA et al., 
2008: p.3) 
  
‘In the USA in 2006 the Centers for Disease Control and Prevention (CDC) 
recommended opt-out testing for all individuals aged 13-64 presenting to any 
healthcare facility (mainly Emergency Rooms) for any reason (18).’ (BHIVA et al., 
2008: p.2)   
 
In principle 6 Wilson and Jungner emphasise the importance of the acceptability of testing to 







The role of the GP   
 
My field notes indicate numerous conversations regarding the role of the general practitioner 
in HIV care at both policy-related events and within general practices.   The feeling was that 
GPs had a larger role to play in HIV, that their direct access to the community and role as the 
first point of contact for health seeking citizens had untapped opportunity for improving HIV 
detection and care.  Additionally, the transition of HIV from an untreatable, deadly infection 
to a chronic, treatable medical condition meant that HIV-positive individuals would 
theoretically rely less on specialist services and could be routinely managed by non-specialist 
GPs, particularly when presenting health concerns that appear unrelated to HIV.   Coupled 
with the data on missed opportunities for testing, the presentation of individuals to primary 
care services with symptoms of HIV indicator conditions and the dawning realisation of the 
importance of early diagnosis, the GP appeared to be gaining ground in the wider HIV health 
services conversation. This will be taken up further in the next chapter as interviews with 
members of the HIV policy network reveal the importance of this occurrence in recent HIV 
policy developments and discourses.   Some of the tension is described by a stakeholder:  
‘So I don’t think they are as bad, you know, they are generalists and I think a couple 
of years ago there was a great movement to put all of our care, about three years ago 
(2010), you know, to get GPs to look after HIV.  They didn’t want it.  They can’t keep 
up to speed with what’s happening in HIV medication etcetera.  And certainly the 
patients didn’t want it.  I mean, you know, if you’ve got anything wrong with you, 
you want to see a specialists and not a generalist.  But I think GPs actually get bad 
press when they seem to serve our patients quite well and I think the other thing is, if 
a patient says oh, I had a really bad time, I say, well then we can change your GP.’ 
(Patient representative at local HIV clinic) 
 
Some of what is described in this quote will be further explored in Chapter 7, the discourse 
analysis, however, the point here is to demonstrate how central general practice was 
becoming in the response to HIV.  
 
The economic case for the early detection of HIV   
 
The combined effects of a late diagnosis for HIV have economic implications.  Onward 




interventions means that late diagnosis is understood as expensive for the NHS.  This was 
outlined in the 2008 National Guidance: 
‘modelling in the US has also suggested that routine screening for HIV infection is 
cost effective and comparable to costs of other routinely offered screening where 
prevalence of HIV exceeds 0.05 per cent (12).’ (BHIVA et al., 2008: p.2)  
 
‘The 2/1000 was extrapolated from the States because they had been a year ahead of 
us.  Whatever they are, the CDC and Mortality and Morbidity, had done this in the 
states a year or 18 months ahead.  They had done a cost effective risk analysis and 
came up with 1/1000 as the tipping point to make it worth it money wise.  That’s 
where it came from and we adopted that.  There wasn’t any other analysis to tell us 
where to go.’ (HIV consultant with role in professional medical associations related to 
HIV)  
 
Wilson and Jungner discuss the economic rationale and the cost of testing as compared the 
larger medical budget as an important consideration in recommending screening approaches 
in principle 9 (Wilson and Jungner, 1968).   At the time of guidance, evidence existed on the 
economic impacts of late detection but not on the cost-effectiveness of screening approaches 
for HIV. The RHIVA2 trial was coupled with an economic analysis in an attempt to build this 
evidence base.  
 
Micro-stream 4: Socio-cultural dimensions of HIV infection   
 
A number of societal factors also come into the calculus enabling HIV testing as 
recommended in the 2008 National Guidance and enacted in RHIVA2.  While these factors 
can be more difficult to pinpoint and clearly articulate, discourses and socio-cultural factors 
related to HIV infection in the UK play an important role in shaping policy possibilities.  The 
themes described here outline some of the normative dimensions of medicine which positions 
treating and caring for people with HIV as a public health priority.  
 
This micro-stream relates strongly to the ‘politics stream’ of Kingdon’s model in that it is 
based on data related to the tempo and general feeling of the wider population, and the 
political climate in relation to HIV policy (2003).  This micro-stream also allows for 
comment on the ‘culture’ of HIV policy making in the UK.   In regards to Wilson and 




problem’, Principle 1 of the criteria, as well as feasibility and acceptability (contained in 
principles 2,5,6) (1968). Broad themes will be roughly summarised here, to enable their 
inclusion in the micro-streams, however a more nuanced discussion of these factors will 
follow in the next chapter. 
 
HIV and ‘big P’ politics in the UK  
 
Sexual activity outside of marriage, male same-sex practices, multiple partnerships, the 
selling of sex and injection drug use, all considered risk factors for HIV, are both explicitly 
and implicitly discussed in UK policy documents, including in relation to HIV. Those 
applying for citizenship are not subject to an HIV test prior to gaining official entry, unlike in 
other countries with a similar global position to the UK (changed in the US in January 2010) 
(DOHS, 2015). The implications are that HIV policy can be developed overtly, including in 
relation to practices considered as societally undesirable and of equivocal legal standing (i.e. 
sex work and injection drug use).  That HIV can be explicitly discussed within government 
and acknowledged as a health issue in the UK is fundamental to the development of policy 
related to the infection, and that HIV can occupy this space politically and within government 
is not a given.  Kingdon’s policy stream acknowledges the politicised aspects of policy 
making, that HIV policy appears to have been relatively unaffected by political forces at the 
time of the guidance meant that while the politics stream did not appear to play a strong role 
in the opening of the policy window, it was an integral factor to allow other elements of the 
policy process to come forward, such as the policies stream.  Below, a civil servant in the 
HIV field discusses this dimension of her work: 
‘We’ve got a very supportive…it doesn’t tend to be, I think HIV and sexual health 
generally don’t tend to be party political.  There aren’t many differences.  I have 
worked under two…you know, the Labour administration and now the Coalition 
Government, and we’ve not changed our policies on sexual health. We’ve produced 
documents and we’ve changed the broader language. Obviously the broad structures 
have changed around the NHS, how healthcare generally is commissioned or 
delivered.  But for patients, you know, yes they’ll probably see some changes down 
the line, but I don’t think it’s political with a big ‘p’ at all.’  






Community resources for HIV-positive individuals  
 
Various organisations related to HIV and living well with an HIV infection are active across 
the UK7.  That such services and organisations exist for patients to access, if desirable, 
creates a setting where outside of the medical and diagnostic aspects of HIV, policy makers 
are aware that there is on-going psychosocial support available for citizens. Civil society 
organisations regularly participate in consultations and policy development briefs and patient 
and public involvement in HIV research is widely encouraged and considered best practice 
(see Terrence Higgins Trust, National Institute of Health Research, BHIVA). While this is a 
less tangible aspect of policy making, this factor is present in the background of any medical 
changes in HIV and HIV care. The shift in pre and post-test counselling, for example, may 
rely on these community resources to provide psychosocial support in cases where it remains 
required.   This important role is described by a GP with an interest in HIV: 
’You can have the quickest test in the world in terms of physically doing the test but 
the stuff that goes around the side of the test and particularly if you get a positive 
result from it, is absolutely not going to be quick and I think for me, one of the kinds 
of payoffs of having, as you say, sort of abbreviated consent is that if someone gets a 
positive result there is then a very good system for picking up and dealing with that 
immediately so that someone isn’t left high and dry with an apparently positive test 
and sort of chucked back out on the street again as it were…. One of the biggest 
issues is to make sure that that person is going to be supported after you get a positive 
test.’ (General practitioner with a special interest in HIV and role in the development 
of the guidance) 
 
 
The culture of the HIV network  
 
‘I suppose another theme that goes through this epidemic, is courage and bravery and 
having to take a step into some unknown place and going ‘Okay, come on then, come 
with me and we’ll try it’. (HIV Consultant with role in professional medical 
associations) 
 
Often, when the formal interviews were complete, conversation with participants would 
continue.  Palpable in many occasions, among those working with HIV for many years, was 
some sense of nostalgia, triggered by recounting the transitions in HIV care throughout the 
interview.  One participant cited how the pioneers of HIV care were beginning to pass away 
                                                
7!!Some predominant HIV-related community organisations include: Terrence Higgins Trust, Positive East, 




and retire.  The participant remarked on the loss of important historical information that was 
left un-captured in the minds and hearts of these professionals as well as the loss of 
community felt when leaving their professions.  The character of the HIV community, 
throughout my 10+ years of experience in the field, has appeared a passionate, dedicated and 
political one with a somewhat unique status amongst infection diseases or health concerns in 
general.  Global HIV events, for example, often appear to serve as spaces for reunions 
amongst those working hard and with many dramatic losses and gains over years in HIV 
work; triumphs and tragedies of personal, political and scientific natures.  At a recent event at 
the London School of Hygiene and Tropical Medicine on creating an archive of HIV health 
promotion materials, I was struck by one HIV consultant who interrupted an anthropologist’s 
presentation on archive construction to discuss, at length, the personal archive of HIV 
materials he was gathering in his spare room. Thirty years of pamphlets, scientific reports, 
personal mementos etcetera were being systematically organised for eventual museum 
donation to ensure that the activism and history of clinicians in HIV was captured in medical 
history.   This was not an anomalous occurrence.  It seems a mistake not to include some 
discussion of the wider HIV network culture in this analysis and consider it as a factor in 
policy making.   I developed the strong impression from my fieldwork, interviews and 
documentary analysis that the culture of HIV activism and its intensity attracted a particular 
kind of talent and mobilising force to the field and is responsible for much of the pressure 
leading to scientific and social progress in HIV.    
Figure 4 on the following page summarises the themes related to the move towards opt-out 









Key themes and the coupling of the ‘problem’ and ‘policy’ streams 
 
While a number of themes converged to enable the recommendation of HIV testing for new 
new registrants in general practice in areas highly endemic with HIV, some key themes stood 
out as particularly strong in enabling the policy window. The policy ‘problem’ (a public 
matter requiring attention (Gulbrandsson and Fossum, 2009) came into sharp focus after the 
publication of the BHIVA mortality audit which presented strong quantitative evidence on 
the role of late-diagnosis in HIV-related deaths.  This was cited as a turning point in the 
policy document as well as by members of the policy community.  These data allowed for the 
pulling together of other related indicators (economic arguments, transmission by 
undiagnosed HIV-positive individuals), which when taken together made the case for a 
pressing policy problem.  
 
 The problem was positioned as late-presenting HIV with associated knock-on effects for 
individuals, population health and the economy.  With this came a focus on the ‘undiagnosed 
population’ and a push to normalise testing to increase the opportunity for individuals to 
become aware of their HIV status.   Much of what comprises the epidemiology and public 
health micro-stream relates to the defining and clarifying of this policy problem.  That the 
problem was being defined in the form of epidemiological evidence facilitated acceptance by 
the biomedical HIV policy-making community regarding the existence and scope of the 
problem.  Policy entrepreneurs (those introducing and promoting potential problems and 
solutions (Gulbrandsson and Fossum, 2009), were then able to pull upon much of the existing 
practice in HIV testing (opt-out testing, moving testing to non-traditional settings), including 
widely accepted and touted practices such as antenatal screening, to promote population 
screening style approaches for HIV testing. That existing policies of a similar nature were 
operating in the US, with an indicator of the necessary epidemiological picture (1/1000 in the 
US data) (CDC, 2006) for cost effectiveness was widely cited as precedence setting. The 
coupling of the epidemiological indicators, creating the policy problem, with the knowledge 
of successful and cost-effective existing practice elsewhere enabled the opening of a policy 





 Increasing testing in general practice was positioned as a solution to the problem of late-
diagnosis due to the level of contact with the general population. As the existing 
epidemiological data was compiled to strengthen the case of the problem, general practice 
(amongst other sites) was positioned as a source of untapped testing potential in HIV care and 
as a fertile space for encountering the ‘undiagnosed’; thereby constituting a strong actor in 
the policy stream.   
 
Striking throughout the interviews was how little debate there appeared to be around the 
development and promotion of the 2008 National Guidance.  Any tension appeared to be 
around ‘targeted’ versus ‘universal’ testing but even this was a difference of opinion that all 
agreed was unresolved until more data were made available. A dimension of likely 
importance to the ‘politics’ stream, and how cohesive the policy community appeared to be 
around this particular recommendation, is how the policy described here was in the form of 
guidance and it was unattached to resource in terms of funds or allocated staff and services. 
The policy did not come directly at the expense of other policies, but formed a part of a 
plethora of recommendations for increasing HIV testing.  As will be discussed, most policy 
stakeholders interviewed felt that a multitude of approaches were required in tackling HIV 
and the recommendation was seen as another potential strategy in the mix. Had the policy 
come with allocated resource, or been promoted to the direct exclusion of other HIV services, 
the guidance may have become more politicised.   The guidance was compiled and debated 
within the larger HIV policy community and received very little attention outside of this 
realm.   
 
Kingdon discusses how policy windows tend to be open for a limited time due to the 
converging and diverging of policy streams and changes in the policy climate (2003).  As a 
result, he argues that policy entrepreneurs generally need to act quickly to take advantage of 
potential policy windows (2003).   Zahariardis questions this assertion, indicating that the 
temporality of policy windows is a little-explored area without sufficient evidence to come to 
a firm conclusion (Zahariardis, 2007).  In the case of the policy discussed here, Kingdon’s 




policy, or the factors justifying it, was the 2012 Health and Social Care Act8 and its impact 
on the HIV policy arena (Government of the United Kingdom, 2012). Despite the interview 
being about the 2008 recommendations, many participants were keen to discuss recent policy 
shifts.  The general feel was that changes made in the 2012 Health and Social Care Act 
compromised HIV care, education and testing in negative ways by fragmenting existing 
services and re-structuring commissioning in a way that worked against well proven 
approaches in health promotion for HIV.  This is discussed by an HIV consultant with a 
policy role: 
 ‘It’s like a Fair Isle jumper. You know, we had a Fair Isle jumper. It wasn’t perfect 
but we had one. Now it has unravelled completely (since the Health and Social Care 
Act 2012).  The red wool is with one person and the blue wool is with someone else 
and the green wool with someone else and we are trying to produce a knitting pattern.  
But if you don’t want to buy the red wool, it ain’t going to be the same pattern.  And it 
won’t fit so well or it will be a different shape, or it may be better.  But those 
components of the whole are now sitting in different hands who don’t necessarily 
relate or have shared agendas yet.  And HIV testing is plop in the middle of that. It is 
the highest risk time we have had for a long time, I feel.’ 
(HIV consultant with role in professional medical HIV related associations)  
 
Many participants felt that the guidance discussed here or a further bolstering of the BHIVA 
guidelines or subsequent NICE clinical guidance would be impossible with the contemporary 
changes in the policy landscape.  A strong sense of ‘we are going backwards’ was felt among 
most involved in the policy process and they expected to be able to identify this set-back in 
the epidemiological data.  Rather than pushing forward with new forms of testing and 
screening, emphasis appeared reoriented towards maintaining what was already in place and 






                                                
8!The 2012 Health and Social Care Act ushered in large-scale changes to the organisation of HIV services.  
Primary Care Trusts (PCTs) were dissolved and power was re-oriented to Clinical Commissioning Groups 
(CCG’s), local authorities and NHS England (All Parliamentary Group on HIV and AIDS, 2013). Public health 
including sexual health promotion and testing was allocated to local authorities while NHS England was tasked 





Wilson and Jungner’s principles  
 
Wilson and Jungner’s principles for the early detection of disease as applied to the thematic 
analysis of the policy stakeholder interviews and principle policy document demonstrate that 
population screening approaches for HIV can be justified from an epidemiological point of 
view. The majority of the criteria for the early principles have been met and while some 
divergence of opinion was detected throughout the analysis, there was no outright rejection of 
any of the principles.  The table below is colour coded to represent areas where criteria 
appeared to be strongly met (green) and moderately met (orange), based on the analysis 
undertaken in this chapter.   The criteria have been narratively linked to the themes uncovered 
in the micro-streams and quotations.  








A thematic analysis using Kingdon’s policy windows theory and Wilson and Jungner’s 
principles for the early detection of disease have revealed important insights regarding the 
justification for the RHIVA2 trial.  A policy window appeared due to a convergence of 
factors related HIV in the realms of epidemiology and public health, treatment technology 
and techniques, health systems and the socio-cultural dimensions of HIV infection.  Analysis 
using Wilson and Jungner’s principles for the early detection of disease reveal that screening 
approaches for HIV can be epidemiologically justified through broad fulfillment of the 
criteria and little opposition.  
 
My analysis continues in the next chapter. I will describe key discourses related to the 
justification of a screening approach for HIV, which allows for a deeper exploration of the 
policy interviews and additional policy documents; it also assists in painting a picture of the 




Chapter 7:  SCREENING FOR A ‘NORMALISED’ HIV: A DISCOURSE ANALYSIS 




After an in-depth description of the factors leading into the development of the guidance in 
Chapter 6, I now explore three discourses in operation in the UK HIV policy community 
between 2008-2011.  Four key policy documents, including and relating to the 2008 National 
Guidance recommendations and the interviews with members of the related policy 
community are analysed with the question:  What were the key discourses informing HIV 
testing strategies at the time of the RHIVA2 trial? Using Parker’s framework for discourse 
analysis, as adapted by Shaw in relation to health care policy (Shaw, 2009), I determine three 
key discourses justifying and upholding contemporary approaches to HIV screening in UK 
primary care 2008-2011.  I will demonstrate how, during this period, large shifts in the 
conceptualisation of HIV risk, the ‘normalisation’ of HIV testing and the concept of HIV 




Parker’s method of discourse analysis, as adapted by Shaw, is described in Chapter 4.  The 
data sources used to produce these findings were outlined earlier in Part 1 in section 5.5. 
 
For each interview and policy document a ‘thick’ document was compiled.  This included a 
cover sheet with a summary of the document, a description of first impressions and themes 
when first engaging with the document including any ‘stand out’ aspects. A second sheet was 
appended including key terms, phrases and turns of phrase.   These steps correspond with 
Parker’s list of questions when undertaking discourse analysis (See points 2-5 on Table 2).  I 
then attempted to list roles and responsibilities of the discussed subjects and how this related 
to objects, attempting to, as suggested by Parker, ‘map the social world’. This ‘thick’ 
document became the core of the discourse analysis work for each piece of these data 
forming the corpus for analysis.   Additional questions from Parker and Shaw’s guidance on 




different discourses and how do different discourses interact with one another. 
Acknowledging that discourses are ‘historically situated’ and that ‘discourses contain other 
discourses’ (Shaw, 2010; Parker, 1992) as well as support and interact with other discourses, 
I then dialogued my early findings with the existing literature on discourses in HIV. 
 
My analysis of the interviews and policy documents, using Parker and Shaw’s models, 
demonstrated a number of discourses in operation, of which three were dominant. The first is 
the surveillance/risk discourse that resonates strongly with Armstrong’s discussion of 
‘surveillance medicine’ and the ‘medical’ and ‘medico-moral’ discourses identified by Siedel 
(Armstrong, 2005; Siedel, 1993).  Here, the undiagnosed sub-population of HIV-positive 
individuals represent contemporary HIV risk.  With this shift, the general population comes 
under surveillance and takes on new responsibilities.   Second, the HIV ‘normalisation’ 
discourse (Persson, 2013), which relates to the ‘HIV-exceptionalism’ discourse as posited by 
Smith and Whiteside (2010), was predominant throughout the policy documents and 
interviews.  Apparent here is a tension between the ‘normalisation’ project suggested in the 
HIV policy documents and technologies such as population screening, with the 
‘exceptionalist’ practices previously associated with HIV testing and care.  New forms and 
practices for HIV testing come into focus and impact upon professional relationships. Third, 
a discourse around HIV temporality and multiplicity is also present, which relates strongly to 
the ‘HIV generations’ discourse first described by Newman and colleagues (Newman et al., 
2010). HIV’s dynamic history and variability in regards to survivorship, biomedical 
expectations and practices multiplies experiences of HIV and HIV care leading to 
multipronged policy, fragmented policy language and challenges to professional roles. 
Together these discourses both inform and uphold the recommendations of testing all new 
registrants in general practice for HIV in highly endemic areas.  I will now describe each of 
these discourses with reference to existing discourses in the HIV literature. 
 
7.3 Findings  
A discourse of surveillance and risk  
 
‘The strangest thing is people don’t often see themselves in a high-risk group.  Everybody’s 




The push to be aware of one’s HIV status and to increase testing in the UK population at 
large is directly related to the changing biomedical context of HIV treatment.  HIV-positive 
individuals who access and adhere to drug therapies, achieving an undetectable viral load, 
have little chance of transmitting HIV, yet remain HIV-positive.  This transformation of the 
HIV-positive body from one of risk and disease to one of relative safety and health inspires a 
shift in how HIV risk is presented and understood.  David Armstrong’s description of 
surveillance medicine discusses transitions in illness and health and how these changes alter 
conceptualisations of risk: 
‘The techniques of health promotion recognise that health no longer exists in a strict 
binary relationship to illness, rather health and illness belong to an ordinal scale in 
which the healthy can become healthier, and health can co-exist with illness; there is 
now nothing incongruous in having cancer yet believing oneself to be essentially 
healthy (Kagawa-Singer 1993).’ (Armstrong 1995: p.400) 
He outlines surveillance medicine as operating around three themes: a problematisation of 
normality, a redrawing of the relationship between symptom, sign and illness, and the 
localisation of illness outside the corporal space of the body (Armstrong, 1995).  Within this 
logic, illness becomes something with endless potential and always in waiting.  One may 
begin to survey oneself and question one’s state of health and normality, alert to risk factors 
and signs and symptoms of illness in development, an activity encouraged by the ‘know your 
status’ messaging of HIV campaigns (Banda, 2014).  Screening activities, such as the 
RHIVA2 trial, adhere to this logic, attempting to direct and interrupt the anticipated march of 
illness from early possible indicator to full blown disease.  
 
The undiagnosed as the new risk site for HIV  
 
The surveillance/risk discourse problematises the unknown and presents this lack of 
knowledge as a threat to the individual and society.  Here, this manifests as emphasis on the 
‘undiagnosed’ HIV-positive population.  This oft-referred-to category of individuals are an 
important imaginary in HIV; as future patients, as the promised deliverable of HIV policy, as 
victims, as embodied risk and as a pesky elusive goal representing a final challenge in 
controlling the UK epidemic.   With a large percentage of the HIV-positive population in the 
UK being undiagnosed, the untested population at large becomes the new site of HIV risk. 




‘The biomedical activism is now around testing in a very focused way.  The burden of 
responsibility, the messages that are going out.  In the old days the person who was 
tested and was positive was somehow the victim and was somehow responsible and 
took blame.  Now the message is the untested person who is the potential victim 
because they don’t know.  And so your social responsibility, your herd responsibility 
as an individual, has suddenly come into sharp focus I think.  A lot of the social media 
stuff now is ‘Would you rather have sex with someone who has never had a test?’  
Actually the former is considered to be at lower risk, which means there is something 
now about both clinicians, practitioners and the general population about some burden 
of responsibility being put on the untested.’  (HIV Consultant, Departmental head and 
senior position in a professional medical association)  
 
It is estimated that the majority of HIV transmission in the UK is by those unaware of their 
status, a category anticipated to grow as biomedical practice moves towards the earlier 
prescribing of ARVs to HIV-positive individuals, regardless of their CD4 count (presently an 
important indicator of when to begin treatment) (HPA, 2011; BHIVA et al., 2008; NICE, 
2011a; NICE, 2011b).  With this comes the wide-scale achievement of an undetectable viral 
load among HIV-positive individuals adhering to medication, and therefore little to no 
transmission. 
 
There has been a push to learn more about ‘the undiagnosed’ in the HIV policy field. The 
seemingly wholesale support for testing raises interesting questions around those who do not 
accept or seek out tests and the persistent category of undiagnosed HIV-positive individuals.  
The opacity of ‘the undiagnosed’ is presented as an obvious challenge in the documents 
reviewed and interviews undertaken.  A GP with a special interest in HIV describes this 
tension below: 
‘you have to do bundle testing otherwise, you know, how can you pick up the ones 
who you don’t see?  And, you know, that population might actually be very different 
than the ones who actually come and see you.  And so, you know, are you potentially 
causing a problem with equity when you only test people that you see and you don’t 
test the people that you don’t see…you only see who you see.  And in order for any 
screening program to work you have to look at the population.  And yeah, it’s difficult 
to screen anyone who might not be at risk, but you know, at least they get asked.’  






Surveillance of the general population  
 
‘If you tested everybody in the country, mandatory, there would be no undiagnosed.  
There would be no more late diagnosis.  We could sort the problem straight away.’ 
(Employee at local HIV-positive patient organisation and member of local health 
organisation) 
 
‘Surveillance medicine requires the dissolution of the distinct clinical categories of 
healthy and ill as it attempts to bring everyone within its network of visibility.’ 
(Armstrong 1995: p.395) 
The reorientation of risk as ignorance of one’s HIV status centralises individual risk-
behaviour on the one hand, and population-based approaches, such as the universal offer of 
testing, on the other. It works to bring the general population into view and under the 
surveillance of public health infrastructure.  Settings such as primary care come into focus. 
The population is informed that knowledge of their HIV status is protective of their health.  
According to HIV specialists, techniques such as home and rapid testing mean it is ‘easier 
than ever’ to access a test.  Outreach means individuals are tested in a variety of settings, 
such as pubs and churches along with seemingly unrelated health settings such as 
dermatology and colposcopy clinics, for example. The emphasis on ‘tracking down’ HIV-
positive individuals is described by a patient representative in the quote below:  
‘We need a “it’s better to know” campaign really, you know kind of which would 
take huge pressure I think off GPs.  My GP who has people in tears, it could help 
educate people to look for the effects, you know, the potential signs of HIV 
pneumonia, TB, you know what I mean? Or you know, a whole range of things, yeah, 
and we could track down those 30,000 people who don’t know that they’ve got HIV 
who are going around spreading the virus.’  (Patient representative at HIV specialist 
clinic)  
Regardless of this apparent easy access to testing, one would imagine it is difficult to always 
be aware of one’s status, and while it is suggested that individuals test after every ‘risk 
behaviour’, determining when one has truly been at risk of HIV infection can be difficult, 
inconvenient or undesirable. Analysis of the discourses around the untested population 
assumes the objectives of the citizen to be their health and the health of the population, with 
health defined in narrow terms.  Based on biomedical rationality alone, we might expect 
individuals to want to learn their HIV status and to then, if positive, adhere to medications 




ignores the complex psychosocial factors related to HIV infection which may not, and 
indeed, historically have not, always lead individuals to make choices around HIV that speak 
to particular biomedical rationalities alone.  Here the medical and medico-moral discourses 
(Siedel, 1993) also become apparent, as individuals are imbued with a responsibility to 
monitor their HIV status for the good of the population.  
 
A discourse of ‘normalisation’  
 
‘I would suggest that in primary care the person coming in with an ingrown toenail is 
not thinking about a life changing diagnosis’ (HIV consultant with role in professional 
medical associations) 
The ‘normalisation’ of HIV testing was an explicit objective in the policy documents 
analysed.  Despite this, normalisation appeared as an unsettled discourse, relating to tension 
with the ‘HIV exceptionalism’ discourse (Smith and Whiteside, 2010) and in some senses the 
‘rights’ and ‘activist’ discourses (Siedel, 1993), which have long been in operation in the HIV 
field. The ‘HIV exceptionalism’ discourse, which describes the ways in which the approach 
and techniques, as well as the large attention, funding and action HIV garnered 
internationally are comparatively exceptional in the realm of infectious disease.  Smith and 
Whiteside, quoting Lazzarani, describe the discourse:  
‘Descriptively, exceptionalism posited that in the early years of the HIV epidemic, 
HIV was considered so different, so ‘exceptional’ in comparison to other 
communicable diseases that advocates and public health officials agreed that HIV 
policy should cater to the uniqueness of the epidemic rather than treat it like all other 
communicable diseases.  Supposedly, the argument goes, public fear was so great, the 
political power of gay men so substantial, and concern over stigmatization so real, 
that public health authorities abandoned ‘traditional’ approaches to communicable 
disease control in favour of a civil liberties approach [9].’  (Smith and Whiteside 
quoting Lazzarani 2010: p.2). 
The ‘HIV exceptionalism’ discourse is informed by the rights and activist discourses, 
identified by Siedel as well as Smith and Whiteside (Siedel, 1993; Smith and Whiteside, 
2010). Patient and public networks, calling upon the human rights framework to support 
access to HIV therapies and reduce stigma towards HIV-positive populations, largely drove 
these discourses.  Both were strongly influenced by international perceptions of HIV and 




less developed countries (Smith and Whiteside, 2010).  Arising largely in response to the 
medical and medico-moral discourses (Siedel, 1993), the rights and activist discourses 
centralise the patient as a person deserving of rights and highlight the societal, psychological, 
economic and gender-based aspects of HIV infection.  Smith and Whiteside describe some of 
HIV’s historic exceptionalism in the quote below: 
‘During the 1980s public health adopted a human rights framework that took societal-
based vulnerability into consideration and increasingly became involved in societal 
transformation efforts [5].  HIV/AIDS was positioned not only as a health condition, 
but also as a social issue that required a political, as well as medical, response [4].  
The scientific establishment’s control on public health was challenged, and a new 
type of public health initiative was called for: one that provided counselling, protected 
privacy, and empowered the patient’ (Smith and Whiteside 2010: p.2)  
Emphasis on privacy and confidentiality, counselling and psychological services and a social 
movement to ensure access to high-level treatment and care are seen as the legacies of these 
mobilisations and discourses (Smith and Whiteside, 2010).  In the case of the corpus explored 
here, the rights and medical discourses often appeared merged, appearing as a sort of public 
health discourse of biomedical rights, an observation also noted by others in the literature 
(Parkhurst, 2012). 
 
The related normalisation discourse contains, challenges and colludes with aspects of the 
exceptionalism and rights/activist discourses.  In recent years, “HIV exceptionalism’ has been 
challenged (Mazanderani, 2015; Persson et al., 2014; McGrath et al., 2014; Mattes, 2014). 
Much of what was seen to inspire the exceptionalism, at least in high resources settings, is 
thought to have been overcome with changes in technologies and treatments for HIV, which 
have altered the clinical picture and also strongly impacted survivorship.  In response, a 
discourse of ‘normalisation’ has appeared. Within this discourse ‘biomedicine’ is arising as a 
synergistic agent of protection and normalisation, promising to turn people with HIV “into 
regular, unremarkable citizens, just like anyone else” (Squire, 2010: p.407)’ (Persson et al., 
2014: p.1066).  Throughout the interviews, many participants spoke freely about the 
normalisation of HIV testing, however HIV infection itself as ‘normal’ was often discussed 
with caveats.  This reflects a trend in the literature. The transition of HIV from a ‘plague’ 
model of illness (Beaudin and Chambre, 1996: p.684; McGrath et al., 2014) to a chronic 




began to significantly increase the life course of HIV-positive individuals from the early 
1990’s (McGrath et al., 2014).  The discourse on normalisation has appeared to gain 
prominence since the groundbreaking findings of the Swiss HIV Cohort study in the early 
2000’s and the defining HPTN 052 study of 2011 which established the role of ARVs in 
rendering HIV virtually non-infectious with appropriate adherence (Vernazza et al., 2000; 
Cohen at al., 2011).  The emergence of the undetectable viral load and the HIV-positive body 
as potentially non-infectious has made what was a nascent discourse on normalisation an 
entrenched discourse in the HIV field in recent years (Mazanderani, 2015; Persson, 2013; 
Persson et al., 2014; McGrath et al., 2014; Mattes, 2014). A swell of critiques have emerged 
in response, and while they may be critical of the historical exceptionalism surrounding HIV 
as well as the normalisation discourse, they tend to call for a continued form of 
exceptionalism largely due to the impact of HIV infection on the social reality of individuals 
and its status as a quintessentially ‘biosocial’ infection (Persson et al., 2014: p.1088).   
 
These critiques emphasise the impact of a HIV diagnosis on identity and relationships, and 
the burden of medication and the everyday management of the illness on dimensions such as 
socio-economics and feelings of safety (McGrath et al., 2014; Mazanderani, 2015;  Persson, 
2013; Persson et al., 2014; Moyer and Hardon, 2014; Mattes, 2014; Philbin, 2014).  These 
authors would argue that a potentially sexually infectious condition with such a long-standing 
social stigma, with direct impacts on intimate relationships, and an ongoing dependency on 
health care services and biomedical relationships, struggles to fit into a categorisation of 
‘normality’ (McGrath et al., 2014; Persson, 2013; Persson et al., 2014; Mazanderani, 2015).   
The socio-economic dimensions of an emphasis on and prioritising of one’s health so as to 
ensure drug therapies are optimised, they argue, tend to be overlooked.  Recognising, 
according to this literature, that individuals with HIV who have better and more access to 
material resources, a more stable everyday life or more inclusive and accepting communities 
of support will have a differential ability to ‘live well’ with HIV is critical.  For example, 
McGrath et al. as well as Kalofonos found that food prices directly impacted individuals’ 
sense and ability of managing their HIV well (McGrath et al., 2014; Kalofonos, 2010). Even 
when treatment may be freely supplied and health services equally offered to the general 
population, such as in the UK, other socioeconomic, psychosocial and contextual factors 




Normalisation and primary care  
 
The tension between HIV’s historic exceptionalism and the more recent normalisation project 
was evident in the policy documents and the accounts of those active in the wider policy 
community. From this flowed many implications for practice and for the primary care setting.  
The ‘normalisation’ of HIV testing was positioned as a way of reaching the undiagnosed 
population and ensuring citizens were aware of their HIV status. Normalisation as an 
objective was stated within the policy documents and was supported with a variety of 
language in less direct ways throughout the documents (‘as with any other medical 
investigation’ (BHIVA et al., 2008: p.10) ‘like in usual medical practice’ (HPA, 2011). See 
these quotes from the policy documents:  
‘PHIAC considered that the routine offer and recommendation of an HIV test in 
certain settings would go some way towards normalising HIV testing.’ (NICE 2011a: 
p.17) 
‘Historically, HIV testing has been associated with genitourinary medicine and sexual 
health settings.  PHIAC recognized that if other healthcare and community and non-
clinical settings were used for HIV testing this would help make such tests the norm.’ 
(NICE 2011a: p.18) 
As seen by the policy maker and HIV expert speaking in the quote below, the term 
‘normalisation’ is often used with caveats, which I believe reflects the nuance and attention to 
patient experience emphasised by the rights discourse and an unsettled tension between an 
‘exceptional’ or ‘normal’ status for HIV infection.  This careful way of speaking about HIV 
and those impacted by the infection is a strong theme throughout all interviews and policy 
documents, a dimension I will further discuss later in the chapter. This continues to be 
evident in the quote below: 
‘I mean, we talk about universal testing, we talk about normalising testing which is 
probably an inadequate use of normalise obviously when you test for HIV it’s not 
normal.’ (Public health consultant with a research role and position with national 
health organisations) 
 
The changes called for through the normalising of HIV testing posed a number of challenges 
in practice, stemming from the history of HIV exceptionalism and in some senses the 
unresolved merging of new and old practices surrounding HIV.  This was evidenced in three 




HIV testing into focus, by centralising general practice in the response to HIV and by 
challenging prior best practice in HIV testing and care.  
 
Bringing new forms, sites and practices of HIV testing into focus 
 
‘So we need to address testing.  There are a number of ways of doing that.  That is 
how do we get testing more prevalent, how do we encourage people for testing… So I 
mean there is that one about community testing which we have a very mixed view on.  
You know, do you really want to be told that you are HIV-positive while you are 
sitting in the pub one evening?  Because they do testing in pubs.  Who wants to 
receive their cancer diagnosis sitting in a pub?’  (Head of HIV-positive patient 
organisation) 
 
The HIV normalisation discourse brings new sites and methods of testing into focus, for 
example rapid tests. In emphasising the normality of testing for HIV infection, spaces where 
tests are offered expand.  Providing testing as a part of one’s overall health check within 
general practice is a relatively new mode of offering testing.  Other important sites within the 
policy document were ‘community’ spaces.  This includes churches and community centres, 
among others.  Such sites were often those where the ‘undiagnosed’ might be encountered.   
Along with recommendations for screening style approaches in primary care were guidelines 
for testing in other ‘non-traditional’ clinical settings. The HINTS (HIV Testing in Non-
Traditional Settings) study was also underway at the time of the RHIVA2 trial.  This study 
assessed the acceptability and feasibility of testing in emergency, acute care, dermatology and 
primary care settings (Rayment et al., 2012).  In April 2014, home testing was approved in 
the UK and HIV tests are now available for purchase at local pharmacies (Stephens, 2014). 
Rapid testing and what it brings forth is discussed by a GP in the quote below:  
‘So the rapid test brings- it’s a cluster isn’t it?  A rapid test? So it means you get 
results quickly.  It also means it’s been linked with healthcare assistants.  So it 
suddenly means a different person is doing the test as well... and so by implication, 
’cause this is task shifting then by implication, you know is a health care assistant 
qualified to do any sophisticated chats? So therefore, we’re now by default dumping 
the counselling… there is a constellation of things kind of going on here isn’t there?’ 





In this case, offering tests as a part of new patient health checks represents a change to a 
number of the practices that were previously thought to exceptionalise HIV.   These may 
include consent procedures, pre and post-test counselling and care in specialist clinics.   Once 
hard-won dimensions of HIV care, such practices are now positioned as barriers to testing 
and as contributors to stigma surrounding HIV tests.  An HIV consultant describes how this 
tension plays out in the clinic: 
‘The complication we have got now is that it is all muddled up.  So half the 
medical/clinical workforce have to do counselling and you are going ‘Well you have’ 
‘Oh yeah yeah, because I went on a course in 1992 and I know that you have to do 
counselling.’  Then you have the bright young things coming out of medical school 
who look at you as if you are mad.’ (HIV consultant with role in professional medical 
associations)  
Changing professional understandings of best practice for HIV are further discussed later in 
the chapter.  
 
The growing role of general practice: ‘Thinking HIV’ 
 
‘I think testing is still the biggest issue for general practice.  I think that there’s still a lot 
of work to be done on getting routine HIV testing for certain clinical presentations.  I 
think that there are still issues about the opportunistic testing of people who are at risk 
and there are some issues around how you identify those in general practice so, you 
know, it is difficult in general practice to have a way of identifying say a man who has 
sex with men because at the moment we can only code that as an illness in our systems 
and clearly that’s unacceptable to do that so there is no- so you can record it in 
someone’s record but then as time goes it cause falls into the background because it’s just 
a written thing in there, you know…so there are still issues, not only issues about 
practices making it somewhere where people feel it’s acceptable to identify themselves as 
say MSM or someone who’s used drugs, but then also about how that’s recorded in a 
way that can be clinically useful and then there is that next step of actually offering HIV 




Primary care occupied an interesting space in the discourse on normalisation.  Across the 
board in the interviews and policy documents, primary care was positioned as an opportunity 
and as an underperformer in HIV care.   The data on missed opportunities for testing along 
with the changes in the technology, techniques and treatment landscapes (as discussed in the 




testing potential and an important site in the ‘normalisation’ logic.  All manner of health 
professionals are now able to offer tests and patients with stable HIV infections should be 
seeing their GP for health concerns unrelated to HIV at a seemingly cheaper cost to the NHS.  
What emerged in the interviews however was wide-scale support for the ‘normalisation’ of 
HIV and HIV testing, but also inter-professional tensions affected by the legacy of ‘HIV 
exceptionalism’ and to some degree its related ‘activist’ discourse.  Of additional frustration 
for GPs was the clash between the pragmatic dimensions of primary care and the exceptional 
practices of historic HIV care.   This tension often played out around targeted versus 
universal testing and its feasibility in a primary care setting.  Some GPs considered the 
‘exceptional’ status of HIV amongst infectious diseases affecting the general population as a 
challenge to their sense of an appropriate dedication of resources. This is described in the 
quote below, with reference to resource splitting:  
‘And then what are we saying, you know, about Hepatitis screening.  I can’t do that.  
There’s far more people dying, getting their liver cancers and their liver failure from 
viral Hepatitis frankly.  And in all honesty, the figures make HIV in the UK, you 
know…, and you just want to laugh sometimes, you know?  Like I can’t as a GP 
single out HIV for this special treatment in the London setting, you know? Hepatitis 
is, we should be spending far more time and energy on Hepatitis.’ (GP with special 
interest in HIV and participant in HIV related medical associations) 
 
Typically, HIV-positive patients in the UK have been cared for in specialist secondary care 
services.  The expert knowledge around HIV treatment options, the virus itself and the 
psycho-social dimensions of the infection could all be tackled in such centres, which typically 
house specialist HIV consultants, health advisors, psychologists, research nurses and patient 
representatives, amongst others.  It appears that inter-professional tensions around best 
practice for HIV-positive individuals has contributed to the problematic way HIV in primary 
care has been positioned.  While it is difficult to determine how evidence based many of the 
‘vague swirling fears’ (GP with specialisation in HIV, member of professional medical 
association) surrounding general practice may be, what is relevant here is their interaction 
with existing discourses in HIV and how they impact the policy agenda.   Cited problems in 
primary care tend to include issues of confidentiality, drug contraindications, stigma, missed 
opportunities for testing and in the words of one of my patient representatives for this project, 




‘[there are] lots of historical influences, and lots of kind of slight vague, swirling fears 
about confidentiality and discrimination in choosing not to use their general practice.  
So, I felt we were kind of in a vicious circle whereby if GPs weren’t seeing people for 
HIV they weren’t ‘thinking HIV’ and therefore they were less likely to think about 
testing people for it.’ (GP with specialism in HIV and participation in professional 
medical association) 
 
Interviewees with experience of primary care discussed the occasional clash between 
suggested practices emerging from the expert HIV community with the structures of primary 
care.  Primary care appeared assigned with a number of recommendations but little resource 
or consideration of existing structures.  Resource was continually mentioned, along with the 
growing load of responsibility placed on general practice to incorporate complex health care 
needs in a streamlined fashion.  The quote below reveals some of the frustration along with 
the pragmatic dimensions of delivering generalist medical service: 
‘But they don’t understand how general practice works and they don’t understand oh, 
you know, I mean this comes back from…there is still a whiff of it that specialists 
think that in their area of expertise they have clinical governance, leadership and 
responsibilities over what happens in general practice as opposed to lying within 
general practice.  So I’d say so does that mean that the patient I see in the first 
minutes, if their consultation was about diabetes, that the person responsible for my 
quality of care is the local endocrinologist?  And then the second part of my 
consultation is about renal problems or HIV and then suddenly the clinical 
governances in that part of the consultation is the responsibility of? You know, it is 
just nonsense.  General practice has its own professional structures and 
responsibilities and there is an idea that, you know, we cook up something that’s 
meant to be good and you’re all meant to be doing and actually it’s my responsibility 
to get you doing it and it’s fine.’ (GP with special interest in HIV and membership on 
professional medical associations)   
 
As primary care became centralised in the response to HIV the tensions between the 
exceptionalism and normalisation discourses played out in real terms by challenging existing 
structures and practices.  Primary care was assigned new roles and the changing nature of 
HIV infection and the multiple practices surrounding it transitioned.  What were also present 
within these discourses however were the temporal dimensions of HIV and its care over the 





A discourse of HIV temporality and multiplicity  
 
Throughout the PhD, I have come across points of tension when considering HIV 
contemporarily.   One has been related to the infection’s transition into a chronic treatable 
medical condition and the subsequent effects.  This initially struck me as a challenge for 
health promotion, where on the one hand the message has been: ‘do not get HIV, it is 
dangerous to you and your partners, you might die’ and on the other hand: ‘HIV is a treatable 
medical condition, you can live well and for a long time and be unlikely to transmit the 
infection by taking medications’.  The tension appears to be around how one can be both 
healthy and ill while having an HIV infection, how the infection can be both ‘chronic’ and 
‘acute’ within one body, and how testing can be normal or dramatic depending on the stage 
of the infection and situated factors.  Temporal dimensions appear important within the 
infection for a single person (i.e. early/late detection), yet considering HIV historically also 
reveals how diverse HIV has been in its social and clinical enactments.  One could begin to 
consider that there has been a multiplicity of HIVs (Mol, 2002). Essentially, pulling HIV and 
HIV infection into a unifying definition or summary of descriptions and experiences has 
become more difficult as the treatment possibilities, ways of managing the infection clinically 
and negotiations of ‘survivorship’ have diversified (or possibly just been made known to 
official bodies) (Newman et al., 2010).   Considering HIV temporally and multiply allows for 
a description of the findings around the varied history of HIV testing practices, multipronged 
policy approaches and unsettled policy language as well as the alterations in professional 
relationships surrounding HIV infection.  
 
This discourse presents challenges for policy and is reflected in the suggested ‘multipronged’ 
approach to health promotion and HIV testing activities, a strong theme throughout all four 
policy documents and most interviews.  This has also meant that different providers and 
patients may have had widely variable training and experiences around HIV infection.   
 
Newman et al. identified the discourse of ‘HIV generations’ in their paper: ‘HIV 
Generations? Generational discourse in interviews with Australian general practitioners and 
their HIV-positive gay male patients’ (2010).  While the primary objective of their study was 




experience was impacting the meaning of HIV for patients and practitioners.   The 
generational discourse is defined through the three main features of ‘treatment histories’, 
‘socioeconomic status’ and ‘modes of survivorship’:  Newman describes the discourse below: 
‘A pre-HAART generation is imagined as burdened by the limited availability, 
effectiveness and side effects of early treatments.  Their socioeconomic lives are seen 
as shaped by an inability to sustain employment, leading to entrenched disadvantage.  
The surprise renewal of a long-term life course means this pre-HAART generation is 
now represented as dealing with ‘survivorship’ issues relating to body image, 
community and family support, and social status.  The post- HAART generation, on 
the other hand, is imagined with far less clarity (particularly by the GPs), perhaps 
because there are such a diversity of issues that affect PLHIV now, whether they were 
diagnosed pre- or post-HAART.  However, in so much as a ‘picture’ of post-HAART 
generation is being painted here, it could be best characterized by a more 
individualized experience of health and illness, a greater focus on the challenges of 
balancing work and health priorities, and complex new social and survivorship issues 
relating to sexual ethics, community and responsibility.’ (Newman et al. 2010: 
p.1726) 
 
While Newman et al.’s description of HIV generations is fairly specific to patient experiences 
with some reflection on impacts for general practitioners, it highlights important temporal 
and historical aspects of HIV as they relate to broader changes in HIV treatment possibilities 
but also the stage and treatment of HIV infection within individuals alone.      
 
HIV testing’s varied history  
 
‘We used to make it so difficult to take a test in the old days, you used to have to be a 
PhD just to propose it.’ (Patient representative at local HIV specialist clinic)  
A look at the varied history of HIV testing helps articulate the temporal shifts in HIV testing 
as well as shed lights on the current enthusiasm for universal HIV testing.   Transitions in the 
professional community around approaches to testing are well summarised by an HIV 
consultant with a senior position in a HIV related professional medical association. She 
describes her work in HIV since the early days of the epidemic: 
‘If we go back to the very beginning when we didn’t know HIV was causing AIDS 
and there wasn’t a test, the way the subject of testing was approached was very 




complicated place because the issue was then if you test, what difference will it 
make? In those early years of the epidemic not only did it make little difference to 
your own future, it potentially made things a great deal worse.  So there was a really 
difficult moment about what you do with this new test we’ve got.’  (HIV consultant, 
departmental head with senior position in national medical organization)  
The consultant goes on to discuss the relevance of changes in the treatment possibilities to the 
experience of offering testing.  She then puts the zeal of the HIV community to endorse and 
promote testing into context:  
‘It became clear that AZT on its own was buying something… so suddenly, or not 
even suddenly, the thrust of our testing grew because there as an intervention that 
made sense.  That was quite an important tipping point because at that point there was 
enough experience of nothingness, no follow up, for this to be quite a strong event.  
And so moving forward into testing became quite complex and it took quite a lot of 
influencing around health professionals because the mantra had been, you don’t do 
that.  Suddenly, we were saying ‘you know what, you do do that!’ That has only 
grown as treatment has improved.  And so as we have got to the point that treatment is 
now as good as it is in securing longevity and preventing death then of course 
something that is in the hands of biomedical practitioners, that you are able to do that 
with, you want to do it.  And so now the expert medical community really can’t test 
enough people.’ (HIV consultant, departmental head with senior position in national 
medical organization)  
The social and biomedical mobilisations of the research community around HIV have long 
appeared as fast-paced, dynamic and impassioned, with HIV taking on a unique status among 
communicable disease, particularly sexually transmitted infections.  With a number of 
committed health practitioners long witnessing the suffering of their patients, now armed 
with the treatment possibilities available in the UK, the contemporary HIV testing context 
and the support for policies around early detection and population wide testing become more 
understandable.  
 
How ‘multiplicity’ plays for policy and unsettled policy language 
 
This diverse character of the infection and its various presentations can also be mobilised in 
multiple ways to support policy objectives and interests.  In regards to the policy in question, 
offering HIV tests to all new registrants in general practice in areas highly endemic of HIV, 
multiple aspects of HIV infection can be called upon to justify and uphold the policy. HIV as 




support of policy objectives.  One logic would go: if HIV is a chronic, treatable medical 
condition, then it should be normalised as a part of regular health checks and it is acceptable 
to be offering tests to everyone with little pre or post-test counselling with reduced time and 
resource allocation.  Another might be: if HIV is a life threatening, infectious disease with 
serious impacts on population health and resource, then new ways of detecting and 
diagnosing the condition are justified, supported by a danger and risk discourse, as discussed 
earlier in the chapter.  While both statements are evidentially supportable it means that 
various, sometimes competing, other times colluding, discourses can be mobilised to support 
the policy in question, which may impact its widespread support, along with the enabling of a 
policy window, as discussed in Chapter 6.  
 
Another tension appeared in the policy documents between generalising HIV infection or 
communities affected by HIV, while also attempting to discuss broad strategies and 
populations.  In the NICE guidance on testing black African communities for example, a list 
appears defining ‘additional identities’ black Africans may have.  See this quote from the 
guidance:  
‘Throughout the guidance the term ‘black African’ includes anyone who identifies 
themselves as black African, whether they are migrants from Africa, African descendants 
or African nationals.  Black African communities encompass diverse population groups 
including people: 
: from a range of cultural, ethnic and faith backgrounds 
: who may be heterosexual, bisexual or homosexual 
: who may have physical or learning disabilities 
: whose knowledge or understanding of English may be limited’ 
(NICE 2011a: p.4) 
 
This stood out in my analysis as incorporating aspects of the ‘rights’ and ‘activist’ discourse, 
and recognising the range of ways HIV interacts with populations, but also as a struggle to 
sensitively speak about populations in a generalised way.  It appears that even the policy 
documents struggle to acknowledge the situated, individualised aspects of HIV infection 
while making population-based recommendations.  
 
 





‘there was this whole sub-profession of counsellors built up around it frankly.  There 
were a whole load of specialists who were grabbing and white knuckling patients.  
This is me being very cynical now.  Some of my best friends are HIV specialists but 
there was a keep off our precious territory thing going on for ages, right? (GP with 
specialism in HIV and participation in HIV professional associations)  
The generational shifts in both the nature of HIV infection and the culture of practices 
surrounding the infection were also evident when discussing the expanding role of primary 
care and the role of HIV practitioners.  One young HIV consultant felt that there were strong 
differences between her generation of specialist consultants and the older providers who 
treated HIV in the pre-HAART era.  She felt that while primary care received much of the 
blame for not better incorporating HIV care, there were aspects on the side of expert 
consultants that impacted this impression. See this quote:  
‘There are still a few kind of stalwart absolutely not.  I will never see my GP for 
anything.  I want you to manage my HIV care.  But I think it’s just about how we spin 
it with people.  So, you know. I can pinpoint the clinicians that work within my unit, 
whose patient they are because they will be the clinician having negative impression 
about primary care that’s led the patient to believe that, do you know what I mean? A 
session with a different doctor would perhaps put a different slant on it for me.’   
(HIV consultant with membership on HIV related professional medical associations)  
 
Present here are also the ‘rights’ and ‘activist’ discourse (Siedel, 1993).   Throughout the 
interviews it was clear how much care and nuance are valorised in discussing the infection 
and the patient population in relation to HIV.  As aforementioned, a great many of the older 
HIV specialists have been treating HIV since it was a deadly condition for which they could 
provide little more than therapeutic and palliative care.  Some have journeyed through the 
transitions of the infection and its implications alongside their long-standing patients.  The 
early years of the HIV epidemic were often cloaked in war terminology. The language around 
the ‘fight against AIDS’ has now transformed (‘the response to HIV infection’ (NAPWHA, 
2013) and it is feasible to imagine that early practitioners felt and may continue to feel 
engaged in an epic battle for lives and against social injustices.   The young consultant 
continued, as was echoed in a quote earlier by a specialist GP, about the sense of territoriality 




‘I think that HIV practitioners have been quite guilty of closeting their patients and sort 
of keeping them all in house and making them feel like we can manage all aspects of 
their healthcare better than primary care physicians or whatever so we have kind of 
fostered this attitude amongst patients as well that HIV is not accepted by the wider 
community’ (HIV consultant with membership on HIV related professional medical 
associations)  
The consultant highlights some of the generational differences in HIV care and experience, 
describing some of the territoriality that may have ensued and its impact on the perceptions of 
patients.  
 
7.4 Discussion  
 
Through analysis of three dominant discourses HIV appears as an active and changing entity 
as it interacts with science and society. Language, practices and locations for HIV have 
diversified in the face of a disease in transition and it becomes apparent that practitioners 
have been treating different HIVs dependent upon the site, the timing and the individual 
(amongst other variables).   HIV discourses are mobilised in different ways and alter material 
practices.   
HIV screening activities such as those seen in RHIVA2 are centralised and upheld by 
discourses of risk and surveillance, HIV normalisation and of HIV generations.  These 
discourses interact, challenge and inform each other.   
 
Positioning undiagnosed HIV and therefore ‘healthy’ civilian bodies as sites of danger and 
risk represents shifts in how risky bodies in relation to HIV are conceptualised, particularly as 
those known to be HIV-positive begin to gain new claims on health and lose their ‘infectious’ 
status. As a result, activities such as population wide screening bring the general population 
into view and encourage individuals to survey their own bodies and behaviours for signs of 
potential infection and illness in waiting.   Practices shift to streamline HIV testing activities 
with knock on effects for professional roles and responsibilities.  The tension between being 
healthy and normal with HIV infection, while still recognising the exceptional circumstances 
being HIV-positive brings into being, represents a strong tension in the discourse, but also a 




and a potential space for greater HIV care.  This challenges historic best practice and 
professional identities.  The multiplying of known experiences around HIV, the temporal 
dimensions of the illness within individuals and over the history of infection and this 
relationship to practices and providers means that HIV has been enacted in multiple ways 
over diverse spaces and times.   
 
One way of integrating these findings is by thinking of HIV as multiple, as suggested by 
Annemarie Mol in her praxiography of disease, The Body Multiple (2002). In this suggested 
ontology, disease may be seen as ‘more than one but less than many’ dependent on situated 
factors.  Instead of imagining one singular HIV sitting in various sites and individuals and 
undergoing diverse practices, Mol may suggest that there are many HIVs, constituted by 
these factors, not only subjected to them (2002). 
 
Thinking of HIV as an emergent and multiple object, as suggested by Mol, allows for the 
consideration of how HIV has been presented in the policy documents and interviews more 
fully and may allow for the accounting of the infection’s diversity in a way that can neutralise 
tensions and let policy, providers and settings adapt without encountering such degrees of 
dissonance.   The fragmented policy language becomes more understandable, as do the 
multipronged policy approaches. In this frame, HIV as both normal and exceptional, the HIV 
of yesterday’s specialists and of the new ‘bright young’ medical students coheres.  This way 
of thinking about disease may be more helpful than struggling to bring HIV into one unifying 
definition as space for multiplicity is created and a reconciliation of descriptions and 
definitions becomes less necessary.  
These themes will be considered throughout the thesis and more centrally in Part 3 where 
patient experiences in RHIVA2 are explored.  As I describe the enactment of the RHIVA2 
trial, the patient experience of testing and the work on the pragmatic trial design it is possible 
to trace the influence of these key discourses, including their role in constituting the two 






7.5 Conclusion to Part 1 
 
The discourse analysis presented above in Chapter 7, combined with the empirical analysis in 
Chapter 6, introduce what constitutes Story 1 of this thesis.  The logic of normalisation 
becomes evident and ushers in new populations for testing and sites such as general practice 
take on increased responsibilities in HIV care.   
 
‘Normalising’ HIV came about in response to HIV’s historic exceptionalism and aims to treat 
HIV ‘like any other medical condition’.  This logic reflects shifts and tensions in 
transforming understandings of health and illness and in practices related to detection and 
diagnosis.   Here, the normalisation of HIV is aspiring and aims to reorganise perceptions, 
practices and experiences of the infection to align them with biomedical shifts in the 
implications of the disease on the body.  Shifts positioned as available and desirable if one 
adheres to HIV medication and participates in medical services. Screening, once considered 
an inappropriate method of testing for HIV is enabled by this move and informed by HIV’s 
biomedical transformation into a treatable condition. As a ‘normalising technology’ (Philbin, 
2014) screening for HIV in primary care represents a new mode of testing and aims to detect 
an ‘abnormality’ that enables medical intervention.  Such intervention may translate into 





PART 2:  RHIVA2 in practice: Implementing and evaluating a complex intervention  
 
In Part 2, I explore the implementation of the RHIVA2 trial across a sample of primary care 
organisations.  It is here that ‘logic of normalisation’ and the ‘logic of the pragmatic trial’ 
converge in practice. In RHIVA2 20 GP surgeries in a borough with a high prevalence for 
HIV were tasked with implementing the policy described in Part 1, the offer of an HIV test to 
new registrants in general practice.  Meanwhile, the RHIVA2 team evaluated, using a cluster 
RCT design, whether offering testing in this way would lead to a greater and earlier detection 
of HIV.  While Part 1 described  Story 1: ‘the logic of normalisation’ through analysis of the 
policy context and an exploration of population screening approaches for HIV, Part 2 begins 
to draw out Story 2: ‘the logic of the pragmatic trial’.  Using the Greenhalgh et al. model of 
the diffusion of innovations for health care organisations, I explore variation in the uptake of 
rapid testing amongst the intervention practices.  Process evaluation methodology is used to 



























Chapter 8: EVALUATING COMPLEXITY: INTRODUCTION TO PART 2  
 
I begin with an exploration of methods and how the research community has broadly aimed 
to measure and evaluate health interventions, with attention to the important issue of 
‘context’.  I will then introduce the findings in Chapter 9. 
 
8.1 Methodological considerations: The RCT and Its ‘Origin Stories’9  
 
RCTs are widely considered the key evaluative design for evidence-based medicine 
(Goldenberg, 2006).  Presently, such trials are known as the ‘gold standard’ and the backbone 
for producing clinical evidence.   Evidence in this case can be considered as ‘information that 
gives a reason for believing something to be true’ and this supposes an audience for whom 
this will make a difference (Kelly, 2008).   RCTs comprise a number of key components 
including intervention and control arms, randomisation and blinding (Friedman et al., 2010).  
Research subjects are randomly allocated to either the experimental arm or the control arm of 
the study.  Commonly, the experimental group receives the health intervention while the 
control arm continues with care as usual or receives a placebo (Friedman et al., 2010). 
Randomisation includes assigning subjects to either arm of the study in a random way.  This 
is meant to reduce bias or the potential for confounding variables by ensuring that there is 
likeness between the 2 arms, save for the intervention being delivered (Singal et al., 2013).   
 
The sample size calculation, which indicates the number of participants required to achieve 
statistical validity, forms an essential aspect of randomisation, as if the group is too small, the 
beneficial effect of randomising will not be achieved, invalidating the findings (Friedman et 
al., 2010).  Allocation to arms should be conducted with the help of a technology that 
removes human bias, such as a random numbers machine (Friedman et al., 2010). Trials can 
be conducted with variable levels of blinding. Double blinding is considered the strongest 
design, where both the researchers and the participants are unaware of which research 
subjects are allocated where (Friedman et al., 2010). Depending on the trial design or the 
                                                
9 I first heard the term ‘origin stories’ used to discuss the history of RCTs during a talk by Ann Kelly entitled:  
Ebola Clinical Trials:  Accelerated Experiments, Repurposed Evidence at the Brocher Foundation, February 16, 




intervention, blinding may be more or less possible, in some cases, such as in some pragmatic 
trials of complex interventions, blinding is not feasible (Foster and Little, 2012).  
 
At the end of the trial, the two groups are compared and, all other factors holding even, the 
effect of the intervention can be determined.  This is considered the beauty and strength of 
this evaluative technique, a relationship can be determined between the intervention and the 
outcome and this is claimed to be causal and deterministic of the efficacy of particular 
interventions (Godwin et al., 2003). These aspects are the tenets of the RCT and are valued 
for their understood role in reducing bias, controlling for confounders and producing 
objectivity, causality and rigour.  It follows that data produced by this method are interpreted 
as evidence and subsequently contribute to decision-making in medicine.   
 
Within biomedicine, RCTs have been widely considered the best method of determining the 
efficacy of an intervention.  The aim is to control the conditions to maximise the likelihood of 
an intervention effect (Singal et al., 2013). If, under such conditions, there is a statistically 
significant effect demonstrated by the intervention, it can be considered to have high internal 
validity, which is the confidence that the intervention did cause the effect and the subsequent 
causal implications are valid (Rothwell, 2005). Explanatory trials or efficacy studies are 
considered a fundamental first step in determining the value of an intervention, determining 
the efficacy indicates that under controlled conditions the intervention is or isn’t effective, 
allowing for the determination of added values or harms of an intervention (Treweek and 
Zwanrenstein, 2009).    
 
Recognising methodologies as being historically and culturally situated requires some 
reference to their origins.  A number of scholars exploring the RCT method describe the 
device in historical context to better understand its current value and historical articulations 
(Löwy, 2000; Kelly, 2008; Meldrum, 2000). For centuries, the curious have been exploring 
comparative and controlled methods, developing some of the early foundations of 
experimentality now integrated into the RCT design (Meldrum, 2000). Marcia Meldrum has 
done significant work tracing the origins of the RCT and describes these early experiments as 




now term ‘treatment options’ (2000).  Meldrum describes how Johannes Fibiger used the 
earliest well-documented RCT design in 1898 on patients with diphtheria (2000).  This was 
followed in 1930 by a study using a similar method to look at digitalis for pneumonia 
(Meldrum, 2000). The RCT design increased in value with the burgeoning of drug 
development and pharmaceutical companies in the early 20th century.  Doctors and patients 
felt they had very little means to evaluate the ever-growing number of drug options appearing 
on the market (Löwy, 2000).   Despite the existence of studies using principles of the RCT 
design, such as the use of controls, large questions about generalisability and replication 
remained.  As a result, clinicians and researchers began to develop methods for the 
production of what could be considered more robust evidence.    
 
The RCT had some major champions, including Austin Bradford Hill and Archie Cochrane 
(Kelly, 2008). Bradford Hill wrote a series of papers, published in the Lancet in 1937, which 
mark a period of greater consideration of investigator bias and controlled methods (Meldrum, 
2000).   Meldrum describes the importance of this move in the quote below:  
‘by removing decisions about patient selection and allocation from the physician and 
forcing the use of standardized, non-qualitative criteria to assess outcome, the RCT 
model eliminated opportunities for deviation based on physician judgment of bias 
while providing a powerful basis for conformity’ (Meldrum, 2000: p.753) 
Around the same time others developed the principle of blinding and soon came the first 
attempts at methodological guidance from Feldman, Hinshaw and Mann who published a set 
of trial design principles that aimed to bring together the emerging thinking in a way that 
standardised design techniques (1945).   The first officially documented randomised 
controlled clinical trial is often considered the MRC’s 1947 study of the treatment of 
tuberculosis with streptomycin, which used randomisation, blinding, and intervention and 
control arms (Meldrum, 2000). For this project Bradford Hill developed a system of random 
number assignment, despite having stated concerns about the ethics of randomisation 
(Meldrum, 2000). Bradford Hill is also important in producing a scenario where the 
unintended effects of trials are clearly evident, his support and enrolment of patients in trials 
served as a method of enabling access for members of the public to treatments, which were 
otherwise inaccessible to the patients in need (Stavrou et al., 2014; Kelly, 2008; Meldrum, 
2000). This period saw a coalescence of prior work and findings into what was hoped to be a 




designed trials were then successfully replicated in the United States, reinforcing the value of 
the approach. Ilana Löwy, in her discussion of trials as a ‘soft’ biomedical technology also 
highlights how the RCT increased the role of the statistician and forced the entry of other 
‘experts’ into the biomedical realm, resulting in shifts in the enactments of expertise and 
decisional power (2000). 
 
Archie Cochrane, himself a student of Austin Bradford Hill and whose legacy as the 
namesake of the Cochrane reviews and collaborations remains, was also an important figure 
(Stavrou et al., 2014).   He saw the RCT as the key to a rational health service (Kelly, 2008).  
Cochrane is considered a key paternal figure in the development of evidence-based medicine. 
Concerned by bias and inconsistency in medicine, he believed the systematic gathering and 
evaluation of robust evidence was much needed in the British medical service (Stravrou et al., 
2014).   Cochrane emphasized the importance of experimental methods and systematic 
reviews, feeling that medical interventions should always be evidence based and that such 
evidence should be produced in the form of trials (Shah and Chung, 2009; Stravrou et al., 
2014).  These views culminated in his 1971 monograph: ‘Effectiveness and Efficiency: 
Random Reflections on Health Services’ which garnered much attention and support 
(Cochrane, 1971; Shah and Chung, 2009). Cochrane stressed the importance of cost 
effectiveness and the appropriate and prudent selection of interventions (Shah and Chung, 
2009).  His insistence on the value of systematically gathering and organising evidence was 
the impetus behind the Cochrane Collaborations and Reviews (Stavrou et al., 2014). 
 
Much has moved on from the time of Austin Bradford Hill and Archie Cochrane.  While 
RCTs still reign in the hierarchy of evidence, a proliferation of critiques has spawned 
important adaptations to the traditional trial and a re-thinking of the suitability and 
application of RCTs to diverse phenomena.    
 
While the benefits of the RCT are widely acknowledged, for some time a growing body of 
academic work has highlighted the problems inherent to the design (Goldenberg, 2006; 
Oakley, 1990; Cartwright and Munro, 2010).  The majority of critiques of the explanatory 




groups and situations (Rothwell, 2005).  While efficacy is useful it does not take into account 
the social, cultural and practical interactions that will determine if an intervention can be 
applied to a representative population of patients (Blackwood, 2010).  Some feel RCTs keep 
medicine focused on disease and not patients and that they fail to incorporate context and the 
important ‘evaluations grounded in the individualized and embodied skills of the practitioner’ 
(Löwy, 2000: p.50) as well as the experiential life worlds of patients.  The movement of 
methods from the lab and its crafted environment to an active clinic has a troubled 
transferable capability (Löwy, 2000). There is a diversity of approaches presented in these 
critiques.   Some feel the solution lies in tinkering with the design of trials to match more 
complex environments but that a greater challenge to the overarching claims of evidence 
produced by trials is not required. Others feel that the objectivity and outcomes claimed by 
the RCT are overstated and represent a portion of reality, that they are crafted within a 
particular approach to science and thought that could do with epistemological and ontological 
shift or destabilisation (Cohn et al., 2013; Rosengarten and Savaransky, 2015).   
 
A number of concerns regarding trials also centre on practice.  Along with the rise of the trial 
has been the growth of a number of safeguarding and governance requirements to ensure the 
ethical use of the method.  It is understood that the promise of trials can only be achieved 
when they adhere to best practice, which is outlined in various stipulations and frameworks 
(Freedman, 1987). The ever-changing number of articulations of said best practice in the 
conduct of trials may be summarised through their potential ethical concerns.  These are 
outlined briefly below by trial phase.  
 
In the design stage, important questions concern the general necessity of a trial and the 
relevance of the research question.  This may also bring in more practical considerations 
around costs and the temporal relevance of the work (Friedman et al., 2010).  Here the 
concept of equipoise - ‘a state of genuine uncertainty on the part of the clinical investigator 
regarding the comparative therapeutic merits of each arm in a trial’ - is important (Freedman, 
1987:142).   Ethically, trials should be discontinued and both arms offered treatment should 
there an obvious beneficial effect (Freedman, 1987).  Additional concerns may arise around 
the randomisation procedures, the appropriateness of a control group and the acquisition of 




the recruitment, the data collection and the way power is practiced.  Trials conducted in 
resource-poor settings have evidenced some of these concerns through examples of 
exploitation, coercion to participate and the unethical use of placebos (Miller and Brody, 
2002).  Additional problems may arise in the reporting phase with publication bias and the 
lack of reporting on ‘negative trials’ (where findings are not determined statistically 
significant, signaling a lack of effect), the suppression of trial findings or delays in reporting 
(Goodchild van Hilten, 2015; Turner et al., 2012).  Conflict of interest is woven through the 
trial process as an overarching concern (Lo et al., 2000). 
 
In summary, conventional RCTs act in various ways.  They demarcate a standard, work as an 
evaluative tool, and are a symbol of contemporary valuations of evidence and science (Löwy, 
2000; Kelly, 2008).    Moreover, the methods used help create the ‘reality’ produced and 
measured and a trial in and of itself may be considered an intervention, regardless of what the 
actual intervention seeking measurement may be (Law, 2004).  In some cases, trials may be a 
mediating device between science, corporations, the government and the public. In others, 
they may be means for patients to access treatment (Kelly, 2008).  In the face of significant 
dispute and contestation over aspects of the RCT, other designs have emerged, sometimes in 
an attempt to compensate for the evidence that cannot be produced by this design, in other 
cases to tinker in ways that allow the beneficial principles of the RCT to remain intact while 
achieving other stated objectives.  The RHIVA2 trial was developed within these approaches.  
As a pragmatic trial it is meant to be a better directive for evidence related to contemporary 
health care practice.   
 
8.2 Tinkering with trials: The rise of adjunct designs and the pragmatic RCT 
 
Critiques emerging from the use and status of efficacy trials and the need to evaluate 
treatments and interventions in practice gave rise to the ‘pragmatic’ clinical trial (Treweek 
and Zwarenstein, 2009). These trials aim to measure the applicability of an intervention in the 
‘real world’ and everyday setting of routine medical practice (Kelly, 2008).  Such trials aim 
to produce results more generalisable and instructive for broad clinical practice with greater 
utility for policy makers, health professionals and patients (Foster and Little, 20012) 




Lellouch, who felt that ‘there is ambiguity about which two radically different kinds of 
problems they [trials] are designed to address’, referring to the difference between efficacy 
and effectiveness (Foster and Little, 2012).  Eldridge and others discuss a resurgence of 
interest in the pragmatic trial with an expanding conversation about the best practice, 
regulatory processes and overall design of such studies (Eldridge, 2010; Sugarman, 2014; 
Blackwood, 2010; Rothwell, 2005; Kelly, 2008; Singal et al., 2013).  This corresponds with a 
maturing conversation on complex interventions, critiques of evidence based medicine and 
the appropriate methodologies for acknowledging and measuring complexity and context 
(Greenhalgh, 2014; Hawe et al., 2004; Mowles, 2014). 
 
Pragmatic trials differ from efficacy trials in various ways in trying to achieve the 
complementary objective of effectiveness. Pragmatic trials usually include a high external 
validity, large sample size, an emphasis on diverse settings, a heterogeneous and 
representative research sample and variations on understandings of bias, such as blinding 
(Treweek and Zwarenstein, 2009).    In a pragmatic trial, procedures should reflect everyday 
clinical practice, changing as little as possible about the setting in which the interventions and 
treatments are delivered (Macpherson, 2004; Selby, 2012; Roland, 1998; Treweek and 
Zwarenstein, 2009; Patsopoulos, 2011). Along with acknowledging the importance of 
context, and the challenges to the evidence based medicine paradigm, has been a greater 
proliferation of guidance, tools and reflections on pragmatic trials, making the pragmatic trial 
a recognised member of the contemporary methodological class (Zwarenstein et al., 2008). 
The extension of the CONSORT statement to include reporting on pragmatic designs in 2008 
is indicative of this (Zwarenstein et al., 2008). Pragmatic trials may also require cluster 
designs and a more intensive reporting on the specificities of the intervention (Eldridge, 
2010). There is increasing acknowledgement that many trials exist on an explanatory – 
pragmatic spectrum, often containing a mix of elements (Foster and Little, 2012; Eldridge, 
2010; Thorpe et al., 2009).  This is demonstrated in the PRECIS tool, established to 
determine the extent to which a trial is pragmatic by thinking through a set of questions, then 
evaluating against a scale and applying the results to a final PRECIS ‘wheel’, which 





As pragmatic trials are meant to be rolled out in ‘everyday’ settings, they often call upon 
implementers who are not professional researchers, including a wide range of health 
professionals.  This has led to the acknowledgement of the importance of behavioural and 
relational dynamics in the conduct of trials as well as cognisance of the ‘therapeutic 
relationship’ and its interaction with trial findings (Foster and Little, 2012; Eldridge, 2010; 
Sugarman and Califf, 2014).  In a pragmatic trial, the practical realities of capacity and 
economics in the research implementation also weigh in.  Primary care research recognises 
pragmatic trials as an important methodology due to the ‘everyday’ setting, access to patients 
and range of services normally provided in primary care.   Some writing has been focused 
specifically on the pragmatic trial application in primary care (Foster and Little, 2012; 
Lancaster et al., 2010; Eldridge, 2010). 
 
Despite how many of these interferences demonstrate how ‘the shackles of simple 
intervention thinking prove hard to throw off’ (Hawe, 2004: p.1583), the experimental 
method has continued to gain prominence and attempts are being made to measure a plurality 
of phenomena using a trial design (Marchal et al., 2013). This has resulted in variable 
success, with frustration among those who feel their interventions have clear merit but find 
themselves with insignificant findings and methodologies that do not appropriately reflect 
their interventions (Munro and Bloor, 2008).  This may be in spite of other ‘evidence’ 
affording value to the intervention.  This, in part, has given rise to the greater articulation of 
‘complex interventions’ and reflection how best to measure them. 
 
At present, complexity and accounting for context in the measurement of interventions is a 
pertinent subject in biomedicine.   Ray Pawson describes the challenge in the quote below: 
‘Every attempt to conduct an evaluation is beset with the impossibility of covering 
every angle; every attempt to conduct a review is faced with the impracticability of 
chasing down every single issue.  So, too, have the evaluation paradigms floundered 
in the face of complexity: experimentalists struggle to maintain control over every 
event, variable, whistle and bell; constructivists ply constructions on the co-
constructions of an endless supply of stakeholders; formative evaluators excavate to 
discover there are processes within processes within processes. And so whether 
evaluation seeks to judge, describe, inspire or explain, there is an ever-present 
predicament in claiming to have achieved closure in covering all eventualities.’ 





The literature on complex interventions relates to literature on pragmatic trials, with much 
conceptual overlap. The MRC defines complex interventions as those health interventions 
containing ‘a number of components which may act both independently and inter-
dependently’ and recognise the challenge this may pose in determining the ‘active 
ingredients’ exerting an effect (Craig et al., 2008 p.7; Shiell et al., 2008).  According to the 
MRC, this complexity is found in a number of areas including the number of interacting 
parts, the behavioural dimensions of delivering and receiving interventions, the number of 
players involved in the process, the recognising and measuring of numerous variable 
outcomes and the extent to which the intervention can be tinkered with while maintaining 
fidelity (Craig et al., 2008; Pettigrew, 2011).  They may also be difficult to describe and 
replicate, the pathways and mechanisms of action related to the ‘active’ ingredients may be 
uncertain or unknown (Lewin et al., 2009). In other words, it is not always clear what makes 
a complex intervention ‘work’ or not and so the impact of the intervention and the 
generalisability of findings to other settings can be unclear.  
 
The definitions of complexity presented in the MRC guidance, and the general terms of the 
conversation on complex interventions, have been problematised.  Alan Shiell and Penelope 
Hawe were some of the first to distinguish between complexity and complicated in relation to 
complex interventions (Shiell et al., 2008).  They outline complexity as drawing from 
complexity science and discuss the term as the property of a system versus an intervention 
(Shiell et al., 2008). In this sense, a complex system is: ‘adaptive to changes in its local 
environment, is composed of other complex systems (for example, the human body), and 
behaves in a non linear fashion (change in outcome is not proportional to change in input)’ 
(Shiell et al., 2008: p.1291).  The difference may not always be easy to tease out but this 
approach suggests a wider consideration of an ecological approach and the marco and micro 
interactions inherent to complex systems.  Cohn et al. also seek to pull apart the term 
‘complex intervention’, again problematising the definition of complexity:  
‘addressing complexity requires more than the simple adoption of an ever expanding 
number of variables or array of statistical tests. Rather, we have suggested that the 
notion of ecological complexity perhaps best captures the specific dynamics of 
complexity in the domain of health and illness.  Such an approach emphasizes not 




elements become meaningful and change as they travel through and interact in 
particular contexts.’ (Cohn et al., 2013: p.42)  
The acknowledgement of complexity as related to context, relations, interaction and  
situated dynamics has been raised by a number of scholars who call for a re-tooling of  
methods and concepts to better suit the ‘real world’ (Hawe et al., 2004; Shiell et al., 2008; 
Cohn et al., 2013; Greenhalgh et al., 2014); a world rife with complexity and seemingly 
limited in its methodological options.  
 
Some have used lenses such as realist evaluation in approaching complexity (Pawson and 
Tilley, 2006). The approach was suggested as a potential approach for the RCT (Bonnell et 
al., 2012), but was refuted, including by Pawson himself (Marchal et al., 2013), 
demonstrating the challenge in aligning epistemologies, research strategies, methods, data 
and reporting in the time of experimental effectiveness studies and complex interventions.  
 
‘Fidelity’ is considered a key aspect of the RCT design and the measurement of interventions.  
Simply put, fidelity can be considered whether the intervention was ‘delivered as planned’ 
which would allow for   the ascertainment of the interventions effect on the outcome and lend 
support to the research conclusions (Horner et al., 2006: p.80).  A call for reconsideration of 
the concept of fidelity in the measurement of complex interventions and pragmatic trials has 
been discussed (Hawe et al., 2004; Moore et al., 2014).   When attempting to replicate trial 
designs and demonstrate wide-scale applicability, it is suggested that the traditional concept 
of fidelity could be altered, losing some of its literal precision while maintaining the over-
arching concepts (Hawe et al., 2004).  Acknowledging the importance of situational factors 
(time, place, people, culture etc.) may mean that an intervention can be delivered in different 
settings in a way that adapts aspects of the intervention, and admits their relevance to the 
evaluation, while retaining conceptual congruency so that the intervention is faithful to trial 
features.  Hawe and Shiell suggest it may be prudent to define fidelity functionally rather than 
compositionally (Hawe et al., 2004).  This is considered in the most recent guidance on 






The contributions of social science have been widely recognised in the field of medicine and 
a number of researchers have been keen to determine the ways qualitative and quantitative 
data could be more meaningfully coupled (Lewin et al., 2009; O’Cathain et al., 2008; Hesse-
Biber, 2015).   Despite this acknowledgement and advances in ‘mixed’ methodologies, doubt 
remains regarding the actual proliferation and successful combining of the approaches 
(O’Cathain, et al., 2008; Lewin et al., 2009).  A systematic review by Lewin at al. in 2009 
demonstrated that research teams have involved qualitative methodologies alongside trial 
designs but true integration, in the form of inclusion at the design and analysis phases, was 
uncommon.  More often, qualitative methodologies were ‘tacked on’ either before or after 
and quite often reported separately (Lewin et al., 2009; O’Cathain et al., 2008).  Despite this, 
enthusiasm remains and qualitative methods have even been included in the Cochrane 
reviews (Gülmezoglu et al., 2013), a hallmark of experimental evidence and evidence based 
medicine.   
 
Some critiques of mixed methods research relate to the longstanding incommensurability 
thesis, suggesting that methods developed in particular paradigms and with radically different 
philosophical underpinnings cannot be meaningfully mixed (Lincoln and Denzin, 2011; 
Hesse-Biber, 2015). In her paper ‘Mixed Methods Research: The Thingness Problem’, Hesse-
Biber suggests getting past the ‘thingness problem’ in mixed methods research, a problem she 
suggests is reflected in the formalisation of mixed methods approaches, the ‘unexamined 
belief in the ‘synergy’ of mixed methods and the growing approach of ‘whatever works’ as 
the philosophical stance to the mixing of modes of inquiry (2015: p.776). Hesse-Biber’s 
analysis serves as a useful summary of various critiques of mixed methods and she 
emphasises reflexivity, considering power and control, the articulation of the research 
question and generally a more thoughtful engagement with cross disciplinary work as a way 
forward  (2015).  Greater reflection of the impacts of working with different epistemological 
and ontological assumptions will be considered throughout the thesis.   
 
Alongside conversations on the evaluation of complex interventions has been a growing 
interest in process evaluation as a research method. This approach was described in Chapter 
4.   This evaluative strategy can be used alongside an RCT to better illuminate the relational, 




(Moore et al., 2014). Essentially, process evaluation alongside an RCT allows each method to 
‘retain their paradigmatic natures but are intermeshed with each other to deepen 
understanding of the phenomenon under study.’ (Munro and Bloor, 2010)   The idea is that 
the process evaluation can unpack the ‘black box’ of what ‘truly’ happens throughout the trial 
process, and produce explanatory data to better guide decisions and future implementation in 
other or wider scale settings. Process evaluation explores implementation, setting, delivery, 
uptake and other possible aspects of interventions and can be useful in interpreting and 
explaining outcomes (Moore et al., 2013).  They may also determine important differences 
between delivery sites in multi-centre or cluster trials, or help determine which aspects of 
interventions are linked to which effects (Oakley et al., 2013).  Importantly, process 
evaluations can help determine whether the intervention itself is ineffective or if there has 
been a problem with the study conduct or implementation process (Oakley et al., 2006).  
‘Typically aspects evaluated would include fidelity to the implementation plan, 
intervention dose delivered and received, the level of reach or participation, the 
recruitment process and the ‘context’ (Saunders et al., 2005).  
 
For example, a trial on peer-delivered sex education in scholastic settings with an integrated 
process evaluation, by Oakley et al., used surveys, focus groups, interviews, observations and 
field notes and a number of innovative statistical techniques, developed in an attempt to 
meaningfully combine the various forms of empirical data, to develop an in-depth 
understanding of the intervention.  The results provided nuanced findings that allowed for the 
teasing out of the value of consistency of implementation and what might be the key 
interactions and circumstances in which the intervention is most likely to be effective 
(Oakley et al., 2006). Process evaluation shows explanatory promise for understanding 
negative trial findings as well and may allow for the finer tuning of interventions to 
environments (Munro and Bloor, 2010).   
 
While some see the combining of process evaluation alongside trials as the way to maximise 
the benefits of experimental designs but account for complexity, pragmatism and context, 
others still see the approaches as incompatible (Munro and Bloor, 2010).  Alison Munro and 
Michael Bloor clearly highlight some of these tensions in their article ‘Process Evaluation: 




not a miracle at all (2010).   Challenging some of the touted best practice of process 
evaluation such as conducting the preset analysis plan prior to the outcome analysis so as not 
to influence the findings, they stress how without this ‘20/20 hindsight’ at the design stage 
the process evaluation is not able to account for emergent or unexpected findings using this 
evaluative sequencing (Munro and Bloor, 2010).   Additionally, they discuss how qualitative 
research uses inductive thinking and how this sits in contrast to ‘pronouncing’ 
generalisability and external validity; how making generalisations from contextually situated 
instances may be problematic, an epistemological tension discussed elsewhere in the thesis 
(Munro and Bloor, 2010).  They conclude that is it ‘a mistake to think of qualitative and 
quantitative findings as commensurate in some straight-forward fashion’ (Munro and Bloor, 
2010).  Despite this, other researchers have found the inclusion of process evaluations 
alongside trials to be fruitful in gaining explanatory insights into research outcomes (Oakley 
et al., 2006).  
 
Situating Efficacy  
 
Considering the philosophical underpinnings of the RCT and undertaking critical work on the 
ontological assumptions inherent to research designs is another approach to accounting for 
the challenges of evaluative strategies.  In 2015, a conference entitled Situated Efficacy: 
Biomedicine, Interdisciplinarity and the Politics of Intervention was held at the Brocher 
Foundation.  Academics writing in the fields of sociology, anthropology, design, translational 
research, international health policy and public health sciences were invited to submit texts 
discussing the ways in which our current experimental evaluative models and specifically the 
concept of efficacy, as produced by trials, isn’t ‘working’ (Rosengarten and Savaransky, 
2015). As a result, a set of unpublished papers was produced that speak around the concept of 
‘situated efficacy’. This work is introduced here as it evidences new forms of 
interdisciplinary thinking about research designs and enactments.  This is an example of a 
radical conceptual shift to the thinking underpinning current explanatory and pragmatic trials 
and a call for an interdisciplinary approach to tackling contemporary methodological queries, 





Marsha Rosengarten and Martin Savaransky wrote the concept papers to orient the event.  
Essentially this work tries to trouble the concepts of efficacy and effectiveness.  Roughly, 
using concepts from Alfred North Whitehead and other pragmatist thinkers such as Dewey 
and James, the conference leads asked how the current conceptualisations and enactments of 
trials limit what is knowable.  They challenged the static approach to reality inherent in the 
trial design and wondered how weaving speculation into our methods might allow for the 
emergence of different and more helpful data, knowledge and representations (2015). They 
problematise the boundaries created by the current mobilisations of ‘efficacy’ and ask what is 
left out and if these modes of inquiry in fact produce the evidence they claim and whether 
such evidence is in fact helpful.  They ask what happens during the process of translating an 
efficacious treatment into an effectiveness trial and what is lost, overridden, closed down and 
unconsidered in such a translation (2015). 
‘the distinction between ‘efficacy’ and ‘effectiveness’ upon which RCTs rest, makes 
available a specific centre-periphery mode of multidisciplinarity: biomedical 
researchers deal with the central question of ‘efficacy,’ while social researchers, 
policy makers and implementers (in public and non-government organisations) 
engage with contextual issues and practices of remediation rendered peripheral to the 
intrinsic success or failure of an intervention itself.’ (Rosengarten, 2015: p.1)  
If health is a process of becoming, or a state of continuous positive adaptation, and reality is 
processual and emergent, then how do our current evaluative tools account for this, or not?  
‘Situated efficacy’ therefore calls for a research design that acknowledges the processual 
nature of reality, bodies and interactions, that accepts speculation and uncertainty as 
necessary, essential and potentially helpful in research despite the challenges this may present 
to current valuations and concepts of ‘generalisability’ and applicability’ (Rosengarten and 
Savaransky, 2015). This work will be further discussed in Part 3. 
 
At times it is unclear what the suggested direction of travel might be within the various 
critiques of the aforementioned methods and their suggested remedies.  It appears that a 
number of researchers are happy to ‘tinker’ with the current set of evaluative designs, hoping 
to incrementally reduce the relevance of such criticisms. This may include beginning to use 
adaptive trial designs, for example, or further refining the design elements of a pragmatic trial 
(Hirschhorn et al., 2015).  Others appear to suggest a re-tuning of the hierarchy of evidence, 
with an emphasis on better matching research to its questions and situations along with a 




forward. The rise of mixed methodologies is an example of this.  Others still would describe 
the above as a never-ending quest to ‘capture’ context, a band-aid set of alterations to deeper 
epistemological problems and a resistance to the radical rethinking required.   Such scholars 
would prefer a re-conceptualisation of our tools, environments and interactions that allows 
for ruptures in widely held views of reality, science and evidence (Savaransky and 
Rosengarten, 2015; Cohn et al., 2013; Mol, 2002).  What can be concluded, however, is that a 
greater and more modest claim to what experimental research tools can and do produce, and 
what can be considered evidence, may be required. 
 
What does this mean for the overall doctoral project?  The pragmatic, cluster trial approach 
used in the RHIVA2 trial was born of critiques of the traditional RCT.  The design is meant 
to include more ‘reality’ and to guide clinical practice with its findings.  The RHIVA2 
intervention is seen as effective, however, the trial presents a partial view, much else was 
taking place. The intervention of rapid HIV testing has complex features but still sits fairly 
low on the scale of complex interventions.  The rapid test is short and requires a single 
occasion of consent and participation for most patients.  Despite this, the setting, the social 
reality of HIV infection and the behaviour change required by health professionals add to the 
complexity. The conducting of a retrospective process evaluation has been useful in gaining 
insights into the implementation process.  In the findings to be presented below, some of the 
complexity of the RHIVA2 trial becomes clear.  The model used to elicit some of this 
complexity is the Greenhalgh et al. model of the diffusion of innovations in healthcare 




Chapter 9:  EXPLAINING THE VARIATION IN RAPID HIV TESTING AMONG 
RHIVA2 INTERVENTION PRACTICES USING DIFFUSION OF INNOVATIONS 
THEORY  
 
‘To a greater or less extent (and differently in different contexts), individuals seek 
innovations out, experiment with them, evaluate them, find (or fail to find) meaning in 
them, develop feelings (positive or negative) about them, challenge them, worry about 
them, complain about them, develop know how about them, modify them to fit 
particular tasks, and attempt to improve or redesign them – often (and most 
successfully) through dialogue with other users.  Furthermore, except in a few 
circumstances, organisations should not be thought of as rational decision-making 
machines that move sequentially through an ordered process of awareness-evaluation-
adoption-implementation.  Rather, the adoption process should be recognised as 
complex, iterative, organic and untidy.’ (Greenhalgh et al., 2008: p.113) 
 
The work of this chapter has also been published in a paper: Explaining variation in an HIV 
testing trial: A new model based on diffusion of innovations theory by myself and colleagues 
(McMullen et al., 2015) (attached as Appendix 1). Both my supervisors and another 





As discussed in the introduction and methods chapter, process evaluation is a methodology 
with increasing application to RCTs.  The qualitative and process focussed aspects of the 
method are meant to illuminate the implementation process, test theory and explore model-
reality gaps (Moore et al., 2015; Lewin et al., 2009). While trials are meant to indicate if an 
intervention ‘worked’, a process evaluation might aim to elucidate ‘how’ the results took 
hold.  
 
In this chapter, I use process evaluation methodology along with the diffusion of innovations 
in health care organisations model by Greenhalgh et al. to explore the variation of uptake of 
rapid HIV testing in RHIVA2 intervention practices (Greenhalgh et al., 2004).  Wide 




practices, with some practices offering tests in the single digits and others offering over 1000 
tests (Leber et al., 2015).  The aim of this section is to better understand what went on in the 
process of the trial and explore factors which facilitated and impeded the uptake of testing.   
The research explored here was my entry point into the PhD project and was the site where 
the two stories structuring the thesis became apparent.  In RHIVA2 the ‘logic of 
normalisation’ was being implemented through the intervention of HIV screening as part of 
the new patient health check (Story 1) and this was being evaluated through a pragmatic trial 
design (Story 2).  On site, in 20 general practice organisations this chapter begins to reveal 
some of the trial ‘surplus’ and collect information that was not considered as ‘data’ in the trial 
logic.  
 
9.2 Theoretical frame  
 
The emerging field of implementation science in healthcare emphasises the exploration and 
understanding of processes in which interventions are implemented, adopted and enacted in 
their contexts of use and promotes the uptake of research findings on such processes into 
routine practice (Damschroder et al., 2009; Nilson, 2015).  Research related to 
implementation aims to:  
‘recognize the need to evaluate not only summative endpoint health outcomes, but 
also to perform formative evaluations to assess the extent to which implementation is 
effective in a specific context to optimize intervention benefits, prolong sustainability 
of the intervention in that context, and promote dissemination of findings into other 
contexts’ (Damschoder et al., 2009: p.1) 
Various theories, models and frameworks have been developed to explore the implementation 
process and range from those considering specific factors affecting implementation to those 
which aim to consider the broader process from multiple dimensions and others which do not 
aim to reveal processual aspects but evaluate interventions being implemented (Nilsen 2015).  
Nilson, in his wide-ranging review, articulates five approaches to implementation research: 
process models, determinant frameworks, classic theories, implementation theories and 





The theoretical approach chosen here is diffusion of innovations theory.  According to 
Nilsen, this is a classic approach to exploring implementation and considered ‘the single most 
influential theory in the broader field of knowledge utilisation of which implementation is a 
part’ (Nilson 2015: p.7).  Everett Rogers developed this approach to evaluating innovation 
adoption in the 1950s to explain the adoption and spread of innovations by individuals in a 
social network (Rogers, 2003).  Greenhalgh et al. extended the theory in 2004 specifically to 
the healthcare setting and to address the assimilation and implementation of service-level 
innovations in health care organisations (Greenhalgh et al., 2004).  In 2010, Robert at al. 
published an update to that systematic review, using a similar search strategy that aimed to 
identify more recent publications (Robert et al., 2010).   The review confirmed the findings of 
the 2004 study and in particular validated the model produced by these authors in 2004; 
additional empirical studies were found in relation to the routinisation and sustainability of 
innovations (on which there had been little data in the original review).   
 
Greenhalgh et al. define an innovation as ‘a novel set of behaviours, routines, and ways of 
working that are directed at improving health outcomes, administrative efficiency, cost 
effectiveness, or users’ experience and that are implemented by planned and coordinated 
actions’ (Greenhalgh et al., 2004: p.582).  The definition offered by Greenhalgh et al. aligns 
with the MRC definition of a complex intervention (see the introduction to Part 2) where an 
intervention comprises multiple elements, all of which seem essential but whose ‘active 
ingredient’ may be difficult to specify as they typically operate at multiple levels (individual, 
team, organisation) (Campbell et al., 2000; Craig et al., 2008; Guise et al., 2014). 
 
In RHIVA2, as discussed in the Background chapter, the innovation was not solely the rapid 
HIV test but also the tests offer as a part of a screening program for new registrants in 
primary care.  In the Greenhalgh et al. model, which synthesizes work of previous authors, 
innovations are conceptualised as having a ‘hard core’, the elements that constitute ‘fidelity’, 
and are less changeable, and the ‘soft periphery’, which can and must adapt to accommodate 
it, concepts developed from the work of Denis et al. (Denis et al., 2002).  Here the ‘hard core’ 
could be considered the rapid HIV test itself, and the ‘soft periphery’ aspects, the tests 




because of its emphasis on the innovation itself, which in the case of population screening for 
HIV, and the novel entry of rapid testing into this setting, was considered a key aspect in 
need of in-depth exploration (May, 2009; Murray et al., 2010).    
 
Greenhalgh et al.’s wide-ranging systematic review of the diffusion, spread and sustainability 
of innovations in the organisation and delivery of health services identified six interacting 
components: (1) the innovation itself; (2) the intended adopters; (3) communication and 
influence; (4) the inner organisational or system context, comprising general antecedents for 
innovation-specific readiness for a particular innovation; (5) the outer (inter-organisational 
and environmental) context; and (6) the implementation process. The model emphasises the 
importance of linkage between different components of and feedback regarding the 
consequences of innovation to other parts of the system. The Greenhalgh et al. model is 
summarised in the diagram below:  
 






Applying this model to RHIVA2 was not straightforward.  This may have been in part due to 
the model’s retrospective application but also because of the trial’s pragmatic nature, where 
we were aiming to measure the ‘real world’, a task which will be more deeply considered in 
Part 3 of the thesis.  Some aspects of the model appeared as immediately less relevant due to 
the context of the trial, where attributes such as communication and influence were included 
as part of the trial’s training programme, which was standardised across intervention 
practices. Nevertheless, the pragmatic design of the trial meant that many real-world 
influences were built into the study design. For example, participating practices were open to 
communication from other practices locally as well as from other, ‘outer context’ influences, 
such as the economic recession, new immigration and changes in national and local HIV 
policies, as discussed in Part 1 of the thesis.  
The following table summarises the key components of the model.  
 
Table  7. Components of the diffusion of innovations model represented by McMullen et al. 2015 from 
work by Greenhalgh et al. (McMullen et al., 2015: p.5; Greenhalgh et al., 2004). 
 
COMPONENT  DEFINITION 
Attributes of the 
innovation 
How the potential adopter views the pros and cons of the innovation 
Relative advantage  A clear, unambiguous advantage in terms of either 
effectiveness or cost effectiveness. 
Compatibility  Compatible with the values, norms and perceived needs 
or intended adopters.   
Low complexity  Composed of simple, easy to implement steps. Able to 
be broken down and learned on an incremental basis. 
Trialability  Can be experimented with. 




Possibility to adapt, refine or otherwise modify the 
innovation to suit adopter needs. 
Fuzzy boundaries  If innovations have ‘hard cores’ (irreducible elements of 
the innovation) and ‘soft peripheries’ (structures and 
systems required for full implementation) adaptation of 
the soft periphery can facilitate adoption. 
Risk  Risks of the innovation (as perceived by the intended 
adopter) are outweighed by its perceived benefits. 
Task issues Extent to which the innovation is relevant, feasible, 
workable and easy to use for the adopter. 
Nature of 
knowledge 
Knowledge required to enact the innovation can be 
transferred – either by codification (explicit knowledge) 
or more informally e.g. shadowing (tacit knowledge). 
Technical support  If the innovation is technical, helpdesk support is 
available, especially in the early stages of 
implementation 
System antecedents for 
innovation (Including 







                                     
Structure  
Size/ Maturity  Practice size is related to innovation adoption with larger 
practices faring better regarding implementation.  A 
proxy for other features such as slack resources and 
functional differentiation. 
Formalisation The extent to which there are rules and protocols 
regarding organisational activities which are upheld. 
Differentiation The extent to which roles and activities are divided. 
Decentralisation Decision making power is appropriately dispersed across 
organisations. 
Slack Resources  The resources an organisation has beyond what it 
minimally requires to maintain operations. 
                  Absorptive 
capacity for new 
knowledge  
A dynamic capability pertaining to knowledge creation and utilisation that 
enhances an organisation’s ability to gain and sustain a competitive advantage. 
Pre-existing 
knowledge / skill 
set  
Existing knowledge and skills within the organisation.  
Particularly faciliatory if somehow related to the 
innovation.  
 Ability to find, 
interpret, re-codify  
and integrate new 
knowledge  
The ability to take on, understand, integrate into existing 
systems and put it to productive use new information.  
Enablement of 
knowledge sharing 
via internal and 
external networks  
Individuals are able to share knowledge regarding the 
innovation internally and externally through established 
networks. 
Receptive context 
 for change  
A combination of factors from both the inner and the outer context that together 




Top management support, advocacy of the 
implementation process and continued commitment 
enhance the success of implementation and routinisation. 
 Good managerial 
relations  
Staff have positive relationships with managers. 
Risk-taking climate  A supportive working culture where practice staff feel 
able to experiment with new innovations without fear of 
reprimand.  
 
Clear goals and 
priorities 
Objectives are clear to the organisation and the staff. 
High-quality data 
capture 
Organisational systems are in place to obtain high quality 
data related to the innovation diffusion. 
System Readiness for 
Innovation  
 The extent to which the organisation is ready for the specific innovation. 
 Tension for 
Change  




The innovation fits with existing values, norms, 
strategies, goals, skill mix, supporting technologies and 
ways of working in the organisation. 
Power Balances  How power and authority is attributed and operating in 
the organisation.  
Assessment of 
implications  
The implications of adoption are known and assessed. 
Dedicated 
time/resources 
There is budget and resource available that is adequate 
and recurrent.  
Monitoring and 
feedback  
Systems and skills are in place to monitor and evaluate 
the impact of the innovation and feedback to adopters. 




 Needs What the adopter needs to be able to adopt the 
innovation. 
Motivation Whether the adopter is motivated to adopt the 
innovation. 
Values and goals  Does the innovation gel with the adopter’s values and 
goals. 
Skills  The skills required to adopt the innovation and whether 
adopters posses these. 
Learning style The ways that adopters learn are considered and catered 
to in the innovation training. 
Social networks  The pattern of friendship, advice, communication and 
support that exists among members of a social system. 
Implementation 
Process  
 The process by which a new innovation is diffused across an organisation. 
 Decision making 
devolved to front 
line teams  
Do lead users of the innovation have control over aspects 





Leaders and managers are involved in the 
implementation process, supporting and assisting 




Have all human resource issues linked to the introduction 
of the innovation (training, workload, supervision, 
performance management) been adequately addressed?  
Dedicated 
resources  
Specific resources of time, budget and other relevant 
resource are dedicated to support implementation. 
Internal 
communication 
Involved bodies communicated effectively with each 




Effective knowledge-sharing links to other organisations 
who are implementing the same innovation. 
Reinvention/ 
Development 
Was it possible to adapt the innovation or the tasks and 
processes associated with it to suit local contingencies?  
Feedback on 
progress  
Are there evaluative and feedback mechanisms in place 
and enacted? 
 
This section of the thesis calls on process evaluation methodology to construct the findings. 
See Chapter 4 section 4.5 for a broader discussion of the process evaluation method.  
 
9.3 Method and Data Sources 
 
Methods were described in Chapter 4.  I will briefly outline the data sources.  
Data were collected through various methods. Interviews were conducted with 23 RHIVA2 
intervention practice staff.  Performance data from the RHIVA2 trial as well as practice level 
data collected throughout the study is also used. Ethnographic field notes were called upon. 
The interview questionnaires were semi structured to allow for comparison and 




practices in the intervention arm of the RHIVA2 trial who had a role in offering rapid HIV 
testing to new patients were invited to take part in the qualitative study. The sample primarily 
included nurses and health care assistants who were charged with offering the rapid HIV 
testing as a part of the new patient health check.  Practice managers and general practitioners 
were also invited if they had a role in rapid testing, either through the management of patients 
who were diagnosed as positive through rapid testing or through overall coordination of the 
testing within the practice.   
 
Providers from 16 of the 20 intervention practices participated in interviews.  Three non-
participating practices had closed and dropped out of the trial at the time of interview request.  
Others never returned the invitation after repeat attempts.  A total of 23 providers were 
interviewed: eight health care assistants, twelve nurses, one practice manger, one clinical 
manager and one GP.   See Table 8 for a presentation of sample characteristics.   
 
Two of the interviews were conducted in pairs upon request of the participants.  In both cases 
this was with a nurse and healthcare assistant pairing.  Interviews lasted between 30 and 60 
minutes and took place at the practice during regular practice hours.  Written informed 
consent was obtained from all participants. Participants were provided with a £10 voucher as 
compensation. 










Table 8. Provider interview participant characteristics 
 
 
 Role  Sex Age 
Range  
Length of time at 
the practice  
Level of 




working with HIV 
1 Nurse Female Over 60 >3 yrs Part time  No 
2 HCA  Female 21-30 >3 yrs Full time  No 
3 HCA  Female 41-50 >3 yrs Full time  No 
4 HCA  Female  41-50 >3 yrs Part time  No 
5 Nurse  Female  51-60 >3 yrs Part time  No 
6 Nurse  Female 51-60 >3 yrs Full time  Yes, in substance 
misuse centre  
7 Nurse  Female 41-50 >3 yrs Full time  No  
8 Nurse  Female 31-40 < 1 yr Part time  Yes, insurance 
testing  
9 Nurse  Female  51-60 1-3 years  Part time  Yes, care for HIV 
patient 
10 Nurse  Female  41-50 >3 yrs Part time  No 
11 HCA  Female  31-40 >3 yrs Part time  No 
12 Clinical Services 
Manager  
Male 31-40 >3 yrs Part time  No 
13 HCA Male  21-30 1-3 years  Full time  No 
14 GP Male  Over 60 >3 yrs Part time  No 
15 Nurse  Female  41-50 >3 yrs Full time  No 
16 HCA  Female  21-30 >3 yrs Part time  No 
17 Nurse  Female 51-60 >3 yrs Part time  No 
18 Nurse  Female  51-60 1-3 years  Part time  No 
19 Nurse  Female 51-60 1-3 years  Part time  Yes, as Infection 
and Immunity 
Nurse  
20 HCA  Female  31-40 >3 yrs Part time  No 
21 Practice Manager  Female  51-60 >3 yrs Full Time  No 
22 HCA Female 41-50 >3 yrs Part time  No 




Data analysis occurred in three phases.  The first phase involved preliminary familiarisation 
and coding and asked the question: What were the experiences and perspectives of providers 
of rapid HIV tests in primary care?  The second phase involved the application of a coding 
frame related to the diffusion of innovations model and asked: What enabled or hindered 
providers in effectively implementing rapid HIV testing in general practice? The third phase 
involved the synthesis of data into case studies. 
Qualitative transcripts (field notes, interviews and extracts from emails and documents) and 
matched demographic data on interviewees were uploaded into NVivo software and 
framework analysis was undertaken (Spencer et al., 2003), first for familiarity and then using 
codes developed related to the Greenhalgh et al. model of the diffusion of innovations.   Box 
2 below demonstrates the application of the Greenhalgh et al. model to the topic guide to 
determine the coding frame.  
 




A spreadsheet of practice size, male HIV testing rate prior to the trial, rapid HIV and 
serological testing and practice HIV diagnoses during the trial period was developed to assist 
in determining the sampling frame for the cases. One surprising finding was that practices 
that had had high rates of HIV serological testing before the trial, which was considered a 




RHIVA2. This sampling frame allowed me to explore the innovation as compared to regular 
HIV testing practice (serology testing) across RHIVA2 sites and consider implementation 
related factors.  The four chosen practices aligned with the sampling frame as follows:  
, Practice A: high serological testing, high rapid testing.   
, Practice B: low serological testing, high rapid testing 
, Practice C: low serological testing, low rapid testing 
, Practice D: high serological testing, low rapid testing 
 The sample frame is pictured in Figure 6 below. 
Figure 6. Sampling strategy for case study construction in the provider-level study  
 
This sampling frame allowed for the determination of four cases to be further developed. A 
‘thick’ file was developed for each case study and included interview transcripts, 
ethnographic field notes, trial performance data and practice level data such as information 
about the ward in which the practice was situated and practice size and structure.   To aid in 
the analysis, a one-page crib sheet on the case studies relationship to attributes from the 
Greenhalgh et al. model was developed.   





Figure 7.  Example of case study findings summary used in analysis   
 
 
The aim with this approach was to develop case studies that demonstrated key dimensions of 
the process of diffusion and assimilation in RHIVA2.  The autoethnographic method was 
called upon alongside the sampling frame and in the writing up of cases to synthesise the 
findings and develop a rich picture of key events.  This shed light on the process of 
implementation in the four practices.  
 
9.4 Findings 
Analysis revealed that the most pertinent aspects of the model were adopter characteristics, 
system antecedents and readiness for innovation along with the implementation and 







Findings common to all four case study sites  
 
Despite the divergence in innovation adoption between the cases, there were some universal 
findings, particularly in relation to the innovation itself.  Informants from all four sites 
perceived a relative advantage in the innovation. Rapid HIV testing as a part of the new 
patient health check in general practice was seen to be advantageous as compared to regular 
practice. This relative advantage can be related to the a) rapidity, b) accessibility, and c) 
patient comfort.  
‘Patient theory of mind’ was also a common finding, demonstrating a triadic dynamic 
between the innovation, the provider and the patient.  
Rapidity  
Providers reported enjoying the rapidity of the test.  They also reported this as seen as 
positive by patients.  The rapid test provides a result in one minute, meaning it can be 
incorporated into the new patient health check and other short consultations.  To obtain 
results from venous testing (usual practice in primary care) requires waiting for a minimum 
of two days for results.   The quick and actionable results of the rapid test mean less waiting 
and administration and may mean a reduction in loss to follow up of patients. A nurse 
describes patient reactions to the test:  
‘Interviewer: Do you like doing the testing? 
Nurse: Actually, yes, I do. 
Interviewer: What do you like about it?  
Nurse: I like the fact that people are so impressed by it.   
Interviewer: By how fast it is? 
Nurse: Not just that, it’s the fact that they get an instant result. And if they’re worried 
about it then that’s very gratifying for both me and them.’ (Nurse, practice B) 
 
The speed in which the test results are available (one minute) can also be beneficial as 
compared to what is often a two day plus wait for venous test results.  Patients enjoy 
receiving their result instantly and providers report satisfaction in being able to provide this 









Placing the rapid HIV test within the new patient health check in an opt-out manner allowed 
for those unwilling or unconcerned by HIV testing to easily access a test.    They felt this 
meant patients who would not have otherwise been tested agreed to testing.  This was also 
borne out in interviews with patients testing positive through rapid testing within the new 
patient health check (See Chapter 11). The test does not require a phlebotomist to perform it 
and so is delivered by a greater range of health care professionals, meaning it can be more 
easily included in the new patient health check.  The HCA describes why she likes offering 
rapid testing in the quote below:  
‘Interviewer: Do you think it’s a good idea to test it in that way? 
HCA: Yes, 100%. 
Interviewer: How come? 
HCA: Because most people don’t even think about it at all. They could go on their 
whole lives not thinking about it and people are quite – I don’t know if ‘ignorant’ is 
the right word to use. If you offer somebody at a consultation on a one on one an HIV 
test they might get a bit offended. But this way if you’re saying it’s something that 
we’re doing at this point in our practice, as a new patient joining us it’s offered 
randomly, it just gives people a chance to think about if they do want it. If they 
decline then at least they can come back and say, “You know, I was offered this test 
and yes, I would like to have it done.” Because people don’t even think about it.  So 
yes, I think it’s a very good idea.’  (HCA, practice C)  
 
 
Additionally, it meant a significant reduction in pre and post-test counselling, particularly 
when compared to historical approaches to HIV testing and counselling, as discussed in Part 
1. For some patients and providers, the need for a sexual history taking can be a deterrent for 
testing. Providers found this streamlined testing protocol beneficial to the consultation and in 
some cases reported greater comfort by patients in not needing to disclose reasons for 
wanting testing but desiring a test.  In other instances, the offer of a rapid HIV test during a 
new registration meant that an entry point was provided into a discussion or request for more 
sexual health services. A nurse describes why this form of testing is more accessible:  
‘I think it is okay because you know, is not many people who likes going to the GUM 
clinic.  They don’t go unless they are worried about something.  But this rapid HIV 
test, offering it at the time they register, I think is very good.  It is more accessible.  It 





Patient comfort  
 
Providers believed that offering rapid HIV testing for new registrants in general practice 
made sense and was advantageous in that it allowed more privacy for patients than 
specialised sexual health centres.   Others providers found it an important way of normalising 
and de-stigmatising HIV testing.   A nurse and healthcare assistant from a RHIVA2 
intervention practice describe their views below:  
‘Nurse: This is a very interesting thing.  It is.  Like it does make a difference.  It does 
make a difference to patients like because then they get to know what stage they are.  
And it’s easier access, quick results, instant results.  It saves them more time. 
HCA: And people who would be really unlikely to go to a clinic because when 
something’s a stigma then it’s very hard for people to be involved because they would 
be part of that, you know, that group. So someone – I mean this testing for me means 
anyone could come in and have it done, a housewife who wouldn’t want to be seen 
dead in the sexual health clinic.  So this test caters for everybody. 
Nurse: Even ethnic minorities because in some groups like especially in Asian groups 
they all think okay.  If another Asian person sees me in a sexual health screening and 
if I know them and you know. 
HCA: Anybody because it’s a broad thing really.  So having this test in the surgery I 
think it’s a brilliant thing and it should get more advertised.’  (Nurse and HCA, non-
case study practice)  
 
In sum, providers viewed the innovation positively with cited reasons including speed, 
accessibility and patient comfort. 
 
Patient ‘theory of mind’  
 
Another crosscutting finding related to how providers tended to interact with innovation.  As 
providers described their experiences of rapid testing they reported significant reflections on 
their perception of patient reactions and feelings and how these perceptions of patient 
interiority was a key aspect of the testing consultation. Throughout the interviews this patient 
‘theory of mind’ was a prominent theme and clearly patterned provider impressions. Many of 
the models and assumptions implicit in theories of the diffusion of innovations imply a 
dyadic relationship between an innovation and a single adopter.  What was apparent in the 
data was how providers considered rapid testing in primary care as a triadic interaction 




this relationship, the arrows represent the projections of the patient and the provider onto 
each other and the test device.   
 
Figure 8. A visual representation of the triadic relationship between the provider, the patient and the 
INSTI test. 
 
Greenhalgh et al. acknowledge that greater research and theoretical development is required 
on the psychological aspects of the diffusion of innovations and that many lessons may be 
drawn from cognitive and social psychology (Greenhalgh et al., 2004).  A health care 
assistant describes how she considered the views of her patients about testing in the quote 
below:  
‘When we did the training, we were sort of told, with the reactive result, you are to 
leave the room and get a doctor. I haven’t had to do that yet, but I don’t know how 
that would make the patient feel, if I am just getting up and walking out…. I mean, I 
don’t think it was as abrupt as all that in the training…. I don’t know how people feel 
about that, but obviously something is going on…. Would I just make them more 
nervous?’ (HCA, non-case study practice)  
This ‘theory of mind’ regarding the patient entered the provider calculus and was an 
overarching finding across the case studies. This finding is an underdeveloped aspect of the 
diffusion of innovations model, which precludes a more nuanced discussion of the health care 
consultation, the role of the patient and the impact of new innovations within it. 
 
9.5  Findings 
 








Practice A was selected due to their high offer of rapid and serology HIV tests during the trial 
period (see the upper right quadrant on Figure 6). 
 
Table 9. RHIVA2 trial performance data for practice A 
 
Practice A 
Practice Size  Large  >7000 registrants  
Total serology tests 
offered in the trial 
period  
301 serology tests performed  
Total rapid tests 
offered and 
performed in the trial 
period  
1258 rapid tests performed  
2039 rapid tests offered  
Decline rate  42% of rapid tests declined  
Rapid HIV testing 
detection  
1 case of HIV was detected through rapid testing  
 
Rank amongst other 
intervention 
practices  
Highest number of rapid tests offered of all 
intervention practices. 
Decline rate was low compared with other 
practices.  
 
Practice A implemented the rapid testing intervention very successfully, offering more rapid 
tests than any other practice with a comparatively low decline rate.  One case of HIV was 
detected via rapid HIV testing. Effective implementation of the test appeared to be the result 
of key system antecedents for innovation, high system readiness for the rapid test, as well as a 






Practice A is a large and busy practice.  It is mature and well organised with a clear 
differentiation of functions and staff roles as well as good managerial relations. For example 
the practice nurse and HCA had been with the practice for some time.  They felt their roles 
were clear, and they understood who should be called upon and at what stage if a test was 
reactive. Both expressed the importance of GPs in making diagnoses both for the patient and 
their own comfort in offering tests.  If needed, they sought information and clarification from 
senior staff: 
‘I’ve had a couple of patients said that they didn’t want the test at the time I offered it, 
in the new patient health check, but is it okay if I go away, think about it, and then 
maybe come back, and I’ve said well, you know, this is something that we offer now, 
if you come back then I’d have to question that with the Doctor as to whether you can 
have it as a, you know, fully registered patient.  I’ve spoken, I did speak to a Doctor 
actually, and they said that it would be okay if they hadn’t been registered too far 
down the line.’ (HCA, Practice A)  
 
Junior practice staff were mentored by more senior staff, providing both pastoral support and 
opportunities for individual and team learning which links to one of the diffusion of 
innovations key constructs of absorptive capacity. Due to regular meetings and the provision 
of feedback to practice staff there appeared to be opportunities to integrate new knowledge 
and reflect on work practices. Practice A showed interest in the monitoring of progress and 
the study’s overall performance, often asking how they rated in relation to other trial 
practices.  
 
Leadership, organisation and communication appeared to be strong factors in practice A. For 
example, a lead was assigned for the intervention and provided support to junior staff tasked 
with delivery. While roles were well differentiated, support was provided promptly when 
required.  
 ‘Interviewer: But you’ve had a reactive? 
 Nurse: That was early one. 
 HCA: Yeah. 
 Nurse: Trying to, I’m trying to recall it. 
 Interviewer: Okay. 
 Nurse: As to what, as what I actually said.  I remember I sent a screen message to 
(GP A) and I, I think I just said something like oh, that I needed the Doctor to verify 
the result, and that I needed him to look at it.  I think it was something like, that, it’s 
such a long time ago now, and then (GP B) came in and I had a chat with him and 
we did the blood test, gave him some information, and I think (GP A) said that he 




Key staff in practice A believed that offering patients testing in this way improved their 
service, inducing a sense of pride and value in their work.  This can be seen in the 
quote from 2 providers of rapid testing below:  
‘Nurse: Yeah, I think, the impression I get is that they think that we’re been quite 
thorough and that we’re, you know, so I think it, I think it promotes us  
HCA: That we’re very organised, well she said I’m very organised and thorough. 
Nurse: Yeah that we care and that we’re offering a good service.’    
(Nurse and HCA, practice A)  
 
Positive views on the intervention by staff tasked with delivering it may have impacted the 
quick adoption of testing in practice A.  The staff member also appeared well supported and 
was the only one of the 16 practices interviewed who did not mention time constraints. These 
findings may have indicated that there was better ‘innovation-system fit’ in the practice and 
that ‘slack resources’ were available (see Table 7).   Another finding which may have bearing 
on the quick adoption of rapid testing by practice A, identified in the model as 
‘observability’, is how fairly early in the trial the practice identified a case of HIV through 
rapid testing.  This tangible and demonstrable experience that the intervention does produce 
the intended results may have gone some way in motivating the practice to continue testing.  
 
The innovation of rapid HIV testing as part of the new patient health check was well adopted 
in practice A and there was a good innovation-system fit. Key front-line staff believed in the 
value of the intervention and had early evidence of its effectiveness.  Practice A was a setting 
where key system antecedents for innovation were present, including a large formal structure, 
a strong absorptive capacity for new knowledge and a readiness for change.  Slack resources 
appeared available and positive work place relations with role differentiation, feedback loops, 
knowledge sharing and reflexive practice dimensions already in operation enhanced the 
potential for the intervention to be successfully adopted.  There was no detectable intra-
practice opposition to the intervention and due to the high-quality data capture, good 




Practice B was selected due to its high offer of rapid tests without much change in the offer of 




antecedents, high performing front line staff and internal synergies that facilitated the 
adoption of the new innovation.   
 
Table 10.  RHIVA2 trial performance data for practice B 
 
Practice B 
Practice Size  Medium >5000 
Total serology tests 
offered in the trial 
period  
101 serology tests performed  
Total rapid tests 
offered and 
performed in the 
trial period  
556 rapid tests performed  
870 rapid tests offered  
Decline rate  37% of rapid tests declined  
Rapid HIV testing 
detection 
4 cases of HIV were detected through rapid testing  
 
Rank amongst other 
intervention 
practices  
3rd highest number of rapid tests performed of all 
intervention practices. 
Highest number of cases of HIV detected through rapid 
testing. 
One of the lowest decline rates of all intervention 
practices.   
 
Practice B performed well throughout RHIVA2, offering a high number of tests and 
assimilating testing into the new patient health check.   The practice is small-to-medium in 
size with relatively low turn-over of patients and new registrants.   Despite this, practice B 
diagnosed the most cases of HIV through rapid testing, twice as many as any other 
intervention practice.  There was a high number of tests offered (n =  870) and the rate of tests 
declined was low (36 %). This practice had high rapid testing and low serology testing, and 
was in the bottom five of the 40 participating practices in RHIVA2 (fourth amongst the 40 




respectively).  Various factors at both the organisational and individual levels may help 
explain the success of the practice in delivering rapid testing.   
 
Practice B demonstrated moderate system antecedents and readiness for innovation. A well-
organised and harmonious practice, there was a clear division of roles for staff and staff 
tended to hold their colleagues in good esteem. The practice had a calm feel and compared to 
many of the practices visited throughout the trial there appeared to be a strong capacity for 
new knowledge and receptivity to change. There appeared to be pre-existing willingness to 
learn and a context in which new knowledge could be incorporated.   The practice appeared 
concerned about supporting patients beyond their immediate medical needs, a finding also 
demonstrated by the longer time allocations for patient visits such as the new patient health 
check. An example of intra-practice harmony was demonstrated when the lead nurse was 
concerned about the misinterpretation of a rapid test.  She discussed her concern with the GP 
and the two developed a plan together, without reproach, with the patient’s safety in mind. 
This example may also point to a practice with a risk-taking climate and positive managerial 
relations, which are facilitators in the uptake of new innovations. In the quote below, the lead 
nurse describes this example:  
 
‘Respondent: There was one which did … that was indeterminate. There was … you 
know, the pots. It was … it was supposed to be non-reactive, but inside that pot it was 
like a line.  
Interviewer: Okay. Right. Just a straight line.  
Respondent: And when I told the doctor, he say, probably … no, not the doctor; the 
lady that came the other day. He said probably it is damaged or something like that. 
But I told Doctor A, and he said I should call the patient back, you know. So, we call 
the patient back, and I explain, even to the patient as well, that this result, it doesn’t 
mean you have HIV now, but it might be one thing or the other that is making the … 
you know, the test to being invalid. So … and she decided … she came back.  
Interviewer: Had another test.  
Respondent: Yes. And it was non-reactive.’ (Nurse, practice B)  
 
The intervention was adopted quickly and the lead nurse, who was tasked with providing all 
new patient health checks, was enthusiastic about the innovation and saw the value of the 
trial.   That a single nurse undertook all new registration checks and was provided 30 minutes 
to perform it was unusual as compared to other participating practices in the trial. In addition, 




appeared well respected by both staff and patients.  This was recounted in stories she would 
tell about her clinical interactions.  She was patient-centred and saw HIV testing as an ethical 
imperative and an important service for the wider population.  She describes these sentiments 
in the quote below: 
‘I think I just like doing it because it is good. When you think about the end result, is 
good. It makes you feel you have done something good as well. At least for somebody 
who doesn’t know that is positive and is not, because although the news of being 
positive, it has a lot of effect on them, but after counselling…. But I believe it will 
prevent other people as well, or protect other people. Either prevent or protect from 
catching it because if it is known, then the patient can take precaution not to infect 
other people.’ (Nurse, practice B)  
When visiting the practice and speaking with the lead nurse it became apparent that she 
managed to ‘reinvent’ the test and the algorithm to suit her workplace practices.  She did this 
without compromising the delivery of the intervention and therefore maintained fidelity to the 
trial. She was concerned by the potential effect of a reactive result on the patient undergoing 
testing and so began to perform the definitive aspect of the test away from the patient’s view.  
This was an adaptation that was not in the original training. Additionally, she did not disclose 
to the patient that the test took one minute.  She took these steps to give herself some space to 
interpret the result and plan how she would share it with the patient, demonstrating reflection 
on her practice and concern for her patients.  She describes this in the quote below:  
 
‘Interviewer: Yes. How did you feel the first time you saw a reactive?  
Nurse: I was … but I was looking, but he wasn’t looking at me.  
Interviewer: Yes, because you do it on that side of the room.  
Nurse: Yes. On that side. So he was sitting down there, so … but he was looking at 
me as well. But because I was facing that side, he couldn’t see my face.’ (Nurse, 
practice B)  
 
Another adaptation, which may reflect positive work place relations, trust in the lead nurse 
and aspects of reinvention, was how the GP would refer patients to this nurse for rapid 
testing.  This included patients who were not newly registering. The nurse reported that at 
least one patient for whom the possibility of HIV infection was being considered was 
persuaded to have the rapid test due to their dislike of more invasive serology testing. As in 
practice A, a positive HIV diagnosis through rapid testing was made early in the trial, 




Numerous system antecedents were present in practice B.  There was high readiness for 
innovation along with pre-existing facilitating factors for implementation.  The role of the 
lead nurse as a keen and committed front line staff member was crucial.  What was also 
theoretically important and noteworthy about practice B is the way that the facilitating factors 
combined on site to enable a smooth and effective roll out of rapid testing.  The combination 
of practice level factors such as the specified role, space and time allocation for the new 
patient health check combined with the patient-centred and personally motivated lead nurse, 
along with her sensibility to reinvent the test to fit her personal work practices greatly 
impacted on the level of innovation adoption.  The practice appeared calm and to possess a 
culture of openness and improvement that supported the embedding of the intervention.  
Inter-collegial respect was evident in the description of how patient cases were managed as 
well as in how problems were solved.  The lead nurse’s competence was recognised which 
facilitated testing and the flow of patients towards the rapid test.  Elements conducive to the 
adoption of new innovations were able to build upon themselves in a synergistic manner.  
Practice C 
Practice C did not perform many rapid HIV tests in the course of RHIVA2.  The practice had 
low system antecedents for innovation and front line staff who were reluctant to take on rapid 
testing and implement the new innovation. Practice C was chosen for their low offer of both 






















Table 11.  RHIVA2 trial performance data for practice C 
 
Practice C 
Practice Size  Medium >5000 
Total serology 
tests offered in 
the trial period  
59 serology tests performed  
Total rapid tests 
offered and 
performed in the 
trial period  
36 rapid tests performed  
73 rapid tests offered  
Decline rate  50% of rapid tests declined  
Rapid HIV 
testing detection  





Low serology and low rapid testing throughout 
the trial period.  
One of the poorest all around performers in the 
trial. 
 
Practice C was a low performing practice.   It took a few months for the practice to offer their 
first rapid test and there was never full routinisation of testing, despite encouragement by the 
research team and some members of the practice staff.   I visited the practice to 
‘troubleshoot’, including one occasion where there was a request for more tests despite the 
electronic system indicating not a single test had been performed at the practice.  Upon 
delivering new test kits I realised that practice staff were unaware where the test kits were 
being stored and that the box remained unopened. There was a low HIV serology testing rate 
prior to and throughout the trial. Individual and practice level factors appeared to combine 
and make for a practice unable to effectively adopt a new innovation such as rapid testing.  
 
System antecedents for innovation appeared to be low in practice C. A small practice, it 




checks), one practice manager and two receptionists. Located within a large building housing 
multiple surgeries, practice C, always seemed crowded and very busy. 
 
The practice showed little interest in, or gave time to accommodate, new innovations, and 
there were few resources (human or financial) available to invest in new projects. Overall, the 
practice appeared to find a new service model difficult to integrate into business as usual. 
There was frustration expressed with changing NHS policy and guidance as well as broader 
changes in health care culture. A low absorptive capacity for new knowledge was also 
evident. One of the doctors, for example, asked the research team how to access information 
and register for GP training courses unrelated to the intervention, suggesting that this 
individual found locating and navigating information difficult. Significantly, practice staff did 
not perceive a great need for HIV testing in the borough, suggesting that there was little, if 
any, tension for change. The nurse described herself as ‘overstretched’. She gave the 
impression of barely being able to complete her existing work and having almost no personal 
capacity for additional tasks: 
‘[The rapid HIV test] really is not a problem. It’s just, you know, having the time. I 
mean, often I get to the end of a morning, and I feel like a rag.’ (Nurse, practice C)  
Considering the demand upon practice C and the sense among practice staff of being in a 
constant state of rush it is understandable that practice C never fully routinised the 
intervention.  The majority of patients having new patient health checks were not offered the 
test and no cases of HIV were detected with rapid testing.   As a result, observability of the 
effect of the intervention never came into view.  As the member of the research team most 
frequently visiting the practice, I had the sense that practice C viewed rapid testing as a 
research activity and an ‘add-on’ but not as a part of routine practice.  
 
In contrast to practice B, an issue of key importance in practice C was reluctance and 
compatibility between the test and the values of the HCA, who was the front-line staff person 
principally tasked with delivering testing.   The HCA appeared uncomfortable with HIV and 
with the test, expressing reluctance in the training session.  As testing data is aggregated per 




trial period.  A nurse, who joined the practice at a later stage in the trial and who was more 
comfortable with the test, describes her frustrations in trying to improve the uptake of rapid 
testing in the quote below:  
‘I don’t have any problem with doing [the rapid HIV test]; the actual doing of the tests 
is straightforward. My colleague who should be doing them as well hasn’t done one. I 
don’t know. I went through it with her again a while ago; I don’t know, two or three 
weeks back I went through it again with her to remind her how to do it. And I do it 
whenever I can, but my problem is time…. I don’t know if it’s a religious thing, 
maybe [explanation of perceived religious views of colleague]. I don’t know if it’s 
something to do with that. But she’s a health care assistant; she’s not a nurse. That’s a 
difference as well.’  (Nurse, practice C) 
 
The nurse emphasises professionalism as an important aspect of delivering testing, beyond 
the technical capabilities.  She sees testing as a professional interaction that calls upon her 
experience with patients and training as a nurse.  While the test might seem technically 
simple, it is testing for HIV, an infection that remains highly stigmatised, potentially adding 
complexity and emotionality to testing.  My interview with the nurse revealed that she was 
proud of her patient-centred approach and described any success she herself had with testing 
as down to her ‘way’ with patients. HIV remains a stigmatised condition, and the line 
between a screening test and a diagnostic test can be fine, particularly in the case of the test 
used in the trial, which may be interpreted by patients as well as providers (two dots as a 
reactive result, one dot as a non-reactive result). It may have been that reluctance to offer 
rapid testing relates to the need to provide immediate feedback regarding test results. 
Whereas GPs are called upon to share test reactive results, HCAs and nurses expressed 
significant concern about managing reactive results and patient reactions as well as the 
interval between the test and calling upon the GP. This may have been a factor in the HCA’s 
reluctance to test. The nurse, though personally motivated and more professionally 
experienced, had only limited opportunity to offer rapid HIV testing, as most new patient 
health checks were performed by the HCA. 
 
The nurse discussed felt responsible for trying to improve the testing performance of the 
HCA.  She reported raising the issue with her superiors with no avail.  In general, the practice 




the intervention may not suit her. Whereas practices A and B demonstrated good managerial 
relations and a problem solving ethos, the approach in practice C was less involved and a 
there was a sense of resistance to change.  
 
The frustration of the practice nurse is understandable as she appeared to make numerous 
efforts to increase the offer of testing. For example, she showed creativity in ‘reinventing’ the 
finger-prick aspect of the test. (“As long as I get a decent drop of blood, just occasionally 
people don’t bleed terribly well. I don’t like the finger-pricker they give with it. I tend to use 
my ones…. They’re a bit more gentle.”)   Despite this, as she was not tasked with delivering 
the majority of new patient health checks her efforts did not translate to much of an increase 
in the testing numbers. The practice’s low absorptive capacity was evident in the lack of 
encouragement for skills sharing and communication, with the result that her local 
adaptations and reinventions were not shared with other staff and, notably, were not adopted 
by the front-line staff with the most responsibility to offer testing.  
 
Practice C did not have many attributes that would enable the effective adoption of a service-
level innovation.   The key staff member on which the implementation of the test depended 
was personally reluctant, and this stance persisted despite efforts from colleagues and the 
research team.   The lead nurse, who was motivated, demonstrated local reinvention and 
valued the intervention, but she was not able to overcome other more hindering contextual 
factors such as poor system readiness and few system antecedents for innovation. Progress 
was further hindered by what appeared to be reluctance related to the focus of the 
intervention, HIV testing, and very little tension for change.  
Practice D 
Practice D was chosen due to the low offer of rapid HIV tests and high offer of HIV serology 








Table 12.  RHIVA2 trial performance data for practice D 
 
Practice D 
Practice Size  Large Practice <10,000 
Total serology tests 
offered in the trial 
period  
696 serology tests performed  
Total rapid tests 
offered and 
performed in the 
trial period  
302 rapid tests performed  
557 rapid tests offered  
Decline rate  54% of rapid tests declined  
Rapid HIV testing 
detection 
No cases of HIV detected through rapid testing.  





Highest number of serology tests offered in the borough. 
Low rates of offer for rapid testing considering size and 
number of eligible patients.  
Moderate to high decline rate.  
No HIV detected through rapid testing.    
 
Despite the expectation of practice D being a high-performer in RHIVA2, practice D 
struggled to implement rapid HIV testing.    While the figures in the table above demonstrate 
that a number of rapid HIV tests were offered during the trial period, considering that practice 
D was one of the largest practices in the trial, with a demonstrated interest and capacity in 
HIV testing and a high number of newly registering patients, the offer of HIV rapid tests was 
low. The missed opportunities appeared to reflect a number of practice level factors and 
analysis demonstrates that while there were periods of increased testing, the intervention was 
not ever truly adopted and routinised.  
 
Practice D is large and diverse and includes a large mix of staff including numerous part time 




over 10 receptionists and administrators. A lack of time and slack resource meant that the 
practice was constantly busy and conversations with administrative staff revealed how this 
placed pressure on intra-practice relations and service delivery.  
 
The striking contrast between the very high HIV serology rates but very low rapid testing 
rates may be related to my finding that there were two distinct work cultures within the 
practice. Many of the GPs were highly qualified with some involved in community-based 
projects including work in sexual health.  As mentioned, the practice had a very high 
serology testing rate prior and throughout the trial.  However, the nurses, health care 
assistants and other practice staff appeared to have little involvement in these activities.  
Knowledge appeared to circulate poorly throughout the practice perhaps due to the large 
number of staff with differing working arrangements. Some staff worked part-time and 
appeared to have a very task-oriented attitude toward their work (i.e., they came to work, 
completed what was expected of them and went home). There appeared to be relational 
tensions between some staff in the practice that affected the implementation of the study 
protocol. For example, reception staff had been asked by the lead nurse to hand out leaflets 
about the study to patients at the reception desk, but this did not always happen. I was asked 
to speak to the reception staff and describe the study and the role of the patient information 
sheets to help mediate the issue.  
 
Despite feeling overstretched the staff involved in the trial appeared enthusiastic about rapid 
testing.  Throughout the trial and expressed in interviews however was the sense that rapid 
testing was an additional task and as it was not assigned to important practice indicators it 
was an easy thing to ‘leave off the list’.  So while the GPs saw the value of participating in 
research other practice priorities trumped and it was unclear that the value placed on the 
intervention by senior staff was ever made clear to front line deliverers of the intervention.  
The inconsistent pattern of rapid testing across the trial period is likely a result of practice 
deadlines and occasional intervention from senior GPs aiming to increase testing.   This may 
have been as a result of our study team intermittently reporting results to the senior GPs. So 
while perhaps reluctant opponents of the intervention, the front-line staff were unable to 




‘But because it was coming up to the end of the financial year and everyone had to 
tally up QOF points for diabetes and these and this and that, it took priority. If people 
had come in, obviously if there were new patients, we wouldn’t turn anybody away, 
but we were phoning up and pre-booking patients to come in for their diabs or their 
foot checks or their blood pressure. And because I’m only now doing 3 days a week, I 
literally split sessions between here and (another practice). I do here three sessions 
and there three sessions. So, when I am here, they get me to do loads of ECGs and 
different other things, and then when I’m there, I’m doing things over there that they 
need doing.’ (HCA, practice D) 
 
Unusually, one nurse involved in delivering rapid testing also struggled with the technical 
aspects of the test.  Citing an issue with mobility, she found the test difficult to unwrap and 
use, meaning that it took longer to perform and was a source of frustration.   She indicated 
that over time her offer of testing reduced as a result.  While all the front-line staff in practice 
D expressed enthusiasm for testing and saw value in the study it appeared that a convergence 
of factors meant that testing was never fully implemented. A lack of slack resources, 
oversight, consistency of role and poor communication were strong factors hindering 
adoption.  
 
These organisation-level factors significantly overshadowed other, more positive elements of 
this practice in relation to HIV testing, including the perceived relative advantage of the rapid 
test in comparison with the widely used serological testing, and the compatibility of the test 
with the values and goals of the practice. It may also have been that despite the obvious 
relative advantage of rapid testing the practice had on-going and significant serology testing, 
reducing the tension for change.  
 
While practice D was a large and enthusiastic practice with an interest in HIV and a 
significant number of newly registering patients, adoption was impeded by various factors. 
Structural, capacity-related and cultural factors along with individual adopter traits, combined 






9.6 Summary of findings 
The process evaluation undertaken here combined with an analysis using the Greenhalgh et 
al. model of the diffusion of innovations in health care organisations has demonstrated a fit 
between the method, the theory and the data.  The approach was able to elicit a nuanced 
discussion of findings that goes some way in explaining the variation of rapid testing in 
RHIVA2 intervention practices. Six dimensions of the Greenhalgh et al. model of the 




Attributes comprising the section of the model related to the innovation itself were generally 
positive across intervention practices.  The relative advantage of the test as compared to 
existing HIV testing practices was an overarching finding. Practices reported finding the 
speed and portability of the test as generally positive. This finding links to the 
aforementioned overarching finding related to ‘patient theory of mind’, as provider views 
appeared largely informed by the positive review the test received from patients.  
 
System antecedents for innovation 
 
Practices with strong system antecedents appeared better able to adopt the innovation.  This 
was largely related to how practice staff were organised and treated. More formally organised 
practices with clearly differentiated roles and senior support appeared more able to 
implement the innovation.  This may relate to the greater provision of slack resources, 
support and feedback as well as better communication.  These positive managerial relations, 
role comfort and ability to access support when required influenced practice performance. 
 
System readiness for innovation 
 
 If practices saw a role and need for increased HIV testing, known in the model as ‘tension 




organised and consistent new patient health check was present in the practice, then the 
mechanism for delivering rapid testing was more stable and facilitated implementation.   If 
regular staff were provided with dedicated time, support and resource to add this additional 
task to their new patient health check, such as in practice A, then the intervention appeared 




As seen in both practice A and B, adopters who are personally motivated, see the broader 
value of the innovation and find it easy to use are more likely to implement.  In practice A, 
the nurse felt she was personally helping her community, while in practice B staff reported 
feeling that the innovation improved the community perception of the practice as a whole.  
However, as seen in practice D, even if staff are individually motivated, this may not 
overcome other organisational factors.  
 
The implementation process  
 
The process of implementing the innovation was facilitated by an involved approach from 
senior staff (practice A) or the devolution of the task to highly competent and stable staff 
members (practice B).  If practices assumed implementation would take place without 
practice level consideration and tailoring post trial GP training session (practice C), there 
appeared to be less likelihood of the innovation being implemented.   If feedback and support 
were not provided throughout the early stages of implementation, practices were less likely to 
adopt the innovation.   Implementation was more likely when stable, dedicated staff provided 
the new patient health checks, and slack resource was generally more available in the 
practice.  
 
Re-invention and local customisation 
 
Some staff demonstrated small local adaptations to testing.  This ability to tinker with the 
‘soft-periphery’ aspects of the innovation appeared key to adopter comfort and ease in 




was more technically simple (practice C), in other cases, this meant accounting for the patient 
experience (practice B).  While this factor alone may not have been enough to overcome a 
general lack of practice attributes in some cases, this aspect appeared important and 
demonstrated a willingness and ownership toward the innovation that may be key in an 




Positive and negative synergies  
 
An important finding, and consideration in articulating the findings, is how various attributes 
facilitate, enable, depend upon and converge with other attributes creating both positive and 
negative synergies for implementation.  In the case of practice B for example, the personally 
motivated nurse was enabled by adequate time, space and support to deliver a consistent new 
patient health check.  That the practice was organised in this way reflects broader structural 
system antecedents.  Together this allowed her to offer more tests which led to greater 
detection and significant observability.  Similar descriptions of compounding attributes can 
be described in all case studies resulting in the variable adoption success. This may also be 
evidence of the ‘interlocking interactions’ described by Dopson et al., where the 
characteristics of contexts, communities and practices interact to enable innovation or not 
(2002).  What is described here reinforces the argument that there is no singular or fail-proof 
method of ensuring implementation.   It may be unhelpful to conceptualise of innovations as 
discrete entities to be added on to existing structures. Innovation adoption is likely best 
conceived of as a process comprised of numerous formal and informal decisions at multiple 
levels (2010).  
 
Innovation specificity  
 
While the model of the diffusion of innovations in healthcare settings explores attitudes 




innovation interacted with the evaluation of feelings about the innovation itself, including the 
material aspects.  It appeared that if a provider had a view of HIV, for example, that was 
negative, then despite many positive organisational attributes the innovation may never be 
adopted.  This links to the ‘compatibility’ attribute in the diffusion of innovations model and 
was a finding raised in the aforementioned systematic review, where ‘the specific innovation 
concerned’ was relevant to the adoption journey (Robert at al., 2010: p. 247).  The specificity 
of HIV patterned many of the provider behaviours, including the adaptations of the nurse in 
practice B, for example.  This also links with the previous discussion on ‘theory of mind’ and 
the triadic relationship between the test, the patient and the adopter.  Considering the patient 
and the innovation ‘subject’ more explicitly in the theorising of the diffusion of innovations 




Practices who were successful in implementing the rapid HIV test as part of the trial had 
routinised the innovation not merely by assigning its component tasks to particular staff 
members but also by encouraging and rewarding those staff for embedding it in the day-to-
day work of the practice and linking it to other routines. This crucial distinction between 
‘complex intervention as a set of tasks’ and ‘complex intervention as embedded routine’ 
aligns with Denis et al.’s notion of the ‘hard core’ of a complex intervention (the elements 
that constitute its ‘fidelity’) and the ‘soft periphery’ which can and must adapt to 
accommodate it (2002). This further consideration of routinisation as a key processual 
dimension of adopting new innovations has been the subject of a number of more recent 
studies (Robert et al., 2010; Greenhalgh, 2008).   In RHIVA2 it is possible that practices 
more quickly able to routinise rapid testing were either previously, or quickly became, more 
comfortable with the innovation through the proposed benefits of routinisation, such as a 








Adopter autonomy and innovation as a workplace lever 
 
Some low-recruiting practices raised concerns about leadership, staff relations, role 
distributions and possible internal hostilities.  It was also obvious to me on a few occasions 
when visiting intervention practices that such issues were impeding the implementation 
process.  In some cases, the innovation itself appeared as a sort of “bargaining chip”, or 
further piece of evidence to demonstrate intra-office inequalities and in these cases the 
behaviour regarding the innovation appeared to have very little to do with the innovation 
itself but reflected these broader organisational problems.  Such issues make the routinisation 
of innovations extremely difficult, and it may be that sensitive exploration of the system 
antecedents and key success factors for implementation may allow practices with such ‘risky’ 
characteristics to be identified in advance of the trial and offered targeted support or even be 
excluded from the sampling frame.  Robert et al., indicated the need for great importance to 
be ‘placed in the interactions between groups than previous (non-healthcare based) literature 
predicts’ (2010: p. 247).  Their additional finding that the converging of various professional 
groups in the delivery of new innovations may act as a barrier may also have been evident in 
the cases described above, where professional understandings, training and experiences 
influenced provider perceptions about the innovation and their ability to deliver it, such as in 
practice C (Robert et al., 2010). 
 
What was described above also reflects who makes the decision for the practice to participate 
in a trial and roll out a new innovation.  This aspect was discussed by the forefather of 
diffusion of innovations work, Everett Rogers and highlighted again in the Robert et al. 
systematic review (Rogers, 2003; Robert, 2010).  Rogers observed that adopting an 
innovation is optional, collective or authoritarian (2003).  Robert et al. described how there is 
rarely a single instance of adoption, or a predictable lead adopter (2010). It is unclear how the 
adoption decision was made in RHIVA2 intervention practices but the data reflects that in 
some cases the approach was authoritarian, where the decision is imposed by more powerful 
members of the organisation. The collective, where a group decision is made, or individual 
decision model, where each member opts in or out, may have led to increased 
implementation.  As HCAs were most likely to deliver rapid testing in RHIVA2 and often 




influence organisational decisions and occasionally expressed resentment regarding this 
during interviews. Authoritarian decisions lead to high rates of initial adoption but also to 
high levels of front-line resistance, particularly in practices where human resource issues are 
already present (Rogers, 2003). Ideally, the decision for an organisation to join a trial of a 
complex intervention should be made collectively and should certainly include the staff 
whose job it will be to deliver the intervention. 
 
The unsurprising role of ‘slack resources’ 
 
A more general way to improve the uptake of interventions is to consider the role of slack 
resources and work with organisations to consider this issue as related to adopting a new 
intervention.  Organisations such as practice B, who had a dedicated consultation room for 
the lead nurse and a full 30 minutes for each new registration check, obviously had more time 
and potential for continuity in rolling out the intervention.   Conversely, in practice D, key 
staff were pulled from research projects when other key practice priorities loomed.  Working 
with practices to consider the planning and true costs of implementation may help guard 
against such issues, perhaps calling on supplementary resources (overtime pay, for example) 





In the findings chapter presented above, I used an evidence-based model of the diffusion of 
health care innovations and applied it to various data emerging from the RHIVA2 trial 
(quantitative) and interviews with those implementing the intervention (qualitative).   To my 
knowledge, this was the first instance of application for the Greenhalgh et al. model of the 
diffusion of innovations to a cluster randomised controlled trial.  The model proved a useful 
way to explore the RHIVA2 trial and the trial itself a good way to test the Greenhalgh et al. 
model through four contrasting practice experiences of testing.   In this analysis, the model 
was applied retrospectively; the potential for the model to be used prospectively will be 




trials, trials of more complex phenomena and with greater theorisation of the triadic 
relationship between the intervention, the provider and the patient. The findings presented 
above support the conclusion that there is not, nor can there ever be, a universal 
implementation model for complex interventions. Site-specific characteristics and realities 
need to be considered.  
 
In Part 2, the two stories threaded through this thesis converged with differential effects 
across 20 intervention practices in RHIVA2.  The logic of normalisation for HIV, which 
justifies screening approaches and prioritises the general population, merged with the logic of 
the pragmatic trial, which aims to evaluate interventions in their context of use. In Part 3 we 
move to the imagined end point of the RHIVA2 trial, the HIV-positive patient, as detected 
through rapid HIV testing. The patient body represents another site where the two stories 
converge. It is here in Part 3 that the logic of the pragmatic trial will come more clearly into 
view, enabling an in-depth discussion of ontology, experimentation and the impacts of the 



























PART 3:  Experimental end-points: Patient experience and the pragmatic trial  
 
Having thus far encountered some of the complexity that RHIVA2 engendered in practice, in 
Part 3 I aim to provide a deeper analysis of the findings and provide insights at the 
methodological and theoretical level.  Through two findings chapters where I consider both 
RHIVA2 patients testing HIV-positive with the rapid test and the trial results (both 
conceivable end points in the view of the trial and the policy). I explore how the logic of 
normalisation is encountered by those testing HIV-positive with rapid testing, and how the 
logic of the pragmatic trial organises study findings.    
 
Chapter 11 introduces five in-depth patient case studies that describe how the trial became 
meaningful for each patient, each of whom tested positive for HIV with the first test being a 
rapid HIV test as part of RHIVA2.  I also trace the work of ‘normalisation’ through the 
patient case studies exploring how this logic patterns patient experiences of HIV testing and 
diagnosis.  Chapter 12 acts as a synthesis of findings from studies at the policy, provider and 
patient level.  This chapter explores the logic of the pragmatic trial explicitly and aims to 
make a methodological and theoretical contribution and also works as an introduction to the 
discussion chapter.   Through the presentation of two cases, termed ‘ambiguities’, I 
demonstrate how the pragmatic trial logic occludes much of the productive work of the 
RHIVA2 trial.  I begin with a discussion of some relevant literature from the fields of science 

















Chapter 10: INNOVATIONS IN PRACTICE:  INTRODUCTION TO PART 3 
 
What has become apparent in the collection of the data presented here is how innovations are 
not straightforward, predictable objects that interact neutrally with individuals and settings.  
The literature described below encourages the discussion of objects and their interactions 
with greater complexity.  
 
People survive HIV as a result of innovation and technology.  At present there is no real 
‘living with HIV’ without HIV treatment. The process of uncovering and then ‘living with’ 
HIV relies on devices, both material and conceptual.  Matter such as blood, tests and 
monitors, as well as concepts such as the definition of HIV as a series of levels of CD4 
counts, viral loads and antibodies, construct our understanding and experience of HIV.  We 
rely on these concepts and tools to make the infection knowable and bearable. This way of 
approaching HIV represents a disciplinary slant related to Science and Technology Studies 
(STS), material semiotics and some realms of anthropology.  These approaches complicate 
the view of HIV and screening as presented in the typical biomedical literature and provide 
productive lenses to consider what was pronounced in the PhD data.  
 
STS researchers take interest in the social processes that produce scientific and technical 
knowledge and propose that knowledge and technology shapes and is shaped by society 
(Law, 2004).  How this knowledge is positioned as evidential and valid and how it is 
inscribed in ‘texts, people, machines, images or other forms’ is considered alongside its 
contestations, transformations and role in relations (Cornell, 2015: p.1).  STS draws heavily 
on actor network theory (ANT), as first developed by Bruno Latour and Michel Callon 
(Latour, 2005).   While the term has been widely interpreted and disputed, Latour describes 
his work as a science of associations and not only as the science of the social (Latour, 2005).    
 
In his paper ‘Actor Network Theory and Material Semiotics’, which I draw largely upon, John 




material semiotic approach where ‘entities take form and acquire their attributes as a result of 
their relations to other entities’ (Law, 1999: p.3). For example, CD4 counts only become 
markers of HIV level when they are linked through blood tests for HIV antibodies.  HIV 
diagnosis requires the choreography of concepts and materials into a particular relationship 
within a particular network to make HIV ‘real’.  ANT is often classified as a constructivist 
approach to knowledge and reality, though others have called it ‘performative’ because of its 
emphasis on actors and action rather than talk and text (see quote below). In ANT, there is 
not one knowable truth of the world ‘out there’ and the realities of people and things are 
constructed through interaction.  ANT is outlined by Law as: 
‘a disparate family of material-semiotic tools, sensibilities and methods of analysis 
that treat everything in the social and natural worlds as a continuously generated 
effect of the webs of relations within which they are located.  It assumes nothing has 
reality or form outside the enactment of those relations.  Its studies explore and 
characterize the webs and the practices that carry them.  Like other material-semiotic 
approaches, the actor-network approach thus describes the enactment of materiality 
and discursively heterogeneous relations that produce and reshuffle all kinds of actors 
including objects, subjects, human beings, machines, animals, ‘nature’, ideas, 
organisations, inequalities, scale and sizes and geographical arrangements’ (Law 
2009: p.2). 
 
He goes on to further nuance the term.  Law indicates the inability to describe ANT 
accurately in the abstract as it requires empirical case studies to be known and understood.  
Law articulates ANT is not a theory per se due to its descriptive rather than explanatory role.  
He highlights ANT’s lack of status as a single entity or approach before finally defining ANT 
as ‘empirical post-modernism’.  ANT is best understood, according to Law as a ‘toolkit for 
telling interesting stories’, a ‘sensibility to the messy practices of relationality and materiality 
of the world’ and a ‘diaspora that overlaps with other intellectual traditions’ (Law, 2009: p.2).   
 
The description is not straightforward, and fitting to the discipline, Law rejects having the 
‘objectivity of an overall view’ (Law, 2009: p.3). Helpfully Law continues to describe 
important developments in the field, including ‘enactment’, ‘multiplicity’, ‘fluidity’, ‘realities 
and goods’ and finally ‘ontological politics’. Some of these themes have already been present 




chapters.  I will now briefly describe enactment and multiplicity before moving onto a 
discussion of paradox and non-coherence. 
 
10.1  Enactment and multiplicity  
 
Law discusses the importance of ‘enacting’ and performing practices to bring realities into 
being.  He describes this as a slight move away from constructivism as this mode of thought 
posits a primary constructer of realities (2009).  Law’s proposition is that a focus on 
enactment demonstrates the ways beings and non-beings play a relational part of what 
emerges as the real, and it is through these performances that these realities take shape.   He 
calls on Latour’s exploration of pasteurisation in France and Garcia-Parpet’s work on the 
performance of strawberry markets to illustrate his point (Garcia- Parpet, 2007; Law, 2009).  
Work by Annemarie Mol also further demonstrates ‘enactment’ and an exploration of her 
work on medical practices forms part of the intellectual ‘diaspora’ Law refers to (Mol, 2002; 
Mol, 2008; Law, 2004).  
 
In The Body Multiple, Mol’s ‘praxiography’ of atherosclerosis, she traces the disease 
throughout various spaces in the hospital setting and discovers a multiplicity of reality in 
practice.  Proposing this as ‘empirical philosophy’, Mol tackles ontology, social theory and 
method (2002).  She explores how reality is constantly being enacted through practice and 
how there is a merging of subject and object in an ongoing ontological process of reality 
shaping, demonstrating a multiplicity of disease and medicine and highlighting the social, 
collaborative and complex ways in which we ‘enact’ medical practices and technologies 
(2002).   Lisa Blackman summarises Mol’s The Body Multiple in the quote below: 
‘The aim of Mol’s research which focuses on how arteriosclerosis is enacted is to 
‘study the multiplication of a single disease and the coordination of this multitude into 
singularity’ (2002:82) The coordination of multiple objects so that they ‘hang 
together’ is not due to the discreteness of the object itself, but rather to the strategies 
and practices which distribute the objects across different sites, locations, activities, 





Enactment is key to Mol’s contribution on multiplicity. Through tracing atherosclerosis 
through the hospital she uncovers and then proposes that there are multiple ‘atheroscleroses’’ 
and that we should not think of disease as a singular object but as multiple, dependent upon 
the coordination of relations in which it is enacted.  For example, under the microscope it is 
one thing, for a patient another.  In describing this assertion, Mol states: 
‘If practice becomes our entrance into the world, ontology is no longer a monist 
whole.  Ontology-in-practice is multiple.  Objects that are enacted cannot be aligned 
from small to big, from simple to complex. Their relations are the intricate ones that 
we find between practices.  Instead of being piled up in a pyramid, they rather relate 
like the pages in a sketch book.  Each new page may yield a different image, made 
with a different technique and in as far as a scale is recognizable, it may again, each 
time, be a different one.  There is no fixed point of comparison.’ (Mol, 2002: p.157)  
 
As reality is enacted through practice it multiplies. Not infinitely and randomly however, but 
as ‘more than one but less than many’, it is ‘manifoldness but not plurality’, the practices 
enacting this multiplicity somehow hang together and often coordinate or compete to allow 
for decision making (Mol, 2002). 
 
In another important work, briefly mentioned in the Introduction, The Logic of Care, Mol 
continues to explore medical practice through the lens of care and patient choice (2008).  She 
problematises the concept of patient choice, discussing it’s positioning of health care in a 
rationalistic model based upon the tenets of consumerism and citizenship.  The ‘logic of 
choice’ is contrasted with ‘the logic of care’, where both patients and practitioners, dually 
acknowledged as active negotiators of complex illnesses and bodies, collaboratively and 
continually attempt to use technology, science and other available means to develop liveable 
outcomes for patients (Mol, 2008). 
 
Mol’s discussion of interventions and technologies and their effects bears relevance to 
contemporary thinking in medical and social sciences. She demonstrates throughout her 
praxiographies and monographs that innovations are not obedient means to certain ends but 
are actors themselves, she goes further to propose a new ontology for thinking through 
medical interactions, that of enactment, multiplicity and ontological politics. I will further 







10.2 Paradox and non-coherence 
 
In Vicky Singleton’s book chapter: ‘Stabilizing instabilities: The role of the laboratory in the 
United Kingdom cervical screening program’, she describes how local adjustments in a 
cervical screening program diverge from clinical protocols resulting in instabilities in the lab 
work.  Conversely, instead of being a problem these instabilities help to maintain stability and 
produce the intended results (1998).   In the same book, Charis M. Cussins describes other 
seemingly paradoxical findings.  In her work, by exploring female patients in an infertility 
clinic, she questions whether ‘forms of objectification per se…are antithetical to 
personhood.’ (Cussins, 1998: p.167).  She argues that medical technologies do not necessarily 
entail a loss of agency, challenging what she describes as longstanding ideas that 
technologies are objectifying and alienating, and potentially ‘usurping selfhood’ (Cussins, 
2008: p.167) (a similar approach is evident in the work of Jeanette Pols, 2012).  What she 
demonstrates is that women seeking impregnation objectify their infertility so as to pass 
through a number of medical spaces that may help the women to alter their identities as 
infertile women. The women, she argues, render themselves compatible with various 
instruments and materials so as to achieve potential transformation:  
‘She is locally and temporally reduced to a series of bodily functions and parts, 
working in a mechanistic way that forge a functional zone of compatibility with the 
means of medical intervention.  The instruments, drugs, physician, gametes, and so 
on, all take on some form of her by standing in for the phases diagnosed as not 
working.’ (Cussins,1998: p.192).   
Cussins describes this work as ‘ontological choreography’ and concludes:   
‘woman’s objectification, naturalization, and bureaucratization involve her active 
participation, and are managed by herself as crucially as by the practitioners, 
procedures and instruments.  The trails of activity…wrought in the treatment setting 
are not only not incompatible with objectification, but they sometimes require periods 




Objectification is not necessarily an affront to the self and in some cases the women 
transform what it means to be objectified, medicalised women, with implications for 
conceptualisations of subjectivity.   
 
The work summarised here could be considered as examples of practices where non-
coherences and inconsistencies are managed, as working with multiplicities, subjectivities 
and possible non-coherences in a way that enables outcomes. In their paper ‘Modes of 
Syncretism: notes on non-coherence’, John Law et al. explore the concept and ideal of 
coherence and the ‘will to purity’ (2013).  They describe six styles of syncretism (non-
coherence) that they see operating in the modern world. The authors take the term 
‘syncretism’ from religious and anthropological studies where it is used to ‘characterise more 
or less messy processes which combine, or perhaps particularly, secure, the temporary 
coexistence of practices and doctrines from a variety of dissimilar religious backgrounds.’ 
(Law et al., 2013: p.176).  Syncretism describes non-coherence made workable.  In their 
paper, they ask how practices that do not cohere might be conceptualised and worked with if 
consistency and coherence were less idealised (Law et al., 2013).  Of interest is how practices 
hold together when (as the authors suggest) all practices are syncretic (non-coherent). They 
describe denial, domestication, separation, care, conflict and collapse as syncretic styles.  
For example:  Separation keeps non-coherent aspects apart through temporal, social and 
spatial divisions: ‘different logics can co-exist so long as they do not collapse together in the 
same space and time’ (Law et al., 2013: p.180).   Care, another example, is described as a 
form of tinkering which is experimental and works on a bit by bit basis of small adaptations 
in the face of unfolding uncertainties and may allow for an imperfect and provisional holding 
together of effects in an ongoing process (For more on tinkering see Mol, Moser and Pols, 
2013, for more on care see Mol, 2008 and Pols, 2010).  
 
The authors do not describe this list of approaches to syncretism as exhaustive, complete or 
mutually exclusive.   The different modes may depend upon each other and still represents a 
reduction of the described phenomena.  This is what Hastrup would describe as an inherent 
process of knowledge claims, where reduction and selection are required to render the 




how non-coherence is managed in an aim to avoid yet another attempt at the ‘will to purity’.  
What they suggest is that:  
‘the lesson we need to draw is that location, together with purpose or concern, 
unavoidably frames what will count as a good mode of syncretism…there is no place 
outside of time, space, place, and concern, where what is good or bad can be weighted 
up in an overall way’ (Law et al., 2013: p.182). 
What is of interest in the work described in this section is the idea of ‘holding together’ in the 
face of complexity, multiplicity and non-coherence; how particular practices enable outcomes 
by managing potential paradox and multiplicity. The authors describe what the work may be 
in rendering non-coherence workable. This work also demonstrates how outcomes may come 
to be in unexpected and seemingly heterodox ways.   
 
Each of the findings chapters below will include a discussion of literature relevant to the 
theoretical frame used to inform the analysis and construction of findings.  The approaches 
used fall within the realms of science and technology studies, philosophy of science and 
anthropology and call upon the central themes introduced above.  
 
10.3 Data Sources 
 
The two findings chapters in Part 3 call on different data sources.  Chapter 11 considers the 
experience of patients testing HIV-positive in RHIVA through rapid testing specifically.  The 
findings call on five in-depth interviews which are transformed into patient case studies.   The 
methods used here are in-depth interviews and thematic analysis (See Chapter 4).   Chapter 
12 considers a synthesis of findings from the provider and patient level sub-studies to provide 
comment on the pragmatic trial method. I will now outline the data sources informing 
Chapters 11 and 12. 
 
Data sources for Chapter 11 
Throughout the trial period, 11 patients (of 4978 tested) were diagnosed HIV-positive in the 




tests were delivered as a part of the RHIVA2 trial.  Patients diagnosed in this way, who 
received their HIV care at the local hospital, were invited for interview. The department of 
sexual health’s research nurse, who was a member of the RHIVA2 trial team, was the first to 
approach patients about participating.  It was only after a first occasion of consent, obtained 
by her, that I was introduced to potential participants.  In all cases but one this was on the day 
of the interview, in the booked consultation room.  On one occasion I undertook the 
coordination of the interview with the patient via email, after he had provided consent to the 
research nurse. Prior to beginning interviews I reintroduced the patient information sheet and 
consent form, discussing any questions before re-obtaining written consent and beginning the 
research. When possible, the interview took place when a patient was attending the clinic for 
a medical consultation, but in other cases the patient attended the clinic solely for the purpose 
of the interview.   Participants were provided with a £20 voucher for their participation to 
cover travel expenses and the time given to participate.  The amount was determined in 
consultation with the research nurse, who cited this amount as standard for this form of 
participation. Interviews with patients lasted approximately one hour and 15 minutes 
including the time allocated for introductions and consenting.  
 
Six interviews took place with five participants, from a possible 11 who were eligible to 
participate.  One patient, as a result of a mix up with recruitment at the local hospital, was 
interviewed twice.  It is unclear as to whether all eligible patients were invited to participate 
and at least one patient opted to receive their care at a different hospital and so was not 
invited for an interview.  
 
The small number of 11 patients diagnosed through rapid testing limited the potential sample 
of participants to be invited for interview.   The research nurses reported some participants to 
be so fearful of social stigma and resistant to diagnosis that they did want to participate in any 
HIV related activities beyond the biomedical tasks of diagnosis and treatment. The sample 
presented here, five patient cases, is not claimed to be representative or to have reached any 














Table 13. Participant characteristics for patient-level study  
 
Sex Age Range Ethnicity 
Female 25-35 Black African 
Male 35-45 Latin American 
Male 25-35 Mixed white / Asian 
Female 45-55 Black Caribbean 
Male 45-55 White British  
 
Interviews were in-depth and open ended. A topic guide was developed, identifying the 
following themes:  
The experience of diagnosis: 
• the GP setting 
• the use of the rapid test  
• the placement of the testing within the New Patient Health Check 
 
Post diagnosis care: 
• Pathways post diagnosis – How was your experience of entering services? 
• Actual locations of receiving care  
• Preferences for receipt of care  
• Specialists vs. GP 
 
Relationships with providers: 
• Relationship with GP who diagnosed the patient 
• Perceptions of the GP surgery  
• Specialist vs. GP care  
• Concerns 
 




• Preference of health care locations 
• Concerns about having HIV care in primary care settings  
 
I introduced a number of questions as prompts if required but largely followed the lead of the 
patient in discussing their diagnostic experience.  
 
A broader discussion of the patient case study features is described within the chapter.  
Briefly, interview transcripts were analysed thematically.  Transcripts were uploaded onto 
NVIVO and coded twice.  The first phase identified emerging themes.  Following this, a 
coding frame was developed and applied to the transcripts.  The second phase coded along 
the determined frame. The second coding frame contained the following themes:  
• individual characteristics 
• the experience of testing 
• biosocial factors 
• contrast to the imagined patient 
• normalisation versus exceptionalism 
• positive versus negative feelings and experiences.  
 
Data sources for Chapter 12  
 
Chapter 12, related to the pragmatic trial, calls upon data from the various sub-studies and the 
findings of the RHIVA2 trial.  These include the interviews with nurses and health care 
assistants providing rapid HIV testing in intervention practices as well as interviews with 
patients testing HIV-positive as a part of the RHIVA2 trial with the first test being a rapid 
HIV test.  My ethnographic attention to, and experience of, the pragmatic clinical trial also 
informs and in some ways provides the impetus for this chapter.  Trial documents such as the 
trial protocol and training slide deck are used to articulate aspects key to the findings 
presented here.  The results of the RHIVA2 also form a part of the data sources for this 
chapter.  A broader and more detailed description of the methods and data sources used can 
be found in Chapter 4 (methods), as well as the previous 4 findings chapters. A further 
discussion of the approach to the findings, and how they emerged and were analysed is 









Chapter 11:  PRODUCING DIFFERENCE IN RHIVA2: HIV-POSITIVE PATIENT 
EXPERIENCES OF RAPID HIV TESTING   
   
11.1 Introduction  
 
‘The HIV test locates a spectrum of diseases waiting to happen, but not a disease 
itself.  Partly because of this diagnostic ambiguity, the use of the test to assign 
meaning has engendered contentious social, political, moral and medical debate.  
When should it be used? On whom? What does the test really tell us? It has become 
clear that the social and political turmoil surrounding AIDS (the context) shapes the 
meaning of any HIV test.   For some observers, the HIV test appropriately identifies a 
‘sick’ and dangerous individual.  For others the test itself has become dangerous, a 
vehicle for labeling, perpetuating social discrimination… Depending on its user, its 
interpreters, and the context, such a technology can have both oppressive and 
liberating effects.’ (Wailoo, 1997: p.2). 
 
In Part 1, I demonstrated how the recommendation of considering HIV testing for new 
registrants in general practice was justified and enabled and the key discourses informing the 
policy.  In Part 2, I explored the implementation and evaluation of the policy at the 
organisational level, outlining the factors inhibiting and facilitating the delivery of testing 
through the diffusion of innovations in health care organisations model by Greenhalgh et al 
(Greenhalgh et al., 2004).  I now turn to the patient experience of rapid HIV testing as part of 
the RHIVA2 trial. 
I begin by describing how the RHIVA2 trial team conceptualised the patient and their 
movement through the trial.  I call this conceptualisation the ‘imagined’ patient.  I then 
present the theoretical frame and the findings from the patient interviews before describing 
how the findings contribute to my understanding of Story 1: the ‘normalisation’ of HIV and 
the role of screening technologies in this process and Story 2: the logic of the pragmatic trial.  
 
RHIVA2 as a ‘difference machine’  
 
 ‘They are like spider webs, something will be caught in them, but one does not know 
exactly what it will be nor when it will come.  They are devices for the creation of 




making the future’ (machines a fabriquer de l’avenir’), and thus of difference 
machines.’ (Rheinberger, 2015: p.169) 
 
Broadly the RHIVA2 trial aimed to detect and demonstrate difference:  A difference in the 
body represented by HIV and a difference between intervention and control arms in the trial. 
Hans-Jörg Rheinberger, a German historian and philosopher of experimentation in the life 
sciences, describes experiments as ‘difference machines’ (Rheinberger, 2015: p.168), as 
machines that attempt to make difference visible.   Screening programmes aim to detect 
differences between members of the general population, which enables surveillance and 
medicalisation.  The rapid HIV test works to make HIV intelligible, to make a particularity of 
the body visible and observed as a difference in need of care.  The pragmatic trial aims to 
detect a difference between the intervention and control arms of the trial, this aggregated 
difference is then meant to be applied more generally. In a sense, RHIVA2 is all about 
determining difference. 
 
In RHIVA2, this process begins with a patient attending medical services and agreeing to an 
HIV test.  Patients are the key in this production of difference, determined by the answers to 
these questions: ‘can we detect a difference (HIV) in the body of this patient?’  The answer is 
produced by the rapid test. Another question is ‘is there enough difference in the bodies of 
these patients to help determine if we should look for difference in this way?’ The answer to 
this question is determined by aggregating the difference (HIV) between patients to 
demonstrate a difference between trial arms (trial outcomes: proportion of HIV and mean 
CD4 cell count). In this chapter I explore the patient role in producing these important 




A difference in the patient body:  
The rapid HIV test aimed to detect a difference in the body of patients, through the 
detection of HIV antibodies.   This image below was taken from the RHIVA2 GP 
training slide deck and was a tool to help clinicians learn how to detect HIV in patient 
bodies, made intelligible by the rapid test. 
  
A difference in trial arms  
The trial aimed to detect a difference between intervention and control arms of the trial, 
demonstrated through the rate of newly diagnosed patients and CD4 cell count.    
This text was taken from the trial protocol:  Effectiveness of HIV screening in Primary Care: 
Study Protocol V 5.1, dated 02 August 2012 
 
‘The primary objective is to demonstrate that rapid HIV testing offered in the new patient 
health check or at first consultation, when combined with an educational package for 
health care professionals, reduces the proportion of newly diagnosed patients who 
present with advanced HIV infection from 30% to 10%. An advanced HIV infection is 
defined as CD4 count lower than 200 cells per cubic millimetre of blood. This is 
estimated from the mean CD4 count, using the Normal distribution.’ ’ (Leber at al., 
Effectiveness of HIV screening in Primary Care: Study Protocol V 5.1 2012:8) 
‘The secondary objectives are to demonstrate (1) an increase in proportion of new HIV 
cases that qualify for the start of antiretroviral therapy, defined as a CD4 count less than 
350 cells per cubic millimeter of blood (this will also be estimated from the mean CD4 
count) (2) an increase in proportion of patients newly diagnosed in general practice (3) 
an increase in the rate of standard HIV tests performed opportunistically (4) a reduction 
in proportion of HIV cases with a high risk of progression to AIDS, defined as a viral 
load of higher than 200,000 copies per million peripheral mononuclear cells and (5) a 
reduction in financial and economic costs incurred to the PCT.’ (Leber et al., 
Effectiveness of HIV screening in Primary Care: Study Protocol V 5.1 2012:8) 
 






























The ‘Imagined patient’ 
 
In designing the RHIVA2 trial, we imagined and re-imagined the trial patient: what their 
pathway through services would be, what their CD4 counts and viral loads might represent if 
they tested positive, how they would feel about the rapid nature of the test, amongst other 
things.  Before the first test was performed, a long anticipated patient was embedded in trial 
documents, training slide decks and ethical approvals.   
In determining the eligibility criteria, we delineated who could form a part of the trial.  
Figure 10.  RHIVA2 Inclusion criteria slide from GP training slide deck. 
 
 
Prior to undergoing the rapid HIV test the trial patient was to:  
• Register with their general practice as a new patient. 
• Receive and read a patient information sheet outlining the trial and notifying them 
that they would be offered a rapid HIV test. 
• Attend a new patient health check (ideally within six months of registering so as to 
meet our data cut off for a new patient).  





At the new patient health check, if offered, the patient would agree to the rapid test and have 
their finger pricked and their blood tested for HIV antibodies.   Here a number of other 
assumptions are at work: 
• The patient will be comfortable enough to notify the clinician if they are HIV-
positive, despite it likely being their first visit to the practice for a ten-minute 
consultation with a health care assistant or nurse (not the GP).   
• It will be clear when a patient is able to engage in a conversation and provide 
informed consent to undergo testing.  
• The test requires sufficient blood sample (50µl).  The patient needs to produce 
sufficient sample for the test to work. 
•   The test kits will be in date and properly stored as well as correctly operated by the 
clinician.  
 
Our planning prioritised those receiving reactive results, as this required more extensive 
coordination.  The two dots represented on the test membrane (See Figure 9.) would trigger a 
set of algorithms that transport individuals, body fluids and data to a number of locations to 
be met by various actors with key roles in the diagnostic journey of the patient and the 
success of RHIVA2.  Figure 10 demonstrates an algorithm I developed in my role as 
















Ideally, a patient would receive a clearly visible reactive result on the rapid HIV test 
membrane if their blood contained HIV antibodies.  The nurse or health care assistant would 
then immediately access the GP who could explain the result to the patient and perform a 
confirmatory serology test.  We developed phrases for health care assistants and nurses to 
assist them in enacting the algorithm and a desktop aid was provided to those offering rapid 








Figure 12.  RHIVA2 algorithm desktop aid 
 
 
In the case of a reactive result, the algorithm assumed that:  
• The patient’s HIV status is unknown prior to the rapid test. 
• The patient will agree to the serology test. 
• The patient will await the GP and remain located in the consultation room. 
• The patient will accept the provisional result of the rapid test while awaiting 
confirmatory HIV testing. 
• A GP would be available to speak to the patient.  
• The patient will not participate in any ‘risky behaviour’ or defect from health care 
services while awaiting the confirmatory result.  
 
The ‘imagined’ patient behaves in a rational, linear way, adherent to the suggestions of the 
medical setting and willing to participate in research.  Some authors have critiqued the 
‘normal science’ of trials and such conceptualisations of the patient. In their paper: ‘An 
epidemic of orthodoxy? Design and methodology in the evaluation of the effectiveness of HIV 
health promotion’, Susan Kippax and Paul Van de Ven critique the use of experimental 
methods, particularly the randomised controlled trial, in evaluating HIV interventions.  They 
suggest that this form of investigation assumes research participants as ‘asocial individuals 
who occupy non discursive space in ahistorical time’ (Kippax and Van de Ven, 1998: p.371).  
Calling on an Australian health promotion strategy as an example, they conclude that the 
posited relationship between the variables measured, the health promotion materials, and the 
behaviours is over-simplified and that drawing associations would be inappropriate. They 
challenge the ‘orthodoxy’ of RCTs and describe a fundamental flaw in the trial logic, as even 




‘people are social beings and as such they cannot be positioned as individual or 
atomized bodies as they can be in the clinical trial paradigm in which drugs are 
evaluated.  Their lives are geographically and historically positioned; and they belong 
to groups according to age, ethnicity, sexuality, life circumstances, neighbourhood, 
employment and so on.  In short they are socially and historically located.’ (Kippax 
and Van de Ven, 1998: p.376).  
Understanding the conceptualisation and expectations of patients in RHIVA2 is important to 
allow for the contrast against the actual patients encountered to become clear.  I will now 
outline my theoretical frame for this chapter before moving on to describe the patient cases.   
 
11. 2 Theoretical Frame  
 
‘diversity will remain a feature of any complex practice, medical practice included.  
Instead of countering it, it would therefore be better to find more creative ways to 
handle it’ (Mol and Berg, 1998: p.7). 
The body and subjectivity have been widely theorised in relation to health and illness.  
Important theoretical perspectives have included medicalisation, phenomenology, affect, 
enactment and performance, amongst others (See Lupton, 2012; Blackman, 2008; Mol, 2002; 
Pols, 2010). While this chapter discusses patient experiences of rapid HIV testing as part of 
the RHIVA2 trial, the subject of study is less the phenomenological, medicalised and sentient 
body, but what patient experiences of rapid HIV testing tell us about Story 1: HIV screening 
approaches as implementing a ‘normalised’ HIV and Story 2: RHIVA2 as an experimental 
design aiming to account for context using an RCT method.  I pay attention to the 
specificities of HIV infection, particularly the normalisation of HIV and the enabling of the 
testing practices explored here and how this informed patient reactions to the trial algorithms 
and the intervention.  I also attend to the construction of trial participants by first outlining 
how the patient was imagined in the view of the trial before describing how the actual 
patients encountered this conceptualisation and produced the trial results.   I will begin with a 








HIV normalisation, multiplicity and the specificity of disease  
 
The work of Annemarie Mol and her ontology of disease has been described elsewhere in the 
thesis (See Introduction to Part 3).   Of importance here is the proposition of a multiple 
ontology of disease and how this can come into view by exploring medical practices enacted 
in different sites, in different ways and by various actors.  As described in Chapter 7, a 
diversity of HIVs can be seen operating in the policy literature and I have described one of 
the two stories informing this thesis as RHIVA2 aiming to implement a ‘normalised’ HIV’, a 
HIV that is a chronic, treatable, potentially non-infectious, long-term condition better 
detected in the early stages.   To reiterate, screening for HIV, can be seen as a ‘normalising 
technology’ (Philbin, 2014) or practice, and considered as part of the discursive push to 
‘normalise’ HIV for which there is a nascent body of literature that both explores and 
challenges how this ‘normalisation’ is experienced by individuals with HIV (Persson, 2013; 
Newman, 2015; Mazanderani, 2015; Mattes, 2014; Philbin, 2014; Moyer and Hardon, 2014; 
McGrath et al., 2014; Flowers, 2013) (As discussed in the Introduction of Part1 and in 
Chapter 7). These authors explore the complexities of interacting with an infection that holds 
such a socially and symbolically charged history from a patient perspective with emphasis on 
the push towards ‘normalisation’.  This work could be considered a form of ‘sociology of 
disease’, where emphasis is placed on the impacts of particular diseases on aspects of social 
life (Timmermans and Haas, 2008).   
 
In their article ‘Toward a sociology of disease’, Timmermans and Haas explore the recent 
history of the sociology of health and illness articulating areas for broadening sociological 
work on disease (Timmermans and Haas, 2008). They begin with the seminal work of Talcott 
Parsons, who conceptualised illness as a deviant form of behaviour that required medical 
professionals to legitimise illness and restore patients into functional citizens. Parsons 
delineated the roles of both patients and providers and highlighted the social factors involved 
in different stages of illness and cure.  Many sociologists of medicine, according to 
Timmermans and Haas in their wide-ranging review, emphasised ‘experience, culture, and 
social structuring of illness while bracketing the biological bedrock of disease’ (Timmermans 
and Haas, 2008: p.660).  This, they argue, has resulted in a rich writing of sociological 




unwell, but, they argue, ‘the price paid for conceptual amalgamation is an important loss of 
specificity’ (Timmermans and Haas, 2008: p.664). Their review outlines four critiques and 
calls for a broadened and more biologically based sociology of disease.  A sociology of 
disease, they argue, should take interest in disease specifics:  
‘social scientists rarely make specific diseases central to their inquiries.  Instead, 
sociologists tend to study health conditions at an abstract level of conceptual 
aggregation, or, alternatively, focus on the multiple ambiguities of disease diagnosis.  
In everyday life, however, most patients and health professionals deal with specific 
diseases (Rosenberg 2003).’ (Timmermans and Haas, 2008: p.662) 
 In calling for a more robust sociology of disease which does not ignore the specificity of 
particular diseases including their biological basis they provide three broad critiques.  These 
include how social scientists: rarely make specific diseases central to their inquiries, rarely 
include clinical markers of disease in their analyses and tend to ignore the normative purpose 
of health interventions.  They summarise by stating how: 
‘these omissions reflect a social science studying medicine pragmatically as a site of 
social action, while ignoring what makes medicine medicine: its existential, 
ontological, and purposeful dimension of diminishing human and social suffering.’ 
(Timmermans and Haas, 2008: p.662).     
This insight will be considered throughout the findings presented in this chapter.  
 
Experimentation and subjectivity  
 
Vinciane Despret is a philosopher of science and a psychologist.  Her work, exploring 
experiments and human-animal relationships, suggests alternative ways of thinking about 
science, objectivity and experimentation.  One of her themes is ‘the subject’ and subjectivity 
in science (Despret, 2013; Latour, 2004).  Of central importance to Despret is the space and 
the awareness for the subjects of research to ‘respond’ to the experimental probe, potentially 
with their own questions.  She describes this in the quote below: 
‘One of the ways to resist an apparatus is to lead the experimenter to transform his/her 
question into new ones that are appropriate questions to ask that specific individual.  
In other words, an apparatus that does not have a stake in docility is an apparatus that 
is designed to give the opportunity to the ‘subject’ of the experiment to show what are 
the most interesting question to address to him; what are the questions that make him 




One way the experiments explored by Despret create their outcomes is through a process of 
what she calls ‘attunement’ (2004), where the researcher and the subject attune themselves 
(through reactions and responses) to each other and to the experimental probe. In ‘The body 
we care for: figures of anthropo-zoo-genesis’, Vinciane Despret describes experimentation 
and explores the example of Hans the horse.  Here, a number of scientists were intrigued by 
the apparent ability of Hans the horse to solve mathematical problems and queried how this 
could be possible.  What becomes apparent in Despret’s analysis of events is that the horse 
became an experimental apparatus with the ability to affect the researchers as well as be 
affected by them. Affect is described by Clough as the:  
"potential bodily [and] often autonomic responses" (2); different from emotion, which 
reflects in part the product of meaning-making processes, affect exceeds 
consciousness: it refers to pre-subjective agency, a force that delimits bodily 
boundaries, determining "bodily capacities to affect and be affected" (2). (Hoon, 
2009: p.155) 
The horse responded to the small unconscious body movements of the researchers and as a 
result knew when to stop or continue counting.   The researchers unconsciously 
communicated with Hans the horse to help produce the result. Hans could read bodies, but he 
could also affect the bodies of the researchers without their knowledge. Together, in this 
process of what Despret calls ‘attunement’, the researches and Hans could make articulations 
visible, the horse became ‘a device that enabled humans to learn’. (Despret, 2004: p.126).  
What there was evidence of, in this case, was attunement versus counting, per se.   
 
Similarly in describing the scientist Irene Pepperberg’s work on language learning with a 
parrot named Alex, Despret develops insights on translation and misunderstanding in 
experimentation.  Again Despret describes a process of attunement, which becomes the 
experimental apparatus.   It is in this process of adjusting to reactions and responses and 
research subject participation and agency (conscious or otherwise) that the results can take 
hold.   In the quote below she describes the importance of ‘overlapping desires’ between the 
experimenter and the subject:   
‘Alex talks because Pepperberg desires it and demands it of him, and because she was 
able to subordinate her desire to what makes sense for Alex in the matter of speaking. 
She was able to negotiate with Alex over what in speech could interest him. Alex 
talks because for diverse reasons his desire overlaps with that of Pepperberg. In other 




scientists, but in the name of a ‘‘we’’ constituted by the assemblage of a parrot and 
human beings equipped with an apparatus aimed at making the parrot talk well.’ 
(Despret, 2008: p.127-128) 
Despret describes a coming together of subjects, researchers and an experimental apparatus 
that adjusts to combine both the desires of the parrot and the researcher to produce particular, 
situated results. Following this, Despret determines that ‘generalisability is always possible, 
but it is constructed in another way: it is constructed bit by bit’ (Despret 2008: p.128).  She 
goes on to further delineate her concept of attunement, referring back to the work of 
Pepperberg: 
‘Meanings are constructed in a constant movement of attunement, which makes them 
emerge.  This strategy which tunes up meanings, which gives them and adjusts them, 
is inscribed more broadly in Pepperberg’s work in an apparatus that redistributes 
control’ (Despret, 2008: p.125).  
While Despret uses these concepts to further delineate findings on embodiment and affect 
quite specific to animal and human experiments, the broad conceptualisations she presents in 
regards to attunement, experimentation, subjects and generalisability are relevant to this 
thesis and can be used to explore how participants interacted with the experimental 
intervention and therefore constructed the trial results.  
 
The work described above can be seen to pull together a number of broad themes relevant to 
what is presented here; the sociology of disease and diagnosis, relevant to Story 1, and 
theories of experimentation and attunement, relevant to Story 2.   Some of what this 
theoretical frame describes is how what may seem paradoxical or non-coherent can be what 
produces particular outcomes.  These outcomes are contextual and involve the specificities 
and subjectivities of diseases, individuals and materials to produce the results. How 
experiments, practices and interventions are situated is key, as is the space for emergence, be 
it of participant questions, the practices that render non-coherence workable or for the 
attendance to multiplicity. It follows that objectivity and subjectivity as understood in an 
evidence based medicine paradigm are destabilised and actor agency (conscious or otherwise) 






11.3 Introduction to the findings  
 
In consideration with the literature outlined above, in this chapter I ask: how did the 
participants explored here make the intervention, and therefore the trial, meaningful to them? 
What was good for patients in RHIVA2? To follow Despret: What questions were patients 
asking of the intervention?  This approach allows for insights into both the patient experience 
of the trial and rapid HIV testing but also into how the trial outcomes were produced, 
explicitly taking into account what was of interest to the patients.   According to the logic of 
experimentation outlined by Despret, if there is space for the questions of the research 
participants to emerge and ‘attunement’ takes place, here is where the experiment has the 
opportunity to become meaningful for both the patient and the research, and for the results to 
take hold.  How did this happen in RHIVA2?  By exploring the role of the ‘normalisation’ of 
HIV in patient experiences, I attend to the specificities and temporalities of HIV infection 
locally, responding to the call by Timmermans and Haas for a sociology of disease concerned 
with disease specificity. By drawing out what was ‘the good’ for patients, I attend to the 
normative dimension of medicine as improving the lives of patients and make an applied 
contribution to the field of HIV testing and care.  
The small sample of patients has allowed me to develop thick descriptions that explore 
various dimensions of patient experience in the trial.  Each patient experience will be 
described in a similar way that describes key themes as they relate to the questions explored 
in this chapter.  I will briefly describe each finding theme explored in the patient write ups 
before going on to introduce the patient findings.  
 
The patient/ the individual / the research participant/ the subject/ the service user  
 
Knowing how to describe the individuals’ diagnosed HIV-positive as a part of the RHIVA2 
trial has not been straightforward.  In the field of HIV much care and nuance is used in 
describing those living with and affected by the virus.  I consider this approach a key aspect 
of the culture of the HIV community, where patient rights, respect and attention to identity 
and the power of words are much discussed and considered. I have chosen to provide fake 
names and to change patient details to ensure confidentiality and anonymity. Otherwise I 




patients of the NHS and participants in research. Under this heading I introduce the 
participant and describe how they encountered the RHIVA2 trial. 
 
The test  
 
In this section I recount experiences of testing to provide empirical examples of how rapid 
HIV testing played out for patients in RHIVA2.    
 
HIV as ‘biosocial’  
 
Under this theme I describe some of the social and relational context for each participant. As 
HIV is an infection passed between particular human bodily fluids (blood, semen, vaginal 
and rectal secretions, breast milk) it is inherently social: it was acquired through someone in a 
bounded way. As a result, an HIV infection could be seen as an embodiment of particular 
social relations or acts. The social practices that transmit HIV are among the most intimate: 
having sex, being born to a mother living with HIV, sharing injection equipment or 
undergoing a medical procedure with infected blood products. A relationship with someone 
and likely a practice undertaken with them resulted in a new category of illness and likely a 
shift in identity and behaviour with profound long-term implications. What was apparent in 
the data was how an HIV diagnosis inspired a form of social investigation.  Individuals 
immediately began to trace social interactions, sexual experiences and behaviours, as well as 
anticipate the reactions of loved ones.  What was pertinent to participants was the 
transformation the diagnosis would have on social life and how it recast relationships and 
experiences.   Those interviewed spoke more about their relationships, their sense of self and 
their futures post-diagnosis than about their biomedical indicators or general physical well- 
being.  Social realities impacted participant’s relationship to testing, as said by one 
participant: 
‘What I think is missing from this survey is more emphasis on the relationships that 
the individual, the patient is within prior and post diagnosis.  …It’s perhaps the 




It follows that a section highlighting the ‘biosocial’ context of HIV for each patient forms an 
essential part of the findings.  
 
The imagined and the actual patient  
 
In this section I describe how the patient encountered sits in contrast to the ‘imagined 
patient’, as described earlier in the chapter.  It becomes apparent that many of the categories 
and algorithms assigned to the imagined patient and their journey through RHIVA2 sit in 
contrast to the experiences of the patients encountered.  We find that patients are not 
necessarily newly registering, asymptomatic, HIV-negative or agree to testing for the purpose 
of diagnosis.  Initially, one might consider these findings as demonstrating non-coherence, or 
that this presents problems to the trial findings, but what becomes apparent is that these 
instances that enact patient particularities and subjectivities are essential to constructing the 
trial results.  
 
What was ‘the good’ here?  
 
Various social scientists suggest considering what is ‘good’, for who and where, versus trying 
to determine a singular ‘truth’ of particular interventions or experiences (Mol, 2002) (Law, 
2011). Here, I follow Despret’s suggestions of considering the questions research participants 
pose to experimental research and explore what was meaningful for patients in the 
experimental interaction.  I extend this to discuss what was ‘good’ for the patient testing 
HIV-positive through rapid testing in RHIVA2.   What is ‘good’ for patients sometimes sits 














Joy is a friendly African woman in her thirties.  New to the UK, she was feeling generally 
unwell with fatigue and a sore throat. At the encouragement of her cousin, Joy registered with 
her local general practice.  When Joy was offered an HIV test, she agreed.  She had no reason 
to believe she had been at risk for HIV but was keen to figure out why she had been feeling 
so unwell, as a result she was agreeing to any tests that were suggested.   
The test  
 
When the rapid test was reactive Joy was shocked.  She is unsure of how she may have 
contracted the virus but believes it may have been through a medical procedure performed in 
her home country a few years prior.  Joy was a late diagnosis. She began treatment 
immediately and had a very low CD4 count (an indicator of the stage of infection).   
 
HIV as ‘biosocial’  
 
Coming to terms with her status has been challenging and very few people are aware Joy is 
HIV-positive.  The majority of her concerns relate to relationships, dating and the opportunity 
to have a family.  She finds negotiating disclosure of her status very difficult when beginning 
new relationships and fears that her status will become known in her wider community if she 
tells the wrong person. She does not want to be gossiped about.   As a recent migrant, Joy did 
not have a pre-existing network of friendship and support and she relies heavily on her 
cousin, who is aware of her status, to assist her with her financial and emotional needs.   
 
Joy and the ‘imagined’ patient  
 
Joy meets the inclusion criteria for the trial and aligns fairly closely to the imagined trial 




unaware of her infection, Joy is the type of patient whom population screening in primary 
care aims to locate and enter into specialist services. She didn’t report any problems with the 
trial algorithms or her diagnostic experience. 
 
What was ‘good’ for Joy in RHIVA2?  
 
What is good for Joy in RHIVA2 is learning why she is feeling unwell, being treated kindly 
and supportively and learning that much has changed in HIV.  
As Joy was unaware of her risk for HIV, the offer of an HIV test was perceived by Joy as part 
of a thorough health check up.  Receiving and coming to terms with the result however has 
been a challenging process and not something she would describe as ‘normal’.  This may go 
some way towards explaining why Joy loves the HIV clinic.  This is a space where she feels 
accepted and cared for.  Socially marginalized in multiple ways and apparently isolated, 
attending the specialised HIV clinic appears as a positive event and activity in her life.  She is 
keen to participate in research and was interviewed twice.  Joy says she would be resistant to 
receiving care in general practice, because of the positive feelings she feels at the specialist 
clinic, in particular for her Doctor (‘I love him. He is a good man.’). 
 
 Joy also described her relief at learning she would be able to become a mother while HIV-
positive, without passing the infection onto her child.  It became apparent that the HIV Joy 
thought she was being diagnosed with was different from the HIV understood to legitimate 
HIV screening.  Unaware of the improvements in treatment and prevention that have 
reorganised the biomedical meaning of HIV infection, Joy believed she was being diagnosed 
with an HIV that was more lethal and limiting.  The work of the specialist here could be seen 
as ‘aligning’ HIVs, the ‘new’, normalised HIV with the HIV understood by Joy, which may 
go some way toward explaining why Joy finds specialist services so comforting.  
 
Casey 
‘I’ve never got tested before, I’m that kind of person that won’t go to the doctor 




didn’t go to the GP and get tested there because I would never go to a health clinic to 
get tested, no.  It’s just the type of person I am.’  (Casey) 
Casey, a young gay man from the Americas, has been living in London for a few years.  
Following a difficult break up and a few sexual encounters he contracted HIV.  He decided to 
register with his local general practice due to some skin irritation that didn’t seem to be 
healing. He describes himself as ‘not the kind of person who goes for tests’, and did not 
undergo regular sexual health screens. He was generally reluctant to go for medical checks of 
any kind.  
 
The test  
 
‘It was just lots of waiting around and I guess the anxiety came from being told you 
would find out a certain day and not finding out that day. If it was the case that they 
said to me we won’t know for sure until we get the result three weeks from now, then 
that would’ve been easier to deal with and cope with than saying you’ll know two 
days from now and oh shit, we’ll let you know next week, and actually you have to go 
for another blood test to confirm it the next week and they can’t really tell you if you 
have it or not a week from then, which is not very fun. I joked that I got told I was 
positive three times in a month!’ (Casey)  
 
Casey’s experience of diagnosis was fraught with logistical problems which resulted in 
preventable emotional stress.  First, he did not realise he may have contracted HIV.  
Professionally trained in science, he had considerable insights into the mechanisms of the 
rapid test.  Casey claims to have known the result prior to the GP becoming available to share 
it with him and had to endure the nervousness of a nurse who told him it might be a ‘false 
reactive’ in what appeared to be an attempt to provide comfort.  The GP he then spoke to was 
unsure of the algorithm for confirmatory testing.   Casey was assured that he would receive 
his results within the next two days but did not; he was then contacted by the GP to indicate 
his results had been lost.  In total it took him approximately two weeks to get a confirmed 
HIV diagnosis and furthermore, while having his blood taken at the local hospital there was a 
fire drill.  Despite this, Casey expresses gratitude for the rapid test, indicating that his lack of 
health seeking behaviour would have meant his HIV infection would have gone undetected 





HIV as ‘biosocial’ 
 
‘The difficult part was telling my ex-boyfriend and making sure he got tested and 
figuring out if I gave it to him or if he gave it to me but it turns out he was ok so I 
must’ve gotten it after him, which made it even worse actually. I don’t know if that 
makes any sense, it’s worse for me to have gotten it from some random stranger 
because I was upset over breaking up with my ex-boyfriend and going through all the 
hell.  Then at the back of my head, maybe he was lying to me, I don’t really know.  
That was the hardest part.  The moment he told me he was fine was the hardest day 
probably of my experience so far in my young [X] years of age’ (Casey) 
Casey is still coming to terms with his diagnosis and expressed a range of coping 
mechanisms throughout the interview.  He feels lucky to have a work place that is supportive 
of his status as well as friends who support him and have taken it upon themselves to learn 
more about HIV and attend his appointments with him if he wishes. The majority of Casey’s 
distress surrounds the end of a relationship just prior to him contracting HIV.  In the midst of 
heartbreak, Casey found having to tell his former partner about his status extremely difficult.  
He also describes an urge to tell his family, so as to be open with them about his life, but also 
feels some reluctance to do so fearing it might cause them pain.    
 
Casey and the ‘imagined’ patient  
 
Broadly, Casey is close to the trial’s ‘imagined patient’:  He was a non health-seeking 
individual who as a man having sex with men in London was at high risk of HIV. He was 
unaware of his status and likely would have remained undiagnosed for some time. As a result 
of the trial he was diagnosed early and transitioned effectively into secondary care.  However, 
Casey’s transition through the algorithms set out in RHIVA2 was far from seamless and a 
number of issues presented themselves in his journey through the research and medical 
algorithms. Consequently, Casey’s experience of ‘rapid’ testing was not so rapid.  While the 
initial rapid test did provide a quick result, the nurse initially struggled to present this 
information to him effectively and his confirmatory testing results were lost in the process.  
Overall, Casey’s diagnosis took much longer than if he had received testing in the traditional 
sense of attending a GUM clinic or undergoing a venous blood test at the GP, however, as 





What’s ‘good’ for Casey in RHIVA2?  
 
It’s quite funny coming in here (the hospital) because I sit down and everyone has to 
grab a ticket and fill out a form and I’m just like, I don’t need to do that.  I’m 
special…at the GP, I wouldn’t be doing that.’  (Casey) 
For Casey, what is good is feeling ‘special’ but also feeling like HIV is less of ‘a big deal’. 
Casey expresses many of the tensions in the normalisation logic.  He enjoys the specialised 
care and attention he receives in the specialist setting as well as the way the consultants treat 
HIV as if it is not such a ‘big deal’ while still attending to the specificities of the infection.  
‘Because it isn’t a big deal anymore, so it makes it less of a big deal if you are just 
going to the GP. You only really need to see a specialist if it’s something that’s 
untreatable or you’re going to die in ten years or need constant care.  But I don’t need 
constant care. I need to be able to get myself blood tested every six months or so. But 
then from someone who’s just been diagnosed, not more than a year ago, I’m just like, 
I think I’m a bit of a special case, a bit more special than other people.  It’s also just 
the perception of it, not just from the clinical point but from the general world.  
People still think it’s a bit like, you might die soon.  I still think I am going to die 
soon but we’ll see!  For the future, having it slowly transition to the GP level makes a 
lot more sense and the more people learn about it, the more people realize it’s not a 
big deal and you’re not going to get infected by sharing the same toothpaste or 
something, the better.’ (Casey)  
 
What was not good for Casey was waiting around and being a liminal position regarding his 
diagnosis.  Feeling like he had more knowledge than the providers at the general practice 
about HIV and enduring a nurse telling him ‘it might be a false reactive’ were also unhelpful.  
He understands why HIV should be ‘normalised’ but does not feel the way HIV is perceived 
publicly or experienced by somebody recently diagnosed represents normalcy.  As a result 
what is good for Casey are services that make him feel like HIV is normal while still 










‘The partner that I had at the time, he passed HIV onto me and then I don’t know if he 
had himself checked out because he was losing a lot of weight too, but I didn’t think 
of anything, but it is surprising he just cut me off with no explanation, nothing, he just 
cut me off.  He just stopped seeing me completely and then a few months down the 
line a friend of mine told me he was in intensive care with [an indicator condition].  
He died and I’m still here.’ (Angelique)  
 
Angelique is an English  Afro - Caribbean woman in her fifties; she is a mother and is 
currently in a loving relationship.  She suffers from a number of health problems.  Angelique 
became very concerned when she began to lose weight, she felt something was not right.   
 
The test  
 
Angelique went to the GP and pushed her Doctor to uncover what might be causing her 
weight loss.  After a few visits and undergoing tests for other conditions her GP thought she 
should be offered an HIV test after researching her symptoms online.  Instead of offering her 
a blood test, the GP booked her an appointment with the practice nurse for a rapid HIV test at 
a separate visit. Angelique returned to the practice for this appointment and the rapid test was 
reactive.  The GP was not immediately available to meet with her but Angelique decided to 
wait at the surgery until close in order to discuss her result with her doctor. Angelique 
demonstrated significant tenacity in obtaining her diagnosis and getting the care she needed.  
She is now taking medications regularly and feels some sense of satisfaction for being so 
proactive in her diagnosis.   
 
HIV as ‘biosocial’  
 
Angelique’s persistence in achieving a diagnosis may hold particular emphasis as her 
previous partner suddenly stopped speaking to her, was admitted to hospital and then died.  
Realising that this was likely HIV related, she feels that by insisting on her investigating her 




medications she needs to take a burden and suffers from depression which she relates to her 
numerous health conditions. In general, she feels she is living fairly well with HIV and 
despite her exhaustion regarding medications she is glad the ‘drugs are doing their job’.  
Angelique acknowledges the important role her family members and her new partner whom 
she thought ‘would run a mile, but didn’t because he said he was in love with me’ play in 
helping her manage her various conditions and medications and in keeping her feeling ‘ok’.  
 
The regular medical appointments, medications and overall maintenance of her health is 
troubling for Angelique.  HIV adds another level of complexity to her existing health 
concerns and contributes to her depression. It appears that Angelique’s partner may have 
hidden his HIV diagnosis from her.  This may be representative of the stigma attached to 
HIV.  As a result, Angelique sought medical services and persisted in gaining an explanation.  
 
Angelique and the ‘imagined’ patient   
 
Angelique was not a new patient.  She demonstrated significant tenacity in reaching the HIV 
test. Her doctor improvised the use of the rapid HIV test to help her receive a diagnosis.  
However, this was curious, as instead of immediately taking blood, she was booked a 
separate appointment and did not have immediate access to a doctor when receiving her 
diagnosis.  Angelique had time to mentally prepare for the test.  Despite this and having had 
her doctor already raise the possibility of HIV with her, she wanted to speak to him 
immediately after the test.  She demonstrated resolve once again in waiting for the practice to 
close so that she could have a few minutes to speak to her GP.  Angelique’s experience 
disrupts the assumptions of the trial as she was symptomatic and seeking diagnosis, not a new 
registrant; was a candidate for venous blood testing and could not immediately access an 
appropriate professional to discuss her result.  Despite this she is read as a new patient with a 








What was ‘good’ for Anqelique in RHIVA2?  
 
What was good for Angelique was getting answers to questions about her ill health and the 
behaviour of her partner.   What has also been good for Angelique are specialist services who 
were able to provide information and support to her family members so that they may better 
support her and her multi-morbidities.  What is not good for Angelique is managing the 
biomedical regimens of visits and pills. While Angelique did not complain about the multiple 
visits and various health personnel involved in her diagnosis and is generally grateful for her 
diagnosis and care, the tenacity demonstrated by Angelique reflects a personal characteristic 




‘I had been using recreational drugs for two years, and they greatly influenced the risk 
taking behaviour.  Everybody knows it but it’s a huge difference.  I’d been safe for 18 
years.  I’m not saying I regret it, because the awful thing about being safe all your life 
is you see sex as something dangerous and scary, and in some ways it’s not worth 
living like that.’ (Tom) 
 
Tom is a Londoner in his fifties.   A gay man, he describes himself as a spiritual person who 
loves his family, nature and animals and who is very interested in ‘truly becoming the person 
that I am’.  He also describes himself as ‘growing up with AIDS’.  Prior to becoming HIV-
positive, he felt that HIV was a part of his identity due to its prevalence in the gay 
community, to having lost many friends to AIDS, and to participating in large scale 
awareness raising campaigns (‘it’s inescapable for a gay man of a certain generation’).    
 
The test  
 
‘It was a Friday afternoon. I was in a state. I wasn’t expecting it. I didn’t go to the 
clinic for an HIV test. I had no psychological preparation.  I had that split second 
where I decided okay I’ll do it.  And so I started feeling 20 years of fear, and I think 
we said that we would  do (the test) again and we did it again and it was the same and 




the other end.  He was supposed to be on call, and he said he wasn’t going to see 
anyone, and I was very upset with this.’ (Tom)  
 
Tom had recently moved general practices quite reluctantly.  He had become close with a 
clinician at his previous surgery and it was felt inappropriate by his former GP for him to 
continue there.  Tom regularly attended GUM clinics for sexual health screening including 
HIV testing. He has recently been enjoying ‘chem sex’, where individuals take a number of 
pleasure enhancing drugs and engage in sex with multiple partners, often over a period of 
days (Bourne et al., 2015).  As a result, and despite doing his best at practicing ‘safe sex’ by 
beginning with condom use, he realised he may be at risk of infection. Tom attended his new 
surgery for a new patient check on a Friday afternoon and was surprised at how unprepared 
the practice was in dealing with his reactive result. He agreed to a test when it was offered 
despite usually opting for HIV testing at a specialist centre. Tom describes himself as ‘urban’ 
and prefers the hospital to the ‘mom and pop units’ of general practice.  Upon learning of his 
reactive result, the nurse told him it may be a false reactive (also seen with Casey). She then 
went to contact the GP to share the result, only to find that there was not a GP present in the 
surgery. Additionally, the last blood tests had been picked up for the weekend and so Tom 
was referred to the hospital for confirmatory testing.   As then hospital was also closed, Tom 
spent the weekend without a confirmatory test or any professional support for his reactive 
HIV test result. 
 
HIV as ‘biosocial’  
 
Tom feels privileged that he was able to share his result immediately with his partner and 
close friends.  He accessed a circle of support within his community and has taken his 
diagnosis as an opportunity for personal and spiritual growth.  He is keen to participate in 
research and help improve services.  Tom feels the impact of an HIV diagnosis on identity 
and relationships needs to be further considered in biomedical research as the diagnostic 






Tom and the ‘imagined patient’   
 
Tom’s knowledge about HIV and sexual health service best practice impacted his opinion of 
the way HIV testing was offered and dealt with in RHIVA2.  The ‘expert’ knowledge Tom 
had regarding HIV may be a hallmark of its historical exceptionalism: involvement in a 
disease-related social movement, heavy promotion of safe sex practices to his community and 
being well versed in patient rights and best practices in HIV care.  Tom was much more 
educated in these domains than the ‘imagined’ patient. 
What is ‘good’ for Tom in RHIVA2?  
 
‘What I am trying to say is there wasn’t a sort of consultation.  It was rather business 
like, and added into this mix was something which for them was routine but for me 
was not.’ (Tom) 
‘My only thing is, it’s not having it sprung on me.  It’s being dropped at the end of 
it… you’ve got to anticipate what you would do with a positive result, a first positive 
result, and this primary care trust had not gone that far on its thinking, certainly not on 
this particular afternoon.’ (Tom) 
 
For Tom, the trial algorithms did not kick in as intended.  He strongly feels that rapid HIV 
testing in general practice without greater access to psychological services is inappropriate. 
As a result, Tom found testing as done in RHIVA2 acceptable in theory but unacceptable in 
how it was practised.   He did not feel the test was optional. The specialist knowledge (GP, 
HIV specialist or counsellor) he felt he needed was not accessible.   What is good for Tom is 
specialist services, which he feels better attend to his identity as a gay man with expert 
knowledge of HIV.   What would have been better for Tom are services that are prepared to 
deal with psychological impact of a positive HIV result.   What also appeared to be good for 
Tom was personalised care and feeling linked into the wider HIV community, which 




‘Despite me knowing for 10 years, I had already been a carrier for 10 years without 




knowing, for me, so much time.  This step was difficult for me.  To make this step, to 
continue doing this bit for my family, so much harder knowing that they would go 
through pain because of me.’  (Oscar)  
Oscar is in his forties and from the Americas.  He is a father and a gay man who spent many 
years living in a European country prior to migrating to the UK to be closer to family. Oscar 
had been aware of his HIV status for over a decade and was successfully receiving treatment 
for many years.  When moving to the UK he made a conscious decision, in collaboration with 
his specialist doctor in the European country, to discontinue his HIV medication until he 
could effectively transition into the health service here in the UK.  He feared that disclosing 
his status would bar him entry to the country or result in deportation, compromising his 
prospects of building a new life in London.  Oscar decided to risk destabilising his HIV 
infection in order to try and make a smoother transition into UK life.   
 
The test  
 
When Oscar registered with his local general practice he was pleasantly surprised to be 
offered a rapid HIV test.  Oscar does not speak English and was accompanied by a family 
member.  The health care assistant offered him the HIV test, using the family member as 
interpreter.  Oscar’s HIV-positive status was not known to his extended family and friends 
network. He saw the rapid HIV test as a way to manage his transition into the UK health 
system that did not require him to actively disclose his status. Additionally, Oscar’s need for 
an interpreter to register with the GP meant that a family member was present during his test.  
This unexpected occurrence provided Oscar with the opportunity to share his status with his 
family.  Oscar is now feeling healthy and comfortable with his open status. However, 
throughout his transition into the UK and into the health service Oscar was admitted to 
hospital with an infection, which both his specialist and the neurologist speculate is related to 
his HIV infection and his interruption in treatment.  This caused Oscar temporary disability.  
 
HIV as ‘biosocial’  
 
What is perhaps of greatest significance to Oscar is overcoming his guilt of fathering a child 




HIV-negative.  Now that his status is ‘out’ he has been able to put this guilt aside and 
successfully continue his happy family life in the UK.   Oscar recovered from his infection 
and is living well with HIV.  He feels that HIV services in the UK are helpful and supportive.  
He values free HIV care as he paid for private care in his former country, partially due to this 
immigration status. 
 
Oscar and the ‘imagined’ patient  
 
‘Yes, it was very hard. It was a bit of a shock because I was already scared that the 
GP wasn’t going to accept me, and plus, on the other side, I was scared to tell my 
family, then I had to do both at the same time.’  (Oscar)  
If Oscar was experiencing another illness he may not have feared entry into the UK or put off 
disclosing to his family.  He may not have undertaken a complex coordination of medications 
and strategic action with his former specialist to conceal his illness to achieve other 
objectives.   HIV as a socially stigmatised infection shaped Oscar’s interaction with his 
family, the state, the health care service, his medications and his own body. Additionally, 
Oscar did not fit the inclusion criteria for the trial (HIV-positive/ ‘suitable’ translation). Oscar 
repurposed the rapid HIV test for his own means. He used testing as a way to manage other 
aspects of his life, his immigration and his relationships.   The RHIVA2 trial assumed that 
rapid testing would detect patients unaware of their infections.  Oscar’s experience challenges 
the linear process assumed by the trial and the compliant way that patients would experience 
testing.   Oscar also raises important questions about how the RHIVA2 results were achieved.  
 
What is ‘good’ for Oscar? 
 
What was good for Oscar is finding a way to resolve his fears around disclosure and 
deportation; he was relieved to find that the UK was more ‘HIV friendly’ than he anticipated.  
What is also good for Oscar is being able to restart treatment with the help of specialists.  
Oscar also describes being able to share his status with his family as enabling him to get past 
his guilt for having a child while being HIV-positive. Oscar was able to achieve these aims 







How did the intervention become meaningful for patients?  
 
In the form of experimentation outlined by Despret, when the desires of the researcher and 
those of the research subjects overlap, there is an opportunity for the experiment to become 
meaningful (Despret, 2008). What becomes apparent through the exploration of patient cases 
is how patients sought answers to various questions through RHIVA2.  Joy, Casey and 
Angelique had health concerns. Angelique also wondered if her ill health was related to her 
former partner’s disappearance, she persisted for answers to the point of being offered rapid 
HIV testing, and so gained entry to the trial.  Tom wanted to resolve his logistical health care 
issue, he had not moved boroughs but needed to register with a new practice after being 
asked to find a new GP.  Oscar wanted to know how he could safely enter and remain in the 
UK without disclosing his HIV-positive status.  RHIVA2 enabled him to do this, while also 
giving him an opportunity to disclose his status to his family. In attending to their own 
questions some patients inverted the assumed relationship of the patient to the trial and 
transgressed the trial logic. The RHIVA2 trial becomes effective when patients can resolve 
questions or problems through the intervention and this enables the trial results.  When the 
desires of the research intervention overlap enough with the desires of the patients the results 


























How did the results take hold (?):  Generalisability ‘bit by bit’ 
 
Inspired by Despret’s concept of ‘attunement’ between research and participants as a lens to 
consider what took place in the accounts provided to enable the trial to ‘work’?  it is clear that 
in some cases strict inclusion criteria was forgone, for example, patients who were not new 
and not HIV negative were included in the trial.  This was done through the actions of the 
health care providers and by the patients themselves and may represent an occasion of 
‘attunement’.  
 
The trial in this case was also an intervention, this meant that the trial acted and was enacted 
in multiple ways.  That patients encountered the research as ‘care as usual’ aligns with the 
pragmatic design of the trial but also produces an equivocation, where the trial is being 
enacted as an intervention while also being an evaluation.  Potentially as a result of the trial 




including patients who were not new, perhaps not able to agree to a test, and not HIV 
negative.   The setting and the individuals allowed for experimental attunements.  The space 
enabled by the pragmatic design allowed for attuning between patients, providers and the 
intervention. Despret’s description of how generalisability was determined (in Pepperberg’s 
parrot study) indicates how the experimental apparatus can enable similar outcomes with 
different parrots replete with their own attunements and overlapping desires.  Despret 
describes this idea below: 
‘Consequently, this generalization bit by bit, from success to success is no longer 
expressed in terms of what parrots are, but in the terms of the possibilities that the 
apparatus could actualize.  Generalisation has changed sides: it is no longer on the 
side of parrot neither on the side of the researcher, who ought to represent an anyone 
guaranteeing objectivity: now it qualifies the appropriate apparatuses.’ (Despret, 
2008: p.128). 
With RHIVA2 being open enough to allow for the entrance of different patient questions and 
to be resolved with the experimental device, generalisability is developed ‘bit by bit’.  A form 
of intersubjectivity is determined between the trial, the intervention and the patients, where 
intersubjecitivty is considered as: 
‘becoming what the other suggests to you, accepting a proposal of subjectivity, acting 
in the manner in which the other addresses you, actualizing and verifying this 
proposal, in the sense of rendering it true.’ (Despret 2008: p.135).  
In RHIVA2, loose inclusion criteria here, a potential solution to a patient problem there, 
aggregate to create results that hold and create RHIVA2 participants, despite potential non-
coherence.  Following the description of intersubjectivity above, the patients are able to 
accept the role of research subject offered by RHIVA2 and render the results true, despite 
having their own potentially challenging questions and identities. The concepts introduced 
here will be further explored in the following chapter, related to the pragmatic clinical trial. 
 
The patient cases demonstrate that a good intervention and a good experiment is one where 
patient meanings are enabled and patient questions attended to.  Post diagnosis, good care 
appears to attend to patient subjectivities and the multiplicity and specificity of HIV.   I will 
describe how the work of normalisation and the role of specialist services interacted with 





The paradoxical work of normalisation 
 
The ‘normalising technology’ of screening allows patients such as Oscar, who is 
experiencing HIV quite exceptionally (fearing deportation, coordinating his own medical 
management), to treat his HIV in a way that enables him to achieve his goals without needing 
to disclose his status.  Casey, who would have never gone for testing, despite being in a high 
risk group, is able to access testing without needing to make a specific appointment.  Here 
‘normalising’ HIV is successful particularly because HIV is experienced exceptionally.  
However, the support for this version of normalisation, which centres general practice and 
screening approaches, does not carry through in the same way post-diagnosis.  Here, 
participants find specialist services more ‘normalising’ than general practice, as services that 
attend to the multiplicity and specificity of HIV infection and both the biomedical and 
identity impacts of the infection allow patients to experience HIV as ‘less of a big deal’.  So 
while the conclusions of RHIVA2 promote a greater role for general practice in HIV 
detection and care, this is only partially supported by the patient data.  ‘Normalising’ testing 
is helpful in obtaining diagnoses, however it appears that specialist services are preferred 
from this point onward. 
 
Specialist services: Aligning multiplicity, attending to specificity and acknowledging patient 
experiences 
 In specialist services, the multiple understandings and experiences of what an HIV infection 
may be appeared better attended to and to some degree aligned. Various clinical indicators, 
specificities of disease transmission and manifestation, treatment regimes etcetera are 
determined in specialist care and attending to patient narratives appeared central in this work 
of alignment.  
 
Rita Charon describes medicine as requiring narrative competence, defining this as ‘the 
ability to acknowledge, absorb, and act on the stories and plights of others’ enabling of ‘more 
humane and effective medical practice’ (Charon, 2001: p.1897).  In regards to diagnosis, a 
narrative may enable the construction of meaning, supply useful analytic clues or categories, 




experiencing illness for the patient (Greenhalgh and Hurwitz, 1999).  In further describing the 
role of narrative in health and illness Greenhalgh and Hurwitz state: 
‘Episodes of sickness are important milestones in the enacted narratives of patients' 
lives. Thus, not only do we live by narrative but, often with our doctor or nurse as 
witness, we fall ill, get better, get worse, stay the same, and finally die by narrative 
too. The narrative provides meaning, context, and perspective for the patient's 
predicament. It defines how, why, and in what way he or she is ill. The study of 
narrative offers a possibility of developing an understanding that cannot be arrived at 
by any other means.’ (Greenhalgh and Hurwitz, 1999: p.318).  
What was evident in the data was how the form of delivering HIV testing in RHIVA2 
(rapidly and in the new patient health check) limits the possibility for a personalised 
interaction with the patient.  To a degree this was the point of the complex intervention tested 
in the RHIVA2 trial, to wrap HIV testing into a screening approach for which a risk factor 
history, or the request for an HIV test is not required, an active avoidance of a personalised 
and narrative based approach.  While this may have enabled testing in some cases, it 
impacted participant impressions about services. Casey and Tom describe their experience of 
specialist services in the quotes below:   
‘I just feel comfortable.  They’re always nice, they smile. Some of them remember me 
and say hello.  They just don’t make it seem like a big deal. ‘Just going to take your 
blood, see you later’. . . it’s not a big deal when I come here at all.  The only person 
really freaking out is me and other than that, they’re always happy to talk to you if 
you’ve got anything...if you need to talk about travel insurance, there’s a brochure 
somewhere there.’ (Casey)  
‘It’s everybody and they work together.  They care and they treat you as an 
individual, and it’s been reassuring, because it’s not easy to deal with this, particularly 
after a lifetime of fearing it.’ (Tom) 
 
Often, general practice is seen as a site where the ‘life world’ (Greenhalgh et al., 2006) of the 
patient can be better encountered and explored and as a space more amenable to the practice 
of narrative based medicine and ‘person-centered generalist care’ (Reeve et al., 2013: p.1).   
As patients described their experiences of primary and secondary care services, there was a 
preference to receive care in specialist HIV settings.  This preference related to the 
participants’ experience of HIV as ‘not normal’ for them and a space specific to HIV better 
attended to this, as well as the identity effects of an HIV diagnosis.  Complicating the logic of 




specialised to HIV, replete with clinicians who encounter HIV regularly it allowed patients to 
see it as ‘less of a big deal’. HIV appeared to be experienced less exceptionally in a service 
specialised to HIV than in a general practice where HIV remains a ‘big deal’.  
 
11.6  Conclusion 
 
Broadly a narrative, personalised medicine approach appeared to take place in the specialist 
setting a setting attentive to the specificities of HIV allowed patients to experience it as ‘less 
of a big deal’, whereas the test procedure in the GP practices was designed to be run as a 
technical process driven by a strict algorithm.  While in the first instance it may appear that 
this relates to the mechanism of test offer (rapid, new patient), it became apparent that this 
preference extended beyond this into the importance of a service with specialist HIV 
knowledge, extensive experience with HIV- positive individuals and a culture and ethos of 
acceptance, affirmation and friendliness. The specificities and relational aspects of HIV 
infection were acknowledged in this setting and the individual’s complexity better realised 
and attended to.    
Historian of science, Charles Rosenberg describes how ‘we are never illness or disease, but 
rather, always their sum in the world of day to day experience’ (Rosenberg, 2002: p.258). As 
seen in this chapter, results between biological indicators and subjective realities are 
constitutive of the trial results.  While we may rely on health bureaucracies to connect us to 
spaces, techniques, personnel and onwards to enable us to live, attention to disease discourses 
and the practices they engender remains necessary so as not to be ‘fragmenting and 
alienating’ forces in managing an individual’s relationship to larger society (Rosenberg, 
2002: p.258). 
 
Normalising HIV within health bureaucracies and for populations at large may be strategic, 
but for individuals normalcy may remain variable and individually defined.   This was borne 
out in the findings of this chapter, where a population screening approach aiming to 
normalise HIV resulted in the achievement of broad public health objectives and allowed 
individuals to interact with their potential HIV infections in ways that generated 




that could attend to the more situated aspects of disease with varying anomalous realities for 
an individual.  
 
The findings presented above shed further light on the patterning of experience by the logic 
of normalisation and the experimental logics of the pragmatic trial. The patient case studies 
reveal how normalising HIV testing may allow individuals to gain answers to a variety of 
subjective questions of a health, logistical, migration and relational nature.  The trial becomes 
meaningful to patients and therefore constitutive of the results in its ability to respond to 
these subjectivities.  In the following Chapter, I take a closer look at the logic of the 
pragmatic trial, synthesising findings from across parts 1,2 and 3 gaining greater insight into 












‘Simply engaging with the complexity of people’s lives and desires – their constraints, 
subjectivities, projects – in ever-changing social worlds constantly necessitates the 
rethinking of our theoretical apparatuses.  What would it mean for our research 
methodologies and ways of writing to consistently embrace this unfinishedness, 
seeking ways to analyse the general, the structural, and the processual while 
maintaining an acute awareness of the inevitable incompleteness of our theories?’ 
(Biehl and Locke, 2010: p.320) 
Thus far in the thesis I have explored the justification and enablement of the HIV screening 
policy under investigation, its impact on general practice organisations implementing the 
policy as a part of a pragmatic trial of rapid HIV testing, and the impact of the policy on 
patients testing HIV-positive as a part of the trial.  Throughout, I have attended to the two 
stories that inform this thesis: Story 1: the logic of normalisation implied in the HIV 
screening intervention; and Story 2: the logic of the pragmatic trial, the mechanism of 
implementation and evaluation for RHIVA2.  I have developed a picture of the RHIVA2 trial 
as a complex situated event with manifold effects on the involved populations and 
organisations. I have offered evidence to support the argument that participant accounts of 
diagnosis as a part of the trial ruptured some of the assumptions embedded in the trial logic.   
In this chapter, which is focused on the pragmatic clinical trial more broadly, I seek to 
complicate the picture further through a more theoretical consideration of the findings.  It is 
here that Story 2: the logic of the pragmatic trial will be most developed. 
 
In this chapter, I focus specifically on the trial method and consider the broad case study 
presented within this thesis.   I aim to consider data from a large-scale synthesis of methods 
which ‘work(s) to understand the macro without reducing or bounding the micro’? (Biehl and 
Locke, 2010: p.336). Findings from the various sub-studies are considered alongside the 
results from the RHIVA2 trial, in order to draw out the wider implications for the assertions 
of generalisability and reproducibility implicated in the pragmatic trial design. My goal in 
this chapter is to question the pragmatic trial as a device aiming to measure what is 
commonly thought of as both the scientific (for example, the establishment of causality 




confounding variables) and the social (for example, the role of context and behaviour) in 
measuring the ‘real world’ of ‘everyday’ practice.  
 
The pragmatic trial  
 
‘By accommodating the human unpredictability attendant to the ‘real clinic’, the 
pragmatic clinical trial locates its evidentiary context between the rigour of an 
experimental protocol and the specificities of the health care environment.’ (Kelly, 
2008: p.7) 
The value and promise of the pragmatic trial lies in its claim to successfully integrate the 
‘social’ into a randomised controlled trial logic, to account for contextual factors while still 
providing the standard of transferability desired by the evidence based medicine paradigm 
(Kelly, 2008, 2010).  As discussed in Chapter 8, the RCT is valued for its alleged ability to 
reduce bias and produce objective, reproducible, generalisable and robust results, as well as 
determine causal pathways. In many ways, the responsibilities assigned to the pragmatic 
clinical trial are more far-reaching than those of its forefather, the RCT, because the 
pragmatic trial contains not only the measures of efficacy (does X work under ideal 
experimental conditions?) ideally demonstrated by the RCT but also attempts to establish 
effectiveness (will X work here?), the outcome desired by policy makers, public health 
professionals and all those aiming to determine how the intervention might hold up in a ‘real 
world’ full of context.  Broadly, the pragmatic trial aims to explicitly account for social 
practices in ways the traditional RCT does not (Kelly, 2010).  While efficacy demonstrates 
the integrity of the effect in ideal conditions, effectiveness asks how it performs in its context 
of use.   Kelly argues that these ‘models of “everyday practice” embed experimental 
protocols in the clinic’ (Kelly, 2008: p.4) and as a result the pragmatic trial simultaneously 
‘implements the evidence it produces’ (Kelly, 2008: p.4).  
 
As a result, the pragmatic trial design and those enacting it have a number of responsibilities 
in their attempts to demonstrate effectiveness; they aim to realise multiple objectives 
simultaneously.  They must adhere to the logics of the randomised controlled trial design and 
its positing of a discoverable, measureable reality that is objective and transferable.  But they 




technologies, cultures, material practices, illnesses and more.  Pragmatic trial designs are 
expected to combine these substantial demands in a demonstrable way that adheres to 
predefined protocol; is feasible for, and reflective of, ‘everyday’ practice; and is implemented 
in a way that is acceptable to patients and providers (ideally with their explicit involvement) 
(Kelly, 2008, 2010; Wills and Moreira, 2010).  In the case of RHIVA2, it was through the 
trial mechanism that national policy was implemented and evaluated.  Clearly, these public 
experiments (Kelly, 2008) are complex, active and productive events.  
 
Complexity, context and the promise of generalisability 
 
In response to the calls for a greater understanding of complex interventions and techniques 
for evaluating them, authors have suggested a reconceptualising of ‘context’ and ‘complex’.   
Cohn et al, in ‘Entangled complexity: why complex interventions just are not complicated 
enough’, challenge the use of the term complex, arguing for a more ‘ecological’ approach and 
a reconsideration of the aims of fidelity and reproducibility (2013). They challenge 
hierarchies of evidence that unreservedly promote the randomised controlled trial design, 
particularly for interventions that are explicitly outside the laboratory and are acknowledged 
as ‘complex’ and situated in the ‘real world’ (Cohn et al., 2013).  In their view this 
mechanistic approach to complexity, where researchers are encouraged to reduce phenomena 
to their component parts, misses the dynamic, integrated and emergent nature of many 
interventions and inappropriately attributes causality and claims of fidelity and 
reproducibility as a result. 
 
Hawe et al. also call for a greater theorisation of complex interventions.   They question the 
role of ‘standardisation’ and ask ‘could one of the reasons for the interventions not working 
be that the components have been overly standardised?’ (Hawe et al., 2004: p.1561).  In 
promoting openness and higher-order thinking their calls relate to the proposition by Cohn et 
al. that suggests a more ecological approach where social processes, such as those being 
measured in complex interventions, are emergent and situated (Cohn et al., 2013). Hawe et al. 
propose that aligning fidelity conceptually, prioritising function over form might allow for 




adapt (Hawe et al., 2004).  The approach suggested by Hawe et al., however, could be seen as 
an example of ‘tinkering’ with RCT logic to better ‘capture’ the real and not put into question 
enough of the assumptions made by the RCT.  By tinkering with design aspects while 
retaining the RCT logic one could suggest these authors have not challenged the underlying 
ontological assumptions of a pragmatic trial, an issue other authors have tried to tackle more 
directly. 
 
‘Situated Efficacy’  
 
Critical work on the randomised controlled trial and its claims by sociologists Savransky and 
Rosengarten explores RCT logic and problematises RCT ontology.   They propose the 
concept of ‘situated efficacy’ in considering our contemporary experimental and evaluative 
models.   
At a conference at the Brocher Foundation in 2015, Rosengarten and Savransky explored the 
RCT and concepts of efficacy and effectiveness ontologically through the work of 
metaphysician and pragmatist Alfred North Whitehead.  They proposed that the 'RCT and its 
‘evidence’ are epistemologically and ontologically different from what has earned it the 
status of ‘gold standard’ for evidence based medicine.’ (Rosengarten and Savaransky, 2015: 
p.1).    The authors take issue with the idea that contingency is placed external to 
interventions and how the intervention remains static while the external determines its effects 
(Rosengarten and Savaransky, 2015: p.2).  The authors suggest that interventions are always 
situated and participate in the active construction of the effects.  In proposing the notion of 
‘situated efficacy’ they reconceive of research as: 
‘a milieu of objects and relations shaping each other in complex but also varying 
ways, it becomes possible and indeed necessary to abandon the presumption of 
objects with distinct causal effects and, hence, that the task of isolation is valid and 
enables future prediction.’ (Rosengarten and Savaransky, 2015: p.3).    
 
These authors have recently published a paper that takes these ideas further, including further 
insights on the pragmatic trial (2016). They frame their overarching question as ‘what is 




practices’ (2016: p.1).    Emphasising their view of the pragmatic trial as a situated 
achievement, they suggest what is required is:  
 ‘an ethos that, in resisting clear-cut bifurcations between “the essential” and “the 
accidental”, “the biological” and “the social”, “the natural” and “the cultural”, may 
become oriented towards the construction of new, inventive, plural, and always partial 
descriptions and proposals concerned with the question of what the realities of health 
and disease are made of’ (Savransky and Rosengarten, 2016: p. 4).  
 
What the authors appear to be moving towards, is the consideration of research designs that 
acknowledge the processual nature of reality, bodies and interactions and that accept 
speculation and uncertainty as inherent and potentially helpful in research despite the 
challenges they present to trial principles such as generalisability and fidelity.  The approach 
proposed by Savransky and Rosengarten may better align with post-positivist understandings 
of ‘the real’ and may work to recognise some of the ontological tension that may be 
encountered in the pragmatic trial logic. 
 
Partial / Multiple / Enacted 
 
In another approach to reconciling accounts of the real, theorists propose partial views and 
encourage explicitly situated accounts of events (See Haraway, 1999; Mol, 2002).  The 
dominant conception of ‘objectivity’ is also challenged (Haraway, 1984). 
 
In her article ‘Situated knowledges: The science question in feminism and the privilege of 
partial perspectives’, Donna Haraway discusses conceptions of objectivity and proposes how 
to integrate more embodied accounts, which acknowledge ‘historical contingency for all 
knowledge claims and knowing subjects’ but that also have a ‘commitment to faithful 
accounts of a “real” world’ (Haraway, 1984: p.280).  She proposes a doctrine of ‘embodied 
objectivity’, a feminist objectivity she entitles ‘situated knowledges’ (Haraway, 1984: p.581).   
This sits in contrast to a positivist ontology which proposes ‘self appearing’ knowledge and 
universal claims (Goldenberg, 2006).  For Haraway, all knowledge is situated and aligns with 




someone (Hastrup, 2004).  Haraway develops the character of the ‘modest witness’ to ascribe 
the positivist ontological claims (Haraway, 1996).  This witness is imbued with  
‘a distinguished epistemological and social power concealed by modernist ideals of 
“rationality”, “objectivity”, and “value neutrality”.  His modesty guarantees his 
legitimacy as an “authorised ventriloquist for the object world, adding nothing from 
his mere opinions, from his biasing embodiment.  And so he is endowed with the 
remarkable power to establish the facts. He bears witness.’ (Haraway, 1996: p.429)  
Haraway goes on to propose that ‘objectivity turns out to be about particular and specific 
embodiment and definitely not about the false vision promising transcendence of all limits 
and responsibilities.’ (1984: p.583).   She argues for ‘situated and embodied knowledges and 
(an) argument against various forms of unlocatable, and so irresponsible, knowledge claim’ 
(1984; p.583).  Here irresponsible means ‘unable to be called into account’ (Haraway, 1984: 
p.583).  She describes her views on objectivity, and the role of partiality in making 
responsible knowledge claims the quote below:   
'I am arguing for politics and epistemologies of location, positioning, and situating, 
where partiality and not universality is the condition of being heard to make rational 
knowledge claims.’ (Haraway, 1988: p.589)  
Annemarie Mol also suggests the importance of multiplicity and a re-thinking of ontology in 
her work, The Body Multiple, discussed elsewhere in the thesis (section 10.1.2). The point 
made by these authors is that there may be multiple, though not limitless, interacting realities, 
each of which is constituted through the processes of enacting and performing the object 
(Mol, 2002; Blackman, 2008). 
 
Situated versus generalisable 
 
A theme emerging in the literature considered for this chapter has been the problematising of 
a scientific ‘view from nowhere’ which underpins positivist biomedical discourse in general 
and the design and reporting of RCTs more specifically. The numerous micro practices, 
decisions and contexts of success in the trial are concealed. Summaries of numbers, assumed 
to be reproducible if certain aspects of the protocol are followed, are fore grounded while the 
dynamic and ecological processes that produce results and contribute to ‘evidence’ are played 
down (Cohn et al., 2013; Goldenberg, 2006). Of interest to various theorists is what is at 




or socio-temporal locations?  The pragmatic trial design can be seen as a move towards 
acknowledging the impact of social processes and practices on the evaluation of interventions 
and in some ways a destabilising of the positivist ontology assigned to trials.  Yet, in 
retaining the logic of the RCT how far can this move travel?  
 
In the case of the pragmatic trial, one might ask: To what extent are the findings of a 
pragmatic trial situated in context to a degree that limits their possibilities for external 
applicability? How do our experimental devices conceal the productive work of such 
experiments in a way where particular yet integral accounts would be occluded?   
 
In the case of RHIVA2, even when the trial is successful (in the sense of producing 
statistically significant findings), and we can also report contextual detail on the mechanisms 
through which these results were achieved, to what extent should the published findings be 
viewed as situated and contingent as opposed to generalisable and reproducible?  While it is 
beyond the scope of this PhD to attempt to answer this question in full, in this chapter I will 
briefly explore some theoretical approaches to the question in relation to data emerging from 
my overarching case study.   
 
To illustrate my findings, I will present two ‘ambiguities’.  Ambiguity 1: Interpreting 
RHIVA2’s ‘active ingredients’ was uncovered during the provider-level study when 
interviewing practice staff about their experience of RHIVA2.  Ambiguity 2: New for whom? 
‘Diagnosing’ Oscar’ was encountered while interviewing a patient who tested HIV-positive 
through rapid testing.  He was introduced in Chapter 11.  I will now describe my 
methodological process.  
 
12.2 Methodological orientation 
 
In undertaking the qualitative work that informs this PhD, it was not my initial intention to 
explicitly explore the pragmatic trial design. Whilst I began with some questions about what 




became as the empirical and analytic work unfolded. A chapter on the pragmatic trial itself 
emerged as a key component of my findings.  Each sub-study complicated the picture of what 
the pragmatic trial was producing outside of what had been predefined as “the results” in the 
trial. Accordingly, a synthesis of data and methods produced the findings presented here. 
 
Hastrup discusses knowledge as organised information which is by nature reductive and 
selective:  ‘it is reductive because it renders empirical complexity and messiness in clear, but 
therefore also more limited, propositions about the world’ (Hastrup, 2004: p.456).  In 
RHIVA2, only particular information gained status as data and this was selected based on the 
pre-established outcome measures and informed by the trial logic.  As discussed in Chapter 3, 
this PhD explores the ‘surplus’ of information that never gained status in the trial. However, 
what has been reduced and selected as data here also requires explanation, see this quote by 
Hastrup:   
‘Evidently, when it comes to analysis and writing, a sense of closure must be attained; 
the network must be “cut”, so to say (Strathern, 1996), in my terms implying a 
temporary objectification of relational knowledge, from which others may then 
proceed – provided they are satisfied about the soundness of the argument.’ (Hastrup, 
2004: p.458)  
 
 The main methods used in this chapter are autoethnography and case study (see Chapter 4 
for a description of these methods).   Here I call upon anthropological ways of knowing, 
which privilege explicitly relational accounts, reflexivity and a synthesis of various data 
forms to produce a hopefully compelling account of a research event. The data presented 
consists of unique events and once-occurring acts (Hastrup, 2004) and would struggle to 
conform to any positivist idea of evidence.  This approach valorises ethnographic data and 
aligns with what Anne Kelly describes in the quote below: 
‘Conventionally, medical anthropologists reconcile the pragmatic and theoretical 
dimensions of their work by focusing their ethnographic attention on the practices, 
experiences and understandings that medical knowledge excludes.  Illustrative in 
biomedicine in context, ethnographic data reveals the contingent and site-specific 
relations invisible to the universalizing and purifying gaze of medical science.’ 





The literature outlined above which argues against singularity and a positivist ontology 
informs this chapter and my choice of how to ‘cut’ the data and make a knowledge claim.  
The aim of this chapter is not to suggest a more ‘real’ account of the trial, but is to explore 
other ways of understanding and interpreting the research event which allows for speculation 
about alternative conceptualisations. The findings presented point to openings for such 




The object in this case is the pragmatic trial; the findings appeared to me as ruptures in the 
operating trial assumptions.  In describing abduction, Locke et al. outline a concept that 
resonated with my experience of encountering these findings.  Describing Czarniawska’s 
ideas, they write:   
‘abduction in research as much like detective processes, involving the recognition of 
puzzling observations that enable us to discern and construct new plots. She 
emphasizes that the process does not entirely conform to the scientific method, but 
instead involves a certain amount of mystery about how method produces the 
outcome’ (Locke et al., 2008: p.908) 
Abductive reasoning relies on emotion, surprise, doubt and confusion to generate a process of 
inquiry and search for ideas to suggest possible means of reconciling the emotions, to 
generate ‘belief’ and produce a resolution (Locke et al., 2008).   To get at an explanation for 
the findings presented here, and this sense of ‘belief’ and ‘resolution’, a deeper understanding 
of ways of knowing was required and a move towards theory which deals in ontology and 
epistemology felt necessary.   Locke et al. describe Van de Ven’s view that abduction begins 
with an anomaly or surprise, which motivates researchers to sustain inquiry (Locke et al., 
2008).  This also relates to the case study literature, for example in how Flyvberg describes 
the Popperian principle of falsification, where ‘what appears to be “white” often turns out on 
closer examination to be “black” (2006: p.11).  The experience of encountering a ‘black 








The analytic process 
 
My analytic approach draws on the analytic autoethnography method as well as case study.  
This analytic approach (described in section 4.2) is evident through evidence of the five 
aspects of autoethnography described by Anderson (2006).  First, participation as a ‘complete 
research member’; I was the RHIVA2 trial manager.    Second, analytic reflexivity; as 
demonstrated throughout the thesis and undertaking the PhD. Third, narrative visibility; I 
describe my experiences in first person narrative with explicit reference the subjective 
dimensions of my involvement.  Fourth, dialogue with informants beyond the self; 
demonstrated in my undertaking of interviews and membership in the trial team.  And finally, 




The construction of the two cases presented here called on a variety of data sources.  These 
are listed below as well as in Figure 13 where I visualise my analytic process. 
 Within each of the two cases (‘ambiguities’) put forth as findings for this chapter I call upon 
the following:  
• My initial queries about the inclusion criteria for the trial. (See upcoming Box 2)  
• The experience of negotiating the ‘accompanied patient’ aspect of the training with 
the trial team (see upcoming Figure 14.). 
• My experience of delivering training to RHIVA2 intervention practices in my role as 
research assistant and trial manager. 
• Analysis of the trial protocol. 
• Knowledge of the RHIVA2 results.  
• Qualitative interviews with patients and providers.  
• Conversations with trial team members. 
• My ongoing reflections on the trial.  
• My feelings of surprise and doubt while undertaking the qualitative research and 










Ambiguity 1: Interpreting RHIVA2’s ‘active ingredients’  
 
During a qualitative interview in the provider level sub-study, one of the clinicians began 
discussing his experience of two HIV-positive rapid testing events, revealing that in both 
cases the patient did not speak English and attended their new patient health check 
accompanied by a friend or family member who acted as an informal interpreter. An 
interview in the patient level sub-study also revealed another individual diagnosed in this 
way. As a result, it became apparent that at least two and possibly three of the 11 patients 




their diagnostic journeys with the assistance of informal interpretation by a friend or family 
member.    
 
Below, the aforementioned health care professional discusses one of the cases where a 
reactive result was received by a non-English speaking accompanied patient.  
‘This patient came from [European Country], a [X] year old boy and the mother was 
interpreting.  We asked all the questions for physical … he was qualifying for the 
Chlamydia as well because he was under [X].  Then I said leave your urine and let’s 
do the blood.  He was afraid of the needle and the mother said, “No, you should take 
it.’  We did it and it came two dots, sharp, right and this was the first time this 
happened so I thought I had to get this book [referring to trial instruction booklet] to 
see the algorithm and then I called the doctor.  The interpreter was there and she was 
the mother and…so I said I need to find out, I’m having a doubt about the test, that’s 
what I said to him so let me go verify it with my colleague.  I talked to him and he 
said that’s it, that is positive and because this is the test that is coming up positive, 
we’ll have to do the blood test to confirm positive or negative but by and large it’s 
positive.  Mother was ok to understand what I say but I said while we are here, you 
should explain it to your son in the presence of us so we know the information passed, 
otherwise you don’t know.  Then she explained.  I thought he was a little bit anxious, 
he became anxious when this happened and then he said ok.’ (Health care provider at 
RHIVA2 intervention practice) 
 
The same health professional goes on to discuss another non-English speaking patient who 
was offered testing through the interpretation of a friend accompanying him to the new 
patient health check.  
‘The second one, he was [from the Americas] but came from [European country] with 
his passport.  The friend was interpreting.  He came along…he was feeling weak.’ 
(Health care provider at RHIVA2 intervention practice) 
Unsure that the friend was able to adequately translate the result of the rapid HIV test, the 
healthcare professional booked the patient in the following day with formal translation to 
conduct the confirmatory venous blood tests.  
‘When [it is] the registration time, we don’t bother that much about troubling with the 
interpreter or we will be wasting time but when we did the venous blood, we booked 
the interpreter the next day, then we can explain in very professional language so the 




acting as interpreter], then [the interpreter] can explain everything so that’s why we 
call the interpreter next when we’re doing the venous blood.’  (Health care provider at 
RHIVA2 intervention practice) 
The first young man discussed was initially reluctant to have the rapid HIV test. While the 
hesitation is cited as a fear of the finger-prick, it is possible there are other reasons he was not 
eager to accept testing, with his mother acting as interpreter.  He went on to have 
confirmatory venous blood testing immediately and never used formal translation services at 
the surgery.     
 
The second patient was accompanied by a friend who it appears was able to translate the 
initial new patient health check and the offer of the rapid HIV test, including the receipt of a 
reactive test result.  However, the clinician was unclear as to whether he had effectively 
communicated the result to the patient and so arranged for a follow-up appointment with 
official interpretation for the next day where they would conduct the required confirmatory 
venous blood testing.   
 
Context of importance 
 
I explicitly asked about accompanied patients when interviewing providers as a part of the 
organisational level study.   This was an aspect of testing that worried me and I recognised it 
as an area where site-specific divergences in practice were likely.  My concern stemmed from 
a lack of clarity in the study protocol and my view of best practice in HIV testing. Having 
worked for years in sexual and reproductive rights, I understood that HIV testing should not 
be offered to an individual in a setting where they may not be able to make a full, free and 
informed choice.  Offering someone testing in front of a friend or relative may place an 
individual in a difficult position where this right may not be recognised. Yet, I acknowledged 
that there were ethical concerns around not being offered a HIV test.  If we were offering 
HIV screening and excluded non-English speakers, they were receiving a different standard 
of care than other patients, for example. The delivery of the test upon registration and the 
rapid nature of the device meant requiring formal interpretation would mean booking a 
separate appointment, compromising key aspects of the trial and likely also requiring 




integrated in the new patient check and would represent a greater cost and work load for the 
general practice, and patients opting to attend an additional appointment for a new patient 
check may differ from other patients being offered the intervention.  My concerns began 
when reviewing the inclusion criteria for the trial and designing the GP training.  The trial 
inclusion criteria are indicated in Box 3 (highlighting my own):  




(Leber et al., Effectiveness of HIV screening in primary care: A cluster RCT and economic 
analysis: Study Protocol.  Version 5.1, August, 2012). 
 
Indicated in the criteria is that in the case of non-English speaking patients, a ‘suitable 
translator’ is required to offer testing.  At no point in the protocol or during the training, is the 
term ‘suitable’ delineated.  I also noted that while the inclusion criteria mentioned a ‘suitable 
interpreter’, the exclusion criteria focused on the lack of English skills and ability to engage 
with trial materials and not on the ‘suitability’ or interpretation.    
 
Keen to enact fidelity to the pragmatic nature of the trial and a replicate ‘everyday practice’, 
while acknowledging potential ethical implications, the team eventually settled on the 
following approach:  We would recommend what we thought best practice was, and then 
1.1 Inclusion criteria for HIV POCT 
* Individuals aged 16 years or older registering at study practices 
* Individuals able to undertake the pre-test discussion in English or with the use 
of a suitable translator 
* Individuals with unknown HIV status. 
1.2 Exclusion criteria for HIV POCT 
* Age under 16 years 
* Individuals with limited English abilities, who are unable to understand the 
info sheet or, who are unable to engage with the pretest discussion for HIV 
testing 




suggest that clinicians use their clinical judgement, experience and expertise.  In the GP 
training session we included a short discussion about managing accompanied patients, 
eliciting views and experiences while sharing the slide visualised in Figure 15.   
 
Figure 15.  Slide from GP slide deck relating to accompanied patients 
 
 
(RHIVA2 GP training slide deck version 11. 2011) 
The phrasing provided suggested that whenever possible patients should be offered testing 
privately.   How this could be enacted in the case of an individual who spoke no English 
whatsoever and was dependent on the friend or family member, however, remained unclear.  
In an attempt to improve uptake and mitigate language barriers, patient information sheets 
were provided in 10 languages spoken locally10.  The languages were determined upon 
consultation with local nursing staff in intervention practices.   
 
Data collected for the trial did not include collecting the number of accompanied patients 
tested or how often an interpreter was used.  Whether or not a patient tested as part of the trial 
could speak English was unknown to the trial team.  Trial findings were reported without 
discussion of the frequency of use of interpretation, or how accompanied patients were 
managed throughout the trial.  My qualitative interviews revealed diverse preferences for the 






management of accompanied patients and limited English speakers by providers of rapid 
testing.  Some did not offer the test to accompanied patients at all, while others used their 
discretion and had personal thresholds, such as not offering testing if a minor was doing the 
informal interpretation.   
Important to the pragmatic trial method is the mimicking of ‘everyday practice’ in the 
delivery of the intervention being tested, which informed our interpretation of the term 
‘suitable’ from the protocol.  However, if it is recommended best practice that when results 
from pragmatic trials are presented the intervention should be described in sufficient detail to 
enable replication and be applicable to other like settings (Zwarenstein et al., 2008).    The 
example of informal interpretation described above demonstrates how key the interpretation 
of the term ‘suitable’ was not only by the trial team, but by individual clinicians, in delivering 
the RHIVA2 trial results.  Informal interpretation is clearly an ‘active ingredient’ and key 
mechanism of the intervention but was not recognised as such in the trial logic. A further 
delineation of the term ‘suitable’ or a change in the ethical approvals to only offer tests using 
formal interpretation services may have substantially altered the trial results, altering 
statistical significance, and produced different conclusions about the impact of rapid testing 
for HIV in primary care.   With no discussion or acknowledgement of the role of language in 
the trial reporting it could be argued that the results are less easily reproducible or 
generalisable and an understanding of causal mechanisms is in question.  The range of 
behaviours reported by clinicians in offering tests to accompanied patients demonstrates a 
lack of predictability in offering tests under these circumstances While the variable 
interpretation of the term ‘suitable’ could be seen to align with the pragmatic tone of the trial 
and we see the effective enabling of ‘the social’, in that broad social practice was enacted, 
there are implications for the potentially contrasting principles of rigour, standardisation, 
fidelity and reproducibility. 
 
When the protocol was open enough to allow providers to act as they would in the ‘real 
world’ more cases of HIV were detected than for example, if this interpretive approach to 
offering HIV tests to accompanied patients had been closed down by ethical or practical 
dimensions that limited the offer of tests.  This leads one to question how far the success of 
the trial’s pragmatism travels and whether this impinges on other trial principles which help 




of this thesis -the logic of the pragmatic trial- the finding described above highlights some of 
the tension inherent to measuring ‘the scientific’ and ‘the social’.   
 
 
Ambiguity 2: New for whom? ‘Diagnosing’ Oscar  
 
‘Thus, the trial participants would demonstrate the beneficial effects of the program 
by acting as functional elements of the program itself.  Their relationship to patient 
populations would not be merely epidemiological; the pragmatic clinical trial would 
secure the representative nature of the research sample through a series of complex 
experimental moves that cultivated and coordinated the technical and human aspects 
of clinical practice.’  (Kelly, 2008: p.9) 
While undertaking the patient level study, another instance that inspired a feeling of surprise, 
doubt and ongoing consideration was encountered. Oscar, who was introduced in the 
previous chapter and who tested positive for HIV with rapid testing in RHIVA2 also poses 
challenges to the trial logic. The aforementioned RHIVA2 inclusion criteria indicated that 
patients who are known to be HIV-positive should not be offered a rapid HIV test.   The 
inclusion criteria are reproduced in Box 4 (emphasis added). 
 
Box 4. RHIVA2 inclusion criteria with emphasis on HIV status  
 
 
1.1 Inclusion criteria for HIV POCT 
* Individuals aged 16 years or older registering at study practices 
* Individuals able to undertake the pre-test discussion in English or with the use 
of a suitable translator 
* Individuals with unknown HIV status. 
1.2 Exclusion criteria for HIV POCT 
* Age under 16 years 
* Individuals with limited English abilities, who are unable to understand the 
info sheet or, who are unable to engage with the pretest discussion for HIV 
testing 





The onus was placed on the patient to indicate their HIV status on what was theoretically 
their first visit to the surgery for a 10-minute registration health check. Eighteen of the 
patients diagnosed in the trial were found to be on record with the Genitourinary Medicine 
Clinical Activity Data Set as having had a prior HIV diagnosis in the UK (Leber et al., 2015).  
Accordingly, these individuals were discounted from the overall trial results.  Oscar however 
proves an exception.   Aware of his HIV-positive status for approximately a decade, Oscar 
was a non-English speaking new immigrant to the UK.  As a result he had never had an HIV 
diagnosis in England and was therefore unlikely to be listed on the PHE system.  As 
discussed in Chapter 11, Oscar had been very concerned about his ability to successfully 
enter and remain in the UK, so much so that with the help of his former HIV consultant in a 
nearby European country, he planned the discontinuation of his HIV medication and aimed to 
be re-diagnosed here in the UK, seemingly for the first time.  He felt that this would reduce 
his risk of deportation and increase his ability to access free healthcare.  Oscar describes his 
decision in the quote below: 
‘Yes, they asked me for my consent in order to do some tests on me; blood, urine, to 
find out what the state of my health was, and they said this test would check for HIV 
and I gave my consent, because I knew that I had it and I knew…I wanted them to 
know but I wasn’t brave or courageous enough for them to find out because I came 
from another country and I was, I was scared that the country wouldn’t accept me.’ 
(Oscar)   
Through the offer of HIV testing as part of the new patient health check Oscar did not need to 
raise the possibility of HIV testing with his general practice.  He was able to re-enter HIV 
care in the UK at an early opportunity, when registering in primary care services.   He used 
the trial and its opt-out nature to effectively conceal his HIV status from health services until 
he had effectively entered the UK medical system and secondary care services.  
 
Context of importance 
 
Whether Oscar, as a new diagnosis in the context of the UK, achieves the objectives of the 
trial raises interesting questions.  Does Oscar’s diagnosis count as a new diagnosis here? 
Oscar was presented as a new diagnosis in the trial results and contributed to the overall 




decade. Clinically, and in terms of UK population statistics Oscar can ostensibly be a new 
diagnosis, he is new to the NHS and a new migrant.  For the primary outcome of the trial: 
‘mean CD4 count of newly diagnosed patients’ (Leber et al., p.2), it is feasible that Oscar 
would have impacted the outcome calculations, as his previous adherence to HIV 
medications may have altered his CD4 count, if high this may have reflected his use of HIV 
medication and certainly was not an indication of early detection.  For the secondary outcome 
of the trial, ‘rate of new diagnosis (patient’s diagnosed/year/10,000 practice list size)’ (Leber 
et al., 2015: p.2), it may be that Oscar’s nominal contribution to the outcome of the trial 
holds, as his may be considered a new diagnosis in the context of the UK medical system.  As 
discussed in the previous chapter and linking to Ambiguity 1 about interpretation, Oscar 
alone subverts many trial assumptions.  His consultation was not only interpreted by a family 
member, he was also already HIV-positive, challenging trial inclusion criteria.   
 
Annemarie Mol suggests that we pay attention to the effects of our interventions, beyond 
those intended (Mol, 2002).  Oscar is demonstrative of the many ways in which technologies 
and interventions can produce the unintended and go far beyond the result we hone in on.  
Perhaps this is obvious. Many trialists would readily indicate how aware they are that trial 
results do not tell the ‘whole’ story and that rich stories lie behind much of the trial data.  
While it would be easy to conclude that the trial erred by not detecting this ‘false’ new HIV 
diagnosis, the conduct of the trial in this case adhered to protocol and was enacted in line 
with trial practices. There is no practical way of determining if patients are actively 
concealing their HIV status and a key assumption of the trial logic was that individuals align 
with how they present in services, that they live in the borough, are unaware of their status, 
are over 16 and so on. If patients are not upfront about their HIV status, cases like Oscar may 
be unavoidable.   Nevertheless such examples have implications for trial results, including the 
numbers.  Demonstrated here is research subject agency and innovation that challenges the 
way subjects are positioned and represented by the trial.  The linearity and compliance 
assigned to research subjects in the trial logic is challenged and the role of the trial in 
generating particular forms of patients becomes more apparent as was also demonstrated in 
previous chapter. Oscar’s case disrupts trial assumptions with implications for the findings. 







‘Since each diagnostic outcome diverges from others, the idea of gold standards may 
get undermined rather than strengthened.  And if each therapeutic intervention 
achieves something different, what counts as improvement may similarly tend to 
become less obvious.  The question ‘is this intervention effective?’ then dissolves into 
another question: ‘what effects does it have?’  (Mol, 2002: p.183) 
The final RHIVA2 trial paper published in The Lancet HIV indicates: ‘we excluded patients 
who could not understand the information sheet or engage the pretest discussion for HIV 
testing, and those who were HIV-positive.’ (Leber et al., 2015: p.1).  Interpretation and 
translation is not mentioned in the paper as it was not considered key in describing the 
intervention.   Patients testing positive for HIV and on record as previously diagnosed in the 
UK were excluded from the final analysis (Leber et al., 2015).  The point explicated in this 
chapter is not that the RHIVA2 trial findings are incorrect but a larger consideration about 
what can be understood about the enactment of interventions with the pragmatic trial method. 
Ambiguity 1 and 2 reveal the pragmatic clinical trial as a productive but tricky device that in 
some ways is successful at merging the ‘gold standard’ methods of the RCT design with the 
complex and situated social world of everyday clinical practice.   Yet the method is unable to 
account for this effectiveness within the restrictive evaluation and reporting methods 
commonly operationalised in the pragmatic trial logic.  While the method is designed to 
produce definitive and generalisable answers to complex research questions about the ‘real 
world’, in reality, findings may be contestable and much is occluded.  The method limits 
what can be seen and therefore reported on, affecting our understanding of the truly effective 
mechanisms and interactions at play in a ‘successful’ intervention, raising questions of how 
deeply situated events and their accounts can effectively be translated to other locations, with 
their own sets of situated aspects (Savransky and Rosengarten, 2016). 
 
 I now suggest three theoretical perspectives on the findings. I first explore the concept of 
equivocation, espoused by Viveiros de Castro (Viveiros de Castro, 2004), as one way in 
which the results may be ‘taking hold’ in practice. I then consider Mol’s ontological politics 
(Mol, 1999), as a potential way of working with some of the tension described in this chapter.  
I finish with the work of Savransky and Rosengarten, exploring the ontological aspects of the 





Equivocal spaces  
 
One way in which to consider the findings is through the concept of ‘equivocation’. 
On the entirely different matter of Amerindian perspectivism in the article ‘Perspectival 
Anthropology and the Method of Controlled Equivocation’, Eduardo Viveiros de Castro 
presents the concept of ‘equivocation’ and its role and importance in anthropological 
reasoning (2004).   For Viveiros de Castro, intercultural equivocation emerges in attempts for 
translation, in the acts of comparison of anthropologies between two groups, which he 
describes as a central task for the anthropologist (2004).  He is concerned with how to 
acknowledge that anthropologists and the groups they study are in comparative intellectual 
operations, and how to ‘configure the people as theoretical agent rather than as passive 
subject’ (Viveiros de Castro, 2004: p.2). Here, equivocation is the ‘referential alterity 
between homonymic concepts’ and the ‘mode of communication par excellence between 
different perspectival positions’ (Viveiros de Castro, 2004: p. 3). It was this passage by 
Viveiros de Castro which compelled me to consider the findings through a lens of 
equivocality:  
‘An equivocation is not just “a failure to understand” (Oxford English Dictionary, 
1989), but a failure to understand that understandings are necessarily not the same, 
and that they are not related to imaginary ways of ‘seeing the world’ but to real 
worlds that are being seen.’ (Viveiros de Castro, 1994: p.9) 
 ‘Controlled equivocation’, he suggests, may open spaces to allow this. He describes ‘the 
space of equivocation’ in the quote below: 
‘To translate is to situate oneself in the space of the equivocation and to dwell there.  
It is not to unmake the equivocation (since this would be to suppose it never existed in 
the first place) but precisely the opposite is true.  To translate is to emphasize or 
potentialise the equivocation, that is, to open and widen the space imagined not to 
exist between the conceptual languages in contact, a space that the equivocation 
precisely concealed.  The equivocation is not that which impedes the relation, but that 
which founds and impels it: a difference in perspective.  To translate is to presume 
that an equivocation always exists; it is to communicate by differences, instead of 
silencing the Other by presuming a univocality- the essential similarity-between what 
the Other and We are saying.’ (Viveiros de Castro, 2004: p.8)  
In opening and widening the space ‘imagined not to exist’, Viveiros de Castro could be seen 




Viveiros de Castro goes on to delineate an advanced theoretical concept11 related to 
anthropology, however, reading his work inspired thinking around the comparison and 
interpretation of research events. If controlled equivocation is one method of interrogating the 
differences between people’s cosmology, for example, what emerges when variable accounts 
from different methods of the same research event are compared? Could these be considered 
moments of equivocation? And how might the equivocal space be opened up and explored? 
That is moments and spaces in which interpretations about the meaning of certain research 
events are settled in one way in spite of the fact that they concurrently also mean something 
else. 
Perhaps the issue of interpretation for accompanied, non- English speaking patients could be 
seen as a form of equivocation.  The trial understands the intervention to be complete as it is 
described in the protocol and in the final trial paper, significant and ripe for reproducibility 
and generalisability.  However, a key mechanism in the obtaining of the significant results, 
the testing of non-English speaking patients with informal interpretation, goes unrecognised 
by the trial method, was not collected as data and therefore goes unnoticed and unreported.  
As a result, the intervention passes as successful while represented as one set of actions 
and outcomes, but enacted as another.   In other words, the intervention is equivocal. The 
RHIVA2 intervention as described in the study protocol and the trial findings paper (without 
the acknowledgement of informal interpretation) is understood as what produced the results.  
However, could informal interpretation be essential to the intervention in producing the trial 
results?   Here, the intervention passes as one understanding while being enacted as another.  
The ‘looseness’ around ‘suitable’ interpretation and the lack of understanding of what the 
trial is enacted as in practice is occluded through the pragmatic trial logic but encountered 
when explored through methodologies which consider other forms of experience as data.  
 
                                                
11 Viveiros de Castro is careful to designate that ‘equivocations’ are not error or cases of ‘linguistic 
incompetence, ignorance of context, lack of personal empathy, indiscretion, literalist ingenuity, 
commercialization of information, lies, manipulation, bad faith, forgetfulness, and sundry other deformations or 
shortcomings that may afflict anthropological discursivity at an empirical level.  In constrast to these contingent 
pathologies, the equivocation is a properly transcendental category of anthropology, a constitutive dimension of 
the discipline’s project of cultural translation.’ (Viveiros de Castro, 2004: p.10).    For this reason I assert that 
reading Viveiros de Castro’s paper on equivocation inspired new ways of considering the findings but is not a 
theoretical lens that has been applied in full to the data as it is possible that some of what is described in the 
cases presented may also be considered as what is described in the quote above, such as a lack of knowledge of 






Working with incommensurability: Ontological politics  
 
‘A politics-of-what assumes that the end points of trials, the goals sought for, are 
political in character.  But there is more.  Interventions have other effects, too.  They 
bring about more than they seek to achieve.  In current practice, trials deal with a few 
of these, so-called side effects. Usually they take one or two calamities into account’ 
(Mol, 2002: p.155) 
In some ways there is a link between the concept of ‘equivocation’ and that of ‘multiplicity’ 
and multiple ontologies as proposed by Annemarie Mol.  Opening up equivocations could be 
seen as a way of bringing multiplicity into view.   In the act of comparison where 
equivocations are explored, it could be said that different ontologies are encountered. Mol’s 
concept of ‘ontological politics’ may be one way of working with the potential 
incommensurability encountered in such a space.  
 
In concluding her praxiography of disease, Annemarie Mol calls for ontological politics 
(Mol, 2002), a term she elaborates in the paper ‘Ontological politics: A word and some 
questions’ (Mol, 1999).  She describes ontological politics as a composite term:   
‘It talks of ontology – which in standard philosophical parlance defines what belongs 
to the real, the conditions of possibility to live with. If the term ‘ontology’ is 
combined with that of ‘politics’ then this suggests that the conditions of possibility are 
not given.  That reality does not precede the mundane practices in which we interact 
with it, but is rather shaped within these practices.  So the term politics works to 
underline this active mode, this process of shaping, and the fact that its character is 
both open and contested’ (Mol, 1999: p.75) 
In response to the proposition of a multiplicity of disease and the inability to determine one 
singular reality she calls for a ‘politics of what?’ 
 
In attending to some of the inadvertent effects of the trial, it becomes apparent that the trial 
logic presents a singular account of the research event and other versions may interfere.  




values as researchers and acknowledging that many versions exist with differing effects. She 
describes how this raises new questions for researchers in her quote below:  
‘The new normative question therefore becomes which of these interferences are good 
ones. And when, where, in which context, and for whom are they good.  Good 
knowledge, then, does not draw its worth from living up to reality.  What we should 
seek, instead, are worthwhile ways of living with the real.’  (Mol, 2002: p.158) 
Such an approach might make very explicit the role of early consideration of the objectives, 
values and claims of any research study.  Researchers would need to clarify their ontological 
positions, rationale for a trial design, and image of the research problem or otherwise and 
perhaps consider that the study results may always be partial and one of many possible 
accounts.  To propose that a research team can sit down and establish which reality they want 
to uncover, as it may seem is being suggested is overly simplistic.  There is an assumption 
that such choices are apparent, that there are a set of singularities to choose from, that the 
object under study is not interlinked inexorably with other objects, and that the unintended 
effects Mol cautions us to be wary of are not limited (Mol, 1999).  Despite these theoretical 
limitations, taking Mol’s proposal into account, I suggest, could ease some of the ontological 
tension present in the pragmatic trial design and enactment. By opening up the pragmatic trial 
to include some of the surplus (unintended effects) and acknowledging that other versions of 
the research event  (multiplicity) represent potentially important accounts while promoting an 
earlier and broader consideration of the desired effects of our ‘interfering methods’ 
(ontological politics) may do better at accounting for what takes place in a pragmatic trial. 
My sensitising concepts of pragmatism and doubt (Chapter 3), along with the concepts of 
partiality and multiplicity subsequently introduced throughout the thesis, could be seen to 
align with the pragmatist emphasis on abduction and speculation which ‘merely suggests that 
something may be’ (Locke et al., 2008: p.907; Simpson, 2009), and does not rule out other 
possibilities.  
 
Opening this space for speculation and for the ‘surplus’ to be meaningful could lead us to 
alternative and potentially more helpful research outcomes. These ideas are summarized in 
relation to a trial design by Mol in the quote below:  
‘A clinical trial in which the effectiveness of various interventions is assessed, can no 
longer be taken at face value.  For another question must come first: what are the 




information, but also in the techniques we currently live with.  They tend to be 
implicit, entangled and inexorably linked up with the various performances of any one 
disease.’ (Mol 1999: p.86) 
What is suggested here by Mol, resonates with some of what is proposed by Savransky and 
Rosengarten in their aforementioned paper, regarding the ‘pragmatic art of consequences’ 
(2016: p.1).  
 
Ontological consequences  
 
In tackling questions of ontology as they relate to health Savransky and Rosengarten describe 
the problem of:  
‘letting certain methodologies prescribe in advance what is and what is not relevant to 
understanding and intervening in processes of health and disease everywhere and 
always, despite the not infrequent difficulties such directives encounter in becoming 
effective in concrete situations’ (Savransky and Rosengarten, 2016: p.1).  
This resonates with the findings described above.  In some senses the pragmatic trial closed 
down on the pragmatic work of the trial through the assigning of a predetermined protocol, 
intervention definition and final outcome measures.  This meant that despite what took place 
in practice, what would be measured and what would count as ‘data’ was already decided, 
without any space for emergence, or in the words of Savransky and Rosengarten, without any 
space for other ‘consequences’ to be considered.   What interests the authors is the:  
‘possibility of developing an ontological intervention as a pragmatic art of 
consequences…of speculating on the possible consequences of imagining alternative 
images in which the realities of health and disease can prompt novel understandings, 
where the evidence produced by biomedical methods might acquire different 
meanings, and where other forms of knowledge, of evidence and of ignorance may be 
integrated.’ (Savransky and Rosengarten, 2016: p.1).  
In suggesting that those working in biomedical research ‘venture into situated forms of 
learning, understanding and intervening’, it appears that the authors suggest a loosening of 
the grip the mechanistic ontology of the RCT and evidence-based medicine have on 
describing worlds of health and disease and entertain other considerations of ‘what nature is 





Ambiguities1 and 2 presented here within represent an attempt to consider what is required 
by the ‘hold’ of the pragmatic trial logic and what is at stake as a result.  The findings have 
implications for the conclusions of the trial, the potential for reproducibility and 
generalisability of the trial results and for the pragmatic trial method more broadly.  Since the 
publishing of the RHIVA2 trial results in the Lancet HIV, a definitive and closed story of 
RHIVA2 appears to have been presented and the ‘surplus’ sewn up; the evidence, so to 
speak, is complete.   The pragmatic trial is a productive experiment that generates more 
effects than the logic of the pragmatic trial acknowledges.  While tinkering with the trial 
design may be suggested as a way of overcoming what may appear as poor articulation of the 
research outcomes or an ill-informed choice of what data to collect, I suggest such a critique 
does not address a more fundamental issue.  The example of informal interpretation in 
RHIVA2 illustrates a more theoretical issue. The data suggest that how the ‘real world’ 
imagined in the pragmatic trial logic is investigated necessitates an occlusion of inherently 
emergent, situated and contingent phenomena which are integral to producing the trial results.  
Treating ‘the social’ as a set of quantifiable, static factors which can be effectively parsed, 
measured and reported places these social facts into an evidence based medicine paradigm.  
While such phenomena may be considered more broadly in the case of a statistically 
‘insignificant’ trial, where a statistically significant result has not been obtained, in the 
findings presented here it becomes clear that even when the trial is statistically significant and 
the protocol understood as broadly reproducible key events constituting the significant results 
are occluded.    
 
Savransky and Rosengarten provocatively describe the ontological assumptions of evidence-
based medicine or of any claim to the real as a ‘fiction’ (2016: p.6). The RHIVA2 trial 
findings describe a reality that aligns with the mechanistic ontologies required by the RCT 
design. However, dialogical engagement with other ontological assumptions and evidence 
gathered through contrasting methods reveals the trial conclusions as partial, as an act of 
‘temporary objectification for relational knowledge from which other may proceed’ (Hastrup, 
2004: p. 458).  Just as I have parsed a particular story from the experience of the phenomena 
that was RHIVA2 through the methods and orientations described here, the final trial paper is 
a similar artifact.   This raises the question of what I suggest regarding the interpretation of 
the RHIVA2 trial findings.  The proposal here is not a discrediting of the RHIVA2 findings, 




method and in the contemporary biomedical realm the results hold.   The point is broader, and 
relates more to the engagement with evidence.  The grip the RCT and its mechanistic 
ontology appear to have on research in health and disease and the silencing power such 
methodological results place upon the ‘surplus’, on what is produced with other modes of 
inquiry and what can be considered with differing ontological engagements, has 




In exploring these findings I have outlined how the logic of the RCT does not acknowledge 
some of the work the pragmatic trial does in being ‘pragmatic’ in the philosophical sense.  
Exploring the experience of the trial with different methods and epistemological assumptions 
allows for differing accounts of the research event to come forward, which have implications 
for the claims of the pragmatic trial and the presentation of findings from the RHIVA2 trial.  
Aligning with alternative ontologies (Savranksy and Rosengarten, 2016) or seeing ontology 
as multiple (Mol, 2002) or considering the pragmatic trial as a site of equivocation (Viveiros 
de Castro, 2004) may allow us to open up the trial logic in a way that allows for speculation 












Chapter 13:  DISCUSSION 
 
This final chapter offers overarching reflections on the work presented in the PhD.  I begin 
with a summary of findings. I then reflect on the research process before discussing Story 1: 
the logic of normalisation for HIV and Story 2: the logic of the pragmatic trial.  I end with 
recommended areas for further research.  
 
13.1 Summary of findings  
 
I began this PhD with a number of questions about RHIVA2, about evidence creation and 
about how we determine if interventions are effective or not.  The multiple methods, 
theoretical frames, data sources and experiences called upon in the process of producing this 
thesis reflect my aim of moving beyond a singular presentation of the trial to consider other 
versions of the event and the questions they raise.  I also aimed to consider the impact of 
providing HIV testing as done in RHIVA2 on practices, provider and patients.   The findings 
reflect the complexity of evaluating ‘everyday practice’ and of screening for biosocial 
infections such as HIV, and suggest a deeper engagement with ‘the surplus’ is required.  
Part 1: Population screening for HIV and the logic of normalisation presented findings 
from the policy-level study of this PhD.  Through the analysis of 14 in-depth interviews with 
policy stakeholders and of four policy documents, a nuanced description of the policy setting 
was provided. In Chapter 6, through a combination of Kingdon’s policy windows theory and 
Wilson and Jungner’s principles for the early detection of disease a confluence of factors 
which enabled the 2008 National Guidance and therefore the RHIVA2 trial were described 
(Kingdon, 2003; Wilson and Jungner, 1968; BHIVA et al., 2008).  Here, 17 themes were 
identified and categorised into four micro-streams: epidemiology and public health, 
treatment, technology and techniques, the health setting and socio-cultural dimensions of 
HIV infection. A policy window was enabled due to a merging of the problem stream and the 
policy stream.  The policy problem was related to the late detection of HIV and the resultant 
effects on mortality, morbidity and health care spending.  The policy stream offered 
population screening approaches for HIV, enabled by precedent setting policy in the UK and 
abroad, the growing role of general practice in HIV care and the changing nature of HIV 




for the detection of disease were broadly fulfilled, making the population screening approach 
epidemiologically justifiable. Kingdon’s broad model was supported through the inclusion of 
micro-streams to enable a more nuanced discussion of the findings. The combination of 
Kingdon’s model with Wilson and Jungner’s principles was an effective theoretical frame for 
describing the factors enabling the recommendation in the 2008 National Guidance.  
 
Analysis at the policy level continued in Chapter 7 with a discourse analysis of the policy 
maker interviews and four key policy documents.  Three key discourses were identified as 
informing and upholding the population screening approach in general practice.  Firstly, a 
risk/surveillance discourse positions the untested general population as the new risk site for 
HIV while justifying medical practices that bring this population into view, making the role 
of general practice more central (and that of HIV specialists less so).  Secondly, a discourse 
of normalisation aims to treat HIV as a disease ‘like any other’ and new sites, forms and 
practices of HIV testing come into focus, again assigning general practice with greater 
responsibilities in HIV care.  The third discourse, a HIV generations and dynamism discourse 
considers HIV as historically situated and dynamic, with multiple enactments that affect the 
policy language and justification surrounding HIV testing.   HIV’s variability and dynamism 
alters professional roles and identities while resonating with Mol’s proposition of a multiple 
ontology of disease (2002).  Part 1 of the thesis drew out Story 1: the logic of normalisation, 
and described how testing as done in RHIVA2 was justified and enabled.   
 
Part 2: RHIVA2 in practice: Implementing and evaluating a complex intervention explored 
the organisational-level study of the PhD through the application of a retrospective process 
evaluation using Greenhalgh et al.’s model of the diffusion of innovations in health care 
settings (2004).  This analysis, presented in four organisational case studies (constructed with 
both qualitative and quantitative data), identified key characteristics of RHIVA2 intervention 
practices in their ability to implement the complex intervention of rapid HIV testing for new 
registrants.  Practices with strong leadership, good managerial relations, readiness for change, 
a culture of staff training and sufficient time for the innovation were most successful at 
implementing rapid testing.  If staff delivering the intervention believed that testing was 
valuable and were able to observe reactive test results they appeared more dedicated to using 




their work place routines facilitated implementation.  The Greenhalgh et al. model proved an 
effective analytic tool for exploring and explaining the variability in rapid testing amongst 
RHIVA2 practices and also allowed for the exploration of the organisations’ experiences of 
the trial. Uniquely, this was the first application of the model to a RCT of a complex 
intervention.   Part 2 of the PhD saw the combination of Story1: the logic of normalisation 
and Story 2: the logic of the pragmatic trial combine on-site in 20 intervention practices.  It is 
here that some of the tricky issues around the simultaneous implementation and evaluation of 
complex interventions aiming to produce rigorous scientific findings with ‘real world’ 
applicability came into view. 
 
In Part 3: Experimental end-points: Patient experience and the pragmatic trial, the logic of 
the pragmatic trial was drawn out and patient experiences of testing HIV-positive with rapid 
testing were explored.  In considering how the trial results were constructed five patient case 
studies were presented which traced patient subjectivities and interactions with both Story 1 
and Story 2.  In Chapter 11, through an exploration of experimentality and normalisation 
(Despret 2004,2008; Timmermans and Haas, 2008; Persson, 2013) RHIVA2 becomes 
meaningful to patients when the intervention is able to respond to patient questions – and 
these questions are very different for different patients. Forgone inclusion criteria for 
RHIVA2 and the normalisation technology of screening allows for patients to interact with 
testing in unexpected ways.  Despite the declared success of normalised testing in general 
practice to enable patient diagnosis, post-diagnosis patients consider the specialist setting as 
(in many senses) more normalising.  
 
In Chapter 12, I present findings related to the pragmatic trial method.  Through a synthesis 
of findings from the PhD research I argue that while the pragmatic trial method enabled the 
results produced in RHIVA2, key mechanisms by which the results were produced were 
occluded by the logic of the trial device.  Two ‘ambiguities’ are presented where trial 
inclusion criteria are questioned: the case of informal interpretation and the case of Oscar, a 
patient already living with HIV.  Calling on theory from sociology, anthropology and science 
and technology studies I suggest that some ‘active ingredients’ producing the trial results are 
obscured due to the rationalistic ontology of the pragmatic trial compromising the RCT tenets 




theoretical perspective and the pragmatic trial in terms of ontology and ‘equivocation’, a 
unique perspective on the enactment of the pragmatic trial device was presented (Mol, 2002; 
Viveiros de Castro, 2004; Savransky and Rosengarten, 2016).  
13.2 Summary of Limitations 
The broad work presented here includes a number of limitations.   In Part 1, I explore the 
policy that underpinned the RHIVA2 trial.  This guidance was issued in 2008 and in the fast 
moving HIV policy and public health community a number of changes have taken place 
between the issuing of the guidance, the conduct of the RHIVA2 trial and the presentation of 
this thesis.  The views shared by the policy stakeholders interviewed are most likely impacted 
by these changes and it may have been that interviews undertaken at the time the guidance 
was issued would revealed different views on the guidance and the work of RHIVA2.  In Part 
2, I retrospectively explore the application of the diffusion of innovations model to data from 
the trial. A prospective study using this design may have revealed different insights (See page 
180).  In Parts 1, 2 and 3 I call on interview data related to the policy, provider and patient 
level studies.   While 23 interviews were undertaken in the providers study presented in Part 
2, the choice to present the findings through the examples of four practices means that 
interviews from these practices were called upon more heavily than interview data from 
practices which were not featured as examples. Additionally, in Part 3, where I explore the 
experience of patients diagnosed HIV positive through rapid testing in RHIVA2, I call on 
five (of a possible 11) in-depth interviews with patients. While these interviews allowed for a 
rich discussion, they reflect only a small number of patients (See page 190).  While I trained 
most of the providers of rapid testing in how to use the instant test kit as part of my role of 
RHIVA2 trial manager, I did not directly observe testing and did not witness the 
consultations where testing was offered. This may have provided different data and allowed 
for a deeper ethnographic engagement with the study.  
Additionally, as discussed in Part 2 (See page 149) aspects of the diffusion of innovations 
model were not included in the analysis.  As the innovation was rolled out as a part of 
research and therefore followed a recruitment protocol, division of practices into intervention 
and control group, and took place largely prior to my joining of the RHIVA2 team aspects of 
the diffusion of innovations model including ‘outer context’, ‘linkage’ and ‘communication 
and influence’ were not used in the analysis to the same extent as the other dimensions of the 




the trial is also widely considered in Part 1 where I explore the justification for the trial in-
depth.  However, it is possible that greater consideration of these dimensions of the model 
may have impacted the analysis.  
A further discussion of the limitations is wrapped into the reflections on Story 1 and Story 2 
later on in the discussion. 
 
13.3 Reflections on the research process 
 
An interdisciplinary endeavour 
 
The work presented here is interdisciplinary.  I have called upon various schools of thought 
and disciplinary traditions to produce the findings.  Interdisciplinary work holds a much 
discussed and debated status in the social sciences (Callard and Fitzegerald, 2015; Barry and 
Born, 2013; Hesse-Biber, 2016).   In their book: ‘Rethinking interdisciplinarity across the 
social sciences and neurosciences’, Callard and Fitzgerald reflect on interdisciplinarity, 
largely in the neurosciences.  They engage with the concept through reflexive exploration of 
their mutual experiences of attempting interdisciplinary academic work, calling attention to 
the proposed benefits of such endeavors, the difficulty in making such collaborations 
meaningful, the emotions generated in doing so and the ever-present power dynamics at play 
(2015).  Andrew Barry and Georgina Born describe interdisciplinarity as an ideal and a 
promise to bring closer together society and science, to solve emerging global issues through 
new innovations and modes of accountability and to generate potential solutions to economic 
problems (2013).  They aim to consider interdisciplinarity as a field with the potential to 
enable novelty and as containing multiplicity and difference (Barry and Born, 2013).   
Despite these ambitious potentials interdisciplinarity is also often described as highly 
problematic; fragmenting knowledge, straining relations, being overstated in its application 
and success and resulting in a sort of colonization of some disciplines by others in some 
settings (Callard and Fitzgerald, 2015; Hesse-Biber, 2016).  
Hesse-Biber describes how many researchers describe their work as interdisciplinary when 
they are actually doing multidisciplinary research (2016).   Interdisciplinarity, she states, 




synthesis this requires means the interdisciplinary researcher experiences ‘what it is to work 
the tensions’ between disciplinary borders and Hesse-Biber describes how a truly 
interdisciplinary approach requires time, cooperation and an active commitment to reflexivity 
(2016: p.649). I believe the work presented here contains both the strengths and the 
limitations of an interdisciplinary approach. My PhD has benefited from understanding and 
experiencing the processes, mechanics and enactments of trial design and conduct, a history 
of working in public health on sexual and reproductive rights including HIV, engagement 
with theory from philosophy and anthropology and supervisors who are trialists, social 
scientists and general practitioners.   While I hope this has allowed for a creative account of 
the findings, it also means that a complete and impenetrable thesis has been impossible (and 
undesirable) to produce.   That there is not a singular and complete argument presented in this 
thesis in many ways aligns with some of the theoretical frames explored within, where 
partiality and multiplicity are held up as important approaches to reality and to scientific 
inquiry and singular, traditionally objective accounts are problematised aligning strongly with 
the feminist critique of evidence based medicine (Goldenberg, 2006).   
It is also my hope that this PhD offers an account where different methods and analytical 
approaches have been mixed in a meaningful way.  Some researchers describe how much 
mixed methods research presents findings produced from different modes of inquiry 
alongside each other without any meaningful dialogue between the findings produced by the 
diverse methods (O’Cathain et al., 2007; Hesse-Biber, 2015). While this question was not a 
major theme in this PhD, I have pondered the longstanding ‘incommensurability’ or 
‘incompatibility’ thesis oft discussed in mixed methods research where it is proposed that 
methods cannot be effectively mobilized outside of their paradigms of origin, that methods 
contain ontologies and are constrained by them (Morgan, 2007; Hesse-Biber, 2015).  Instead 
of aligning myself with the incommensurability thesis outright I have aimed to engage with 
it, exploring the paradigms and ontologies at play and attempting to move beyond potential 
‘non-coherence’.  
I have aimed to synthesise the findings of the trial and the case study (containing 
autoethnography, process evaluation, document analysis and qualitative interviews) in a 
nuanced and meaningful way (where insights on population screening approaches for HIV 
and the logic of normalisation and on the work of the pragmatic trial in accounting for 
context with an RCT logic); a way that reflects the contribution of knowledge produced by 




through this process that they could be called upon and produced. This led me to wonder if 
the reluctance of many scientists to work with different methods and data sources in this way 
reflects wariness towards ontological politics (Mol, 2002).   Considering the pressures on 
applied health researchers, undertaking an ontologically engaged trial, for example, may not 
be straightforward, quick or likely to produce the form of findings desired in the current 
research climate.  
 
Undoubtedly additional literature and theoretical frames could have been used and different 
conclusions drawn from the findings.  A more positivist approach, for example, may have not 
questioned the ontological assumptions of the pragmatic trial and may have pitched the 
analysis at the level of methodological tinkering. At least in part, I have opted to consider 
RHIVA2 in a way which moves the thesis into a potentially less comfortable territory in 
relation to the scientific cornerstones of objectivity, bias, generalisablity and onwards, 
experiencing this working of the ‘tensions’ described by Hesse-Biber.   This has also meant 
that it has not been straightforward to answer what has proven to be an oft-posed question: 
so, did the trial work? 
 
So, did the trial ‘work’?  
 
Being an interdisciplinary researcher has presented challenges, including often feeling afloat 
in a sea of potential approaches and understandings of the phenomena explored here.  
Throughout the PhD I have been encouraged by colleagues to ‘pick a side’ (‘So are you for 
the trial, or against?’ ‘What you have described is interesting, but did it work, is it right?’).  
There was a push to either align with the trialists or take a more critical and constructivist 
view.   Neither approach has felt entirely accurate, or adequately representative of what has 
been observed and learned in the course of this PhD.  I maintain that the pragmatic trial 
design is useful and generates important knowledge about health innovations in practice, but I 
argue that the approach and interaction with the pragmatic trial device needs greater 
consideration.  A potentially important contribution of the work presented here is how the 
theoretical and methodological insights were gained. It was not my initial intention to explore 




accounting for the data I encountered.  Multiple methods and theoretical frames were, 
ironically, one way of bringing coherence to what felt like increasingly disparate and 
potentially contentious findings.  Rendering the multiple methods, findings and theories 
presented here into a readable, coherent thesis has been one of the greatest challenges (and 
hopeful achievements) in completing this work.  
 
To answer the question of whether the trial ‘worked’ aligns with my reply to the overarching 
research question of the PhD, about whether the implementation of RHIVA2 through a 
pragmatic randomised controlled trial could be regarded as successful.  My intuitive response 
would be: sort of, but it depends.  This unsatisfying reply echoes what Helga Nowotny 
discusses in her book: The Cunning of Uncertainty (2016).  My type of answer, she describes, 
is not one people like, it is not neat or conclusive and effortlessly transformed into a fact that 
can travel and be easily deterministic for policy and politics. Nowotny describes the 
collective will for clear answers and decisive moments as a general ‘human craving for 
certainty’ (Nowotny 2016: p.13) and how in a fast-paced, increasingly connected and 
information laden world certainty may become ever more appealing.  Nowotny encourages us 
to gain comfort with uncertainty, citing its cunning, unpredictable and consistently vacillating 
qualities as here to stay and the parallel impulse towards the definite as potentially unhelpful.  
Instead of providing certainty my reply to ‘did the trial work?’ inspires more questions: for 
whom, in what way and so on, highlighting once again this tricky issue of ‘context’, situated 
findings and understanding who is asking and why. 
 
 
On false dichotomies: Implementing a normalised HIV with a hybrid evaluation device 
 
Throughout this thesis I have woven together two stories, Story 1, about the normalisation of 
HIV and Story 2, about the logic of the pragmatic trial.   The decision to frame the thesis in 
terms of two stories reflects an attempt to make a complex landscape coherent.  Rendering an 
event as complex as the RHIVA2 trial coherent, and distilling the themes and findings 
presented here has been a challenging task. The two stories are a constructed split and such 
false dichotomies have been an informal theme throughout the thesis. The ‘social’ and the 




pulled apart while happening simultaneously; the normal versus the pathological in HIV; the 
‘self’ in contrast to the molecular body and onwards.   In practice these bifurcations 
sometimes hold and other times dissolve.  Throughout the thesis I have considered 
categorisation (into included versus excluded patients, into the two logics described, for 
example) as performative and organisationally essential but also as a potentially problematic 
and awkward social practice with varying aims.   In drawing attention to this point I reiterate 
the partial and constructed nature of the findings presented here and acknowledge that other 
stories could have been told and the phenomena spliced differently. 
 
Reflections on ethics 
 
Undertaking this work involved the negotiation of various dimensions of ethics.  In 
describing the research events care was taken to anonymise participating practices and 
individuals and written informed consent was obtained from all participants.   I undertook 
patient public involvement activities throughout the project and presented my findings in a 
variety of settings including academic fora, community organisations and professional 
trainings and conferences.  
 
At times I felt a dissonance between the trial and the PhD project.  Uncovering some of the 
findings described within this thesis was not straightforward as I was proud and loyal to our 
work on the trial but also wanted to describe cases such as Oscar in an intellectually honest 
manner, which required putting some trial practices into question.  Undertaking work nested 
in a large team study while aiming to produce a thoughtful account of the data my 
independent PhD project was producing was a challenge.  This meant sometimes straddling 
various commitments as a key trial team member but also a social science PhD student and 
negotiating potential ethical dilemmas from a variety of perspectives.   What I have presented 
here, I reiterate, is not meant to be read as a critique of the RHIVA2 trial as such but to shed 
light on the work of the pragmatic trials more broadly.   
I will now provide final reflection on the two stories framing this thesis before considering 





13.4 Reflections on Story 1: The normal and the pathological at once    
 
Aligning a disease picture for HIV  
 
‘This way of thinking about disease – the vision of abstracted disease entities as ever 
more precise mirrors of nature – has become extraordinarily pervasive, yet in its very 
explanatory power, it has posed a variety of intractable social dilemmas, problems 
that in fact underline the cultural centrality and ubiquitousness of contemporary 
disease concepts’ (Rosenberg 2002: p.251) 
Historical and sociological work on disease and diagnosis reflects widely on how disease can 
be categorised or classified (Rosenberg, 2002; Löwy, 1992; Jutel and Nettleton, 2011; 
Timmermans and Haas, 2008).  Within this work, HIV occupies a less contentious space than 
some other disease phenomena subject to screening. Cervical cytology, for example, where 
stages of potential disease are delineated and searched for has been explored and held up as 
an example of an emerging way of considering disease and infection, as in waiting, with 
indicators and markers that may or may not progress into life threatening illness and therefore 
ripe for surveillance (Singleton, 1998). It is broadly accepted that one has HIV or not and 
while some behaviours determine a risk profile for contracting the infection there is not an 
inborn biological predisposition or pre-disease state to be detected.   In some senses this 
simplifies the diagnostic task which despite its ‘collective, cumulative and contingent 
process’ is still widely considered a ‘discrete act taking place at a particular moment in time’ 
(Rosenberg 2002: p.256).   Aligning understandings of HIV presents challenges. The 
diagnostic event cues a corral of associations and disease pictures along with bureaucratic 
events containing diverging social and natural histories of HIV infection.  When treated, HIV 
can lose or at least suspend some of its hallmark characteristics: infectiousness, lethality, a 
steady spiral into worsening health, and yet, one is definitively HIV-positive.  
 
Rosenberg outlines four potential problems with our current definitions of disease and 
diagnosis.  These include: ‘enforcing norms and defining deviance’, ‘fitting idiosyncratic 
human beings into constructed and constricting ideal-typical patterns, patterns necessarily 
abstract yet, in individual terms, paradoxically concrete’, the creation of proto-disease and 
disease states and finally, the bureaucratic imperative (Rosenberg, 2002:  p.251).  By proto-




increasingly detected through screening practices, and the difficulty in giving such a state 
parameters.  By the bureaucratic imperative, Rosenberg describes how nosological tables, 
protocols, infrastructures and disciplines surrounding disease interact and create disease and 
cannot be separated from contemporary understandings of what disease is and how it is 
experienced and enacted (Rosenberg, 2002).  He goes on to describe the ‘central of diagnosis’ 
as linking the individual to the social system which is ‘necessarily a spectacle as well as a 
bureaucratic event’ (Rosenberg, 2002: p.255).   Some of this tension in the quote below:  
‘This is another area of maladjustment or difficultly of fit, not, from this perspective, 
the fit between the individual patient and the generalized disease picture but between 
a reductionist, mechanism-centered understanding of disease and a collective strategy 
for defining and maximizing health.’ (Rosenberg, 2002: p.254) 
The justification of the policy of HIV testing for new registrants in general practice areas 
highly endemic for HIV calls upon both a normalised and a dangerous HIV.  The 
acceptability of rapid testing and of the population screening approach relates to 
contemporary, medicalised HIV in the UK, where with access to medication HIV is treatable, 
potentially non-infectious and resembling more a chronic disease than a lethal infection.  
Despite this, much of the urgency and impetus for the detection of HIV relies on the historic 
framing of HIV in social movements and the understanding of HIV as infectious and deadly.  
Neither approach is wholly inaccurate or accurate, as untreated HIV remains infectious and 
lethal, while treated HIV may be non-infectious with ever growing prospects for 
survivorship.   What becomes apparent is the operation of multiple HIVs, enacted as such 
from the policy through to interactions with patients, while the logic of normalisation works 
to bring new practices, sites and understandings of HIV into being, as described in Part 1 and 
throughout the thesis.  
 
The work presented herein demonstrates that biological survivorship does not translate into a 
lived ‘normalcy’ for many patients and while treating HIV ‘normally’ by offering screening 
may allow individuals to access testing more easily, it does not extend to a preference for 
generalised care once diagnosed.  Specialist HIV services which attend to specificity and 
align the multiplicities of HIV were preferable for patients involved in this study. The use of 
the term ‘normalisation’ for HIV may be unhelpful.  While the aspirations of the logic 
include reducing stigma and streamlining health bureaucracy, it appears that pushing too hard 




impacts of being HIV-positive.   In general, the idea of a ‘normal’ illness goes against much 
contemporary and historical understandings of what it means to be ill.   
 
Perhaps it is best to consider what could be a good way to test for and live with HIV for each 
individual, dependent on their ever-shifting biological, identity and social circumstances. 
Illness is perhaps best regarded as always situated in a dynamic, temporal interplay 
containing the specificities of disease but always in interaction with individuals and in a 
particular setting. Despite this, following both Rosenberg (2002) and Mol (2002), diseases 
can be seen as multiple, ontological entities within themselves, existing outside of and within 
individuals and constituting diverse social realities.  
 
13.5 Reflections on Story 2:  Experimentation and speculation, more possibilities for the 
pragmatic trial  
 
As described in Part 3, some philosophers of science acknowledge the importance of 
openness and a degree of indeterminacy to allow experimental systems to produce results of 
interest and remain relevant (Savransky and Rosengarten, 2016; Rheinberger, 1994). As 
discussed in Chapter 11 Hans-Jörg Rheinberger, the German philosopher of the life sciences, 
discusses the ability of experimental systems to produce difference and novelty as essential.  
Citing the work of Gilles Deleuze, he describes difference and repetition (the title of one of 
Deleuze’s most classic texts), as the driving force behind experiments (Rheinberger, 1994).    
Essential, according to Rheinberger, is for the experimental system to be a ‘generator of 
surprise’ (Rheinberger, 1994: p.167).  In the quote below he describes experimental systems 
in temporal terms:  
‘Research systems, with which I am concerned here, are characterized by a kind of 
differential reproduction by which the generation of the unknown becomes the 
reproductive driving force of the whole machinery.  As long as this system works, the 
system so to speak remains ‘young’. “Being young’, then, is not here a result of being 
near zero on the time scale; it is a function if you will of the functioning of the 
system.  The age of such a system is measured by its capacity to produce differences 





The findings of the PhD demonstrate the pragmatic trial as containing more potential to 
generate insight and surprise than current approaches to the method allow.   I suggest that 
there is a risk of the pragmatic trial device becoming ‘old’ in the Rheinbergian sense, as in, 
reduced in its capacity to produce unexpected knowledge.  Applying the logic of the 
pragmatic trial, with its tenets of standardization, fidelity, pre-determined outcome measures 
and the like, to the social world of ‘everyday practice’ may close down on the possibilities of 
encountering and explaining novel and unexpected findings and to account for the 
productivity of the method.   There is a risk, essentially, of disallowing the experimental 
system to remain ‘young’ by enabling the encounter of the unexpected, through the over-
prescription of the logics of the RCT to the experiment. The findings of this PhD suggest that 
including what would be considered ‘the surplus’, some of what is not in view under the 
current enactments of the pragmatic trial device and the RCT ontology may allow for this 
method to avoid the risk of becoming less relevant as paradigms shift and science takes on 
new meanings.   In the quote below Rheinberger describes what can be seen as ‘the surplus’ 
of experiments:  
‘discoveries’ – never happen in the way in which they become represented in the 
public arena, be it in research publications or in retrospective accounts of the actors.  
The historian of science who is lucky enough to have recourse to preserved laboratory 
notes can have the repeated experience that the order of the so-called discovery and 
the order of representation in science play in two different registers…. Techniques 
being applied can have results other than those intended, which means that such 
techniques create an excess that goes beyond the anticipated effect’ (Rheinberger, 
2015: p.173). 
Discussing one of Robert Merton’s proposed hallmarks of science, ‘specified ignorance’, 
Rheinberger suggests an alteration, ‘unspecified ignorance’. This, claims Rheinberger, is 
‘ultimately what drives science’ (Rheinberger, 2015: p.170).   In contrasting the pragmatic 
trial to the laboratory experiment, this point may come more clearly into view.  Many 
laboratory experiments are oriented towards the encounter of ‘side effects’, for the 
unexpected impacts of a scientific provocation.  Spacio-temporal factors and general 
containment may allow such effects to be in view in the laboratory setting, but  move to the 
world of ‘everyday’ practice and the pragmatic trial and how might such ‘side effects’ be 
encountered?  In this PhD, autoethnography, case study and process evaluation with their 




the pragmatic trial experiment.  An interdisciplinary, multi-method approach has enabled a 
challenging account of the trial to come into view.  
 
I have described the logic of the pragmatic trial as attempting to account for the ‘social’ and 
the ‘scientific’, all the while understanding that these are false dichotomies.  As this binary 
begins to dissolve in the face of evolving understandings of the interferences of the ‘social’ 
into even the hard sciences (See work by Latour, Haraway, Datson, Nowotny), bringing new 
understandings of the scientific into being, we are left with the likelihood that it is all ‘social’ 
and new ways of conceptualising these interactions are required.   
 
Helga Nowotny, in her paper ‘Re-thinking Science: From Reliable Knowledge to Socially 
Robust Knowledge’, describes an emerging era of science where society is beginning to 
‘speak back’ to science, transforming what is understood to be the scientific and challenging 
long held scientific tenets such as objectivity and disinterestedness (Nowotny, 2000).   She 
describes this point in the quote below: 
‘The demarcations between science and non-science are no longer evident, whenever 
the 'context of application' merges seamlessly with the 'context of implication' that has 
been opened up. In this sense, the limits of science too are contested. Its autonomous 
space is no longer guaranteed, since its potential guardians, state, market and culture, 
are no longer recognisable there in their old identities, functions and roles….Our 
thesis is that a Mode 2 society generates the conditions in which society is able to 
'speak back' to science; and that this reverse communication is transforming science.’ 
(Nowotny, 2000: p.3)  
 
Mode 2 knowledge, described as ‘more open systems of knowledge production’ and the 
‘growth of complexity in society’ (Nowotny, 2000: p.2), calls for a re-thinking of how 
scientific objectivity is understood, responding to the growing emphasis on context and the 
accelerating changes to both science and society as understood contemporarily.  Nowotny 
describes an ‘objectivity trap’ where as researchers we need to demonstrate how 
contextualised knowledge can be as rigourous as traditionally ‘disinterested’ knowledge 
(Nowotny 2000: p.6). What she suggest is ‘socially robust’ knowledge production, where the 




historical process, which inevitably renders it partial and contextual’ and places emphasis on 
the ‘specific locations, instances and conditions in which it is produced, applied, contested or 
negotiated’ (Nowotny, 2000: p.10).  This contrasting conceptualisation of reliability would 
transform understandings of science and better incorporate this entrance of ‘the social’. 
 
The pragmatic trial can be seen within the trajectory outlined by Nowotny.  Some of what has 
been proposed here within is the continued consideration of what socially robust knowledge 
might look like in the practice of methods such as trials. Instead of a continued attempt to 
‘hammer down’ on the social and transform context into science style facts that can be easily 
measured and accounted for, I suggest allowing experimental devices to remain open and 
allowing the methodological apparatuses and bureaucracies they carry in their train to 
transform in the space of these new considerations.  
 
What has been described above and considered throughout the thesis is the contemporary 
challenges the entrance of ‘context’ and ‘the social’ has had on the logics of science, 
evaluation and evidence.  This aligns with what Nowotny proposes and would benefit from 
her propositions.  The determination of evidence, production of knowledge, and articulation 
of validity, for example, may be altered in the face of a dissolving bifurcation between the 
scientific and the social.    How to keep the pragmatic trial ‘young’ in the Rheinbergian sense, 
as able to generate novel new insight, may benefit from such considerations, as would what it 
means to be a diseased body that is living well.  Mode 2, socially robust knowledge may be 
better able to account for contingency, emergence, speculation, uncertainty and multiplicity 
and consider these phenomena not as affronts to science in need of traditional containment 
but as what may help qualify new understandings.  
 
13.6 Recommendations for further research 
 
The DOI model as a prospective trial design tool  
 




proved a useful theoretical frame for exploring the variation in rapid HIV testing uptake 
retrospectively.  I also believe the model holds potential to be used prospectively.  In visiting 
the intervention practices in RHIVA2 prior to the start of the trial many of the aspects present 
in the Greenhalgh et al. model could have been considered.  It was obvious from an early 
stage that some practices appeared more open and ready for testing than others, yet I lacked a 
framework through which to consider, evaluate and comment on this.  Using the model 
prospectively would have enabled conversations among the trial team and with the practices 
regarding areas of potential strength and weakness in delivering the intervention and 
participating in the trial.   
As RHIVA2 aimed to implement and evaluate simultaneously, the trial team was not tasked 
with solely measuring the impact of a new innovation but also delivering it and so 
implementation pathways were of consideration all the way through.  This raises the question 
of whether an intervention with a theorised implementation process which accounted for 
contextual factors would have been appropriate alongside a design which aims to measure 
‘everyday’ practice, since it would then be seeking to measure both the implementation 
process and the ‘business as usual’ of everyday practice. Despite this, a theoretical frame that 
complex interventions can be considered against, at the research design stage, may allow for 
a greater understanding of interventions and aspects impacting their implementation.  
 
Situated protocols and re-oriented fidelity 
 
Pragmatic clinical trials are meant to account for the contextual factors implicated in the 
‘real-life’ setting of the clinic (Tosh et al., 2013; Kelly, 2008).  General practices are diverse; 
each with their own set of contextual factors and established routines. What became apparent 
throughout the trial and in applying the diffusion of innovations in health care settings model 
to the practice-level data was the potential utility of allowing – even promoting – flexibility 
in the way practices implement the intervention whilst retaining its in fidelity with the aims 
of the research program versus as an overly standardised set of practices and pathways across 
diverse settings. As discussed by Hawe and Shiell, ‘fidelity defined functionally rather than 




This approach may allow interventions to be meaningfully evaluated while still being 
responsive to their context and respectful of existing practices in the implementation setting 
(McMullen et al., 2015).  This may mean working with intervention sites to develop site- 
specific protocols which retain fidelity and the relative standardisation of the intervention 
required by trial principles, while reflecting how the intervention would actually be rolled out 
in practice (McMullen et al., 2015).  This suggestion reflects on the understanding that as an 
intervention is implemented as a part of research it brings forth its own set of apparatuses and 
bureaucratic processes that impact how an intervention can be implemented.  
 
Trial co-design   
 
Co-design has been an area of rising practical and academic curiosity and evaluation (Bate 
and Robert, 2006). Here, patients and providers are involved in the identification, 
implementation and gradual improvement of health care services with emphasis on their 
experience of services their placement at the centre of service design (Bate and Robert, 
2006).  This aims to move the emphasis away from management processes and emphasizes 
the design of ‘experiences rather than processes’ (Bate and Robert, 2006: 308).  This thesis 
has demonstrated the important role patients and providers play in making research designs 
and new innovations functional and productive, including in unexpected ways.  While the 
piloting of research designs along with feasibility and acceptability studies have traditionally 
been the standard process of testing user acceptability and of attuning designs to their 
context, the more explicit involvement of patients and providers in the design and conduct of 
trials, using models such as patient co-design may open exciting possibilities for more 
socially accountable trials which better respond to patient needs and preferences with 
potentially more sustained impacts.  As explored in Chapter 11, patient subjectivities are one 
way in which trial findings are generated ‘bit by bit’.  The emphasis of the emerging 
approach of co-design for services is relevant to events such as RHIVA2 where new 
innovations are being implemented and evaluated simultaneously.  Co-design of trial 
algorithms may have revealed health care provider concerns around sharing reactive results 
and may have highlighted the issue of interpretation and interpreted consultations at the 
design stage as a potentially important aspect of the intervention.   The logic of 




emphasis on patient experience.  Trials such as RHIVA2 could benefit from a co-design 
approach where ‘the traditional view of the user as a passive recipient of a product or service 
gives way to the new view of users as the co-designers of that product or service, and integral 
to the improvement and innovation process’ (Bate and Robert, 2006: p.308). 
 
13.7 Conclusion: Maintaining space 
 
‘The critique of simplification is so well established it has become a morally 
comfortable place to be (…) the endless mobilizations of this single trope, in which 
simplification figures as a reduction of complexity, leaves a great deal to discover and 
articulate.  We need other ways of relating to complexity, other ways for complexity 
to be accepted, produced, or performed.’ (Law and Mol, 2002: p.5) 
A point of alignment between what many of the theorists introduced in the thesis suggest and 
what has been presented in the findings of this thesis is the importance of a form of ‘space’.  
For example, in Viveiros de Castro’s concept of controlled equivocation he describes the 
space for divergence and meaning to equivocate and be productively interpreted (Viveiros de 
Castro, 2004). Annemarie Mol’s multiple ontology of disease, describes how multiple 
realities take hold around a disease concept (Mol, 2002).  In the pragmatic trial, key is space 
for the ‘real world’ to enter and act (Kelly, 2008). And in the experiment, space for the 
unexpected to be perceived and to occur is described by Rheinberger, as the driving force of 
science (Rheinberger, 2015).  ‘Space’ for response and a lack of uniformity appear key for 
productive inquiry. The RHIVA2 trial was effective because of enacted pragmatism on the 
part of patients and providers and their responsiveness to emerging, unpredictable situations.  
However, the pragmatic trial design as operationalised in RHIVA2 was somewhat unable to 
articulate this pragmatism, as demonstrated in Chapter 12.  Patients were able to have 
divergent, subjective questions answered through the rapid HIV test as shown in Chapter 11.  
Multiple HIV’s were mobilized to justify the original policy tested in RHIVA2 as described 
in Part 1. 
 
Perhaps the overarching recommendation about applied research to emerge from this 
PhD is to be cautious about the will to overly specify, standardise, and hammer down on 
phenomena through constrictive practices.  Allowing for multiplicity, pragmatic practices, 




engage with uncertainty, the surplus and the responsiveness of phenomena to experimental 
probes through an interdisciplinary engagement with methods, theory and the findings is how 
the RHIVA2 trial and the work of this PhD became meaningful to me.  In my view this was 



































AIDS Gov. (2016). A timeline of HIV and AIDS. Available from: https://www.aids.gov/hiv-
aids-basics/hiv-aids-101/aids-timeline/ [Accessed 27 August 2015]. 
All Parliamentary Group on HIV and AIDS (2013). HIV and sexual health: A guide to the 
English NHS changes for MPs from April 2013. London. Available from: 
http://www.halveit.org.uk/resources/Guide%20for%20MPs%20on%20NHS%20changes.pdf 
[Accessed July 16 2015]. 
Andermann, A., Blancquaert I., Beauchamp S. (2008). Revisiting Wilson and Jungner in the 
genomic age: a review of screening criteria over the past 40 years. Bulletin of the World 
Health Organisation. 86(4): 241-320. Available from: 
http://www.who.int/bulletin/volumes/86/4/07-050112/en/ [Accessed 25 August 2016]. 
Anderson, J. HIV Consultant. (Personal Communication, July 13 2012). 
Anderson, L. (2006). Analytic Autoethnography. Journal of Contemporary Ethnography. 
35(4): 373-395. Available from: http://jce.sagepub.com/content/35/4/373.full.pdf+html 
[Accessed 25 August 2016]. 
Antinori, A., Coenen, T., et al. (2011)  Late presentation of HIV infection: a consensus 
definition. HIV Medicine. 12(1): 61-64. Available from: doi: 10.1111/j.1468-
1293.2010.00857.x. [Accessed 25 August 2016]. 
Armstrong, D. (1995). The rise of surveillance medicine. Sociology of Health & Illness 17(3): 
393-404. Available from: doi/10.1111/1467-9566.ep10933329 [Accessed 25 August 2016]. 
Armstrong, D (2007). Professionalism, Indeterminacy and the EBM Project.  Biosocieties, 
vol 2, no. 1, pp. 73-84. Available from: 10.1017/S1745855207005066 [Accessed 25 August 
2016]. 
Armstrong, N. &. Eborall, H. (2012). The sociology of medical screening: past, present and 
future. Sociology of Health & Illness. 34(2): 161-176. Available from: doi/10.1111/j.1467-
9566.2011.01441. [Accessed 25th August 2016].  
Baggaley, R., Hensen, B et al. (2012). From caution to urgency: the evolution of HIV testing 
and counselling in Africa. Bulletin of the World Health Organization. 90(9): 652-658B. 
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442388/ [Accessed 25th 
August 2016]. 
Baker, S. E.& Edwards, R. (2012). How many interviews is enough. Methodological Review 
Paper, National Centre for Research Methods. Available from: 





Banda, J. (2014). "Rapid Home HIV Testing: Risk and the Moral Imperatives of Biological 
Citizenship." Body & Society. Available from: 
http://bod.sagepub.com/content/early/2014/03/27/1357034X14528391 [Accessed 25th 
August 2016]. 
Barry, A. & Born, G. (2013). Interdisciplinarity: Reconfigurations of the Social and Natural 
Sciences. New York, Routledge Taylor and Francis Group.  
Bastalich, W. (2015). Social Philosophy for Business, Social Sciences and Humanities. 
Available from: http://resource.unisa.edu.au/course/view.php?id=1672. [Accessed 5 April 
2015].  
Beaudin C., Chambre S.M. (1996). "HIV/AIDS as a Chronic Disease: Emergence From the 
Plague Model." American Behavioural Scientist. 3(39): 684-706.  
Berg, M.& Mol, A. (1998). Differences in Medicine: Unravelling practices, techniques and 
bodies. Durham,Duke University Press.   
Biehl J., Locke, P. (2010). Deleuze and the anthropology of becoming. Current 
Anthropology. 51(3): 317-351. Available from:  DOI: 10.1086/651466. [Accessed 25 August 
2016]. 
bioLytical Laboratories. (2007). INSTI™ HIV-1/HIV-2 antibody test kit: clinicians briefing 
notes and user guide. Richmond, BC, Canada. Available from: 
http://www.mtnstopshiv.org/sites/default/files/attachments/INSTi%20Package%20insert.pdf 
[Accessed 25 August 2016].  
Blackman, L. (2008). The Body: The Key Concepts. London, Berg Publishers.   
Blackwood, B., P. O'Halloran, et al. (2010). On the problems of mixing RCTs with 
qualitative research: the case of the MRC framework for the evaluation of complex 
healthcare interventions. Journal of Research in Nursing. 15(6): 511-521. Available from: 
doi: 10.1177/1744987110373860. [Accessed 25 August 2016]. 
Bonell, C., A. Fletcher, et al. Realist randomised controlled trials: a new approach to 
evaluating complex public health interventions. Social Science and Medicine. 75 (12) 2299-
3006. Avaiable from: doi: 10.1016/j.socscimed.2012.08.032. [Accessed 25 August 2016]. 
Bourne, A., D. Reid, et al. (2015). Chemsex' and harm reduction need among gay men in 
South London. International Journal of Drug Policy. 26(12): 1171-1176. Available from: 
DOI: http://dx.doi.org/10.1016/j.drugpo.2015.07.013 [Accessed 25 August 2016]. 
Bowker, G.C., Star, S.L. (1999) Sorting things out: Classification and Its Consequences. MIT 





Branson BM, Handsfield HH, Lampe MA, et al. (2006). Revised recommendations for HIV 
testing of adults, adolescents, and pregnant women in health-care settings. MMWR 
Recommendations  Report. 55:1-17. Available from: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm [Accessed 25 August 2016]. 
Branson, BM. (2007). Current HIV epidemiology and revised recommendations for HIV 
testing in health-care settings. Journal of Medical Virology. 79(S1): S6-S10. Available from: 
DOI: 10.1002/jmv.20972. [Accessed 25 August 2016]. 
British HIV Association (BHIVA), British Association for Sexual Health and HIV, British 
Infection Society. (2008). UK National Guidance for HIV Testing 2008. Available from 
http://www.bhiva.org/documents/guidelines/testing/glineshivtest08.pdf. [Accessed 25 August 
2016]. 
British HIV Association (BHIVA) (2007). HIV Related Deaths in the HAART Era. Clinical 
Audit Report 2005-2006. Avaiable from: 
http://www.bhiva.org/documents/ClinicalAudit/AnnualReports/AuditRep2005-6.pdf . 
[Accessed 25 August 2016]. 
Brown, SD (2012). Experiment: Abstract experimentalism. In: Lury, C.& Wakeford, N. 
Inventive Methods: The Happening of the Social. Oxford. Taylor and Francis. pp. 61-75. 
Available from: 10.4324/9780203854921 . [Accessed 25 August 2016]. 
Bryant, C. G. A. (1975). Kuhn, Paradigms and Sociology. The British Journal of Sociology. 
26(3): 354-359.  
Callard, F. & Fitzgerald, D. (2015). Rethinking Interdiscipinarity across the Social Sciences 
and Neurosciences. London, Palgrave Macmillan.  
Campbell, M., R. Fitzpatrick, et al. (2000). Framework for design and evaluation of complex 
interventions to improve health. BMJ. 321. Available from: DOI: 
http://dx.doi.org/10.1136/bmj.321.7262.694. [Accessed 25 August 2016]. 
Campbell, N. C., E. Murray, et al. (2007). "Designing and evaluating complex interventions 
to improve health care." BMJ. 334. Available from: DOI: 
http://dx.doi.org/10.1136/bmj.39108.379965.BE. [Accessed 25 August 2016]. 
Cartwright, N. & Munro, E. The limitations of randomized controlled trials in predicting 
effectiveness. Journal of Evaluation in Clinical Practice 16(2): 260-266. Available from: 
DOI: 10.1111/j.1365-2753.2010.01382. [Accessed 25 August 2016].  
Centres for Disease Control and Prevention (CDC) (2006). Revised recommendations for 
HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 
Recommendations  Report. 55:1-17. Available from: 





Centres for Disease Control and Prevention (CDC) (2007a). Revised recommendations for 
HIV testing of adults, adolescents, and pregnant women in health-care settings. Annals of 
Emergency Medicine 49(5): 575-577. Available from: 
http://dx.doi.org/10.1016/j.annemergmed.2007.03.001 [Accessed 25 August 2016]  
Centres for Disease Control and Prevention (CDC) (2007b). Quality Assurance Guidelines 
for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory 
Improvement Amendments of 1988. Available from: 
https://www.cdc.gov/hiv/pdf/testing_qa_guidlines.pdf. [Accessed 11 May 2015]. 
Centres for Disease Control and Prevention (CDC). (2011). Recommended HIV Testing 
Definitions and Examples. HIV Testing Definitions Working Group.Division of HIV/AIDS 
Prevention. Available from: http://www.cdc.gov/hiv/pdf/funding/announcements/ps12-
1201/cdc-hiv-ps12-1201-attachment-ii.pdf. [Accessed 11 June 2015]. 
Charon, R. (2001). Narrative medicine: A model for empathy, reflection, profession, and 
trust. JAMA. 286(15): 1897-1902. Available from: doi:10.1001/jama.286.15.1897. [Accessed 
25 August 2016]. 
Clarke, A. E. & Casper, M.J (1996). From Simple Technology to Complex Arena: 
Classification of Pap Smears, 1917–90. Medical Anthropology Quarterly. 10(4): 601-623. 
Available from: https://arizona.pure.elsevier.com/en/publications/from-simple-technology-to-
complex-arena-classification-of-pap-sme. [Accessed 25 August 2016]. 
Cochrance, A. L. (1971). Effectiveness and Efficiency: Random Reflections on Health 
Services. The Nuffield Provincial Hospitals Trust. Available from:  
http://www.nuffieldtrust.org.uk/sites/files/nuffield/publication/Effectiveness_and_Efficiency.
pdf. [Accessed 25 August 2016]. 
Coffman, J. (2007). Evaluation based on theories of the policy process.  The Evaluation 
Exchange: A periodical on emerging strategies in evaluation. X111(1&2). Available from: 
http://www.hfrp.org/evaluation/the-evaluation-exchange/issue-archive/advocacy-and-policy-
change/evaluation-based-on-theories-of-the-policy-process. [Accessed 25 August 2016].  
Cohan, D., Gomez, E., et al. (2009). Patient Perspectives with Abbreviated versus Standard 
Pre-Test HIV Counseling in the Prenatal Setting: A Randomized-Controlled, Non-Inferiority 
Trial. PLoS ONE 4(4): e5166. Available from: 
http://dx.doi.org/10.1371/journal.pone.0005166. [Accessed 25 August 2016].  
Cohen, M. S., Chen, Y.Q., et al. (2011). Prevention of HIV-1 Infection with Early 
Antiretroviral Therapy. New England Journal of Medicine. 365(6): 493-505. Available from: 
DOI: 10.1056/NEJMoa1105243. [Accessed 25 August 2016].  
Cohn, S., Clinch, M., Bunn, C., Stronge, P. (2013). Entangled complexity: why complex 
interventions are just not complicated enough. Journal of Health Service Research Policy .18: 




Cornell (2015). What is science and technology studies?. Available from: 
http://sts.cornell.edu/. [Accessed 25 August 2016]. 
Craig, P.,  Dieppe, P. et al. (2008). Developing and evaluating complex interventions: the 
new Medical Research Council guidance. BMJ. 337a.1655. Available from: doi: 
http://dx.doi.org/10.1136/bmj.a1655. [Accessed 25 August 2016]. 
Crotty, M. (1998). The Foundations of Social Research. Sydney, Allen and Unwin.  
Crowe, S., K. Cresswell, et al. (2011). The case study approach. BMC Medical Research 
Methodology. 11(1): 1-9.  Available from: DOI: 10.1186/1471-2288-11-100 [Accessed 25 
August 2016]. 
Cussins, C. M. (1998). Ontological Choreography: Agency for Women Patients in an 
Infertility Clinic. In: Berg, M, Mol. A (eds.) Differences in Medicine: Unravelling practices, 
techniques and bodies. Duke University Press, pp.166-201.  
Damschroder, L. J., Aron, D.C. et al. (2009). Fostering implementation of health services 
research findings into practice: a consolidated framework for advancing implementation 
science. Implementation Science .4 (50).  Available from: DOI: 10.1186/1748-5908-4-50. 
[Accessed 25 August 2016]. 
DeForge, R. & Shaw, J. Back- and fore-grounding ontology: exploring the linkages between 
critical realism, pragmatism, and methodologies in health & rehabilitation sciences. Nursing 
Inquiry 19(1): 83-95. Available from: DOI: 10.1111/j.1440-1800.2011.050550.x. [Accessed 
25 August 2016].   
Denis, J. L., Hebert, Y., et al. (2002). Explaining diffusion patterns for complex health care 
innovations. Health Care Management Review. 27 (3): 60-73. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12146784. [Accessed 25 August 2016].  
Denzin, N. K., Lincoln, Y.S. (2011). The Discipline and Practice of Qualitative Research. In:  
Lincoln, Y.&.. Denzin, NK. (eds). The SAGE Handbook of Qualitative Research. Thousand 
Oaks, California, SAGE Publications Ltd. 4: 1-20.  
Department of Homeland Security (DOHS). (2015). Human Immuninodeficiency Virus (HIV) 
Infection Removed from CDC List of Communicable Diseases of Public Health Significance . 
Available from http://www.uscis.gov/archive/archive-news/human-immunodeficiency-virus-
hiv-infection-removed-cdc-list-communicable-diseases-public-health-significance. [Accessed 
18 July 2015]. 
Despret, V. (2004). The Body We Care for: Figures of Anthropo-zoo-genesis. Body & 
Society. 10(2-3): 111-134. Available from: doi: 10.1177/1357034X04042938. [Accessed 25 
August 2016]. 
Despret, V. (2008). The Becomings of Subjectivity in Animal Worlds. Subjectivity. 23(1): 
123-139. Available from: https://www.humanities.uci.edu/critical/pdf/despret.pdf. [Accessed 




Eldridge, S. (2010). Pragmatic trials in primary health care: what, when and how? Family 
Practice. 27(6): 591-592. Available from: doi:10.1093/fampra/cmq09 [Accessed 25 August 
2016].  
Ellis, C., Adams, T. E., Bochner, A.(2010). Autoethnography: An Overview. Forum: 
Qualitative Social Research. 12(1).  Available from: http://www.qualitative-
research.net/index.php/fqs/article/view/1589/3095. [Accessed 25 August 2016]. 
Egton Medical Information Systems (EMIS) Group. Company profile. Available from: 
http://www.emis-online.com/company-profile. [Accessed 22 May 2015] 
Evans-Pritchard, E. E. & Gillies, E. (1976). Some reminiscences and reflections on fieldwork 
(Appendix IV). Witchcraft, oracles, and magic among the Azande. Oxford, Clarendon: 
pp.240-254.  
Fairclough, N. (2003). Analysing Discourse: Textual Analysis for Social Research.  
Routledge. 
Feldman WH, Hinshaw, H., Mann FC (1945). Streptomycin in experimental tuberculosis. 
American Review of Tuberculosis. 52: 269-298.  
Flowers, P., Knussen, C., et al. (2013). Has testing been normalized? An analysis of changes 
in barriers to HIV testing among men who have sex with men between 2000 and 2010 in 
Scotland, UK. HIV Medicine. 14(2): 92-98. Available from: doi: 10.1111/j.1468-
1293.2012.01041.x.  [Accessed 25 August 2016]. 
Flyvbjerg, B. (2006). "Five Misunderstandings About Case-Study Research. Qualitative 
Inquiry. 12(2): 219-245. Available from: doi: 10.1177/1077800405284363. [Accessed 25 
August 2016]. 
Foster, N. and Little, P. (2012). Methodological issues in pragmatic trials of complex 
interventions in primary care. The British Journal of General Practice. 62(594): 10-11. 
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252516/pdf/bjgp62-
010.pdf. [Accessed 25 August 2016].  
Freedman, B. (1987). Equipoise and the Ethics of Clinical Research. New England Journal of 
Medicine. 317(3): 141-145. Available from: doi:10.1056/NEJM198707163170304 [Accessed 
25 August 2016].  
Friedman, L. M., Furberg, C., D., DeMets, D. L. (2010). Fundamentals of Clinical Trials. 
New York, Springer-Verlag. 
Garcia-Parpet, M.-F. (2007). The Social Construction of a Perfect Market: The Strawberry 
Auction at Fontaines-en-Sologne. Do Economists Make Markets?  In: Mackenzie, D., Siu, L. 




Gardner, J., K. Dew, et al. (2011). Patchwork diagnoses: The production of coherence, 
uncertainty, and manageable bodies. Social Science & Medicine. 73(6): 843-850.Available 
from: doi: 10.1016/j.socscimed.2010.12.010. [Accessed 25 August 2016]. 
Geertz, C. (1973). The Interpretation of Cultures: Selected essays. New York, Basic Books 
Inc.  
Godwin, M., Ruhland, L., et al. (2003). Pragmatic controlled clinical trials in primary care: 
the struggle between external and internal validity. BMC Medical Research Methodology 
3(1): 28. Available from: doi: 10.1186/1471-2288-3-28. [Accessed 25 August 2016].  
Goldenberg, M. J. (2006). On evidence and evidence-based medicine: Lessons from the 
philosophy of science. Social Science & Medicine. 62(11): 2621-2632. Available from: 
http://dx.doi.org/10.1016/j.socscimed.2005.11.031. [Accessed 25 August 2016]. 
Gomm, R., Hammersley, Martyn, Foster, Peter (2000). Case Study Method: Key Issues, Key 
Texts. London, SAGE Publications Ltd. 
Goodchild Van Hilton, L. (2015) Why it's time to publish research failures. Elsevier Connect.  
Available from: https://www.elsevier.com/connect/scientists-we-want-your-negative-results-
too.[Accessed 25 August 2016]. 
Government of the United Kingdom (2012). Health and Social Care Act c.7. Available from 
http://www.legislation.gov.uk/ukpga/2012/7/contents/enacted. [Accessed 25 August 2016 
Greenhalgh, T., & Hurwitz, B. (1999). Why study narrative? BMJ.  318(7175), 48–50. 
Available from: http://dx.doi.org/10.1136/bmj.318.7175.48. [Accessed 25 August 2016].  
Greenhalgh, T., G. Robert, et al. (2004). Diffusion of innovations in service organizations: 
systematic review and recommendations. Milbank Quarterly. 82(4): 581-629. Available 
from: doi. 10.1111/j.0887-378X.2004.00325.x.[Accessed 25 August 2016]. 
Greenhalgh, T. (2008). Role of routines in collaborative work in healthcare organisations. 
BMJ. 337:a.2448.Available from: doi: http://dx.doi.org/10.1136/bmj.a2448. [Accessed 25 
August 2016]. 
Greenhalgh, T., Russell, J. (2010). Why Do Evaluations of eHealth Programs Fail? An 
Alternative Set of Guiding Principles. PLoS Medicine. 7(11). Available from: 
http://dx.doi.org/10.1371/journal.pmed.1000360. [Accessed 25 August 2016]. 
Greenhalgh, T., J. Howick, et al. (2014). Evidence based medicine: a movement in crisis?. 
BMJ. 348:g3725 Available from: doi: http://dx.doi.org/10.1136/bmj.g3725  [Accessed 25 
August 2016]. 
Griffiths, C.,  Sturdy, P. et al. Educational outreach to promote screening for tuberculosis in 
primary care: a cluster randomised controlled trial. The Lancet. 369(9572): 1528-1534. 





Guise, J., Chang, et al. (2014). Systematic reviews of complex multicomponent health care 
interventions. Report No. 14-EHC003-EF. Agency for Healthcare Research and Quality. 
Available from: http://www.ncbi.nlm.nih.gov/books/NBK194846/. [Accessed 25 August, 
2016]. 
Guldbrandsson, K. and Fossum, B. (2009). An exploration of the theoretical concepts policy 
windows and policy entrepreneurs at the Swedish public health arena. Health Promotion 
International. 24(4): 434-444. Available: doi: 10.1093/heapro/dap033. [Accessed 25 August 
2016]. 
Gulland, A.  (2011). Test all patients in high prevalence areas for HIV, says NICE. BMJ. 342. 
Available from: http://www.bmj.com/content/342/bmj.d1900. [Accessed 25 August 2016]. 
Gülmezoglu, A., Chandler, J. et al. (2013) Reviews of qualitative evidence: a new milestone 
for Cochrane[editorial]. Cochrane Database of Systematic Reviews 2013;(11). Available 
from: 10.1002/14651858.ED000073 [Accessed 26 August 2016]. 
Hammersley, M. (2002). The relationship between qualitative and quantitiatve research: 
paradigm loyalty versus methodological eclecticism. In: John, T.E. Handbook of Qualitative 
Research Methods for Psychology and the Social Sciences. Oxford, BPS Blackwell: 159-174 
Haraway, D. (1988). Situated Knowledges: The Science Question in Feminism and the 
Privilege of Partial Perspective. Feminist Studies 14(3): 575-599.  
Haraway, D. (1996). Modest witness: Feminist diffractions in science studies. In P. Galison, 
& D. Stump (Eds.).  The disunity of science: Boundaries, contexts, and power. Stanford: 
Stanford University Press. pp. 428–442 
 
Haraway, D. (2004). The Haraway Reader.  New York, Routledge. 
 
Hardon, A. and E. Moyer "Anthropology of AIDS: Modes of Engagement." Medical 
Anthropology 33(4): 255-262.  
Hastrup, K. (2004). Getting it right: Knowledge and evidence in anthropology. 
Anthropological Theory. 4(4): 455-472. Available from: doi: 10.1177/1463499604047921. 
[Accessed on 25 April 2016]. 
Hawe, P., Shiell, A., Riley, T. (2004). Complex interventions: how out of control can a 
randomised controlled trial be? BMJ .328: 1561-1563. Available from: doi: 
10.1136/bmj.328.7455.1561. [Accessed 25 August 2016]. 
Health Protection Agency (HPA) (2011). Time to test for HIV: Expanding HIV testing in 
healthcare and community services in England: Final Report 2011. London.  Available from: 
http://www.bhiva.org/documents/Publications/Time_to_test_final_report__Sept_2011.pd  
Health Protection Agency (HPA)(2009). HIV in the United Kingdom: 2009 Repor.t London. 
Available from: 
http://www.wales.nhs.uk/sites3/documents/895/HIV%20in%20the%20UK%2020091.pdf 




Hesse-Biber, S. (2016). Doing Interdisciplinary Mixed Methods Health Care Research: 
Working the Boundaries, Tensions, and Synergistic Potential of Team-Based Research. 
Qualitative Health Research. 26(5): 649-658. Available from: doi: 
10.1177/1049732316634304. [Accessed 25 August 2016]. 
Hesse-Biber, S. (2015). Mixed Methods Research: The ‘Thingness’ Problem. Qualitative 
Health Research. 25(6): 775-788. Available from: doi: 10.1177/1049732315580558. 
[Accessed 25 August 2016]. 
Hill, R. (2012) A Guideline to Discourse Analysis: With Personal Construct Psychology 
undertones. Second Edition. Reconstrue Publications. Available from 
http://www.reconstrue.co.nz/Discourse%20Analysis.pdf. [Accessed 25 August 2016]. 
Hirschhorn, L. R,  Semrau, K., et al. (2015). Learning before leaping: integration of an 
adaptive study design process prior to initiation of Better Birth, a large-scale randomized 
controlled trial in Uttar Pradesh, India. Implementation Science 10(1): 1-9. Available from: 
doi: 10.1186/s13012-015-0309-y [Accessed 25 August 2015]. 
 
Hodgson, I., M. L. Plummer, et al. (2014). A Systematic Review of Individual and 
Contextual Factors Affecting ART Initiation, Adherence, and Retention for HIV-Infected 
Pregnant and Postpartum Women. PLoS ONE 9(11): e111421. [Accessed 25 August 2016]. 
Horner S, Rew L, Torres R. (2006). Enhancing intervention fidelity: A means of 
strengthening study impact. Journal for Specialists in Pediatric Nursing. 11:80–89. Available 
from: doi: 10.1111/j.1744-6155.2006.00050.x. [Accessed 26 August 2015]. 
In Practice Systems. Vision for GP practices. Available from: 
http://www.inps4.co.uk/vision/vision-gp-practices. [Accessed 22 May 2015].  
Jutel, A. & Nettleton, S. (2011). Towards a sociology of diagnosis: Reflections and 
opportunities. Social Science & Medicine. 73(6): 793-800. Available from: doi: 
10.1016/j.socscimed.2011.07.014. [Accessed 25 August 2016]. 
Kalofonos, I. A. (2010). All I Eat Is ARVs. Medical Anthropology Quarterly. 24(3): 363-380. 
Available from: 10.1111/j.1548-1387.2010.01109.x. [Accessed 25 August 2016].  
Kaufert, P. (2000). Screening the body: the pap smear and the mammogram. In: Lock, M, 
Yeo, A,  Cambrisio,. A. Living and working with the new medical technologies: Intersections 
of inquiry. Cambridge, Cambridge University Press: 165-183. 
Kelly, A. (2008). Pragmatic evidence and the politics of everyday practice. In: T. H. Lau, 
Chau,L. Questions of evidence - ethnography and anthropological forms of knowledge. 
Cambridge Scholars Publishing.  
Kelly, A. (2010). Pragmatic Fact-making: Contracts and Contexts in the UK and the Gambia. 
In Will, C. & Moreira, T. Medical Proofs, Social Experiments: Clinical Trials in Shifting 




Kingdon, J. W. (2003). Agendas, Alternatives, and Public Policies, Second Edition. Addison-
Wesley Educational Publishers Inc.  
Kippax, S. & Van de Ven, P. (1998). An epidemic of orthodoxy? Design and methodology in 
the evaluation of the effectiveness of HIV health promotion. Critical Public Health. 8(4): 
371-386. 
Krentz, H. B., M. C. Auld, et al. (2004). The high cost of medical care for patients who 
present late (CD4<200 cells/µL) with HIV infection. HIV Medicine 5(2): 93-98. Available 
from: 10.1111/j.1468-1293.2004.00193.x. [Accessed 25 August 2016]. 
Kuhn, T. S. (1970). The Structure of Scientific Revolutions. Chicago, University of Chicago 
Press.  
Lancaster, G., M. Campbell, et al. (2010). Trials in primary care: statistical issues in the 
design, conduct and evaluation of complex interventions. Statistical Methods in Medical 
Research 19(4): 349-377.  
Latour, B. (2004). How to Talk About the Body? The Normative Dimension of Science 
Studies. Body & Society. 10(2-3): 205-229. Available from: http://bruno-
latour.fr/sites/default/files/77-BODY-NORMATIVE-BS-GB.pdf. [Accessed 25 August 
2016]. 
Latour, B. (2005). Reassembling the Social: An Introduction to Actor Network Theory. 
Oxford University Press.   
Laudan, L. (1996). Beyond Positivism and Relativism: Theory, Method and Evidence. 
Westview Press. 
Law, J. (1999). After ANT: complexity, naming and topology. The Sociological Review. 
47(S1): 1-14. Available from: 10.1111/j.1467-954X.1999.tb03479.x [Accessed 25 August 
2016]. 
Law, J., and Mol, A. 2002). Complexities: Social Studies of Knowledge Practices. Durham 
and London, Duke University Press. 
Law, J. (2004). After Method: Mess in Social Science Research. London, Routledge.   
Law, J. (2009). Actor network theory and material semiotics. In Turner, B. The New 
Blackwell Companion to Social Theory, 3rd Edition. Oxford Blackwell: p. 141-158.  
Law, J., Afdal, G., Asdal, K., Wen-Yuan, L., Moser, I., Singleton, V. (2013). Modes of 
Syncretism: Notes on non-coherence. Common Knowledge: Fuzzy Studies 20(1): 172-192 





Leber, W., McMullen, H. et al. (2015). Point-of-care HIV testing in primary care and early 
detection of HIV (RHIVA2): a cluster randomised controlled trial. The Lancet: 382: S7. 
Available from: http://dx.doi.org/10.1016/S2352-3018(15)00059-4. [Accessed 25 August 
2016]. 
Leber, W., Griffiths, C., Kerry, S. RHIVA2 Trial Team Members. (Personal Communication, 
February 5th, 2015). 
Lewin, S., Glenton C., et al. (2009). Use of qualitative methods alongside randomised 
controlled trials of complex healthcare interventions: methodological study. BMJ .339. 
b3496. Available from: doi: http://dx.doi.org/10.1136/bmj.b3496. [Accessed 25 August 
2016]. 
Lincoln, Y., Egon G. Guba et al. (2011). Paradigmatic Controversies, Contradictions, and 
Emerging Confluences, Revisited. In: Lincoln, Y & Denzin, N. (eds). The SAGE Handbook 
of Qualitative Research. Thousand Oaks, California, SAGE Publications Ltd. 4: 97-128.  
Lo , B., Wolf, L.E. , et al. (2000). Conflict-of-Interest Policies for Investigators in Clinical 
Trials. New England Journal of Medicine. 343(22): 1616-1620. Available from: DOI: 
10.1056/NEJM200011303432206. [Accessed 25 August 2016].  
Lock, M., Young A., Cambrosio, A. (2000). Living and Working with the New Medical 
Technologies. Cambrdige Studies in Medical Anthropology. Cambridge, Cambridge 
University Press.  
Locke, K., Golden-Biddle, K., and Feldman, M.S.(2008). Perspective-making doubt 
generative: Rethinking the role of doubt in the research process. Organization Science 19(6): 
907–918. 
Löwy, I. (2011).Labelled Bodies: Classification of Diseases and the Medical Way of 
Knowing. History of Science. 49(3): 299-315. 
Löwy, I. (2000). Trustworthy knowledge and desperate patients: clinical tests for new drugs 
from cancer to AIDS. In: Lock, M., Young, A., Cambrisio, A. (eds). Living and Working with 
the New Medical Technologies. Cambridge, Cambridge University Press.  
Lupton, D. (1993). Risk as Moral Danger: The Social and Political Functions of Risk 
Discourse in Public Health. International Journal of Health Services. 23(3): 425-435. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8375947. [Accessed 25 August 2016]. 
Lupton, D. (1995). The imperative of health: public health and the regulated body. London, 
Sage. 
Lupton, D. (2012). Medicine as Culture: Illness, Disease and the body.  London, SAGE 
Publications Ltd.  





MacPherson, H. (2004). Pragmatic clinical trials. Complementary Therapies in Medicine. 
12(2): 136-140. Available from: http://dx.doi.org/10.1016/j.ctim.2004.07.043. [Accessed 25 
August 2016]. 
Mant, D. and G. Fowler (1990). Mass screening: theory and ethics. BMJ. 300(6729): 916-
918. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1662659/. [Accessed 25 
August 2016]. 
Marchal, B., Westhorp, G. et al. (2013) Realist RCTs of complex interventions:An 
oxymoron. Social Science & Medicine. 94: 124-128. Available from: 
http://dx.doi.org/10.1016/j.socscimed.2013.06.025. [Accessed 25 August 2016].  
Mattes, D. (2014). Caught in Transition: The Struggle to Live a ‘Normal’ Life with HIV in 
Tanzania. Medical Anthropology. 33(4): 270-287. 
May, C. and T. Finch (2009). Implementing, Embedding, and Integrating Practices: An 
Outline of Normalization Process Theory. Sociology. 43(3): 535-554. Available from: doi: 
10.1177/0038038509103208. [Accessed 25 August 2016]. 
Mazanderani, F. &  Paparini, S. (2015). The stories we tell: Qualitative research interviews, 
talking technologies and the ‘normalisation’ of life with HIV. Social Science & Medicine. 
131: 66-73. Available from:http://dx.doi.org/10.1016/j.socscimed.2015.02.041. [Accessed 25 
August 2016]. 
McGrath, J. W., M. S. Winchester, et al. (2014). Challenging the Paradigm: Anthropological 
Perspectives on HIV as a Chronic Disease. Medical Anthropology. 33(4): 303-317.  
McMullen, H., C. Griffiths, et al. (2015). Explaining high and low performers in complex 
intervention trials: a new model based on diffusion of innovations theory. Trials 16(1): 1-16. 
Available from: doi: 10.1186/s13063-015-0755-5. [Accessed 25 August 2016]. 
Meldrum, M. L. (2000). A Brief History of the Randomised Controlled Trial: From oranges 
and lemons to the gold standard.  Hematology/Oncology Clinics. 14(4): 745-760. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/10949771. [Accessed 25 August 2016].  
Migrants Rights Network (MRN) (2012). HIV treatment to be free for undocumented 
migrants and non-UK citizens. Available from: 
http://www.migrantsrights.org.uk/news/2012/hiv-treatment-be-free-undocumented-migrants-
and-non-uk-citizens. [Accessed 11 May 2014]. 
Miller, F. G. and  Brody, H. (2002). What Makes Placebo-Controlled Trials Unethical? 
American Journal of Bioethics. 2(2): 3-9. 
Mol, A. (1999). Ontological politics. A word and some questions. The Sociological Review. 
47(S1): 74-89. Available from: doi: 10.1111/j.1467-954X.1999.tb03483.x [Accessed 25 
August 2016]. 




Mol, A. (2008). The Logic of Care: Health and the Problem of Patient Choice,  
Abgindon.Routledge.   
Mol, A., Moser, I, Pols, J. (2010). Care in Practice: On Tinkering in Clinics, Homes and 
Farms. transcript Verlag, Bielefeld.  
Mol, A. (2015) Exemplary: The case of the farmer and the turpentine: The ethnographic case 
series. Somatosphere. Available from:  http://somatosphere.net/2015/06/exemplary-the-case-
of-the-farmer-and-the-turpentine.html. [Accessed 25 August 2016].  
Moore, G., Audrey, S. et al. (2013). Process evaluation in complex public health intervention 
studies: the need for guidance. Journal of Epidemiology and Community Health. Available 
from: doi:10.1136/jech-2013-202869. [Accessed 25 August 2016]. 
Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L, O’Cathain A, 
Tinati T, Wight D, Baird J. (2015) Process evaluation of complex interventions: a summary 
of Medical Research Council guidance. In: Richards D, Hallberg IR, editors  
Complex interventions in health: an overview of research methods. Abingdon: Routledge. 
 
Morgan, D. L. (2007). Paradigms Lost and Pragmatism Regained: Methodological 
Implications of Combining Qualitative and Quantitative Methods. Journal of Mixed Methods 
Research 1(1): 48-7. 
Mowles, C. (2014). Complex, but not quite complex enough: The turn to the complexity 
sciences in evaluation scholarship. Evaluation 20(2): 160-175. Available from: doi: 
10.1177/1356389014527885. [Accessed 25 August 2016]. 
Moyer, E. and Hardon, A. (2014). A Disease Unlike Any Other? Why HIV Remains 
Exceptional in the Age of Treatment. Medical Anthropology. 33(4): 263-269. Available from: 
http://dx.doi.org/10.1080/01459740.2014.890618. [Accessed 25 August 2016].  
Munro, A. and  Bloor, M. (2008). Process evaluation: the new miracle ingredient in public 
health research? Qualitative Research. 10(6): 699-713. Available from: doi: 
10.1177/1468794110380522. [Accessed 25 August 2016]. 
Murray, E., Treweek,S., et al. (2010). Normalisation process theory: a framework for 
developing, evaluating and implementing complex interventions. BMC Medicine. 8(63). 
Available from: doi: 10.1186/1741-7015-8-63. [Accessed 25 August 2016]. 
National AIDS Trust (NAT) (2014). HIV and Black African Communities in the UK. London 
. Available from http://www.nat.org.uk/media/Files/Publications/NAT-African-
Communities-Report-June-2014-FINAL.pdf. [Accessed 25 August 2016]. 
National AIDS Trust (NAT) (2016). What everyone should know about HIV. Available from: 





National Association of People with HIV Australia (NAPWHA).(2013). Language and Style 
Guide. Available from: 
http://napwha.org.au/sites/default/files/NAPWHA%20Style%20Guide%20March13_0.pdf 
[Accessed August 25 2016]. 
National Health Service (NHS) (2014). What happens at an NHS Health Check . Available 
from: http://www.nhs.uk/conditions/nhs-health-check/pages/what-happens-at-an-nhs-health-
check.aspx. [Accessed 15 May 2015]. 
National Institute for Health and Care Excellence (NICE) (2011a). HIV testing: increasing 
uptake in black Africans NICE Guidelines PH33.  Available from 
https://www.nice.org.uk/guidance/ph33. [Accessed 25 August 2016]. 
National Institute for Health and Care Excellence  (NICE) (2011b). HIV testing: increasing 
uptake in men who have sex with men NICE Guildelines PH34. Retrieved July 1st, 2014, from 
https://www.nice.org.uk/guidance/ph34. [Accessed 25 August 2016]. 
Newman, C., Mao, L.et al. (2010). HIV generations? Generational discourse in interviews 
with Australian general practitioners and their HIV positive gay male patients. Social Science 
& Medicine. 70(11): 1721-1727. 
Newman CE; Persson A; De Wit JB; Reynolds RH; Canavan PG; Kippax SC; Kidd MR 
(2013) At the coalface and the cutting edge: General practitioners' accounts of the rewards of 
engaging with HIV medicine' BMC Family Practice.(14). Available from:  
http://dx.doi.org/10.1186/1471-2296-14-39. [Accessed 29 May 2016].  
Nilsen, P. (2015). Making sense of implementation theories, models and frameworks. 
Implementation Science. 10(1): 1-13. Available from: doi: 10.1186/s13012-015-0242-0. 
[Accessed 25 August 2016]. 
Nowotny, H. (2000). Re-thinking science: from reliable to socially robust knowledge. 
Jahrbuch 2000 des Collegium Helveticum. 221-244.  
Nowotny, H. (2016). The Cunning of Uncertainty. Cambridge, Polity Press.   
Oakley, A., Strange V., et al. (2006). Process evaluation in randomised controlled trials of 
complex interventions. BMJ . 332(7538): 413-416. Available from: 
doi:  10.1136/bmj.332.7538.413. [Accessed 25 August 2016]. 
O'Cathain, A., Murphy E., et al. (2008). The quality of mixed methods studies in health 
services research. Journal of Health Services Research & Policy. 13(2): 92-98. Available 
from:  doi: 10.1258/jhsrp.2007.007074. [Accessed 25 August 2016]. 
O'Cathain, A., Thomas, K.J. et al. (2013). What can qualitative research do for randomised 
controlled trials? A systematic mapping review. BMJ Open .3(6). Available from: 




O’Dowd, A. (2011). Routine testing for HIV is acceptable and effective, show pilot studies 
BMJ. 343 :d6063. Available from:  http://www.bmj.com/content/343/bmj.d6063. [Accessed 
15 July 2016]. 
 
Parker, I. (1992) Discourse Dynamics: Critical Analysis for Social and Individual 
Psychology. London: Routledge. 
Parkhurst, J. O. (2012). HIV prevention, structural change and social values: the need for an 
explicit normative approach. Journal of the International AIDS Society. 15(Suppl 1): 17367. 
Available from: doi: 10.7448/IAS.15.3.17367 .[Accessed 25 August 2016]. 
Patsopoulos, N. A. A pragmatic view on pragmatic trials. Dialogues in Clinical 
Neuroscience. 13(2): 217-224. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181997/. [Accessed 25 August 2016]. 
Pawson, R.& Tilley, N. (1997). Realistic Evaluation. London, SAGE Publications.  
Peräkylä, A., Ruusuvuori, Johanna (2011). Analyzing talk and text. In: Denzin, N.K. & 
Lincoln, Y.S. The SAGE Handbook of Qualitative Research,Thousand Oaks California, 
SAGE Publications Ltd.  
Persson, A. (2013). Non/infectious corporealities: tensions in the biomedical era of HIV 
normalisation. Sociology of Health & Illness. 35(7): 1065-1079. Available from: doi: 
10.1111/1467-9566.12023. [Accessed 11 July 2015]. 
Persson A; Newman CE; Hopwood M; Kidd MR; Canavan PG; Kippax SC; Reynolds RH; 
De Wit JBF, (2014). 'No ordinary mainstream illness: How HIV doctors perceive the virus', 
Qualitative Health Research, vol. 24, no. 1, pp. 6 - 17. Available from: 
http://dx.doi.org/10.1177/1049732313514139 [Accessed 11 July 2015]. 
Pettigrew, M. (2011). When are complex interventions 'complex'? When are simple 
interventions 'simple'?  European Journal of Public Health. 21(4): 397-399. Available from:  
doi :10.1093/eurpub/ckr084. [Accessed 25 August 2016]. 
Public Health England (PHE) (2014). HIV in the United Kingdom: 2014 Report. England. 
London. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_
PHE_HIV_annual_report_draft_Final_07-01-2015.pdf. [Accessed 25 August 2016]. 
Public Health England (PHE)(2015). HIV in the UK- Situation Report 2015: Incidence, 
Prevalence and Prevention. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477702/HIV_i
n_the_UK_2015_report.pdf . [Accessed 25 August 2016]. 
Philbin, M. (2014). What I Got to Go Through: Normalization and HIV-Positive Adolescents. 
Medical Anthropology. 33(4): 288-302.  Available from: 




Pols, J. (2012). Care at a Distance: On the closeness of technology. Amsterdam, Amsterdam 
University Press. 
Pope, C. and N. Mays (1993). Opening the black box: an encounter in the corridors of health 
services research. BMJ. 306(6873): 315-318. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1676885/ [Accessed 25 August 2016]. 
Pope, C; Mays, N (2009) Critical reflections on the rise of qualitative 
research. BMJ, 339 (b3425). Available from: http://dx.doi.org/10.1136/bmj.b3425 [Accessed 
13 August 2016]. 
Prior, L. (2016). In praise of small N, and of N=1 in particular.Critical Public Health. 26(2): 
115-117. Available from: http://dx.doi.org/10.1080/09581596.2015.1130250. [Accessed 25 
August 2016]. 
Prost, A., C. J. Griffiths, et al. (2009). Feasibility and acceptability of offering rapid HIV tests 
to patients registering with primary care in London (UK): a pilot study. Sexually Transmitted 
Infections. 85(5): 326-329. Available from: doi:10.1136/sti.2008.033233. [Accessed 25 
August 2016]. 
Rayment, M., Thornton, A., et al. (2012). HIV Testing in Non-Traditional Settings “ The 
HINTS Study: A Multi-Centre Observational Study of Feasibility and Acceptability. PLoS 
ONE. 7(6): e39530. Available from: doi: 10.1371/journal.pone.0039530. [Accessed 25 
August 2016]. 
Reeve, J., Dowrick, C.F., et al. Examining the practice of generalist expertise: a qualitative 
study identifying constraints and solutions. JRSM Short Reports. 4(12). Available from: doi: 
2042533313510155.[Accessed 25 August 2016]. 
Rheinberger, H.-J. r. (1994). Experimental Systems: Historiality, Narration, and 
Deconstruction. Science in Context. 7(01): 65-81. 
Rhienberger, H. J. (2015). Difference machines: time in experimental 
systems.Configurations. 23(2): 165-176.  
Ritzer, G. (1975). Sociology: A Multiple Paradigm Science. The American Sociologist. 10(3): 
156-176.  
Robert, G., Cornwell, J. et al. (2015). Patients and staff as codesigners of healthcare services. 
BMJ. 350:g7714. Available from: doi: http://dx.doi.org/10.1136/bmj.g7714. [Accessed 25 
August 2016]. 
Robert, G., Greenhalgh, T., McFarlane, F., Peacock, R.(2010) Journal of  Health Services 
Research and Policy. (4):243-50.Available from: doi: 10.1258/jhsrp.2010.009137. [Accessed 




Robson, J., Dostal, I., et al. (2015). The NHS Health Check programme: implementation in 
east London 2009-2011. BMJ Open. 5(4). Available from: doi:10.1136/bmjopen-2015-
007578. [Accessed 25 August 2016]. 
Rogers, E. M. (2003). Diffusion of Innovations. New York Free Press   
Roland, M. & Torgerson, D. (1998). Understanding controlled trials: What are pragmatic 
trials? BMJ. 316(7127): 285. Available from: doi: 
http://dx.doi.org/10.1136/bmj.316.7127.285. [Accessed 25 August 2016]. 
Rose, N. (2001). The Politics of Life Itself. Theory, Culture & Society. 18(6): 1-30. 
Rosenberg, C. E. (2002). The Tyranny of Diagnosis: Specific Entities and Individual 
Experience. Milbank Quarterly. 80(2): 237-260. Available from: doi:  10.1111/1468-
0009.t01-1-00003. [Accessed 25 August 2016].  
Rosenberg, C. (2009) Managed fear. The Lancet. 373(9666): 802-803. Available from: 
http://dx.doi.org/10.1016/S0140-6736(09)60467-0. [Accessed 25 August 2016]. 
Rosengarten, M. (2015).Conference Abstract: Situating Efficacy, Biomedicine, 
Interdisciplinarity and the Politics of Intervention. Proceedings from: Situating Efficacy 
Conference. Brocher Foundation, Geneva. February 16&17, 2015.  
Rothwell, P. M. (2005). External validity of randomised controlled trials: To whom do the 
results of this trial apply. The Lancet. 365(9453): 82-93. Available from: 
http://dx.doi.org/10.1016/S0140-6736(04)17670-8 [Accessed 25 August 2016]. 
Russell, B. (2004). History of Western Philosophy. London, Routledge. 
Sabatier, P. A., Ed. (1999). Theories of the Policy Process: Theoretical Lenses on Public 
Policy. Westview Press.   
Savaransky, M. & Rosengarten, M (2015). Situated Efficacy: What if health were the truth of 
the body? Proceedings from the ‘Situating Efficacy: Biomedince, interdisciplinarity and the 
politics of evidence Symposium at the Brocher Foundation. Geneva.February 16-17, 201  
Savransky, M. & Rosengarten, M. (2016). What is nature capable of? Evidence, ontology and 
speculative medical humanities. Medical Humanities. Available from: doi:10.1136/medhum-
2015-010858. [Accessed 28 July 2016].  
Seidel, G. (1993). The competing discourses of HIV/AIDS in sub-Saharan Africa: Discourses 
of rights and empowerment vs discourses of control and exclusion. Social Science & 
Medicine. 36(3): 175-194. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8426962. 






Selby, P., G. Brosky, et al. (2012). How pragmatic or explanatory is the randomized, 
controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a 
smoking cessation trial. BMC Medical Research Methodology. 12(1): 101. Available from: 
doi: 10.1186/1471-2288-12-101. [Accessed 25 August 2016]. 
Select Committee on HIV and AIDS. (2011). No Vaccine, no cure: HIV and AIDS in the 
United Kingdon. Available 
from:http://www.publications.parliament.uk/pa/ld201012/ldselect/ldaids/188/18802.htm 
[Accessed 25 August 2016}. 
Shah, H. M. &  Chung, A.C. (2009). Archie Cochrane and his vision for evidence-based 
medicine.Plastic and reconstructive surgery. 124(3): 982-988. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746659/. [Accessed 25 August 2016]. 
Shannon-Baker, P. (2015). Making Paradigms Meaningful in Mixed Methods Research. 
Journal of Mixed Methods Research.  Available from: doi: 10.1177/1558689815575861 
[Accessed 25 August 2016]. 
Shaw, S.E. & Greenhalgh, T. (2008) Best research- For what? Best health - For whom? A 
critical exploration of primary care research using discourse analysis. Social Science & 
Medicine, 66, 2506-2519. Available from: http://dx.doi.org/10.1016/j.socscimed.2008.02.014 
[Accessed 25 August 2016]. 
Shaw, S. E. & Bailey, J. (2009). Discourse analysis: what is it and why is it relevant to family 
practice? Family Practice. 26(5): 413-419. Available from: doi:  10.1093/fampra/cmp038. 
[Accessed 25 August 2016]. 
Shaw, S. E. (2010). Reaching the parts that other theories and methods can’t reach: How and 
why a policy-as-discourse approach can inform health-related policy. Health .14(2): 196-212. 
Available from:  doi: 10.1177/1363459309353295. [Accessed 25 August 2016]. 
Shepperd, S., Lewin, S. et al. (2009). "Can we systematically review studies that evaluate 
complex interventions?" PLoS Med. 6.  
Sherzer, J. (1987). A Discourse-Centered Approach to Language and Culture. American 
Anthropologist 89(2): 295-309. Available from: 10.1525/aa.1987.89.2.02a00010. [Accessed 
25 August 2016]. 
Shiell, A., Hawe, P. et al. (2008). Complex interventions or complex systems? Implications 
for health economic evaluation. BMJ. 336: 1281-1283. Available from: 
doi:  10.1136/bmj.39569.510521.AD. [Accessed 25 August 2016].  
Shiffrin, S., Tannen, D., Hamilton, H. (2003). The Handbook of Discourse Analysis. 
Massachusetts and Oxford, Wiley-Blackwell.  
Schubert, C. (2011). Making sure. A comparative micro-analysis of diagnostic instruments in 
medical practice. Social Science & Medicine. 73(6): 851-857. Available from: 




Simons, H. (1989). Ethics of case study in educational research and evaluation. In:R.Burgess. 
The Ethics of Educational Research. The Falmer Press.  
Simpson, B. (2009). Pragmatism, Mead and the Practice Turn. Organization Studies. 30(12): 
1329-1347. 
Singal, A, Higgins, P., Waljee, A. (2013). A Primer on Effectiveness and Efficacy Trials. 
Clinical and Translational Gastroenterology 5: e45. Available from:  doi: 
10.1038/ctg.2013.13. [Accessed 25 August 2016]. 
Singleton, V. (1998). Stabilizing Instabilities: The Role of the Laboratory in the United 
Kingdon Cervical Screening Programme. In: Berg, M. & Mol, A. (eds). Differences in 
Medicine: Unravelling practices, techniques and bodies. Durham, Duke University Press.  
Smith, J. H. & Whiteside, A. The history of AIDS exceptionalism. Journal of the 
International AIDS Society. 13: 47-47. Available from: doi:10.1186/1758-2652-13-47. 
[Accessed 25 August 2016].  
Spencer, L.,  Ritchie, J. et al. (2003). Quality in qualitative evaluation: a framework for 
assessing research evidence. National Centre for Social Research.  London, Government 
Chief Social Researcher’s Office, Cabinet Office.  
Stake, R. E. (1978).  The Case Study Method in Social Inquiry. Educational Researcher. 
7(2): 5-8. Available from: doi: 10.3102/0013189X007002005.  
Stake, R. E. (1995). The Art of Case Study Research. Thousand Oaks, California, SAGE 
Publications Ltd.  
Stavrou, A., D. Challoumas, et al. (2014). Archibald Cochrane (19091988): the father of 
evidence-based medicine. Interactive CardioVascular and Thoracic Surgery.18(1): 121-124. 
Available from: doi: 10.1093/icvts/ivt451. [Accessed 25 August 2016]. 
Stephens, P. (2014). UK law passes sales of HIV home-testing kits before they exist. BBC 
News. London. Available from: http://www.bbc.co.uk/news/health-26888272 [Accessed 9 
July 2015]. 
Stöhr, W., Dunn, D.T.et al. (2007). CD4 cell count and initiation of antiretroviral therapy: 
trends in seven UK centres, 1997–2003. HIV Medicine. 8(3): 135-141.  
Strathern, M. (1996). Cutting the Network. The Journal of the Royal Anthropological 
Institute. 2(3): 517-535. 
Strauss, A. and J. M. Corbin (1990). Basics of qualitative research: grounded theory 
procedures and techniques. Thousand Oaks, CA, Sage Publications. 
Sugarman, J. & Califf , R.M. (2014). Ethics and regulatory complexities for pragmatic 
clinical trials. JAMA. 311(23): 2381-2382. Available from: doi: 10.1001/jama.2014.4164. 




Sullivan, A. Curtis, K. et al. (2005). Newly diagnosed HIV infections: review in UK and 
Ireland. BMJ.330 (7503). 1301-1302. Available from: 10.1136/bmj.38398.590602.E0. 
[Accessed 25 August 2016]. 
The Kaiser Foundation (2014). HIV Testing in the United States. Available from: 
http://kff.org/hivaids/fact-sheet/hiv-testing-in-the-united-states/. [Accessed 5 June 2015]. 
Thorpe, K. E., M. Zwarenstein, et al. (2009). A pragmatic explanatory continuum indicator 
summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology 62(5): 
464-475. Available from: doi: 10.1016/j.jclinepi.2008.12.011. [Accessed 25 August 2016].  
Terrence Higgins Trust (THT). (2016). HIV self-testing. Available from:  
http://www.tht.org.uk/sexual-health/About-HIV/HIV-self-testing. [Accessed 5 May 2015  
Tilley, N. (2000). Realist Evaluation: An overview. Founding Conference of the Danish 
Evaluation Society 1-13. September 2000. Available from: 
http://healthimpactassessment.pbworks.com/f/Realistic+evaluation+an+overview+-
+UoNT+England+-+2000.pdf. [Accessed 25 August 2016].   
Timmermans, S. & Haas, S. (2008). Towards a sociology of disease. Sociology of Health & 
Illness. 30(5): 659-676. Available from: doi: 10.1111/j.1467-9566.2008.01097.x [Accessed 
25 August 2016]. 
Tosh, G., K. Soares-Weiser, et al. (2011). Pragmatic vs explanatory trials: the Pragmascope 
tool to help measure differences in protocols of mental health randomized controlled trials. 
Dialogues in Clinical Neuroscience 13(2): 209-215. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182001/ [Accessed 25 August 2016]. 
Treweek, S. & Zwarenstein, M.(2009). Making trials matter: pragmatic and explanatory trials 
and the problem of applicability. Trials. 10(1): 37. Available from: doi: 10.1186/1745-6215-
10-37. [Accessed 25 August 2016]. 
Tulchinsky TH, Varavikova EA. (2010) What is the “New Public Health”? Public Health 
Reviews. 32:25(5). Available from:  http://www.publichealthreviews.eu/show/f/23 [Accessed 
25 August 2016]. 
Turner, L., L. Shamseer, et al. Does use of the CONSORT Statement impact the 
completeness of reporting of randomised controlled trials published in medical journals? A 
Cochrane review. Systematic Reviews. 1(1): 1-7. 
UK National Screening Committee & Public Health England (2013) Criteria for appraising 
the viability, effectiveness and appropriateness of a screening program. Available from: 
https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-
programmes/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-
screening-programme. [Accessed 15 August 2016].  
Upton, T. A. and M. A. Cohen (2009). An approach to corpus-based discourse analysis: The 




Vasilachis de Gialidino, I. (2009 ). Ontological and Epistemological Foundations of 
Qualitative Research. Qualitative Reserach Forum. 10(2). Available from: 
http://www.qualitative-research.net/index.php/fqs/article/view/1299/3163. [Accessed 25 
August 2016]. 
Vernazza P, Bernard, EJ., Bernasconi  E., et al. (2008). Les personnes seropositives ne 
souffrant d'aucune autre MST et suivant un traitment antiretroviral efficace ne transmettent 
pas the VIH par voie sexuelle. Bulletin des Medicins Suisse. 89(5): 165-169. Available from: 
http://www.unige.ch/sciences-societe/socio/files/4814/0533/6055/Vernazza_2008.pdf. 
[Accessed 26 August 2016].  
Vernazza PL, Bernard EJ. (2016) HIV is not transmitted under fully suppressive therapy: The 
Swiss Statement – eight years later. Swiss Med Wkly. 2016;146:w14246. Available from: 
http://www.smw.ch/content/smw-2016-14246/ [Accessed 25 August 2016]. 
Vivieros de Castro, E. (2004). Perspectival Anthropology and the Method of Controlled 
Equivocation. Tipiti: Journal of the Society for the Anthropology of Lowland South America 
2(1): 3-22. Available from: 
http://digitalcommons.trinity.edu/cgi/viewcontent.cgi?article=1010&context=tipiti. 
[Accessed 25 August 2016].  
Wailoo, K. (1997). Drawing Blood: Technology and Disease in Twentieth Centrury America. 
Johns Hopkins University Press.   
Waller, W. (1934). Insight and Scientific Method. American Journal of Sociology. 40(3), 
285-297. Available from: http://www.jstor.org/stable/2768261 [Accessed 25 August 2016]. 
Wellesley, R., A. Whittle, et al. (2015). Does general practice deliver safe primary care to 
people living with HIV? A case-notes review. British Journal of General Practice. 65(639): 
e655-e661. Available from: doi: 10.3399/bjgp15X686905. [Accessed 25 August 2016]. 
Will, C. &Moreira, T. (2010) Medical Proofs and Social Experiments: Clinical Trials in 
Shifting Contexts. Surrey, England: Ashgate Publishing. 
Whiteside, A. & Smith, J. (2009). Exceptional epidemics: AIDS still deserves a global 
response. Globalization and Health. 5(1): 1-6. 
Wilson J.& Jungner, G. (1968). Principles and practice of screening for disease. World 
Health Organisation Bulletin. Available from:http://www.who.int/bulletin/volumes/86/4/07-
050112/en/ [Accessed 25 August 2016]. 
Winter, R. (1986). Fictional critical writing: an approach to case study research by 






Yin, Z., A. Brown, et al. (2014). HIV and AIDS Reporting Team, HIV and STI Development, 
Centre for Infectious Disease Surveillance and Control, Health Protection Directorate. HIV 
in the United Kingdom: 2014 report. London, Public Health England. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_
PHE_HIV_annual_report_draft_Final_07-01-2015.pdf [Accessed 25 August 2016]. 
Yoon, H. (2009). The Affective Turn: Theorizing the Social (review). College Literature 
36(2): 155-158.  
Zahariadis, N. (1998). Comparing Three Lenses of Policy Choice. Policy Studies Journal. 
26(3): 434-448. Available from: doi: 10.1111/j.1541-0072.1998.tb01911.x [Accessed 25 
August 2016]. 
Zahariadis, N. (2007). The Multiple Streams Framework, Structure, Limitations, Prospects 
Theories of the Policy Process P. A. Sabatier. Boulder, Westview Press Inc.: 65-92.  
Zwarenstein, M., S. Treweek, et al. (2008). Improving the reporting of pragmatic trials: an 
extension of the CONSORT statement. BMJ 337. Available from: doi: 
























































































































































































































































































































Appendix 2: The Diffusion of Innovations Coding Frame  
 
The Diffusion of Innovations Coding Frame 
 
A) The Innovation 
1) Relative Advantage 
2) Compatibility 
3) Low complexity 
4) Observability  
5) Potential for Reinvention 
6) Fuzzy Boundaries 
7) Task Issues 
8) Nature of Knowledge 
9) Technical Support  
 
B) Communication and Influence  
1) Social Networks 
2) Homophily 
3) Peer Opinion 
4) Marketing 
5) Expert Opinion 
6) Champions 
7) Boundary Spanners 
8) Change Agents  
C) Outer Context 
1) Socio-political Climate 
2) Incentives and Mandates 
3) Inter-organisational norm setting and networks 
4) Environmental stability  
 
D) Linkage  
Design Stage  
1) Shared Meanings and Mission 
2) Effective Knowledge Transfer  
3) User Involvement in Specification 
4) Capture of User Led Innovation 
Implementation Stage 
5) Communication and Information 
6) User Orientation 
7) Product Augmentation (technical help) 
8) Project Management and Support  
 
E) Implementation Process  
1) Decision making devolved to frontline teams 




3) Human resource issues, especially training  
4) Dedicated resources 
5) Internal communication 
6) External collaboration 
7) Reinvention/Development  
8) Feedback on progress  
 
F) Assimilation 
1) Complex, nonlinear process 
2) ‘Soft Periphery’ elements  
 
G) Adopter  
1) Needs 
2) Motivation 
3) Values and Goals  
4) Skills 
5) Learning Style 
6) Social Networks  
 
H) System Readiness for Innovation 
1) Tension for Change 
2) Innovation-system Fit  
3) Power Balances (supports vs. opponents) 
4) Assessment of Implications 
5) Dedicated time and resources  
6) Monitoring and Feedback  
 
I) System Antecedents for Change  





v. Slack Resources  
2) Absorptive Capacity for new knowledge 
i. Pre-existing knowledge/skills base 
ii. Ability to find, interpret, re-codify and integrate new 
knowledge 
iii. Enablement of knowledge sharing 
3) Receptive Context for Change  
i. Leadership and Vision 
ii. Good managerial relations 
iii. Risk – taking climate 
iv. Clear goals and priorities 























Appendix 4: Examples of field notes. 
Please see the following examples of field notes.  Names and details have been anonymised. 
Example 1: Primary Issues with Testing  
Daswani practice was trained and supplied with all necessary equipment to start testing on 
June 8th, 2010.  The first round of quality assurance activities was delivered on July 10th, 
2010. Daswani practice never returned their quality assurance information to the lab, scoring 
0 on the assessment. On the 11th I received a phone call from a practice nurse at the Oak 
practice which shares the X Road Medical Centre.  Both practices were trained at the same 
time as they are both small practices in the same building.  Later on in the trial Reyah also 
took on one morning a week at the Oak practice in addition to her work at Daswani practice.  
The nurse from Oak practice wanted to inform me that when the quality assurance arrived, 
Reyah had asked her for some test kits as she didn’t have any.  Daswani was supplied with 
100 test kits at the training.  These were placed in the clinical supplies cupboard along with 
other clinical materials.  It seems that Reyah did not know where the supplies were being 
kept.  I asked CEG to pull up their EMIS testing numbers and it indicated that all tests offered 
were declined.  Reyah had a 100% decline rate in the first year of testing.  She offered 33 
tests, which were all turned down.  There is some reason to believe that they were never 
offered as at least in the beginning she did not have any test kits but was registering results.  
Other low levels of test acceptance in the trial are mostly due to rearrangements of the new 
patient health check, meaning that patients are offered the test on a checklist or need to attend 
an additional appointment to have it.  Even in these scenarios we never saw decline rates 
nearing 100%.  When offered usually between 35 and 70% of patients will agree to the test.  
After learning of the unknown test kits and the declined entries I raised the issue with the 
team worried that she was falsifying data.  I was told not to frustrate the practice or they 
would refuse to participate altogether.  I sent the below email to Reyah and asked to visit the 
practice to see if any retraining was needed.  
Dear x, 
The message was passed along to me that you were unable to find the INSTI test kits required to perform the 
External Quality Assurance Protocol. As I recall, x has stored them in the storage cupboard in a large box.  They 
were one of the first boxes upon entry. 
I suppose this means that you have not started testing at the surgery? Please let me know what you may require in 
terms of support to get started. The surgery is being paid ten pounds per test performed. 










Example 2: RHIVA Power Calculations 
Friday 11/03/2011 15:55 
Hi X,X,X,  
When you get to the stage in the minutes where you define the new power calculations and 
what data is required you can pass it along so that I can document.   
Does this qualify as an adverse event?  How am I meant to reflect these changes in the TMF? 
Also, it was suggested I come up with another time for a meeting next month. 
I am guessing we will need these done before then.  What kind of time frame am I looking 
at?  I want to give people enough notice so that they might actually be able to attend a whole 
meeting, but also make sure we will have what we need by then. 
Thanks,  




















Example 3: Safiye – HCA and Practice Rapid Testing Lead  
Safiye is a large bubbly woman with a strong East London accent, young and energetic she is 
easy to talk to and unpretentious in her manner.  Her family is Middle Eastern but she is East 
London raised. A recent mom, she will quickly begin telling you all about her struggles to 
manage work and being a single parent.  All her anecdotes contain humour, she often pokes 
fun at herself and any story is peppered with check in comments for her audience such as, ‘oh 
my god, can you imagine’  ‘ could you believe it’ etc.  She is very sincere in her interactions 
and is warm in her approach. I imagine patients would feel very comfortable speaking with 
her about their various concerns.  When asking about rapid testing I find that she will reply in 
ways that seem genuine, taking responsibility for things she could have done better and 
replying with answers that one might not be quick to share with most researchers.  
Safiye believes rapid testing in general practice is a good idea and expresses ‘100%’ support, 
she also shows great compassion towards patients demonstrating much concern for their 
feelings and experiences.  
Safiye spoke a lot about the fear of having a positive result however she mentioned on more 
than one occasion how keen she was to see one.  
Safiye valorises the emotional aspects of testing.  She speaks a lot about feelings and 
experiencing feelings. In regards to apprehensions about testing her biggest concern was 
upsetting a patient with a potentially false result.  This example also demonstrates a lack of 
understanding of test kit in that insufficient blood would not give a false negative but an 
invalid result.   
Safiye was really keen to be helpful.  She gave me her personal phone numbers, encouraging 
me to call her on her mobile instead of through the surgery as that would mean that I could 
get through faster with any queries.  She seemed proud to be the practice lead on rapid 
testing. On the occasion where I was actively trying to reach her to confirm training and 
chase up a confusing result from EMIS I was unable to do so with any of the means provided.   
It usually took many attempts and unreturned messages before I could reach her.  I took to 
popping into the surgery when I was in the area if there was anything outstanding.  It was 
often more convenient for me to stop in and try and speak to someone in person rather than 
get involved in phone tag.  
She was quick to take responsibility for her role in the trial when I interviewed her.   In the 
initial meeting I set up to ask about the lack of testing at the practice and to troubleshoot we 
identified there was a problem with the distribution of the Patient Information Sheets, a 
requirement of ethics.   All patients are meant to have received and reviewed a double sided 
patient information sheet explaining that they will be offered a rapid HIV test.  Safiye was 
always quite concerned with ensuring patients understood that testing was part of a research 




that the Patient Information Sheets were being attached in the new registrants pack.  Safiye 
was not performing the test on anyone who had not received the information sheet and 
articulated this as the reason for a lack of testing.   I found this interesting in that if all 
practices had been so pedantic about having evidence of patients viewing the patient 
information sheet I am sure we would have had less tests performed.  From the first training 
we anticipated this may be an issue and I had copies of the PIS printed in 8 languages, in 
different colours, and laminated so that a copy could be kept in the consultation room.  It was 
advised that if patients had not seen the information sheet they could view it then and agree.   
It turned out this approach was counter to the ethical stipulations.   Patients were meant to see 
the patient information sheet 24 hours prior to being offered the test.  Normally this is not an 
issue as most patients wait some time between registering and their NPHC.  However, 
Practice X forced us to look more carefully at this ethical stipulation as they often offer both 
registration and the NPHC in the same day.   A further consideration of the ethical 
requirement made us realise it was barrier to testing.  We also thought that the requirements 
exceptionalised HIV testing.  When discussing with various team members the requirement 
caused significant frustrations, particularly with the HIV liaison nurse who often comes up 
against the exceptionalising of HIV testing in hospital.  She has many anecdotes of patients 
who do not speak English yet have had x-rays, urine tests, some blood tests in the hospital 
setting yet need a patient advocate and consent form for an HIV test.  As we were unable to 
see precedence in primary care for this wait period and saw it as a relic of the past 
implications of being HIV positive we applied for an amendment.  As patients were to be 
offered the test during the new patient health check but were unable to be offered if they had 
not had a 24 hour consideration period, patients of surgeries who performed same day 
registration and health check were missing out on the opportunity to be tested.  This was also 
skewing the numbers for our trial as these patients met the inclusion criteria and were 
undergoing NPHC. The amendment was accepted.   
It was interesting to see how surgery registration routines could exclude some patients from 
the opportunity to test.  None of the other surgeries reported this issue.  Practice X was 
somewhat unique in the borough in it’s organisation of the NPHC.  Another surgery had a 
somewhat similar approach however their NPHC was condensed to the point that it was 
performed by the receptionist at the point of registration.  A scale, height measure and blood 
pressure machine are set beside the registration desk.  The patient fills out a questionnaire and 
proceeds to do their height, weight and BP in plain sight of the waiting room.   When 
speaking to various receptionists across the borough about how the NPHC evolved to this 
point many cited the removal of the NPHC payment and the payment per registrants a major 
incentive.  They were keen to register people quickly but could not afford the resources 
required for long NPHC.  This is another aspect that makes Practice Y so unique, there is 30 
minutes afforded to each NPCH.   The norm is 10-15. I believe this to be strongly related to 














Hi X and X, 
See X response regarding EQAs below and action to be taken regarding serum quantity. 
As for X (X- August 4th) reactive result, as mentioned by X,  it seems that she followed the 
algorithm well and referred to the GP but that the GP sent the patient to X for bloodwork / 
venous blood confirmatory testing, and did not contact X or follow up. At the moment it 
appears the patient never showed up to X for bloodwork. X is now on the case and I am 
expecting an update from her.   
I had a very productive meeting with X this afternoon (where I learned about the reactive 
result) and she is feeling better about testing and performing EQAs. 
I am a bit concerned that we may not know about a few other ‘abnormal’ results and since we 
cannot yet access records via EMIS I am planning a check in with all lead nurses this week 
for an update as to how things have been progressing in the surgeries, this will also provide 
me with an opportunity to see how they are managing to distribute patient information sheets. 
X when would you like to meet this week?  I am not in Wednesday. 


































Hackney&General&Practices.&The&main&objective& is& to&demonstrate& that& rapid&HIV&testing,& if&
integrated& into& the& GP& registration& health& check,& increases& the& rate& of& HIV& testing& and&
detects&cases&at&an&earlier&stage&in&the&infection.&&&&
&
In& addition& to& the& testing& trial& we& want& to& do& some& qualitative& research& to& help& us&









































































































If you have any further questions you may contact Heather McMullen, researcher at QMUL: 




















































































Explaining high and low performers in
complex intervention trials: a new model
based on diffusion of innovations theory
Heather McMullen1*, Chris Griffiths1, Werner Leber1 and Trisha Greenhalgh2
Abstract
Background: Complex intervention trials may require health care organisations to implement new service models.
In a recent cluster randomised controlled trial, some participating organisations achieved high recruitment, whereas
others found it difficult to assimilate the intervention and were low recruiters. We sought to explain this variation
and develop a model to inform organisational participation in future complex intervention trials.
Methods: The trial included 40 general practices in a London borough with high HIV prevalence. The intervention
was offering a rapid HIV test as part of the New Patient Health Check. The primary outcome was mean CD4 cell
count at diagnosis. The process evaluation consisted of several hundred hours of ethnographic observation, 21
semi-structured interviews and analysis of routine documents (e.g., patient leaflets, clinical protocols) and trial
documents (e.g., inclusion criteria, recruitment statistics). Qualitative data were analysed thematically using—and,
where necessary, extending—Greenhalgh et al.’s model of diffusion of innovations. Narrative synthesis was used
to prepare case studies of four practices representing maximum variety in clinicians’ interest in HIV (assessed by
level of serological testing prior to the trial) and performance in the trial (high vs. low recruiters).
Results: High-recruiting practices were, in general though not invariably, also innovative practices. They were
characterised by strong leadership, good managerial relations, readiness for change, a culture of staff training and
available staff time (‘slack resources’). Their front-line staff believed that patients might benefit from the rapid HIV
test (‘relative advantage’), were emotionally comfortable administering it (‘compatibility’), skilled in performing it
(‘task issues’) and made creative adaptations to embed the test in local working practices (‘reinvention’). Early
experience of a positive HIV test (‘observability’) appeared to reinforce staff commitment to recruiting more
participants. Low-performing practices typically had less good managerial relations, significant resource constraints,
staff discomfort with the test and no positive results early in the trial.
Conclusions: An adaptation of the diffusion of innovations model was an effective analytical tool for retrospectively
explaining high and low-performing practices in a complex intervention research trial. Whether the model will work
prospectively to predict performance (and hence shape the design of future trials) is unknown.
Trial registration: ISRCTN Registry number: ISRCTN63473710. Date assigned: 22 April 2010.
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A complex intervention is defined by the Medical Re-
search Council (MRC) as comprising multiple elements,
all of which seem essential but whose ‘active ingredient’
may be difficult to specify; they typically operate at mul-
tiple levels (individual, team, organisation) [1–3]. Such
interventions include new tests and treatments that cre-
ate opportunities for changing how services are delivered
(e.g., near-patient testing that potentially allows diagno-
ses to be made in primary care that were previously pos-
sible only in secondary care).
Much health services research consists of developing
complex interventions and testing them in randomised
controlled trials (RCTs). The MRC framework proposes
five phases (0 to 4), including developmental and pilot
work, the trial itself and an evaluation of post-trial im-
plementation in the ‘real world’ [4]. Complex interven-
tion trials generally require a cluster design (in which
the organisation or service team is the unit of random-
isation) and are studied through a pragmatic lens (i.e.,
seeking to replicate usual care as delivered by the staff
and through systems in participating organisations) ra-
ther than an explanatory one (i.e., seeking to produce
abstracted theoretical models of efficacy with an em-
phasis on scientific purity) [5, 6].
A growing theoretical and methodological literature
addresses the question whether interventions that are
complex can legitimately be tested using experimental
designs in which they are conceptualised as a clearly de-
fined set of inputs implemented in a controlled way with
attention to mediating and moderating variables [4, 7, 8]
or whether their complexity requires a more ecological
conceptualisation as ‘events in systems’ and (therefore)
developmental rather than experimental research de-
signs [9–12]. Either way, a key focus of study is the
interaction between the complex intervention and the
local settings in which it is implemented [3, 13, 14].
An important concept is the idea of a theoretical ‘hard
core’ of a complex intervention (elements that cannot be
compromised without invalidating the trial) and a flexible
‘soft periphery’ (elements of the intervention that can and
should be adapted locally to optimise acceptance and em-
bedding) [15, 16]. In any complex intervention trial, each
unit (e.g., participating organisation or team) will imple-
ment the intervention differently, so a component of trial
quality is ensuring fidelity of the theoretical core [2, 15].
The emerging science of process evaluation uses qualita-
tive research alongside a RCT to capture the experiences
of staff and patients, illuminate tasks and processes, ex-
plore model–reality gaps and develop and test theory [17,
18]. Such approaches can be used both retrospectively (to
explain successes and failures) and prospectively (to in-
form further refinement of the intervention). Specific
theoretical lenses applied in this context include normal-
isation process theory [19] and realist evaluation [20],
though the latter has been contested [21].
One approach that has not previously been used to study
the process of implementing a complex intervention in a
RCT is diffusion of innovations theory. Originally devel-
oped by Everett Rogers in the 1950s to explain the adop-
tion and spread of innovations by individuals in a social
network [22], the theory was later extended by Greenhalgh
et al. to address the assimilation and implementation of
service-level innovations in health care organisations [23].
Greenhalgh et al.’s definition of an innovation as “a novel
set of behaviors, routines, and ways of working that are di-
rected at improving health outcomes, administrative effi-
ciency, cost effectiveness, or users’ experience and that are
implemented by planned and coordinated actions” ([23], p.
582) agrees strongly with the MRC definition of a complex
intervention (paragraph 1). It follows that the multi-level
model developed by Greenhalgh et al. to study the adop-
tion (and non-adoption and abandonment) of innovations
may also prove useful for explaining variation in imple-
mentation success in complex intervention trials.
In this article, we apply Greenhalgh et al.’s model to a
retrospective process evaluation of a complex interven-
tion to introduce rapid HIV testing in a general practice
setting. Below we summarise the trial and introduce the
diffusion of innovations model and then describe our
methodology, findings and conclusions. In the Discus-
sion section, we offer preliminary suggestions for using
the diffusion of innovations model prospectively to opti-
mise organisational participation in trials.
The trial of rapid HIV testing in general practice
A summary of the rationale, methodology and findings
of this trial have been published elsewhere [24, 25].
Briefly, general practice–based screening for HIV is ap-
pealing, given the rising prevalence of the condition in
the United Kingdom (especially London), a good prog-
nosis if treated early, the high proportion of cases (24 %)
that remain undiagnosed in the community and the high
proportion (47 %) of patients diagnosed with advanced
disease [26]. The British HIV Association and the Na-
tional Institute for Health and Care Excellence both sup-
port community-based testing in areas where the
prevalence of diagnosed HIV is above 2 per 1000 adult
population [27, 28], but such testing has not previously
been evaluated experimentally in real-world conditions.
Rapid (near-patient) testing provides an accessible
means of testing large numbers of people in non-specialist
settings. We used the INSTI™ HIV-1/HIV-2 Rapid
Antibody Test (bioLytical Laboratories, Richmond, BC,
Canada), which is quick to learn and easy to use and thus
potentially able to be used by staff with minimal training
(see Box 1). The INSTI test has a high sensitivity of








99.6 %. Considering a local prevalence of 2 in 1000 in the
United Kingdom, this means that only 1 per 125,000 test
results can be expected to be false non-reactive. Owing to
the 3-month diagnostic window period, the test may fail
to detect HIV in the early, acute phase of infection [29].
Patients with a non-reactive result with no recent risk can
be assured of their negative HIV status immediately,
whereas those with ‘reactive’ or ‘indeterminate’ results re-
quire confirmatory serological testing [30]. Potentially,
then, HIV testing (serology or rapid or both) could be in-
corporated into the New Patient Health Checks that are
currently routine in UK general practice [31].
The trial ran for 28 months between 2010 and 2012.
Recruitment took place at 40 of 45 general practises
practices in a socioeconomically disadvantaged London
borough where the baseline prevalence of diagnosed
HIV was 8 per 1000 adult population. Practices were
randomised to an intervention arm (implementing rapid
HIV testing alongside New Patient Health Checks) or a
control arm (usual care). The intervention is described
in Box 1.
The primary outcome was timeliness of diagnosis on
the basis of mean CD4 cell count of all patients newly
diagnosed as HIV-positive in general practice, an indica-
tor of stage of diagnosis. Overall, intervention practices
offered 11,180 rapid tests, and 44.5 % of these were ac-
cepted. In total, 14 tests were reactive, of which 11 were
confirmed to be HIV-positive. Serological testing [e.g.,
opportunistically by general practitioners (GPs) during
routine consultations, and through antenatal screening]
identified 21 (intervention) and 14 (control) further
cases of HIV. Patients identified in intervention practices
had higher CD4 counts (that is, were at an earlier stage
of infection) than those identified in control practices
[24, 25]. Of the patients diagnosed, 79 % were part of
identified risk groups (63 % black African origin, 16 %
men who have sex with men). All patients identified via
rapid testing were successfully transferred to secondary
care, and an economic evaluation showed that the inter-
vention is likely to be cost-effective (unpublished data).
Despite the overall success of the trial and the positive
result, there was marked variation between the 20 inter-
vention practices in how many tests were offered and, of
these, how many were accepted (see the Results section).
This raised important questions and provided the im-
petus for a retrospective process evaluation of why some,
but not all, practices were able to assimilate and sustain-
ably implement rapid HIV testing as part of the New Pa-
tient Health Check, even though all had agreed to
participate in the trial and knew that a goal of the trial
was to increase testing.
The diffusion of innovations model
A wide-ranging systematic review of the diffusion, spread
and sustainability of innovations in the organisation and
delivery of health services identified six interacting com-
ponents: (1) the innovation itself; (2) the intended
adopters; (3) communication and influence; (4) the inner
organisational or system context, comprising general ante-
cedents for innovation-specific readiness for a particular
innovation; (5) the outer (inter-organisational and envir-
onmental) context; and (6) the implementation process.
The model (Fig. 1) emphasises the importance of linkage
between different components of and feedback regarding
the consequences of innovation to other parts of the sys-
tem. The components of the model are defined in Table 1.
Applying this model to a RCT design is not straightfor-
ward, because the evidence on which it is based relates to
free-living individuals operating in real-world conditions.
In particular, the element relating to communication and
influence was less relevant to this evaluation, because all
practices and participating staff received a standardised
training package (Box 1). Nevertheless, the pragmatic
Box 1 The intervention: rapid HIV testing in general practice
The ‘hard core’ of the intervention [16] was the INSTI HIV-1/HIV-2 Rapid
Antibody Test (bioLytical Laboratories, Richmond, BC, Canada). The
single-use test involves 50 μl of finger-prick blood, which was mixed
with a sample diluent and poured onto a membrane unit, followed by a
drop of developer and clarifying solution. After about 1 min, either one
or two blue dots would appear, indicating one of four possible results:
non-reactive (one blue dot, negative), reactive (two blue dots, suggesting
the presence of HIV antibody in patient serum), indeterminate (e.g., two
faint dots or two dots with one displaying a pale centre, suggesting
possible early infection) or invalid (none of the above, suggesting test
performed wrongly or a faulty test kit). A reactive or indeterminate INSTI
test is not definitive; it requires confirmation with a serological test. The
test is 99.6 % sensitive and 99.3 % specific [30]. The ‘soft periphery’ of the
intervention was how this test was introduced and how it became
embedded in the New Patient Health Check and wider organisational
routines. As per trial protocol, each practice received a 90-min training
session delivered by the research team and a consultant or specialist HIV
doctor or nurse, comprising theoretical elements (rationale) and practical
ones (rehearsing pre-test and post-test explanations, if possible with a
simulated patient, and performing the test on samples under supervision).
The practice lead for rapid HIV testing [nurse or health care assistant
(HCA)] received an additional training session on study algorithms and
quality assurance procedures. Quality control procedures were offered
monthly for the first year of the trial and every 3 months in the second.
Dedicated codes were installed on practice computers to capture rapid
HIV testing as part of the New Patient Health Check or other consultations.
Practices received a small one-off payment (£300) plus £10 per test
performed, plus free testing kits and support. The New Patient Health
Check is used mainly to collect baseline data on health and lifestyle
from new registrants by asking standard questions led by computerised
prompts. Raising the possibility of HIV to a new patient in a short,
largely administrative appointment alters the nature of this appointment.
Pre-test counselling is not provided, and there is no preliminary assessment
of risk. Staff are encouraged to use standard phrases when explaining the
test (and offering the opportunity to opt out), delivering it and giving
provisional results. In the case of a ‘reactive’, ‘indeterminate’ or ‘twice invalid’
result, for example, staff were told to ask the patient to wait in the waiting
or consultation room until the general practitioner was available to discuss
the result with them and arrange confirmatory serology.




design of the trial meant that many real-world influences
were built into the study design. For example, participat-
ing practices were open to communication from other
practices locally as well as from other, ‘outer context’ influ-
ences, such as the economic recession, new immigration
and changes in national and local HIV policies.
The aspects of the model that were most relevant to
the process evaluation were staff perceptions about the
intervention (testing was undertaken by practice staff,
who had different views about the value and appropri-
ateness of the test and their own role in it), the organisa-
tional antecedents and readiness for innovation as well
as the implementation and assimilation process.
Methods
Management and governance
Full details of study management and governance, in-
cluding the independent data monitoring committee, are
given in the main empirical report [24, 25]. The trial
(ISRCTN63473710) was approved by Camden and Is-
lington Community Research Ethics Committee (09/
H0722/67). Ethical approval for the qualitative research
was gained from Bloomsbury National Research Ethics
Service committee (11/LO/0324) in April 2011 with an
amendment in December 2013.
Data sources for process evaluation
Various methodologies and data sources were used.
Participant observation
Throughout the trial period, HM was a member of the
study team responsible for practice recruitment, train-
ing, monitoring and general liaison. This work required
her to make frequent visits to practices, which were
typed up formally as field notes as soon as was practic-
able after each visit. Numerous informal conversations
and email exchanges also took place with practice staff
regarding all aspects of implementation, including the
Fig. 1 Greenhalgh et al.’s diffusion of innovation model [23]. Figure taken from article by TG in Milbank Quarterly 2004; 82:595. Reproduced under
author’s original copyright transfer agreement








Table 1 Definitions of components of Greenhalgh et al.’s diffusion of innovations model
Component Definition
Attributes of the innovation How the potential adopter views the pros and cons of the innovation
Relative advantage A clear, unambiguous advantage in terms of either effectiveness
or cost effectiveness.
Compatibility Compatible with the values, norms and perceived needs or
intended adopters.
Low complexity Composed of simple, easy to implement steps; able to be broken
down and learned on an incremental basis.
Trialability Can be experimented with.
Observability Benefits are (or quickly become) visible to intended adopters.
Potential for reinvention Possibility to adapt, refine or otherwise modify the innovation to
suit adopter needs.
Fuzzy boundaries If innovations have ‘hard cores’ (irreducible elements of the
innovation) and ‘soft peripheries’ (structures and systems required
for full implementation), adaptation of the soft periphery can
facilitate adoption.
Risk Risks of the innovation (as perceived by the intended adopter) are
outweighed by its perceived benefits.
Task issues Extent to which the innovation is relevant, feasible, workable and
easy to use for the adopter.
Nature of knowledge Knowledge required to enact the innovation can be transferred,
either by codification (explicit knowledge) or more informally, e.g.,
by shadowing (tacit knowledge).
Technical support If the innovation is technical, help desk support is available,
especially in the early stages of implementation.
System antecedents for innovation (including
structure and/or absorptive capacity and/or
receptive context)
Extent to which the organisation is ready for innovations in general
Structure Size and/or maturity Practice size is related to innovation adoption, with larger
practices faring better regarding implementation; a proxy for other
features, e.g., slack resources and functional differentiation.
Formalisation The extent to which there are rules and protocols regarding
organisational activities which are upheld.
Differentiation The extent to which roles and activities are divided.
Decentralisation Decision-making power is appropriately dispersed across
organisations.
Slack resources The resources an organisation has beyond what it minimally
requires to maintain operations.
Absorptive capacity for new knowledge A dynamic capability pertaining to knowledge creation and use that enhances an organisation’s
ability to gain and sustain a competitive advantage.
Pre-existing knowledge and/or
skill set
Existing knowledge and skills within the organisation; particularly
facilitatory if somehow related to the innovation.
Ability to find, interpret,
recodify and integrate new
knowledge
The ability to take on, understand, integrate into existing systems
and put into productive use new information.
Enablement of knowledge
sharing via internal and
external networks
Individuals are able to share knowledge regarding the innovation
internally and externally through established networks.
Receptive context for change A combination of factors from both the inner and the outer contexts that together determine an
organisation’s ability to respond effectively and purposefully to change.
Leadership and vision Top management support, advocacy of the implementation
process and continued commitment to it enhance the success of
implementation and routinisation.
Good managerial relations Staff have positive relationships with managers.
Risk-taking climate








thoughts and feelings of front-line staff about HIV
testing and their narratives of test enactment. This
‘autoethnographic’ approach is widely used in organi-
sational case study research and can provide a parti-
cularly rich account of organisational culture and
practices [32, 33].
Qualitative interviews
Semi-structured interviews were undertaken with a pur-
posive sample of 21 staff in 16 of the 20 intervention
practices; the other four practices failed to respond to
requests. Most were nurses (n = 11) or HCAs (n = 7)
who primarily offered the rapid HIV test as a part of the
Table 1 Definitions of components of Greenhalgh et al.’s diffusion of innovations model (Continued)
A supportive working culture where practice staff feel able to
experiment with new innovations without fear of being
reprimanded.
Clear goals and priorities Objectives are clear to the organisation and the staff.
High-quality data capture Organisational systems are in place to obtain high-quality data re-
lated to the innovation diffusion.
System readiness for innovation The extent to which the organisation is ready for the specific innovation.
Tension for change Degree to which adopters see the current situation as inadequate
or intolerable.
Innovation system fit The innovation fits with existing values, norms, strategies, goals,
skill mix, supporting technologies and ways of working within the
organisation.
Power balances
Assessment of implications The implications of adoption are known and assessed.
Dedicate time and/or resources Degree to which budget and resources available are adequate
and recurrent.
Monitoring and feedback Systems and skills are in place to monitor and evaluate the impact
of the innovation and feedback to adopters.
Adopter Those meant to adopt and enact innovations.
Needs What the adopter needs to be able to adopt the innovation.
Motivation Whether the adopter is motivated to adopt the innovation.
Values and goals Does the innovation gel with the adopter’s values and goals?
Skills The skills required to adopt the innovation and whether adopters
possess these.
Learning style The ways that adopters learn are considered and catered to in the
innovation training.
Social networks The patterns of friendship, advice, communication and support
that exist among members of a social system.
Implementation process The process by which a new innovation is diffused across an organisation.
Decision making devolved to
front-line teams
Do lead users of the innovation have control over aspects of the
implementation process?
Hands-on approach by leaders
and managers
Leaders and managers are involved in the implementation
process, supporting and assisting problem solving as required.
Human resources issues,
especially training
Have all human resources issues linked to the introduction of the
innovation (training, workload, supervision, performance
management) been addressed adequately?
Dedicated resources Specific resources of time, budget and other relevant resource are
dedicated to support implementation.
Internal communication Involved bodies communicate effectively with each other
regarding the innovation and the implementation process.
External collaboration Effective knowledge-sharing links to other organisations who are
implementing the same innovation.
Reinvention and/or
development
Was it possible to adapt the innovation or the tasks and processes
associated with it to suit local contingencies?
Feedback on progress Are there evaluative and feedback mechanisms in place and
enacted?








New Patient Health Check. One practice manager, one
clinical manager and one GP were interviewed in relation
to their role in rapid testing (e.g., managing patients with
reactive or indeterminate rapid test results, overall coord-
ination of testing within the practice). Interviews were
conducted at the practice during normal working hours
and were one-to-one, except for two nurse and HCA pairs
who asked to be interviewed together. Written informed
consent was obtained from all participants, who also com-
pleted a short demographic survey regarding age, eth-
nicity, length of time at current practice, part-time or
full-time employment and previous HIV-related experi-
ence. Interviews lasted between 30 and 60 min. Interviews
were conducted throughout the final 8 months of the trial
and into the following year. Participants were given a £10
voucher as compensation for their time.
Proust et al., in a feasibility and acceptability pilot
study published prior to the trial, reported on patient
views regarding rapid HIV testing in general practice
[34]. Qualitative interviews with patients offered a rapid
test as a part of the New Patient Health Check found
that patients found the offer of a test acceptable and that
they found the reduced wait time for results and the ac-
cessibility of testing to be appealing. Concerns included
a possible lack of support for the newly diagnosed pa-
tient and patient preparation for testing [34]. Interviews
are currently being undertaken with consenting pa-
tients who were diagnosed as HIV-positive through the
trial and rapid testing. In a forthcoming article, we will
report on patient diagnostic experiences of rapid HIV
testing as part of the New Patient Health Check in pri-
mary care.
Trial performance at practice level
Practice-level performance data were collected through
the remotely accessible electronic record systems used
in participating practices (EMIS [35] and VISION [36]).
This allowed the research team to gather regular data on
the number of rapid HIV tests offered, performed and
declined at each practice. Upon completion of the trial,
data were aggregated and overall trial performance was
analysed. In addition, the number of HIV serological
tests per practice (i.e., tests sent to the hospital labora-
tory either to confirm a rapid test result or for other
clinical reasons) was compiled quarterly.
More generally, practice demographic data (including
practice list size, index of multiple deprivation score,
level of male serological HIV testing prior to the trial)
were collated to enrich the case study and inform the
application of the diffusion of innovations model.
Data analysis and case study construction
Data analysis occurred in two phases: (1) preliminary fa-
miliarisation and coding and (2) synthesis into case
studies. In the preliminary phase, qualitative transcripts
(field notes, interviews and extracts from emails and
documents) and matched demographic data on inter-
viewees were uploaded into NVivo software (QSR Inter-
national, Doncaster, Australia) and framework analysis
was undertaken [37]. Selected transcripts (sampled for
diversity and richness) were used to develop a prelimin-
ary coding frame. This framework was then applied to
all transcripts, with emerging themes noted. Coding re-
ports were generated. This process was applied twice.
The first time it was designed to organise and gain fa-
miliarity with the data using the question, What were
the experiences and perspectives of providers of rapid
HIV tests in primary care? The second time it was used
to bring in the components of the diffusion of
innovation model (Fig. 1) to consider the question, What
enabled or hindered providers in effectively implement-
ing rapid HIV testing in general practice? After produ-
cing preliminary categories, we iteratively refined these
in team discussions using the constant comparative
method—that is, comparing each new item of data with
an emerging picture of the case as a whole [38].
We created a spreadsheet of practice characteristics
that included practice size, male HIV testing rate prior
to the trial, rapid HIV and serological testing and
practice HIV diagnoses during the trial period. One
striking (and initially surprising) finding was that prac-
tices that had had high rates of male serological test-
ing for HIV before the trial (a proxy for the level of
prior awareness and interest in HIV in that practice)
were not always high performers in rapid testing. This
analysis informed the sampling of four contrasting
case studies to help theorise the findings using diffu-
sion of innovations:
! Practice A: high serological testing, high rapid testing
! Practice B: low serological testing, high rapid testing
! Practice C: low serological testing, low rapid testing
! Practice D: high serological testing, low rapid testing
Our aim in constructing the case studies was to pro-
duce a rich and meaningful account of how and to
what extent the rapid HIV testing intervention was as-
similated and implemented in each participating prac-
tice, all of whom showed enthusiasm for adopting the
intervention. We used team discussions and applied nar-
rative as a sense-making and synthesis tool to weave
together the quantitative and qualitative findings for that
practice into a rich picture that depicted key perspectives,
events and upstream causes while also conveying ambigu-
ities and uncertainties [39]. In this way, the strengths and
weaknesses of each practice for the purposes of imple-
menting the intervention were revealed and explored.
We sent drafts of our interpretation to practices who








were interested in seeing them before finalising the inter-
pretations presented below.
Results
Description of dataset and introduction to case examples
The final dataset for the process evaluation comprised
60 pages of field notes, 245 pages of interview tran-
scripts and 70 pages of additional free-text documenta-
tion, plus quantitative data on the distribution of 11,000
rapid HIV tests across 20 intervention practices and
5193 serological (hospital laboratory) tests across 40
intervention and control practices, respectively.
Common findings: relative advantage and simplicity of
the rapid test
Despite wide variation in uptake of rapid testing between
practices, there were some findings common to all, par-
ticularly in relation to the intervention (Box 1). The
front-line staff who delivered the intervention almost
universally perceived a distinct relative advantage (and
considered that patients also saw an advantage) in rapid,
accessible and convenient testing in general practice
compared with usual care (the serological test requiring
venepuncture and at least a 2-day wait for results). The
quick and actionable results would mean less waiting
and administration and, many staff believed, fewer losses
to follow-up. Staff reported that patients appreciated re-
ceiving their results instantly, and they themselves
gained satisfaction in being able to provide this informa-
tion quickly.
Staff and patients felt that placing the rapid HIV test
within the New Patient Health Check with an ‘opt-out’
option allowed people with low awareness of HIV and
low concerns about testing to access a test easily,
thereby extending the reach of testing.
Interviewer: Do you think it’s a good idea to test it in
that way?
HCA: Yes, 100 %.
Interviewer: How come?
HCA: Because most people don’t even think about it at
all. They could go on their whole lives not thinking
about it and people are quite—I don’t know if
‘ignorant’ is the right word to use. If you offer
somebody at a consultation on a one-on-one an HIV
test, they might get a bit offended. But this way, if
you’re saying it’s something that we’re doing at this
point in our practice, as a new patient joining us it’s
offered randomly, it just gives people a chance to think
about if they do want it. If they decline, then at least
they can come back and say, “You know, I was offered
this test, and yes, I would like to have it done.” – HCA
from practice D
Lack of need for pre-test and post-test counselling and
detailed sexual history testing, as well as location of the
test in the context of a routine general practice encoun-
ter, effectively normalised and destigmatised the rapid
HIV test and made it relatively easy for non-specialist
staff to learn and deliver (and for patients to accept).
However, HCAs in particular do not routinely test for
what is considered a stigmatised and serious condition,
so the test did require some change in their role and the
way they related to patients—an issue that played out
differently with different staff and in different practices
(see case studies below).
Staff also commented that patients preferred rapid
finger-prick testing to venous blood sampling. The test
was technically simple, and phlebotomy skills were not
needed. Even patients who disliked needles did not seem
to mind the small lancet used quickly in the rapid test, a
finding we demonstrated previously in a pilot study [35].
They also said that patients preferred the near-patient
test, as they could visibly see that the result was their
own, thereby increasing their trust in the test result.
In sum, the INSTI HIV-1/HIV-2 Rapid Antibody Test
(the ‘hard core’ of the intervention; see Box 1) was
perceived extremely positively by the staff charged with
delivering it. Below, we present four contrasting case
studies of practices where different individual and organ-
isational factors combined to produce four very different
contexts for assimilating, implementing and sustaining
the intervention for the duration of the trial.
Practice A (high recruiter): high system antecedents, high
system readiness
Practice A implemented the rapid testing intervention
very successfully, offering more rapid tests than any
other practiceand having a moderate decline rate
(42 %), though only one case of HIV was detected via
the New Patient Health Check. Our qualitative and
quantitative data showed that effective implementation
of the test was the result of key system antecedents for
innovation, high system readiness for the rapid test and
a smooth implementation process and strong adopter
factors among front-line staff (see Fig. 1).
Practice A was one of the largest practices in the bor-
ough. It was mature and well organised, with a clear dif-
ferentiation of functions and staff roles and good
managerial relations. For example, the practice nurse and
HCA had been with the practice for some time. They
felt their roles were clear, and they understood who
should be called upon and at what stage if a test was re-
active. Both expressed the importance of GPs in making
diagnoses, both for the patient and for the sake of their
own comfort in offering tests. If needed, they sought in-
formation and clarification from senior staff.








I’ve had a couple of patients say that they didn’t want
the test at the time I offered it, in the New Patient
Health Check, but is it okay if I go away, think about
it and then maybe come back? And I’ve said, Well, you
know, this is something that we offer now. If you come
back, then I’d have to question that with the doctor as
to whether you can have it as a, you know, fully
registered patient. I’ve spoken, I did speak to a doctor
actually, and they said that it would be okay if they
hadn’t been registered too far down the line. – HCA
from practice A
Junior practice staff were mentored by more senior
staff, providing both pastoral support and opportun-
ities for individual and team learning (the latter linked
to the key construct of absorptive capacity; see Table 1).
The practice was able to integrate new knowledge
through regular practice meetings and feedback. Prac-
tice A showed interest in the monitoring of progress
and the study’s overall performance, often asking how
they rated in relation to other trial practices.
Leadership, organisation and communication ap-
peared to be strong factors in practice A. For example, a
lead was assigned for the intervention and provided
support to junior staff tasked with delivery. Roles were
well differentiated, and support was provided promptly
when required.
Interviewer: But you’ve had a reactive?
Nurse: That was an early one.
HCA: Yeah.
Nurse: Trying to; I’m trying to recall it.
Interviewer: Okay.
Nurse: As to what, as to what I actually said. I remember
I sent a screen message to (GP A), and I, I think I just
said something like, oh, that I needed the doctor to verify
the result and that I needed him to look at it. I think it
was something like, that, it’s such a long time ago now,
and then (GP B) came in, and I had a chat with him,
and we did the blood test, gave him some information,
and I think (GP A) said that he would be in contact with
him. – Nurse and HCA from practice A
Staff in practice A perceived the intervention positively
and were also proud of the overall quality of service they of-
fered. They viewed the new test as enhancing that quality.
Nurse: Yeah, I think, the impression I get is that they
think that we’re been quite thorough and that we’re,
you know, so I think it, I think it promotes us.
HCA: That we’re very organised, well, she said I’m
very organised and thorough.
Nurse: Yeah, that we care and that we’re offering a
good service. – Nurse and HCA from practice A
Perhaps partly for this reason, rapid testing was
quickly incorporated into the New Patient Health Check
and was viewed by staff as a good fit with that process (a
construct described in the literature as ‘innovation–sys-
tem fit’ [23]). Practice A was also one of the few prac-
tices that did not stress time constraints (linking with
what in the model is called ‘slack resources’, defined in
Table 1).
Early in the trial, a positive HIV diagnosis through
rapid testing was made, demonstrating that the
innovation ‘worked’ and achieved its objective, an attri-
bute known as observability. This is likely to have rein-
forced the implementation process (see feedback arrows
in Fig. 1).
In sum, practice A illustrated many of the key organisa-
tional preconditions for successful assimilation of
innovation, including key elements of structure (large prac-
tice list size, maturity, slack resources, functional differenti-
ation), absorptive capacity for new knowledge (high pre-
existing knowledge and skills base and formal and informal
processes for knowledge sharing among staff from different
professional groups) and high readiness to change (leader-
ship and vision, good managerial relations, risk-taking cli-
mate and high-quality data capture). It also showed high
readiness for the particular innovation (innovation–system
fit) because clinicians were already interested in HIV testing
and keen to promote it further. Importantly, nobody in the
practice appeared opposed to the innovation.
Practice B (high recruiter): moderate system antecedents,
exceptional front-line staff, strong internal synergies
Practice B also assimilated rapid HIV testing very effect-
ively as part of the New Patient Health Check. Despite
being one of the small to medium-size practices and
having a low turnover of patients (and hence fewer new
registrants), this practice diagnosed twice as many pa-
tients through rapid HIV testing as any other practice in
the study. The number of rapid tests offered (n = 870)
was high for practice size, and the rate of tests declined
was low (36 %). Yet, the serological testing rate prior to
and throughout the trial was fairly low [fourth amongst
the 40 (0.66/1000 serological testing rate during the trial
period, and 2.07/1000 prior to the trial, respectively)
participating practices prior to the trial], suggesting that
the practice did not previously place significant emphasis
on HIV testing. A number of factors at both the organ-
isational and individual levels may help explain this
success.
Practice B demonstrated moderate system antecedents
and readiness for innovation (see Fig. 1). The practice
was well organised and had a clear and harmonious dif-
ferentiation of roles; the nurse spoke highly of senior doc-
tors and vice versa. The practice also had high absorptive
capacity for new knowledge and a receptive context for








change. This existing knowledge and willingness to learn
more also point to the practice’s goals and priorities of
supporting patients beyond immediate medical needs. On
one occasion when there was concern about misinter-
preted results, the nurse immediately discussed next steps
with the GP and ensured the safety of the patient. The
good managerial relationships and strong communication
shown here may also indicate a risk-taking climate in
which interacting with innovations is encouraged and so-
lutions to any challenges are found together when
needed.
Respondent: There was one which did … that was
indeterminate. There was … you know, the pots. It was
… it was supposed to be non-reactive, but inside that
pot it was like a line.
Interviewer: Okay. Right. Just a straight line.
Respondent: And when I told the doctor, he say,
probably … no, not the doctor; the lady that came the
other day. He said probably it is damaged or
something like that. But I told Doctor A, and he said I
should call the patient back, you know. So, we call the
patient back, and I explain, even to the patient as
well, that this result, it doesn’t mean you have HIV
now, but it might be one thing or the other that is
making the … you know, the test to being invalid. So
… and she decided … she came back.
Interviewer: Had another test.
Respondent: Yes. And it was non-reactive. – Nurse
from practice B
Although the practice had low serology rates prior to the
trial, once testing was introduced and the staff were trained,
the intervention was quickly adopted. Staff appeared en-
gaged, seeing the relative advantage of the innovation.
An unusual feature of practice B was that a single indi-
vidual (the practice nurse) undertook all New Patient
Health Checks, for which she had a generous time alloca-
tion (30 min for each). She worked full-time and had her
own dedicated consultation room. She had a professional
and strongly patient-centred approach to her job, working
largely autonomously and indicating general enjoyment of
what she did.
The nurse who did all the rapid testing framed it not
merely as a service for individual patients but also as an
ethical imperative and a way to improve public health; in
other words, it had particularly high value and significance
for her as a professional.
I think I just like doing it because it is good. When you
think about the end result, is good. It makes you feel
you have done something good as well. At least for
somebody who doesn’t know that is positive and is not,
because although the news of being positive, it has a
lot of effect on them, but after counselling…. But I
believe it will prevent other people as well, or protect
other people. Either prevent or protect from catching it
because if it is known, then the patient can take
precaution not to infect other people. – Nurse from
practice B
Quality control visits showed that the lead nurse for
rapid testing, along with other practice staff, managed to
‘reinvent’ the test and the algorithm to suit local practice
conditions without losing fidelity. The nurse felt con-
cerned at the potential effect of a reactive result on the pa-
tient in the room, so the nurse began to perform the
definitive aspect of the test away from the patient’s
view—an adaptation that was not in the original training.
She did not disclose to the patient that the test took
1 min, allowing herself a few moments when required to
reflect on test results and plan her next steps.
Interviewer: Yes. How did you feel the first time you
saw a reactive?
Nurse: I was … but I was looking, but he wasn’t
looking at me.
Interviewer: Yes, because you do it on that side of the
room.
Nurse: Yes. On that side. So he was sitting down there,
so … but he was looking at me as well. But because I
was facing that side, he couldn’t see my face. – Nurse
from practice B
Another adaptation in practice B was that GPs would
refer patients to this nurse for rapid testing, regardless
of whether they were booked for a new patient check.
The nurse reported that some patients for whom the
possibility of HIV infection was being considered were
persuaded to have the rapid test when they may have de-
clined the more invasive and less convenient serological
testing.
As in practice A, a positive HIV diagnosis through
rapid testing was made early in the trial, reinforcing staff
confidence in the test.
Practice B is noteworthy, not merely for possessing
many (though not all) key system antecedents and readi-
ness factors for innovation and highly motivated front-
line staff, but also in the way these elements were com-
bined. The very professional and patient-centred practice
nurse, for example, was able to give her very best to the
study because the practice allocated plenty of time and
allowed the nurse to work independently and adapt the
innovation to suit her own working style and local
microroutines. More subtly, the culture of the practice
was to embrace innovations and support their embed-
ding. Doctors recognised the nurse’s competence and
interest in this innovation and began to send her








additional patients for testing. In these and numerous
other ways, the elements of innovativeness built on
one another synergistically.
Practice C (low recruiter): low system antecedents,
reluctant front-line staff
Practice C struggled to implement rapid testing. The
practice was slow to offer the first test, and its rate of
testing remained low throughout the study (in total, 72
rapid tests were offered, and 50 % of these were de-
clined), despite multiple visits and ‘retraining’ from the
research team. It had a low serology HIV testing rate
prior to and throughout the trial. Low recruitment from
this practice was explained by a combination of factors,
both organisational and individual.
System antecedents were low in practice C. A small
practice, it comprised three GPs, one nurse and one
HCA (both of whom undertook New Patient Health
Checks), one practice manager and two receptionists.
Located within a large building housing multiple prac-
tices, the surgery; always seemed crowded and very busy.
The practice showed little interest in, or time to ac-
commodate, other innovations, and there were few re-
sources (human or financial) available to invest in new
projects. Overall, the practice appeared to find a new
service model difficult to integrate into business as
usual. There was expressed frustration with changing
National Health Service (NHS) policy and guidance as
well as broader changes in health care culture. A low ab-
sorptive capacity for new knowledge was also evident.
One of the doctors, for example, asked the research
team how to access information and register for GP
training courses unrelated to the intervention, suggest-
ing that this individual found locating and navigating in-
formation difficult. Significantly, practice staff did not
perceive a great need for HIV testing in the borough,
suggesting that there was little, if any, tension for
change. The nurse described herself as ‘overstretched’.
She gave the impression of barely being able to complete
her existing work and having almost no personal cap-
acity for additional tasks:
[The rapid HIV test] really is not a problem. It’s just,
you know, having the time. I mean, often I get to the
end of a morning, and I feel like a rag. – Nurse,
practice C
Because of the understandable reluctance of busy
front-line staff to accommodate the test, it never became
routinised within the New Patient Health Check in prac-
tice C; it was not offered to most patients having these
checks, and, unlike in practices A and B, it never came
to be viewed by staff as part of that check. With such
low numbers of tests being undertaken, it was not sur-
prising that no cases of HIV were detected using rapid
testing, so its observability was not evident in this
practice.
Our data suggest that there may also have been an
issue about the compatibility of the test with the values
of the HCA, who appeared personally uncomfortable
testing for HIV. Indeed, it is unclear whether this staff
member offered any tests throughout the trial period.
This was a source of frustration to the nurse, who had
tried to rectify the situation:
I don’t have any problem with doing [the rapid HIV
test]; the actual doing of the tests is straightforward.
My colleague who should be doing them as well hasn’t
done one. I don’t know. I went through it with her
again a while ago; I don’t know, two or three weeks
back I went through it again with her to remind her
how to do it. And I do it whenever I can, but my
problem is time…. I don’t know if it’s a religious thing,
maybe [explanation of perceived religious views of
colleague]. I don’t know if it’s something to do with
that. But she’s a health care assistant; she’s not a
nurse. That’s a difference as well. – Nurse, practice C
The nurse raises an important point here—that the
rapid HIV test was not merely a technical procedure but
a professional interaction. Technically, it was simple
and straightforward (albeit hard to accommodate if time
was short), but because of its link to a stigmatising ill-
ness, it also required a professional, rather than merely
transactional and task-oriented, relationship with the
patient. Implicitly, the block to adoption may not have
been the HCA’s views per se but the fact that her
role—in this practice, at least—was not professionalised.
HIV remains a stigmatised condition, and the line be-
tween a screening test and a diagnostic test can be fine,
particularly in the case of the test used in the trial,
which may be interpreted by patients as well as pro-
viders (two dots as a reactive result, one dot as a non-
reactive result). It may have been that reluctance to offer
rapid testing relates to the need to provide immediate
feedback regarding test results. Whereas GPs are called
upon to share test reactive results, HCAs and nurses
expressed significant concern about managing reactive
results and patient reactions as well as the interval be-
tween the test and calling upon the GP. This may have
been a factor in the HCA’s reluctance to test. The nurse,
though personally motivated and more professionally
experienced, had only limited opportunity to offer rapid
HIV testing, as most New Patient Health Checks were
performed by the HCA.
It is also significant in the quotation above that the
nurse took personal responsibility for trying to change








the HCA’s attitude and behaviour in relation to rapid
testing. Despite raising the issue with GPs and the prac-
tice manager, no action was apparently taken to explore
or improve this staff member’s low performance on trial
activities. In contrast to the subtle but important in-
volvement of senior clinicians and managerial staff in
practices A and B, the approach of similar staff in prac-
tice C was distinctly ‘hands off ’.
It is noteworthy that the practice nurse made numer-
ous efforts to implement the rapid test, but those efforts
had very limited success in the context described above.
For example, she showed creativity in ‘reinventing’ the
finger-prick aspect of the test. (“As long as I get a decent
drop of blood, just occasionally people don’t bleed ter-
ribly well. I don’t like the finger-pricker they give with it.
I tend to use my ones…. They’re a bit more gentle.”) This
motivation and creativity did not translate into tests ac-
tually performed, however, because most New Patient
Health Checks were done by someone else, and the low
absorptive capacity of the practice meant that the nurse’s
improved method of testing was not effectively shared
with the front-line staff member who had the most op-
portunity to actually do the test.
In sum, practice C was not an innovative practice, nor
was it ready for the specific innovation of rapid HIV
testing. The member of staff on which the intervention
most depended was personally reluctant, and factors
known to help the implementation phase (notably
hands-on input from senior staff ) were absent. In this
environment, the presence of a single, keen and commit-
ted member of staff had only limited impact on the im-
plementation of the intervention.
Practice D (low recruiter): keen doctors but low system
antecedents and negative synergies
Practice D also struggled to implement rapid HIV testing
as a part of the New Patient Health Check. The 557 rapid
tests that were offered during the trial period (of which
43 % were declined) may appear relatively high, but the
size of the practice and consistent registration of new pa-
tients demonstrated a number of missed opportunities for
testing. The pattern of testing over time suggests that the
innovation was never effectively routinised. Rather, pe-
riods with very low rapid testing were interspersed with
periods in which a number of tests were performed within
a short period of time.
On the surface, this low recruitment rate was surpris-
ing. Several of the GPs had a clinical interest in HIV;
HIV serological testing rates were high both before the
trial and during it (696 performed); and a high turnover
of patients ensured high numbers of New Patient Health
Checks.
As one of the largest and most diverse practices in the
borough, practice D comprised 15 GPs, 9 nurses, 3
HCAs, 2 practice managers and more than 10 reception-
ists and administrators. Many staff worked part-time.
There was time pressure on many activities, and the
practice was constantly busy. The striking contrast be-
tween the very high HIV serology rates but very low
rapid testing rates may be related to our finding that
there were two distinct work cultures within the prac-
tice. Many of the GPs were highly qualified with some
involved in community-based projects. Others had an
interest in sexual health and regularly offered regularly
offered opportunistic regularly offered opportunistic ser-
ology testing for HIV.
However, the nurses and HCAs appeared to have little
or no involvement in these activities or protected time
to become involved. Knowledge appeared to circulate
well among the doctors, but to a much more limited ex-
tent between the doctors and the other practice staff,
suggesting a problem with absorptive capacity (see the
Discussion section). In general, non-medical staff did
not have academic links. Many worked part-time and
had a very task-oriented attitude toward their work (i.e.,
they came to work, completed what was expected of
them and went home). Some staff described a lack of
harmony in practice relationships as well as a sense of
being personally overstretched. There appeared to be re-
lational tensions between some staff in the practice that
affected the implementation of the study protocol. For
example, HCAs had asked reception staff to hand out
leaflets about the study to patients at the reception desk,
but this did not always happen. Unusually, the research
team assisted in mediating this issue.
Although front-line staff expressed enthusiasm about
providing testing and acknowledged the value of offering
the test, they also viewed involvement in the trial as an
additional task in their already high workload. The doc-
tors in practice D viewed involvement in this trial as im-
portant both for them as professionals and for the
practice population, but they did not appear to discuss
with front-line staff how the innovation could success-
fully be incorporated into an already busy practice. As a
result, opponents of the innovation (‘yet another task’)
outnumbered supporters, and because it was nurses and
HCAs who actually delivered the intervention, these in-
dividuals were more strategically placed to do so. Bursts
of trial activity probably reflected periodic encourage-
ment of front-line staff by GPs concerned to increase
the practice’s performance statistics, but this is very dif-
ferent from routinising the innovation as business as
usual (see the Discussion section).
Although decision making about offering the rapid test
was largely devolved to front-line teams, this was com-
plicated by poor communication and strained relation-
ships, to the extent that front-line staff did not appear
inclined to take responsibility for implementation. There








was also a significant problem with time and resources
because HCAs were often called upon to refocus their
work for short periods to meet particular practice goals.
There was little inter-practice feedback unless it was
prompted by the study team, minimising opportunities
for creating the kind of positive feedback loops that were
evident in practices A and B.
These organisation-level factors significantly oversha-
dowed other, more positive elements of this practice in re-
lation to HIV testing, including the perceived relative
advantage of the rapid test in comparison with the widely
used serological testing, and the compatibility of the test
with the values and goals of the practice. In addition,
whilst most front-line staff found the test simple and
easy to use, one HCA (unusually) reported struggles
with the material aspects of the test and indicated that,
on some occasions, this stopped her from offering test-
ing. Even HCAs who expressed strong enthusiasm for
testing felt they were often unable to offer tests, how-
ever, owing to a lack of time as well as a lack of con-
tinuity in their role.
But because it was coming up to the end of the
financial year and everyone had to tally up QOF
points for diabetes and these and this and that, it took
priority. If people had come in, obviously if there were
new patients, we wouldn’t turn anybody away, but we
were phoning up and pre-booking patients to come in
for their diabs or their foot checks or their blood pres-
sure. And because I’m only now doing 3 days a week, I
literally split sessions between here and (another prac-
tice). I do here three sessions and there three sessions.
So, when I am here, they get me to do loads of ECGs
and different other things, and then when I’m there,
I’m doing things over there that they need doing. –
HCA, practice D
Moreover, despite a number of HIV diagnoses made
using serological testing, no diagnoses were made using
rapid tests, indicating a lack of observability. It is telling
that, whereas doctors in practice B altered their behav-
iour during the trial by sending patients to the nurse for
rapid HIV testing, those in practice D continued to use
serological testing when they suspected possible HIV in
a patient. It appears that the rapid testing was seen as
the province of a different group of staff, not something
that was business as usual. GPs become involved in the
rapid HIV testing algorithm in cases of reactive, indeter-
minate or invalid results, but because none occurred at
practice D, this may have impacted their knowledge and
involvement in trial activities.
In sum, despite much initial enthusiasm, practice D
was impeded by a combination of structural, capacity-
related and cultural factors (most crucially, limited slack
resources), along with individual adopter traits and a
weak process of implementation.
Discussion
Summary of findings
This process evaluation of a complex intervention trial
in UK general practice has demonstrated the usefulness
of the diffusion of innovations model in explaining vari-
ation in performance of participating practices. In par-
ticular, five aspects of the model appeared to distinguish
high-performing practices from low-performing ones.
System antecedents for innovation
Larger, more formally organised practices with an appropri-
ate division of roles and slack resources (especially time), as
well as those with strong communication networks and
good managerial relations, were higher recruiters.
System readiness for the innovation
Practices with well-organised New Patient Health
Checks, clear and stable staff roles for these checks, that
had many supporters of rapid HIV testing and that were
able to dedicate time and resources to incorporating the
test smoothly into practice routines were better able to
implement testing.
Adopter characteristics
Staff who perceived the test to be beneficial to patients,
easy to undertake and professionally meaningful under-
took more tests.
The implementation process
Uptake of the intervention was smoother and more
likely when both senior clinicians and managers took a
hands-on approach. If practices devolved decision mak-
ing to front-line teams but did not follow up with sup-
port and feedback, implementation suffered. Dedicated
resources such as time, space and support for implemen-
tation appeared critical.
Reinvention and local customisation
Small adaptations to how, where and by whom the test
was conducted, without losing fidelity of the core com-
ponents, sometimes appeared to make a significant dif-
ference to its acceptance and routinisation within the
practice, though reinvention alone sometimes failed to
overcome wider structural or cultural barriers.
Despite the good fit between individual components of
the model and our case study data, it is important to stress
that our findings also illustrate how these components
may (but do not always) act synergistically and interact
dynamically, allowing strengths in one component to
compensate for limitations in another. Conversely, the
presence of individual elements conducive to innovation








does not guarantee success, since the overall practice dy-
namic may prevent particular factors from having a posi-
tive influence. This is important because it means that,
whilst all the elements described above are ‘evidence
based’, the way they play out in any particular organisation
will be hard to predict.
Additionally, as acknowledged by Greenhalgh et al. in
their discussion of the diffusion of innovations, greater
consideration of the transferable lessons from cognitive
and social psychology is needed [23]. Models of innovation
diffusion are based largely on a dyadic interaction between
a single adopter and an intervention. Rapid testing in pri-
mary care produces a triad between the provider (the
adopter), the rapid test (the innovation) and the patient.
We found that in many cases the views and actions of
providers depended on their assumptions about patient
feelings and reactions to the offer of a rapid HIV test.
When we did the training, we were sort of told, with
the reactive result, you are to leave the room and get a
doctor. I haven’t had to do that yet, but I don’t know
how that would make the patient feel, if I am just
getting up and walking out…. I mean, I don’t think it
was as abrupt as all that in the training…. I don’t
know how people feel about that, but obviously
something is going on…. Would I just make them more
nervous? – HCA
Unsurprisingly, this provider ‘theory of mind’ regarding
the patient entered the calculus of offering testing and was
a strong aspect of the discussion of the innovation. We
feel this is an underdeveloped aspect of the diffusion of
innovations model which precludes a more nuanced
discussion of the health care consultation, the role of
the patient and the impact of new innovations within it.
Implications for involving organisations in complex
intervention research
Our findings support the conclusion that there is not,
nor can there ever be, a universal implementation model
for complex interventions. Site-specific characteristics
and realities need to be considered. Complex interven-
tions, such as other service-level innovations, cannot be
treated as ‘bolt-ons’, but must instead be carefully inte-
grated with practice systems to become part of business
as usual. This process is known as ‘routinisation’. An or-
ganisational routine is a recurrent, collective, interactive
behaviour pattern implemented (often largely subcon-
sciously) by individual actors through shared knowledge
and practice [40]. Routines are path-dependent; that is,
they are shaped by historical particularities in any given
setting, so there is no such thing as universal best prac-
tice. Whilst routines confer stability in an organisation
by conveying a strong sense of what is ‘business as usual’,
they also contain within them the seeds of change be-
cause they depend for their enactment on here-and-now
decisions by individual actors whose creativity can allow
a change to the routine (and hence ‘reinvention’ of the
complex intervention).
Practices who were successful in implementing the
rapid HIV test as part of the trial had routinised the
innovation not merely by assigning its component tasks
to particular staff members but also by encouraging and
rewarding those staff for embedding it in the day-to-day
work of the practice and linking it to other routines.
This crucial distinction between ‘complex intervention
as a set of tasks’ and ‘complex intervention as embedded
routine’ aligns with Denis et al.’s notion of the ‘hard core’
of a complex intervention (the elements that constitute
its ‘fidelity’) and the ‘soft periphery’ which can and must
adapt to accommodate it [16]. In cluster randomised tri-
als, the unit of intervention is large (an entire organisa-
tion, as opposed to individual participants), so poor
uptake of the intervention by one participating unit can
significantly threaten the success of the trial [5].
We cautiously conclude that one way in which re-
searchers might guard against such eventualities would
be to meet with practices prior to recruitment and use
the diffusion of innovation framework to consider the
different ‘soft periphery’ aspects for the proposed inter-
vention. General practices are diverse spaces and vary
widely even within a small geographic locality. Much
may be gained from highlighting the practice’s strengths
and weaknesses in relation to a particular innovation
(‘assessment of implications’ in Fig. 1).
Such an assessment should include, for example, consid-
eration of what is acceptable research ‘fidelity’. Pragmatic
trials are meant to account for the contextual factors im-
plicated in the ‘real-life’ settings where trials are conducted
[6]. In diverse settings such as general practice, greater
consideration of how we define research fidelity may be
required. As discussed by Hawe and Shiell, ‘fidelity de-
fined functionally rather than compositionally’ may be
key [15]. The point is to allow the interventions to be
responsive to their context while still being meaning-
fully evaluated.
Perhaps drafting site-specific mini protocols outlining
how fidelity could be maintained while also accommo-
dating contextual issues could be considered. It may, for
example, mean allocating testing to a particular nurse or
HCA who sees the value in offering testing, finds the
test easy to deliver and enjoys new tasks, or (in busy
practices) extending the time allocated to the New Pa-
tient Health Check, at least in the early stages.
Another, more general way for research teams to guard
against poor uptake of interventions by participating units
is to address the issue of slack resources. Perhaps un-
surprisingly, successful practices in our trial tended to
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Articles
Promotion of rapid testing for HIV in primary care (RHIVA2): 
a cluster-randomised controlled trial
Werner Leber*, Heather McMullen*, Jane Anderson, Nadine Marlin, Andreia C Santos, Stephen Bremner, Kambiz Boomla, Sally Kerry, 
Danna Millett, Sifi so Mguni, Sarah Creighton, Jose Figueroa, Richard Ashcroft, Graham Hart, Valerie Delpech, Alison Brown, Graeme Rooney, 
Maria Sampson, Adrian Martineau, Fern Terris-Prestholt, Chris Gri!  ths
Summary
Background Many people with HIV are undiagnosed. Early diagnosis saves lives and reduces onward transmission. 
We assessed whether an education programme promoting rapid HIV testing in general practice would lead to 
increased and earlier HIV diagnosis.
Methods In this cluster randomised controlled trial in Hackney (London, UK), general practices were randomly 
assigned (1:1) to off er either opt-out rapid HIV testing to newly registering adults or continue usual care. All practices 
were invited to take part. Practices were randomised by an independent clinical trials unit statistician with a 
minimisation program, maintaining allocation concealment. Neither patients nor investigators were masked to 
treatment allocation. The primary outcome was CD4 count at diagnosis. Secondary outcomes were rate of diagnosis, 
proportion with CD4 count less than 350 cells per µL, and proportion with CD4 count less than 200 cells per µL. This 
study is registered with ClinicalTrials.gov, number ISRCTN63473710.
Findings 40 of 45 (89%) general practices agreed to participate: 20 were assigned to the intervention group (44 971 newly 
registered adult patients) and 20 to the control group (38 464 newly registered adult patients), between April 19, 2010, 
and Aug 31, 2012. Intervention practices diagnosed 32 people with HIV versus 14 in control practices. Mean CD4 
count at diagnosis was 356 cells per μL (SD 254) intervention practices versus 270 (SD 257) in control practices 
(adjusted diff erence of square root CD4 count 3·1, 95% CI –1·2 to 7·4; p=0·16); ); in a pre-planned sensitivity analysis 
excluding patients diagnosed via antenatal care, the diff erence was 6·4 (95% CI, 1·2 to 11·6; p=0·017). Rate of HIV 
diagnosis was 0·30 (95% CI 0·11 to 0·85) per 10 000 patients per year in intervention practices versus 0·07 (0·02 to 
0·20) in control practices (adjusted ratio of geometric means 4·51, 95% CI 1·27 to 16·05; p=0·021). 55% of patients 
in intervention practices versus 73% in control practices had CD4 count less than 350 cells per μL (risk ratio 0·75, 
95% CI 0·53 to 1·07). 28% versus 46% had CD4 count less than 200 cells per µL (0·60, 0·32 to 1·13). All patients 
diagnosed by rapid testing were successfully transferred into specialist care. No adverse events occurred.
Interpretation Promotion of opt-out rapid testing in general practice led to increased rate of diagnosis, and might 
increase early detection, of HIV. We therefore recommend implementation of HIV screening in general practices in 
areas with high HIV prevalence.
Funding UK Department of Health, NHS City and Hackney.
Introduction
Timely diagnosis of HIV is a major challenge. 
Undetected HIV and late diagnosis are associated with 
ill health, increased risk of death from HIV/AIDS, and 
onward viral transmission, constituting a substantial 
burden to public health budgets worldwide.1–3 Of 107 800 
people with HIV in the UK, almost one quarter are 
undiagnosed,4 42% are diagnosed late (after they should 
have begun antiretroviral treatment, CD4 cell count 
<350 cells per µL), and 24% are diagnosed very late 
(CD4 cell count <200 cells per µL).4 Likewise, roughly 
half of the 2·2 million people with HIV in Europe and a 
sixth of the 1·1 million people with HIV in the USA are 
undiagnosed.1,5,6
Expansion of HIV testing is key to improving HIV 
outcomes. In 2008, the British HIV Association 
recommended universal HIV testing in primary care in 
areas with high prevalence (>0·2%), in addition to routine 
screening programmes in antenatal care and sexually 
transmitted infection clinics.7 This approach was 
endorsed by the National Institute for Health and Clinical 
Excellence.8,9 Pilot projects have shown the acceptability 
and feasibility of HIV testing in primary care.10–12 However, 
HIV testing in these settings has not been widely adopted; 
there is no evidence about outcomes from robust 
screening trials. The US Preventative Services Task Force 
has noted that “no randomised trial or observational 
study compared clinical outcomes between adults and 
adolescents screened and not screened for HIV 
infection”,13 a conclusion also reached by the National 
Institute for Health and Clinical Excellence.8,9 To our 
knowledge, no randomised trials have shown that HIV 
screening leads to increased and earlier diagnosis. This is 
a key evidence gap in current guidance.14,15
Primary care is ideally placed to off er HIV testing.7 
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registering patients and are a referral point to specialist 
care. HIV testing in general practice is feasible and 
acceptable10–12 and might be preferable for people who 
would not normally attend traditional HIV testing 
settings such as sexual health clinics.11
We did a pragmatic cluster-randomised controlled trial to 
test the hypothesis that a multifaceted educational outreach 
programme promoting rapid HIV testing in general 
practice leads to increased and early diagnosis of HIV. We 
used a cluster-randomised design because the intervention 
was directed at practices, rather than individual patients.
Methods
Study design and participants
We did this cluster-randomised controlled trial in general 
practices in Hackney, a multiethnic, socioeconomically 
deprived inner London borough, which has the ninth 
highest prevalence of diagnosed HIV infection (eight 
patients per 1000 adults) in the UK.1 We invited all general 
practices in Hackney to participate. At entry, practices 
off ered incentivised serology testing for HIV to patients 
attending sexual health checks and did opportunistic 
serology testing when clinically indicated. Visiting 
midwives off ered HIV screening for women receiving 
antenatal care. The study was approved by Camden and 
Islington Community Research Ethics Committee and 
ran from April 19, 2010, to Aug 31, 2012. An independent 
data monitoring committee was established.
We included patients aged 16 years (the age of consent 
for medical procedures in the UK) and older, who newly 
registered with study practices, and who were able to 
have a pretest discussion in English or with a suitable 
translator. Information sheets, available in English and 
eight locally spoken languages, were displayed at 
reception desks. The ethics committee approved a 
process of valid implied consent for patient participation.12 
We excluded patients who could not understand the 
information sheet or engage with the pretest discussion 
for HIV testing, and those who were HIV positive.
Randomisation and masking
Practices were randomly assigned (1:1) between April, 
2010, and August, 2011, to either intervention or control, 
by an independent clinical trials unit statistician with use 
of a minimisation program (Minim, version 1.3),16 main-
taining allocation concealment. Minimisation criteria 
were practice list size (<5000, 5000–7000, or ≥7000 
registered patients); practice deprivation (Index of 
Multiple Deprivation score: <47 or ≥47);17 and male HIV 
testing rate (men tested between April and October, 2009/
men registered × 1000: less than seven or seven or more). 
Both total HIV testing rate and female HIV testing rate 
would have been confounded by the unknown con-
tribution of antenatal HIV screening by midwives. 
Therefore, the male HIV testing rate off ered the best 
representation of how actively each practice screened for 
HIV. Neither investigators nor clinical teams were masked 
to allocation.
Procedures
The intervention consisted of a practice-based outreach 
educational programme with follow-up training for a 
nominated HIV lead nurse or health-care assistant in 
each practice, integration of rapid HIV testing into the 
registration health check and management of reactive 
tests, and provision of free rapid HIV tests and payment 
of £10 per test completed. Control practices provided 
usual care only, which included an off er of serology HIV 
testing opportunistically and on patient request.
The educational programme was based on published 
clinician behaviour change strategies18–20 together with 
our experience of delivering similar interventions. Initial 
training sessions were held at individual practices, lasted 
90 min, targeted the whole practice team, and included 
didactic and interactive elements. Session leaders (WL, 
HM) were trained to ensure intervention fi delity 
(appendix p 1). Rapid HIV test operators completed 
competency-based training. An HIV lead was nominated 
in each practice to coordinate rapid testing and quality 
assurance (appendix p 2).
Registration health checks were done by a nurse or 
health-care assistant, who followed prompts on a 
template in patients’ electronic health records. We added 
prompts to off er rapid HIV testing, linked to bespoke 
Read codes to record test outcomes: non-reactive, 
reactive, indeter minate, invalid, and test declined. Read 
Research in context
Evidence before this study
We searched PubMed for randomised controlled trials, 
published from Jan 1, 2000, to Jan 31, 2015, testing the e! ects 
of screening of adults for HIV in primary care compared with 
usual care on rate of diagnosis, CD4 count, and disease stage at 
diagnosis. We found no studies that met these criteria.
The US Preventative Services Task Force did a similar search in 
2011, as part of their evidence review to update their 2005 
recommendations on HIV screening. They noted that “no 
randomised trial or observational study compared clinical 
outcomes between adults and adolescents screened and not 
screened for HIV infection”.
Added value of this study
These fi ndings provide, to our knowledge, the fi rst robust 
evidence from a randomised study that a screening programme 
leads to increased rate of HIV diagnosis.
Implications of all the available evidence
Public health leaders should consider implementing screening 
for HIV in primary care in high prevalence areas.
For Read codes see 
http://systems.hscic.gov.uk/
data/uktc/readcodes









www.thelancet.com/hiv   Published online April 29, 2015   http://dx.doi.org/10.1016/S2352-3018(15)00059-4 3
coding enabled remote data collection for testing activity 
(appendix p 2). The INSTI HIV1/HIV2 Rapid Antibody 
Test (bioLytical Laboratories, Canada) fi nger prick 
system was used for rapid testing.
The intervention was adaptable to each individual 
practice: staff  could additionally off er rapid HIV testing in 
a range of clinical settings (eg, sexual health checks) and 
were encouraged to continue opportunistic HIV testing by 
serology. The core components of the testing process 
included an off er of a rapid HIV test as part of routine new 
registration health checks including a pretest discussion 
for patients to make informed decisions about testing; a 
rapid HIV test followed by a discussion for patients with 
non-reactive tests; and an immediate notifi cation by the 
rapid test operator to the general practitioner of any 
patient with a reactive, indeterminate, or twice invalid test 
results with confi rmatory serology sampling, and follow-
up by a general practitioner (appendix p 2).
Any venous blood sample detected as reactive to HIV-1 
or HIV-2 on an Abbott Architect ci8200 analyser (Abbott 
Diagnostics, UK) at Homerton Hospital (London, UK) was 
sent on to Barts Health Virology for confi rmatory testing 
with the VIDAS HIV DUO Quick assay (BioMerieux, UK) 
and the ImmunoComb II HIV 1 & 2 BioSpot kit assay 
(Alere, UK).
HIV-positive patients were referred to Homerton 
Hospital for specialist care. Practices implemented rapid 
testing immediately after the educational session. 
Ongoing support from the education team was available 
via telephone or email to practice staff  for queries related 
to rapid testing. Control practices were informed by 
email about current national guidance on HIV testing. 
All study practices continued to provide standard care of 
HIV testing and were supported by a community HIV 
liaison nurse.
At Homerton Hospital, all patients who tested HIV 
positive at participating practices were allocated a unique 
study number. Newly diagnosed patients were dis-
tinguished from known HIV-positive patients already in 
care or defaulted from specialist care with the Geni-
tourinary Medicine Clinical Activity Dataset.21 The 
Homerton clinical team (JA, SM) extracted clinical record 
data into anonymised confi dential clinical case report 
forms. AM, who was masked to study allocation, verifi ed 
the accuracy of data extraction for all patients before data 
were passed to the study statistician (appendix p 4).
We generated rapid HIV antibody test result codes for 
the trial: EMISNQRE117 (reactive), EMISNQNO26 
(non-reactive), EMISNQIN61 (indeterminate), and 
EMISNQIN62 (invalid). We also used the following Read 
codes: HIV (serology) screening test (4JR7) and rapid 
HIV test declined (8I3P). The Clinical Eff ectiveness 
Group at Queen Mary University of London (KP, MAS, 
AC, and JD) remotely extracted rapid HIV testing data 
and serology testing data from general practice computer 
systems (EMIS, Egton Medical Information Systems, 
UK; and Vision, In Practice Systems, UK).
Outcomes
The primary outcome was mean CD4 count of newly 
diagnosed patients (see appendix p 4 for a defi nition of a 
newly diagnosed patient). We included women newly 
diagnosed with HIV by the UK Antenatal HIV Screening 
Programme. We excluded patients who had not been 
tested for HIV before specialist referral, and patients 
who were referred by their general practitioner to 
secondary care at Homerton Hospital either for HIV 
testing or for further management of a suspected HIV-
related illness. Secondary outcomes were rate of new 
HIV diagnoses (patients diagnosed/year/10 000 practice 
list size), percentage of patients with CD4 count less than 
350 cells per µL, and percentage of patients with CD4 
count less than 200 cells per µL.
The original primary outcome was the number of new 
HIV diagnoses. However, our initial assumptions were 
based on few data and the number of new diagnoses early 
in the study was lower than expected. Thus, on June 14, 
2011, with the approval of the data monitoring committee, 
we recalculated statistical power with CD4 count as the 
primary outcome, retaining numbers of new diagnoses as 
the main secondary outcome.
45 general practices in Hackney invited to participate
40 randomly assigned
20 followed up (44 971 newly registered patients) 20 followed up (38 464 newly registered patients)
11 180 patients o!ered rapid testing 0 patients o!ered rapid testing
7706 patients tested
 4978 by rapid HIV testing
 2728 by serology
2465 patients tested
 0 by rapid HIV testing
 2465 by serology
 43 HIV positive 
7663 HIV negative
 21 HIV positive
2444 HIV negative
20 assigned to intervention (99 670 registered 
 patients)
20 assigned to control (96 500 registered 
 patients)
32 patients diagnosed in 14 practices included in 
 primary analysis
14 patients diagnosed in 8 practices included in 
 primary analysis
5 declined
7 known to be HIV positive
 5 retained in care
 2 defaulted from care
11 known to be HIV positive
 7 retained in care
 4 defaulted from care









www.thelancet.com/hiv   Published online April 29, 2015   http://dx.doi.org/10.1016/S2352-3018(15)00059-4 3
coding enabled remote data collection for testing activity 
(appendix p 2). The INSTI HIV1/HIV2 Rapid Antibody 
Test (bioLytical Laboratories, Canada) fi nger prick 
system was used for rapid testing.
The intervention was adaptable to each individual 
practice: staff  could additionally off er rapid HIV testing in 
a range of clinical settings (eg, sexual health checks) and 
were encouraged to continue opportunistic HIV testing by 
serology. The core components of the testing process 
included an off er of a rapid HIV test as part of routine new 
registration health checks including a pretest discussion 
for patients to make informed decisions about testing; a 
rapid HIV test followed by a discussion for patients with 
non-reactive tests; and an immediate notifi cation by the 
rapid test operator to the general practitioner of any 
patient with a reactive, indeterminate, or twice invalid test 
results with confi rmatory serology sampling, and follow-
up by a general practitioner (appendix p 2).
Any venous blood sample detected as reactive to HIV-1 
or HIV-2 on an Abbott Architect ci8200 analyser (Abbott 
Diagnostics, UK) at Homerton Hospital (London, UK) was 
sent on to Barts Health Virology for confi rmatory testing 
with the VIDAS HIV DUO Quick assay (BioMerieux, UK) 
and the ImmunoComb II HIV 1 & 2 BioSpot kit assay 
(Alere, UK).
HIV-positive patients were referred to Homerton 
Hospital for specialist care. Practices implemented rapid 
testing immediately after the educational session. 
Ongoing support from the education team was available 
via telephone or email to practice staff  for queries related 
to rapid testing. Control practices were informed by 
email about current national guidance on HIV testing. 
All study practices continued to provide standard care of 
HIV testing and were supported by a community HIV 
liaison nurse.
At Homerton Hospital, all patients who tested HIV 
positive at participating practices were allocated a unique 
study number. Newly diagnosed patients were dis-
tinguished from known HIV-positive patients already in 
care or defaulted from specialist care with the Geni-
tourinary Medicine Clinical Activity Dataset.21 The 
Homerton clinical team (JA, SM) extracted clinical record 
data into anonymised confi dential clinical case report 
forms. AM, who was masked to study allocation, verifi ed 
the accuracy of data extraction for all patients before data 
were passed to the study statistician (appendix p 4).
We generated rapid HIV antibody test result codes for 
the trial: EMISNQRE117 (reactive), EMISNQNO26 
(non-reactive), EMISNQIN61 (indeterminate), and 
EMISNQIN62 (invalid). We also used the following Read 
codes: HIV (serology) screening test (4JR7) and rapid 
HIV test declined (8I3P). The Clinical Eff ectiveness 
Group at Queen Mary University of London (KP, MAS, 
AC, and JD) remotely extracted rapid HIV testing data 
and serology testing data from general practice computer 
systems (EMIS, Egton Medical Information Systems, 
UK; and Vision, In Practice Systems, UK).
Outcomes
The primary outcome was mean CD4 count of newly 
diagnosed patients (see appendix p 4 for a defi nition of a 
newly diagnosed patient). We included women newly 
diagnosed with HIV by the UK Antenatal HIV Screening 
Programme. We excluded patients who had not been 
tested for HIV before specialist referral, and patients 
who were referred by their general practitioner to 
secondary care at Homerton Hospital either for HIV 
testing or for further management of a suspected HIV-
related illness. Secondary outcomes were rate of new 
HIV diagnoses (patients diagnosed/year/10 000 practice 
list size), percentage of patients with CD4 count less than 
350 cells per µL, and percentage of patients with CD4 
count less than 200 cells per µL.
The original primary outcome was the number of new 
HIV diagnoses. However, our initial assumptions were 
based on few data and the number of new diagnoses early 
in the study was lower than expected. Thus, on June 14, 
2011, with the approval of the data monitoring committee, 
we recalculated statistical power with CD4 count as the 
primary outcome, retaining numbers of new diagnoses as 
the main secondary outcome.
45 general practices in Hackney invited to participate
40 randomly assigned
20 followed up (44 971 newly registered patients) 20 followed up (38 464 newly registered patients)
11 180 patients o!ered rapid testing 0 patients o!ered rapid testing
7706 patients tested
 4978 by rapid HIV testing
 2728 by serology
2465 patients tested
 0 by rapid HIV testing
 2465 by serology
 43 HIV positive 
7663 HIV negative
 21 HIV positive
2444 HIV negative
20 assigned to intervention (99 670 registered 
 patients)
20 assigned to control (96 500 registered 
 patients)
32 patients diagnosed in 14 practices included in 
 primary analysis
14 patients diagnosed in 8 practices included in 
 primary analysis
5 declined
7 known to be HIV positive
 5 retained in care
 2 defaulted from care
11 known to be HIV positive
 7 retained in care
 4 defaulted from care









4 www.thelancet.com/hiv   Published online April 29, 2015   http://dx.doi.org/10.1016/S2352-3018(15)00059-4
Statistical analysis
Allowing for clustering, and assuming 20 practices in 
each group and analysis of CD4 on the square root scale 
with an SD of 6 and an intracluster correlation coeffi  cient 
of 0·05, we expected to identify 72 new HIV diagnoses, 
with 80% power and 5% signi fi cance. This would be 
suffi  cient to detect an increase in the mean CD4 count 
from 300 cells per μL to 470 cells per μL, corresponding 
to a reduction in the proportion of late presenters from 
30% to 10%. We made allowances for practices to identify 
diff erent numbers of patients or none at all.22
We compared intervention and control groups with 
logistic regression adjusted for clustering. We estimated 
the eff ect of the intervention on CD4 count and rate of 
diagnosis with a linear regression model adjusted for 
clustering of practices in Stata (version 12) by use of the 
cluster option (except for rate of diagnosis, for which we 
used practice summary data) and adjusted for mini-
misation factors.23 We transformed CD4 count with a 
square root transformation and we log-transformed rate of 
diagnosis after adding 0·01 to zero counts. Using the 
intervention eff ect from the primary analysis and the 
normal distribution, we estimated the relative reduction in 
percentage of patients with both CD4 count less than 
350 cells per μL and CD4 less than 200 cells per μL with a 
method developed by Peacock and colleagues.24
Although we originally planned an as-treated secondary 
analysis excluding practices that had done less than 50 
tests, this was not feasible because only four practices did 
more than 50 tests and no patients from these practices 
had been diagnosed with HIV.
The UK Antenatal HIV Screening Programme off ers all 
women in antenatal care an HIV test. We did a pre-planned 
sensitivity analysis excluding women diagnosed via this 
programme. Some HIV-positive patients had previously 
been diagnosed but had defaulted from specialist care: re-
diagnosis in general practice therefore led to re-entry to 
specialist care. We did a second sensitivity analysis 
including such patients.
This study is registered with ClinicalTrials.gov, number 
ISRCTN63473710.
Role of the funding source
JF, a clinician employed by NHS City and Hackney, which 
funded the study, was involved in designing the study, data 
interpretation, and writing the report, but had no role in 
data collection or analysis. The Department of Health had 
no role in any aspect of the study. The corresponding 
author had full access to all the data in the study and had 
fi nal responsibility for the decision to submit for 
publication.
Results
40 (89%) of 45 general practices agreed to take part (fi gure). 
The fi ve practices that declined had similar characteristics 
to those that joined the study (data not shown). 20 practices 
were randomly assigned to intervention and 20 to control. 
Three practices in the intervention group withdrew during 
the study (one stopped off ering registration health checks; 
one for workload reasons; and one closed), but all provided 
complete study data and were included in the intention-to-
treat analyses. Practice and population characteristics and 
numbers of newly registering patients were well balanced 
at baseline (tables 1 and 2).
Baseline characteristics of study groups were similar for 
sex (p=0·742), age (p=0·0413), and ethnic origin (p=0·136). 
Baseline characteristics for newly registered patients were 
much the same in each treatment group: number of new 
registrants (p=0·935), sex (p=0·632), age (p=0·416), ethnic 
origin (p=0·136), and age (p=0·416).
Intervention practices off ered 11 187 rapid tests, of which 
4978 (45%) were accepted (table 3). Of these, 4964 were not 
reactive and 14 were reactive, including 11 that were 
confi rmed HIV positive (true reactive) and three confi rmed 
HIV negative (false reactive).
Overall, intervention practices identifi ed 43 HIV-positive 
patients, of whom 11 had previously been diagnosed, 
giving a total of 32 new HIV diagnoses. Control practices 
identifi ed 21 HIV-positive patients, of whom seven had 







<5000 patients 8 (40%) 8 (40%)
5000–7000 patients 5 (25%) 5 (25%)
!7000 patients 7 (35%) 7 (35%)
HIV testing rate in men*
<7 13 (65%) 13 (65%)
!7 7 (35%) 7 (35%)
Index of multiple deprivation score
<47 11 (55%) 10 (50%)
!47 9 (45%) 10 (50%)
Patients
Number of registered patients 99 670 96 500
Age (years)
16–24 15 623 (16%) 13 198 (14%)
25–34 28 200 (28%) 29 292 (30%)
35–49 31 218 (31%) 31 990 (33%)
!50 24 629 (25%) 22 020 (23%)
Men 50 224 (50%) 48 929 (51%)
Ethnic origin
White 40 250 (40%) 48 262 (50%)
Black 20 467 (21%) 17 690 (18%)
Asian 8487 (9%) 8002 (8%)
Mixed 3396 (3%) 4207 (4%)
Other 7134 (7%) 3562 (4%)
Unknown 19 936 (20%) 14 777 (15%)
Data are n (%). *Number of men tested April to October 2009/men 
registered " 1000. 
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diagnoses (fi gure, table 3). The UK Antenatal Screening 
Programme led to three new HIV diagnoses in intervention 
practices, and four in control practices.
Of the 32 newly diagnosed patients in the intervention 
group, 19 (59%) were men, 20 (63%) were of black African 
origin, and six (16%) were men who have sex with men. Of 
the 14 patients diagnosed in control practices, eight (57%) 
were men, and ten (71%) were of black African origin, and 
none were men who have sex with men, although we had 
no data for sexual orientation for three men. No adverse 
event occurred during the study.
CD4 count was available for 30 of 32 newly diagnosed 
patients from intervention practices, and in all 14 patients 
from control practices. Mean CD4 count was not signi-
fi cantly diff erent between intervention practices and 
control practices (356 cells per μL [SD 254] vs 270 cells 
per μL [SD 257]; adjusted diff erence in square root trans-
formed CD4 count 3·1, 95% CI –1·2 to 7·4; p=0·16; 
table 4). Mean CD4 count was signifi cantly diff erent when 
patients diagnosed via antenatal screening were excluded 
(6·4, 95% CI 1·2 to 11·6; p=0·017; table 4), and when 
patients who had been previously diagnosed with HIV but 
defaulted from care were included in the analysis (4·1, 
0·0 to 8·1; p=0·049; table 4).
The rate of HIV diagnosis was 0·30 (95% CI 0·11 to 
0·85) per 10 000 patients per year in the intervention 
group and 0·07 (95% CI 0·02 to 0·20) in the control group 
(adjusted ratio of geometric means 4·51, 95% CI 1·27 to 
16·05; p=0·021). In a sensitivity analysis of newly 
diagnosed patients excluding those diagnosed during 
antenatal screening, the rate was 0·23 (95% CI 0·07 to 
0·70) in the intervention group versus 0·04 (0·01 to 0·11) 
in the control group (adjusted ratio 5·88, 95% CI 1·71 to 
20·17; p=0·006). For all new diagnoses plus those 
defaulted from care, the rates were 0·32 (0·11 to 0·91) 
versus 0·07 (0·02 to 0·21; ratio 4·53, 95% CI 1·25 to 
16·38; p=0·023). 
We estimated that 73% of patients in control practices 
had a CD4 count less than 350 cells per μL, compared 
with 55% of patients in intervention practices (risk ratio 
0·75, 95% CI 0·53 to 1·07). 46% versus 28% had a CD4 
count less than 200 cells per μL (risk ratio 0·60, 95% CI 
0·32 to 1·13).
Discussion
We have shown that an educational outreach programme 
promoting opt-out rapid HIV testing of people newly 
registering in general practice leads to increased rates of 
diagnosis of HIV. Our study did not show signifi cant 
diff erences between groups in CD4 counts at diagnosis, 
although diagnosis seemed to be non-signifi cantly earlier 
in the intervention clinics. These are key goals of HIV-
focused clinical and public health programmes. The 
eff ect of rate of diagnosis was greater in sensitivity 
analyses excluding women diagnosed through the UK’s 
existing antenatal HIV screening programme. Practices 
used both rapid and opportunistic serology testing to 
make new diagnoses. A high proportion of newly 
diagnosed patients were of black African ethnic origin, 
showing successful integration of testing into a 





Total number of new registrants 44 971 38 464
Median number of new 






16–24 7667 (17%) 6207 (16%)
25–34 19 491 (43%) 18 170 (47%)
35–49 10 950 (24%) 9016 (23%)
!50 6863 (15%) 5071 (13%)
Men 20 219 (45%) 17 119 (45%)
Ethnic origin
White 23 947 (53%) 22 365 (58%)
Black 6400 (14%) 5253 (14%)
Asian 3472 (8%) 3011 (8%)
Mixed 1296 (3%) 1442 (4%)
Other 2066 (5%) 1389 (4%)
Unknown 7790 (17%) 5004 (13%)
Data are n (%) unless stated otherwise. 








New registrants 44 971 38 464
Patients o" ered rapid tests 11 187 NA
Patients accepting rapid tests 4978 NA
Patients with unreactive rapid tests 4964 NA
Patients with reactive tests 14 NA
Patients confi rmed HIV positive 11 NA
Patients tested by serology test* 2728 2465
HIV diagnoses
Total (new and previously diagnosed) 43 21
New diagnoses 32 14
By rapid testing 11 NA
By opportunistic serology 18 10
In antenatal screening 3 4
Previously diagnosed 11 7
Defaulted from care 4 2
Retained in care 7 5
Sensitivity analysis
New diagnoses excluding antenatal 
screening
29 10
All new diagnoses plus those defaulted 
from care
36 16
Data are n. *Opportunistic testing, as part of antenatal screening, and confi rmatory 
testing for rapid testing. 
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population.25 To our knowledge, this randomised trial is 
the fi rst to show improvements in clinical outcomes 
from HIV screening.
Strengths of our study included a pragmatic real-world 
design that included almost all practices in the borough, 
improving the generalisability of our fi ndings. Randomi-
sation was robust, maintaining allocation concealment. 
Remote searching of practice computer systems ensured 
that data capture of testing activity and outcomes was 
consistent across practices. Access to test results from 
the regional laboratory ensured complete capture of all 
positive tests, minimising detection bias. The Public 
Health England national surveillance system enabled us 
to accurately distinguish between patients newly 
diagnosed in primary care from those who had previously 
tested positive. Validation of data extraction by an 
independent clinician, masked to allocation, of all newly 
diagnosed patients ensured accuracy and comple teness 
of primary and secondary outcomes.
Our intervention was based on a successful screening 
intervention for tuberculosis in general practice,18 which 
used various behaviour change techniques. Outreach 
visits, and clinician education combining mixed didactic 
and interactive elements, have been shown to be 
eff ective.26 Computer prompts for testing and incentive 
fees might also have enhanced behaviour change.27 A 
quality assurance scheme, which included competency-
based training for rapid HIV testing, regular electronic 
monitoring of point-of-care results, and an assessment 
once every 2 months of staff  using external control serum 
samples, enhanced patient safety by reducing the 
chances of incorrect rapid test results. All patients 
diagnosed by rapid testing were transferred to secondary 
care, showing that the links we established between 
general practice and specialist services were safe and 
eff ective. Some patients who had defaulted specialist care 
re-entered specialist services following a rediagnosis by 
their doctor, suggesting that primary care can play an 
important part in maintaining continuity of care.
A weakness of our study was that three intervention 
practices discontinued testing. These discontinuations are 
a consequence of the pragmatic study design. Never-
theless, we were able to include complete data from all 
practices in the analysis. Registration health checks are 
optional, thus only patients that attend (about 50% of all 
registering patients) can be off ered a test. Increasing 
attendance at checks would increase the eff ect of our 
intervention. Although we could not mask clinical and 
research teams to allocation, validation of data extraction 
by a masked independent clinician helped ensure the 
validity of the study data. Our analysis accounted for 
diff erences between practices in the total list. An additional 
factor that could be used is the consultation rate for adult 
patients for each practice. Our study was potentially 
underpowered: increasing attendance at registration 
health checks would increase the eff ect of our intervention.
Observational studies28 suggest that targeted com-
munity-based approaches to HIV testing achieve high 
uptake and a higher proportion of patients with CD4 
count of more than 350 cells per µL at diagnosis. In 
community centres in the USA, nurse-initiated routine 
universal non-targeted rapid HIV testing achieved 
similar uptake and numbers of new diagnoses to those in 
our study.29 Nurse-initiated rapid testing with streamlined 
counselling in primary care is feasible compared with 
traditional approaches.29,30 These fi ndings lend credibility 
to our results.
Our fi ndings provide fi rm evidence that HIV screening 
in primary care leads to increased and earlier HIV 
diagnosis. This fi nding addresses a key gap in the 
evidence base for HIV testing, lending strong evidence 
in support of guideline recommendations.
Our results justify renewed eff orts to implement com-
munity screening for HIV. This study builds on previous 
work showing that opt-out screening for tuber culosis 
using a multifaceted educational inter vention and valid 
implied consent is eff ective in primary care.18 Screening 
for multiple infectious agents in at-risk populations 
therefore seems justifi able.
Contributors
CG had the original idea for the study. WL, HM, CG, JA, SC, DM, SM, 
JF, GH, RA, KB, SB, SK, ACS, FT-P, and MS designed the study. WL, 
HM, DM, SC, JA, and CG trained and educated general practice staff . 
WL, HM, and MS undertook the quality assurance. SK and NM did the 
statistical analyses. RA provided advice on ethical aspects of the trial, 
including data management and data protection. AM completed data 
quality assurance checks. VD, AB, and GR validated HIV diagnoses data. 
WL and CG wrote the fi rst draft of the report with input from ACS, HM, 
JA, SK, SB, JF, AM, VD, and FT-P. All authors have seen and approved 
the fi nal version of the report.
Intervention practices (n=20) Control practices (n=20) Di! erence (95% CI)*
Number of 
patients
Mean CD4 count 
(SD; cells per µL)†
Square root of 




Mean CD4 count 
(SD; cells per µL)
Square root of 
mean CD4 count 
(SD)
New diagnoses 32 356 (254) 17·7 (6·6) 14 270 (257) 14·7 (7·7) 3·1 (–1·2 to 7·4)
All new diagnoses excluding 
antenatal screening
29 369 (262) 18·0 (6·7) 10 194 (169) 12·4 (6·7) 6·4 (1·2 to 11·6)
All new diagnoses plus those 
defaulted from care
36 411 (288) 19·0 (7·2) 16 259 (242) 14·5 (7·3) 4·1 (0·0 to 8·1)
*Calculated from square root of CD4 count and adjusted for minimisation factors. †CD4 cell count unavailable for two patients.
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consistent across practices. Access to test results from 
the regional laboratory ensured complete capture of all 
positive tests, minimising detection bias. The Public 
Health England national surveillance system enabled us 
to accurately distinguish between patients newly 
diagnosed in primary care from those who had previously 
tested positive. Validation of data extraction by an 
independent clinician, masked to allocation, of all newly 
diagnosed patients ensured accuracy and comple teness 
of primary and secondary outcomes.
Our intervention was based on a successful screening 
intervention for tuberculosis in general practice,18 which 
used various behaviour change techniques. Outreach 
visits, and clinician education combining mixed didactic 
and interactive elements, have been shown to be 
eff ective.26 Computer prompts for testing and incentive 
fees might also have enhanced behaviour change.27 A 
quality assurance scheme, which included competency-
based training for rapid HIV testing, regular electronic 
monitoring of point-of-care results, and an assessment 
once every 2 months of staff  using external control serum 
samples, enhanced patient safety by reducing the 
chances of incorrect rapid test results. All patients 
diagnosed by rapid testing were transferred to secondary 
care, showing that the links we established between 
general practice and specialist services were safe and 
eff ective. Some patients who had defaulted specialist care 
re-entered specialist services following a rediagnosis by 
their doctor, suggesting that primary care can play an 
important part in maintaining continuity of care.
A weakness of our study was that three intervention 
practices discontinued testing. These discontinuations are 
a consequence of the pragmatic study design. Never-
theless, we were able to include complete data from all 
practices in the analysis. Registration health checks are 
optional, thus only patients that attend (about 50% of all 
registering patients) can be off ered a test. Increasing 
attendance at checks would increase the eff ect of our 
intervention. Although we could not mask clinical and 
research teams to allocation, validation of data extraction 
by a masked independent clinician helped ensure the 
validity of the study data. Our analysis accounted for 
diff erences between practices in the total list. An additional 
factor that could be used is the consultation rate for adult 
patients for each practice. Our study was potentially 
underpowered: increasing attendance at registration 
health checks would increase the eff ect of our intervention.
Observational studies28 suggest that targeted com-
munity-based approaches to HIV testing achieve high 
uptake and a higher proportion of patients with CD4 
count of more than 350 cells per µL at diagnosis. In 
community centres in the USA, nurse-initiated routine 
universal non-targeted rapid HIV testing achieved 
similar uptake and numbers of new diagnoses to those in 
our study.29 Nurse-initiated rapid testing with streamlined 
counselling in primary care is feasible compared with 
traditional approaches.29,30 These fi ndings lend credibility 
to our results.
Our fi ndings provide fi rm evidence that HIV screening 
in primary care leads to increased and earlier HIV 
diagnosis. This fi nding addresses a key gap in the 
evidence base for HIV testing, lending strong evidence 
in support of guideline recommendations.
Our results justify renewed eff orts to implement com-
munity screening for HIV. This study builds on previous 
work showing that opt-out screening for tuber culosis 
using a multifaceted educational inter vention and valid 
implied consent is eff ective in primary care.18 Screening 
for multiple infectious agents in at-risk populations 
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